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A b s t r a c t
Understanding the molecular basics of recognition events in chemistry is crucial 
for a wide range of disciplines. Luminescence spectroscopy is an appealing way 
of obtaining information on molecular-scale recognition events, as  sensitive, real­
time detection and subnanometer spatial resolution can be achieved.^ 
M easurements in biological media are generally difficult because of the 
interference from the sample and the non-zero background.
Resonance energy transfer (RET) between a luminescent donor and acceptor 
(D-A) is possible when excitation of the D is followed by energy transfer to A, that 
emits at increased wavelengths. Molecules that undergo RET triggered by the 
presence of a target molecule would allow a specific signal to be identified, as 
emission would occur only in the presence of the species of interest. Due to the 
increased emission wavelengths, interference with sample autofluorescence is 
avoided.
The synthesis of donor-acceptor-quencher (D-A-Q) triads, equipped with 
coumarin donors, nucleoside quenchers,^ and organic or lanthanide acceptors, 
that are able to undergo triggered RET will be presented.
Si/% Si %
OFF ON
Figure 1. D: donor, A: acceptor, Q: quencher, S: substrate 
RET from D to A is quenched by Q that is in the close proximity of the D. In the 
absence of the substrate (S) the quencher quenches the D, and RET is not 
possible. If S is present, the quenching is disrupted by the Q-S binding, and 
emission from A is observed {Figure 1). A cocktail of D-A1-Q1, D-A2-Q2, D-A3- 
Qs,... triads offers the possibility of simultaneous detection of several species.
The photophysical properties of the triads have been determined and their 
behaviour was studied in the presence of their substrates. The information 
gained enables the design of improved triads and the tuning of their 
photophysical properties.
References
1. Molecular fluorescence, B. Valeur, WILEY-VCH Verlag GmbH, Weinheim, 
2002
2. A. M. Seide, A. Schulz, M. H. M. Sauer, J. Phys. Chem., 1996, 100, 5541- 
5553
A c k n o w l e d g e m e n t s
I would like to thank Dr Jam es I Bruce for his supervision, guidance and 
encouragement throughout the three years.
I am grateful to Dr Andrew Beeby and Dr Laurent Porres of the University of 
Durham for their help with the photophysical measurements.
Thanks also to the OU Chemistry Department staff, in particular to Mr Gordon 
Howell, Mr Graham Jeffs, Mr Colin Haynes and Mr Pravin Patel.
I would like to thank the EPSRC MS Service (University of Wales, Swansea) for 
the high resolution MS measurements, and Professor Alan Perkins and Ms 
Elaine Blackshaw for the radioimaging, and for the access to the laboratories and 
equipment at the Department of Academic Medical Physics at the University of 
Nottingham.
I would like to thank The Open University and Universities UK for funding.
Finally a big thanks to my family, and my friends, both in Hungary and the UK, 
Shailesh, Catia, Mad, Kukuc, Pottomke and Fish.
Kosz mindent.
T a b l e  o f  c o n t e n t s
LIST OF ABBREVIATIONS.........................................................................................................................8
INTRODUCTION.......................................................................................................................................... 12
2.1 Re c o g n it io n ..........................   12
2.1.1 Recognition in nature...............................................................................................................................13
2.1.2 Recognition in chemistry......................................................................................................................... 13
2.2 F l u o r e s c e n c e .......................................................................................................................................................................16
2.2.1 Photoinduced electron transfer..............................................................................................................18
2.2.2 Resonance energy transfer......................................................................................................................19
2.2.3 Fluorophores in luminescent probes.....................................................................................................22
2.2.3.1 Organic fluorophores....................................................................................................................................... 22
2.2.3.2 Luminescent transition metal complexes...................................................................................................... 22
2.2.3.3 Luminescent lanthanide complexes............................................................................................................... 23
2.2.3.4 Near IR-emitting lanthanide complexes.........................................................................................................24
2.3 Se n s o r s .................................................................................................................................................................................... 26
2.3.1 Cation probes............................................................................................................................................ 27
2.3.1.1 Transition metal probes...................................................................................................................................27
2.3.1.2 Alkali and alkaline earth metal ion probes.................................................................................................... 29
2.3.1.3 pH sensors......................................................................................................................................................... 36
2.3.2 Anion receptors........................................................................................................................................ 38
2.3.3 Sensing neutral species........................................................................................................................... 46
2 .4  M o lec ular  logic s y s t e m s ............................................................................................................................................55
OBJECTIVES OF THE PROJECT........................................................................................................... 57
3.1 Th e  o rg anic  d o n o r  -  ac cepto r  - q u en c h er  t r ia d ...........................................................................................58
3 .2  Th e  t r iad s w ith  eu ro pium  a n d  terbiu m  lu m o ph o r e s .................................................................................... 59
3.3 Th e  t r iad s w ith  n e o d y m iu m  a n d  ytter biu m  lu m o ph o r e s .......................................................................... 61
3 .4  Exc iplex  fo r  D N A  d e t e c t io n ..................................................................................................................................... 61
EXPERIMENTAL..........................................................................................................................................63
4.1 Organic t r ia d s .......................................................................................................................................................... 65
4.1.1 Triad synthesis with the 4-Amino-3-hydroxybutyric acid scaffold................................................. 65
4.1.1.1 N-Boc-4-amino-3-hydroxybutyric acid........................................................................................................65
4.1.1.2 N-Fmoc-4-amino-3-hydroxybutyric acid......................................................................................................66
4.1.1.3 Coupling NMA to N-Boc-4-amino-3-hydroxybutyric acid.........................................................................67
4.1.1.4 Removal of the Boc protection from 58...............................................................................................  68
4.1.1.5 Alkylation of N-methylaniline with chloroacetic acid....................  68
4.1.1.6 Alkylation of aniline with ethyl bromoacetate............................................................................................. 69
4.1.1.7 Alkylation of N-methylaniline with ethyl bromoacetate.............................................................................70
4.1.1.8 N-Boc-aminoethanol....................................................................................................................................... 70
4.1.1.9 Alkylation of NMA with 65 via the Mitsunobu reaction............................................................................71
4.1.1.10 Coupling N-Boc-glycine to coumarin 120............................................................................................... 72
4.1.1.11 Removal of the Boc protection from 6 9 .................................................................................................. 73
4.1.1.12 Coupling 70 to N-Boc-4-amino-3-hydroxybutyric acid......................................................................... 73
4.1.1.13 Removal of the Boc protection of 71........................................................................................................74
4.1.1.14 Coupling N-Boc-glycine to coumarin 151............................................................................................... 75
4.1.1.15 Removal of the Boc protection from 7 4 .................................................................................................. 75
4.1.1.16 Coupling 75 to 55 ....................................................................................................................................... 76
4.1.1.17 Removal of the Boc protection of 76........................................................................................................77
4.1.1.18 Coupling N-Boc-glycine to coumarin 2 ....................................................................................................78
4.1.1.19 DL-4-Amino-3-hydroxybutyric acid ethyl ester.......................................................................................79
4.1.1.20 DL-N-Boc-4-amino-3 -hydroxybutyric acid ethyl ester...........................................................................79
4.1.1.21 Coupling coumarin 343 to 80 ....................................................................................................................80
4.1.2 Triad synthesis with glutamic acid scaffold....................................................................................... 81
4.1.2.1 Coupling coumarin 120 to N-Fmoc-y-0-‘Bu glutamic acid........................................................................81
4.1.2.2 Removal of the Fmoc protecting group from 85.......................................................................................... 82
4.1.2.3 Coupling coumarin 343 to 8 6 .........................................................................................................................83
4.1.2.4 Removal o f the ‘Bu protection in 8 7 ..............................................................................................................85
4.1.2.5 Coupling 2’,3’-isopropylidene-5’-aminonucleotides to 8 8 .........................................................................86
4.1.2.6 Coupling coumarin 151 to N-Fmoc-y-O-'Bu glutamic acid........................................................................89
4.1.2.7 Removal of the Fmoc protecting group from 92.......................................................................................... 90
4.1.2.8 Coupling coumarin 343 to 9 3 ..........   91
2
4.1.2.9 Removal of the *Bu protection of 94 ............................................................................................................. 92
4.1.2.10 Coupling 2’,3’-isopropylidene-5’-aminonucleotides to 95....................................................................93
4.1.2.11 Coupling coumarin 2 to N-Fmoc-y-0-‘Bu glutamic acid....................................................................... 96
4.1.2.12 5’-Mesyl-2’3’-isopropylideneadenosine.................................................................................................. 97
4.1.2.13 5’-Azido-2’3’-isopropylideneadenosine.................................................................................................. 98
4.1.2.14 5’-Amino-2’3’-isopropylidene-adenosine............................................................................................... 99
4.1.2.15 2’,3 ’-Isopropylideneuridine..................................................................................................................... 100
4.1.2.16 5’-Mesyl-2’3’-isopropylideneuridine.....................................................................................................101
4.1.2.17 5’-Azido-2’3’-isopropylidene-uridine....................................................................................................102
4.1.2.18 5’-Amino-2’3’-isopropylidene-uridine...................................................................................................103
4.1.2.19 5’-Azido-2’3’-isopropylidene-guanosine...........................................   104
4.1.2.20 2’3’-Isopropylidene-cytidine................................................................................................................... 105
4.1.2.21 5’-Mesyl-2’,3’-isopropylidenecytidine...................................................................................................106
4.1.2.22 5’-Azido-2’,3’-isopropylidene-cytidine..................................................................................................107
4.2 L a n th a n id e  t r i a d s ................................................................................................................................................. 108
4.2.1 Lanthanide ligand synthesis from protected cyclen derivatives..................................................108 .
4.2.1.1 N^-Boc-cyclen-1,4-oxamide.........................................................................................................................108
4.2.1.2 Coupling NMA to chloroacetic acid with EDCI........................................................................................ 109
4.2.1.3 Alkylation of 113 with 114...........................................................................................................................109
4.2.1.4 Coupling coumarin 2 to chloroacetic acid..................................................................................................110
4.2.1.5 Coupling coumarin 2 to bromoacetic acid.................................................................................................. I l l
4.2.1.6 Coupling bromoacetic acid to coumarin 120..............................................................................................112
4.2.1.7 Coupling chloroacetic acid to N-Methyl-L-glucamine ........................................................................113
4.2.1.8 Coupling bromoacetic acid to N-Methyl-L-glucamine..............................................................................114
4.2.1.9 Alkylation of 113 with 116...........................................................................................................................115
4.2.1.10 Removal of the Boc protection 124........................................................................................................ 117
4.2.1.11 Alkylation of 113 with 119...................................................................................................................... 118
4.2.1.12 Removal of the Boc protection 127........................................................................................................ 119
4.2.1.13 Alkylation of 128 with N-Boc bromoethylamine................................................................................. 120 '
4.2.1.14 N-Boc Bromoethylamine......................................................................................................................... 121
4.2.1.15 N-Boc Ethanolamine methanesulphonate.............................................................................................. 121
4.2.1.16 Removal of the Boc protection from 129.............................................................................................. 122
4.2.1.17 Uridine-5 ’-carboxylic acid pentafluorophenyl ester............................................................................. 123
4.2.1.18 Coupling uridine-5’-carboxylic to bromethylamine............................................................................. 124
3
4.2.2 Ligand synthesis from unprotected cyclen........................................................................................ 125
4.2.2.1 Alkylation of cyclen with 119.......................................................................................................................125
4.2.2.2 Alkylation of 138 with ethyl bromoacetate................................................................................................126
4.2.2.B Alkylation of cyclen with 116.......................................................................................................................127
4.2.2.4 Alkylation of 140 with 2’,3’-isopropylidene-5’-0-Ms-uridine.................................................................128
4.2.2.5 Alkylation of 140 with 2’,3 ’-isopropylidene-5’-0-Ms-adenosine..........................................................129
4.2.2.6 Alkylation of 140 with ethyl bromoacetate................................................................................................. 130
4.2.2.7 Alkylation of 143 with N-Boc ethanolamine methanesulphonate............................................................ 133
4.2.2.8 Alkylation of 143 with 100........................................................................................................................... 134
4.2.2.9 Alkylation of 140 with N-Boc-bromoethylamine...................................................................................... 135
4.2.2.10 Alkylation of 148 with ethyl bromoacetate...........................................................................................136
4.2.2.11 Removal of the Boc protection from 146..............................................................................................137
4.2.2.12 Coupling 5’-carboxylic nucleotides to 149............................................................................................138
4.2.2.13 Complexation of europium with 150a and 150b..................................................................................140
4.2.2.14 Complexation of terbium with 150a and 150b..................................................................................... 141
4.2.2.15 Alkylation of cyclen with N-Boc bromoethylamine............................................................................ 142
4.2.2.16 Alkylation of 153 with coumarin 2 bromoacetate (117)...................................................................... 143
4.2.2.17 N-Fmoe Bromoethylamine..................................................................................................................... 143
4.2.2.18 Alkylation of cyclen with t-Butyl bromoacetate...................................................................................144
4.2.2.19 Alkylation of 151 with tBu bromoacetate..............................................................................................145
4.2.2.20 Alkylation of 156 with ethyl bromoacetate.......................................................................................... 146
4.2.2.21 Removal of the Boc protection from 157..............................................................................................147
4.2.2.22 Attachment of adenosine to the 158...................................................................................................... 148
4.2.2.23 Removal of the tBu protection from 159...............................................................................................149
4.2.2.24 Attachment of rhodamine B to 147.........................................................................................................150
4.2.2.25 Complexation of neodymium with 161................................................................................................. 151
4.2.2.26 Complexation of ytterbium with 161..................................................................................................... 152
4.2.2.27 Reaction of bromoethylamine with rhodamine.B .................................................................................153
4.2.2.28 Alkylation of cyclen with 165................................................................................................................ 154
4.2.2.29 Alkylation of 166 with N-Boc bromoethylamine.........................   155
4.2.2.30 Alkylation of 167 with ethyl bromoacetate..........................................................   156
4.2.2.31 Removal of the Boc protection from 168..............................................................................................157
4.2.2.32 Attachment of 5’-COOH-nucleosides to 170........................................................................................ 158
4.2.2.33 Complexation of neodymium with 171a and 171b...............................................................................160
4
4.2.2.34 Complexation of ytterbium with 171a and 171b.................................................................................161
5 RESULTS AND DISCUSSION................................................................................................................. 163
5.1 Syn th esis  of the co u m a r in  343 ac cepto r -co n t a in in g  t r ia d s ................................................................163
5.1.1 Functionalising the 4-amino-3-hydroxyhutyric acid........................................................................163
5.1.1.1 Amide bond formation between the coumarin 2 donor and the carboxylic acid of the scaffold 
molecule 163
5.1.1.2 Protection of the 3-hydroxyl of HBA..........................................................................................................167
5.1.2 Amide bondformation between coumarin 2 and haloacetic acids................................................ 170
5.1.3 Alkylation o f the secondary amine o f coumarin 2 ............................................................................ 171
5.1.4 Attachment o f the donor through a glycine linker............................................................................ 173
5.1.5 The coumarin 120 and coumarin 151 donors.................................................................................... 174
5.1.6 Synthesis o f the organic triad held together by a glutamic acid scaffold..................................... 176
5.1.7 Synthesis o f the 5 ’-aminonucleosides..................................................................................................178
5.1.8 Synthesis o f the triads.............................................................................................................................129
5.1.9 Coumarin 151 donor..............................................................................................................................180
5.2  Ch a ra cter isatio n  of the  org anic  t r ia d s .........................................................................................................183
5.2.1 Organic diads.......................................................................................................................................... 185
5.3 Org an ic  t r ia d s  a n d  co m plem entar y  b a s e s ..................................................................................................... 190
5.3.1 Coumarin 120 donor and uridine quencher.......................................................................................190
5.3.2 Coumarin 120 donor and adenosine quencher................................................................................. 191
5.3.3 Coumarin 151 donor and uridine quencher ............................................................................193
5.3.4 Coumarin 151 donor and adenosine quencher................................................................................. 195
5.4  O r g anic  tr ia d s a n d  D N A ............................................................................................................................................ 197
5.4.1 Coumarin 120 donor..............................................................................................................................197
5.4.2 Coumarin 151 donor..............................................................................................................................197
5.5 Ste r n -V o lm er  c o n sta n ts  fo r  the q uen ch ing  of the  t r ia d s .................................................................. 199
5.6 D eter m in atio n  of t of the o rg anic  d ia d s  a n d  t r i a d s ............................................................................... 201
5.7 La n t h a n id e  l ig a n d s ...............................................................................  205
5.7.1 Attachment o f the coumarin 2 antenna to the cyclen........................................................................206
5.7.2 Cyclen derivatisation starting from the bis-protected cyclen-oxalamide..................................... 207
5
5.7.2.1 Sequential synthesis of the asymmetric trisubstituted cyclen.................................................................. 209
5.12.2  Sequential synthesis of the asymmetric ligand..:.......................................................................................214
5.7.2.3 Complexation of 150a and 150b with europium and terbium..................................................................218
5.8 D eter m in atio n  of the  h y d r a t io n  state  of the Eu  a n d  Tb  c o m p l e x e s ............................................219
5 .9  Lu m in esc en t  PROPERTIES of t h e E u  a n d  Tb  c o m ple x e s ..............................................................................221
5.9.1 Europium complexes............................................................................................................................. 221
5.9.1.1 Changes in the luminescence intensity.......................................................................................................221
5.9.1.2 Changes in the luminescent lifetime........................................................................................................... 222
5.9.2 Terbium complexes.................................................................................................................................223
5.9.2.1 Changes in the luminescence intensity.......................................................................................................223
5.9.2.2 Changes in the luminescent lifetime........................................................................................................... 225
5.10 LANTHANIDE TRIADS AND D N A  ..........................................................................  226
5.10.1 Europium complexes............................................................................................................................. 226
5.10.1.1 Changes in luminescence intensity........................................................................................................226
5.10.1.2 Changes in luminescent lifetime............................................................................................................ 227
5.10.2 Terbium complexes.................................................................................................................................228
5.10.2.1 Changes in luminescence intensity........................................................................................................228
5.10.2.2 Changes in luminescence lifetime.........................................................................................................228
5.11 S t e r n - V o lm e r  c o n s t a n t s  f o r  t h e  q u e n c h in g  o f  t h e  c o m p le x e s .............................................23 0
5.12 L a n th a n id e  l i g a n d s  e m it t in g  in  t h e  n e a r  in f r a r e d  r e g i o n ............................................................232
5.12.1 Synthesis o f the ligand with rhodamine B donor.............................................................................. 232
5.12.2 Synthesis o f the ligand with coumarin 2 and rhodamine B donors...............................................234
5.12.3 Synthesis o f the Nd and Yb complexes....................................................................  235
5.12.4 Photophysical properties o f the near IR-emitting complexes........................................................ 236
5.12.4.1 Nd and Yb complexes of the exciplex 161.......................................................................................... 237
5.12.4.2 Emission of the Nd and Yb complexes of 171a and b......................................................................... 239
5.12.4.3 Luminescent lifetimes of the near IR-emitter complexes....................................................................243
5.13 NMR TITRATIONS.........................................................................................................................................................246
5.13.1 Organic triads........................................................................................................................................ 247
5.13.2 Lanthanide ligands................................................................................................................................ 248
CONCLUSIONS AND FUTURE WORK................................................................................................251
6
LABELLING APTAMERS WITH RADIONUCLIDES..................................................................... 254
7.1 In t r o d u c t io n ................................................................................................................................................................... 254
7.1.1 Aptamers................................................................................................................................................ 254
7.1.2 Labelling of biomolecules...................................................................................................................257
7.1.2.1 Radioactive labelling of M UCl...................................................................................................................258
7.1.2.2 Bifunctional ligands for the complexation of technetium and rhenium..................................................262
7.2 Ex p e r im e n t a l ..................................................................................................................................................................265
7.2.1 Ligand synthesis for aptamer labelling.............................................................................................. 266
7.2.1.1 DL-Methionine-ethyl ester chloroamide.....................................................................................................266
7.2.1.2 Alkylation of tri-Boc-cyclen with 177........................................................................................................ 266
7.2.1.3 Removal of the ethyl ester protection from 179......................................................................................... 267
7.2.1.4 Removal of the Boc protecting groups from 180....................................................................................... 268
7.2.1.5 Alkylation of cyclen with 177.......................................................................................................................269
7.2.1.6 Removal of the ethyl ester protection from 182......................................................................................... 270
7.2.2 Complexation with Tc and Re and bioconjugation..........................................................................270
7.2.2.1 Synthesis of the technetium complex of 181.............................................................................................. 270
1.2.2.2 Synthesis of the rhenium complex of 181....................................................................................................271
1.2.2.3 Attaehment of 183 to the modified aptamer................................................................................................ 272
7.3 Resu lt s  a n d  d isc u s sio n .............................................................................................................................................. 273
7.3.1 Ligand synthesis......................................................................................................................................273
7.3.1.1 Ligand synthesis starting with protected cyclen derivatives.....................................................................273
7.3.2 Synthesis o f 181 from unprotected cyclen...............................................................................................275
7.3.3 Complexation o f 181 with technetium and rhenium..........................................................................276
7.3.4 Synthesis o f the radiometal-labelled aptamers.................................................................................277
7.4  Co n c l u s io n s ........................................................................................................................................................   281
REFERENCES............................................................................................................................................. 282
1 L ist of abbreviatio ns
A adenine
A acceptor
A absorption
Ac acetyl
AcN acetonitrile
AU arbitratry units
B any nucleoside base
bipy bipyridyl
Boo tert-butoxy carbonyl
c 120 coumarin 120 (4-methyl-7-aminocoumarin)
c2 coumarin 2 (4,6-dimethyl-7-(N-ethyl)-aminocoumarin)
c343 coumarin 343
CO. concentrated
CE catechol estrogens
CHEQ chelation enhanced quenching
ops counts per second
Cys Cysteine
D Donor
dA deoxyadenosine
dC deoxycytidine
DOG dicyclohexylcarbodiimide
DOM dichloromethane
DEAD diethyl azodicarboxylate
dG deoxyguanosine
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DIAD diisopropyl azodicarboxylate
DMAP A/-dimethylaminopyridine
DMF dimethylformamide
DMSO dimethyl sulphoxide
DNA deoxyribonucleic acid
dsDNA double stranded DMAs
dT deoxythymidine
EDCI 1 -(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
eq equivalent
ES electrospray
Et Ethyl
EtOAc ethyl acetate
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Glu glutamic acid
Gly Glycine
H Host
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HG host-guest complex
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1C internal conversion
IR infrared
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K equilibrium constant
Ln lanthanide
m m ass
MB molecular beacon
MLCT metal to ligand charge transfer
MOPS 3-(A/-morpholino)propanesulfonic acid
mp melting point
MS m ass spectrometry
MW molecular weight
NMA N-methylaniline
NMR nuclear magnetic resonance
PET photoinduced electron transfer
PFP pentafluorophenyl
Ph phenyl
PyBOP (benzotriazol-1 -yloxy)tripyrrolidinophosphonium
hexafluorophosphate 
Q quencher
q num ber of associated water molecules
RET resonance energy transfer
Rho rhodamine B
SBFI sodium-binding benzofuran isophthalate
SBFP sodium-binding benzofuran phthalate
Sn n*^  singlet excited state
ssDNA single stranded DNA
T Temperature
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TLC
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Time
tetrabutylammonium fluoride
Triethylamine
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thin layer chromatography
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quantum yield
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excitation wavelength
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2 Introductio n
Understanding the molecular basics of recognition events in chemistry, biology 
and materials science is crucial for a wide range of disciplines, for example 
medicine, pharmacology, or information technology. In order to gather 
information on these  processes, suitably designed reporter molecules are 
essential. Luminescence is a particularly appealing way of obtaining information 
on molecular-scale processes, a s  highly sensitive, real-time detection, 
combined with subnanom eter spatial resolution is achievable.
The aim of the project is to design and synthesise luminescent molecules that 
are capable of binding to target molecules and can signal the binding event in 
complex media (for example biological samples).
2.1 Recognition
In 1894 Emil Fisher introduced the ‘lock and key' concept of molecular 
recognition.^ He suggested, that the host molecules p o ssess  rigid 
complementary structures (lock) into which the guests (key) can fit perfectly. 
The theory w as modified by Koshland^ and Cram in the ‘induced fit’ model,^ 
who assum ed that a certain preorganisation is essential for the binding to take 
place, but the host (H) can rearrange slightly in order to better accom m odate 
the guest (G) (Figure 1).
12
1Figure 1. Recognition between the host (H) and the guest (G) can be described by the induced 
fit modei. A levei of pre-organisation is required, but both H and G can change their shapes 
during the binding to make the interaction stronger.
2.1.1 Recognition in nature
Nature provides innumerable exam ples for recognition events. These include 
for example enzym e-substrate interactions, DNA double helix formation, nucleic 
acid binding by DNA-binding proteins for several purposes (DNA-duplication, 
gene expression)"^ or antigen recognition by antibodies (which is basically 
proteins complexing other proteins, carbohydrates, lipids and nucleic acids).® 
The information on binding events between cells and viruses, bacteria or other 
cells is scarce but from data already available it seem s likely, that protein-sugar 
and sugar-sugar interactions play important roles.® These processes have been 
monitored by various techniques such as  X-ray crystallography, NMR, UV-Vis 
and fluorescence spectroscopy, m ass spectrometry, which have provided 
valuable information on the nature of the recognition and binding in biological 
system s.
2.1.2 Recognition in chemistry
The subject of supram olecular chemistry is the formation and fate of 
architectures built from small, stable moieties that are held together by forces
13
that are w eaker than covalent bonds. The formation of these architectures can 
usually be described a s  a ‘host’ incorporating a ‘guest’, although there are 
ca ses  when this is not true. For the ‘host-guest’ interaction to be favourable (i.e. 
to have the host H + G HG equilibrium to the right) the free energy of the 
reaction forming the HG has to be negative.
Host-guest system s have been used for several different purposes. Apart from 
modelling biological processes, they have found application in sensors for 
biologically or environmentally important species such as  dissolved oxygen,  ^
metal ions® or DNA.® Sensors are devices that signal the p resence of a 
molecule or ion by a specific signal. The signalling can take place for exam ple 
by a change in their electrochemical, lum inescence or NMR properties. S ensors 
usually contain a recognition unit to bind the target and a reporter unit to enable 
the monitoring of the event (Figure 2).
SignalT arget binding
ReporterSpacerR eceptor
Figure 2. A general sensor, containing a recognition unit and a reporter unit. Although 
sometimes missing, the spacer can play an important role by isolating the two functional units. 
This enables quantitative estimation of crucial sensor parameters, such as binding constants in
the ground and excited states.
Molecules that are capable of emitting light upon certain stimuli (for exam ple 
thermal- or photoexcitation, interaction with other molecules) are convenient 
m eans of monitoring events that take place on the molecular level.
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Luminescence and in particular fluorescence has increasingly been applied for 
the detection of recognition phenom ena. Although in a number of ca se s  it has 
proved superior to the more established techniques (for example radiolabelling, 
colorimetry, NMR), fluorescence sensing poses difficult questions. Despite the 
exam ples of single molecule detection, ® in complex biological media sensitivity 
can be significantly reduced. One of the reasons is autofluorescence of the 
medium, caused by the presence of luminescent species, for example DNA, 
RNA, fluorescent proteins and porphyrin-containing molecules, like 
haemoglobin. Also, the lum inescence intensity of the probes can be affected by 
quenching, caused by solutes in the medium, for example dioxygen or halides. 
In som e cases  it is possible to reduce the quenching, by removal of the oxygen 
by degassing, or by cooling the sam ple to decrease  the diffusion rates of the 
quenchers. Many fluorophores are pH-sensitive, and protonation or d e ­
protonation can change the fluorescent quantum yields significantly.
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2.2 Fluorescence
Luminescence is the emission of photons from electronically excited states.®’^ ® 
Depending on the timescale, lum inescence phenom ena can be divided into two 
major groups, (a) In a singlet excited state the electron in the higher-energy 
orbital is paired up with the second electron in the lower orbital (i.e. they have 
spins of opposite orientation). Returning from the excited sta te  to the ground 
sta te  is symmetry-allowed and the rates of emission are typically 10® s '\  Such a 
transition is called fluorescence, (b) If emission between states o f different 
multiplicity takes place, i.e. the electrons have the sam e spin, return from the 
triplet excited state  to the ground state requires an electron to change 
orientation. This type of transition is called phosphorescence. Phosphorescence 
is spin-forbidden, and as  a consequence phosphorescence lifetimes are on the 
millisecond-second timescale.
Absorption and emission of light can be illustrated using the Jablonski diagram 
{Figure 3). The ground state  and the first and second excited sta tes  are So, Si, 
and 82, respectively. Transitions between electronic energy levels are 
considered instantaneous (femtosecond scale).
ISC
pitosph 0 rescence
Figure 3. The Jablonski diagram .After absorption of a photon the excited fiuorophore can 
undergo a series of events. iSC: intersystem crossing
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After absorption of a photon the fiuorophore can undergo a series of processes. 
If the molecule is excited to one of the higher vibrational levels of the excited 
electronic sta tes (v=  1, 2 ...), it may relax back to the lowest vibrational level (v 
= 0) of the first excited state  (Si). In a condensed phase this is the case  almost 
without exception. From Si the fiuorophore can get back to So by emission of a 
photon (fluorescence). Intersystem crossing (ISC) between Si and Ti (the 
singlet and triplet first excited states) is also a possibility. The Ti->Sq transition 
(phosphorescence) is spin-forbidden and takes place at a considerably slower 
rate than fluorescence. Several other factors can influence the main processes 
(for example solvent effects, quenching, solvent relaxation, excited state  
reaction).®
The efficiency of the fluorescence can be described by the fluorescence 
quantum yield ((%). The quantum yield is the ratio of the excited molecules that 
return to So by emitting a photon by fluorescence and the num ber of the 
molecules in the excited sta te  {Eq 1).
= T s ~ lT  = ^kr • ^5 Eq1Kj.
is the radiative deactivation with emission of fluorescence, is the overall 
non-radiative constant, and is the lifetime of the Si excited state. consists 
of two terms, the rate constant for the Si-^Sq internal conversion {kf^), and the 
rate constant of intersystem crossing {kf^c)- The lifetime of the Si excited state, 
Ts is given by Eq 2.
1
To —
k ! + k i
17
Fluorescence spectra are represented as  the fluorescence emission intensity 
plotted versus wavelength (nm) or wavenum ber (cm’^ ). Emissions are observed 
at longer wavelengths than the excitation wavelengths, as  a loss of energy is 
inevitable. The energy difference between the absorption maximum and the 
emission maximum is called the Stokes shift. There are several factors that 
influence the magnitude of the Stokes shift. Som e exam ples are relaxation from 
higher vibrational sta tes to the lowest vibronic state, excited state reactions, and 
solvent effects.
As the sam e transitions are involved in both absorption and emission, 
fluorescence emission spectra often resem ble the mirror im ages of the 
absorption spectra. Deviations are numerous, and are usually indicators of a 
difference in the arrangem ent of the nuclei in the ground and the excited states, 
or excited state reactions.
2 .2 . 1 Photoinduced electron transfer
Photoinduced electron transfer (PET) is a process that is often responsible for 
quenching of the fluorescence. PET can take place if:
1. the excited fiuorophore (A*) can receive an electron from an electron-rich 
quencher (D). This is called a reductive electron transfer {Figure 4a).
2 . the excited fiuorophore (D*) can donate an electron to an electron-poor 
quencher (A). This is called an oxidative electron transfer {Figure 4b).
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excited electron-rich reduced oxidised swelled cm d i#d  reduged
fiuorophore quencher fiuorophore quencher fiu s fip te re  fiusroptore qusncw r
4a 4b
Figure 4.® PET 4a, reductive eiectron transfer. 4b, oxidative electron transfer. PET is involved in 
many photochemical reactions. Many artificial fluorescent sensors exploit PET, the binding of 
the target to the receptor enabling the ‘switching on’ or ‘switching off’ of the eiectron transfer 
procedure, and thus the ‘switching off’ or ‘switching on’ of the fluorescence.
2.2.2 Resonance energy transfer
The excitation energy of a fiuorophore (donor) can be transferred to a suitable 
acceptor if there is sufficient interaction between the two molecules. The energy 
transfer can occur if the absorption spectrum of the acceptor (A) overlaps the 
emission spectrum of the donor (D). This m eans that there are a num ber of 
vibronic transitions in the donor, which have almost the sam e energy as  
corresponding transitions of the acceptor. The term Resonance Energy Transfer 
(RET) is often used to describe the phenomenon, as  such transitions are in 
resonance.
The interaction between the D and the A can be Coulombic, or due to 
intermolecular orbital overlap. The former consists of both long-range dipole- 
dipole interactions and short-range multipolar interactions, while the latter 
obviously can only be of short range. Long-range non-radiative transfers take 
place according to Forster’s m e c h a n i s m . T h e  transfer rate constant is 
dependent on the sixth power of the reciprocal of the distance betw een the 
donor and the acceptor. Short-range transfers can be described by Dexter’s
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m e c h a n i s m . T h e  rate constant displays exponential dependence from the 
distance of the donor and the acceptor.
RET has been applied for the m easurem ent of distances between biologically 
important molecules. This ‘spectroscopic ruler’ is useful in the 10-100 A range. 
Appropriately labelled pairs of biomolecules can display RET if they are close 
enough to each other, thus revealing the existence of association-dissociation 
processes, their dynamics, or enabling for example the determination of 
m em brane thickness.^"^ {Figure 5)
RET
f
excitation emission
Cell m em brane  i
Ion channel
Figure 5. Using RET for monitoring biological processes. The donor (D) and the acceptor (A) 
have to be dose enough (approximately 80-100 A) for RET to take place. A decrease in the A 
emission intensity reveals an increase in the D-A distance, in this case the opening of the ion
channel.^ '*
Another useful property of RET is the ‘red-shift’ caused in the emission 
spectrum, which m eans that for example in fluorescent biological media the 
emission maximum of interest can be far away from the maximum of the 
background fluorescence.
The energy of the acceptor can be transferred to a non-luminescent acceptor a s  
well as  a luminescent one. This has been exploited in the detection of specific
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oligonucleotide sequences by molecular beacons MBs are single­
stranded oligonucleotides with a D and a quencher (acceptor) attached to the 3’ 
and 5’ ends. In the absence of the target the beacon adopts a conformation 
which brings the D and the A close to each other. Initially the donor emission is 
quenched, and the beacon remains dark. Hybridization with the target sequence 
forces the ends of the beacon apart, energy transfer becom es impossible, and 
the beacon emits light. MBs have been used for example to detect nucleic acids 
in hom ogeneous assays, and the real-time monitoring of DNA-RNA 
hybridization in living cells.^® Tyagi et al. have synthesised wavelength-shifting 
MBs.^^ The donor can transfer its energy to two acceptors, a non-luminescent 
and a luminescent one. If the MB is unhybridized, RET to the quencher is 
preferred and the beacon is non-luminescent. In the presence of the target the 
quencher is removed and upon donor excitation, emission from the luminescent 
acceptor is seen  (Figure 6).
donor
excitation O donorexcitation
Target
Figure 6. The principle of the wavelength-shifting molecular beacons. Hybridization removes the 
quencher from the donor’s proximity, making RET from the donor to the luminescent acceptor
possible.
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2.2.3 Fluorophores in luminescent probes 
2.2.3.7 Organic fluorophores
Organic com pounds with delocalised double bonds are the m ost commonly 
used fluorophores, because the HOMOs and LUMOs of these  molecules are 
divided by relatively small energy gaps, and excitation can be achieved by UV 
or visible light. Similarly, the emitted light is in the UV-Vis region, making the 
detection convenient. Som e exam ples are quinine, porphyrins, coumarins, 
rhodamines and eosin (Figure 7).
NEt
HOOC.
NaOOC
NO.
ONa
Br Br
7-Acetoxycoumarin-3- 
carboxylic acid
rhodamine B eosin B
OH
HO
OH
HO
CH3O
H2O
2HCI
O
Haematoporphyrin quinine dihydrochloride monohydrate
Figure 7. Widely used organic fiuorophores.
2.2.3.2 Luminescent transition metal complexes
Several complexes of the metals of the d-block have luminescence, and many 
have been used a s  reporters in luminescent probes. The rhodium(ll) complex 
Rh(bipy)3^ '" has emission maxima around 590 nm and 645 nm, while
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Ru(bipy)2Cl2^  emits light at 710 nm. Both Pt(IV) and Ir(lll) have luminescent 
complexes, but can easily undergo redox reactions, which reduces the stability 
and the quantum yield of the complexes. The Pd(IV) analogues of platinum are 
usually too unstable to be used a s  fluorophores.^®
2 .2 3 .3  Luminescent lanthanide complexes
Lanthanide ions, for example europium(lll) and terbium(lll) have long-lived 
luminescence, and sharp, line-like emission spectra, which m akes signal 
detection easy. Europium emission is > 550 nm, while terbium emits at 
wavelengths > 450 nm.^^
To obtain a suitably luminescent compound, the lanthanide central ion has to be 
sensitised by a strongly absorbing antenna species, that can transfer its energy 
efficiently to the metal. Lanthanides have low absorption coefficients, as  the f-f 
transitions corresponding to the absorption are parity forbidden. The antenna 
overcom es this by channelling its energy from the lowest lying triplet state. This 
triplet state has to be approximately 1000-2000 cm'^ above the emitting s ta te  of 
the lanthanide. It is also necessary  for the antenna to be physically close to the 
metal, to make the sensitization efficient, as  the energy transfer is distance- 
dependent. The antenna triplet state  can also be quenched by other species 
present, oxygen for example, and this competing reaction is also minimised if 
the m etal-antenna distance is short.
It is important to saturate the co-ordination sphere of the metal to stabilise the 
complex and to reduce quenching of the lum inescence by nearby 0-H, N-H or 
C-H oscillators. This can be done either by providing sufficient num bers of
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carbonyl and tertiary amino donors, or by replacem ent of the hydrogens for 
deuterium atoms, or for fluorine/®
2.2.3.4 Near IR-emitting lanthanide complexes
In general, complexes with europium and terbium central ions are well 
established, and there are exam ples of their use in fluoroimmumoassays and 
fluorescence microscopy. Less work has been done on complexes with near-IR 
emitting lanthanides ytterbium and neodymium. These are of particular interest 
for medical imaging purposes. Luminescence detection in vivo is complicated in 
many cases  by excitation wavelengths < 340 nm, at which wavelength many 
natural species absorb. For europium and terbium complexes aromatic 
an tennae with absorption maxima at 320-360 nm are used. If europium and 
terbium are replaced with the near-IR emitting Nd or Yb, sensitising can be 
achieved by metal complexes or organic molecules absorbing at ~ 500 nm. As 
human tissue becom es more transparent on increasing of the wavelength, it is 
easy  to se e  the advantages of using near-IR emitters for medical imaging. 
Efficient sensitisation of neodymium and ytterbium has been possible with a 
number of antennae. Purely organic materials, like fluorescein, eosin or 
fluorexon^ have been successfully used. They all have absorption maxima 
around 500 nm, and in many cases  several differently functionalised derivatives 
are available, which facilitates the ligand synthesis.
When luminescent metal complexes are used as  antenna chromophores, the 
sensitising metal is usually a d-block element, as  it is synthetically more difficult
^ fluorexon: Bis[A/,A/-bis(carboxymethyl)aminoethyl]fluorescein
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to produce f-f bimetallic complexes. There are exam ples of porphyrin-palladium 
complexes being used a s  antennae, and a terpyridyl complex of platinum has 
been applied for the sensitisation of neodymium.
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2.3 Sensors
Depending on the target, sensors can be categorised as  recognising (a) 
cations, (b) anions, and (c) neutral species. The most abundant exam ples are 
those of cation recognition a s  cations are generally spherical. Therefore the 
host can be constructed by considering only the size of the ion (the radius of the 
sphere) and the charge density. Anions can possess  a wide range of structures 
(for example spherical -  F', trigonal -  COs^', tetrahedral -  S O /') ,  and in solution 
can display pH-dependent spéciation (for example HCO3' and C03 '^). When 
designing a probe for a given anion, both of these  have to be taken into 
account. Also, anions usually have high free energies of hydration (for example 
-1315 kJ m ol'\ C03 '^: -3 3 5  kJ mol"\ HCO3'; -465 kJ m ol'\ F'),^^ making the 
construction of artificial receptors applicable in aqueous media difficult.
The development of efficient fluorescent sensors for biological applications is 
complicated because of the large differences in the concentration of the sam e 
species in various cell types and thus the need for a linear response for a 
concentration range of several orders of magnitude. Useful probes for 
intracellular metal ion m easurem ents would impose strict rules upon the 
properties of the sensor molecules. Apart from high selectivity for the ion in 
question in the presence of other metal ions it would have to:
1. be water soluble
2 . have dissociation constants in the concentration ranges of the metal ions to 
be m easured
3. have a change in fluorescence upon chelation with the ion
4. have excitation wavelength > 340 nm to avoid excitation of aromatic amino 
acids and DNA and the usage of quartz optics
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5. have emission wavelengths > 500 nm to exclude autofluorescence
6 . have fast response time, preferably on the millisecond time scale
7. be able to operate under cellular conditions (pH, toxicity, stability).
2.3 .1 Cation probes
There are several fluorescent probes for all of the alkaline and alkaline earth 
metals^®'®  ^except for magnesium, but only a few exist for som e of the transition 
metals (for example zinc, copper(ll) or mercury(ll) ®^). This is mainly 
because  while ions of the first and second group are spherical, possessing one 
or two positive charges (but only one of them), transition metals can have 
several oxidation sta tes and are able to form complexes of various geom etries.
2.3.7.7 Transition metal probes
Tsien and co-workers constructed the fluorescent Zn^ "" sensors Zinpyr-1 (1) and 
Zinpyr-2 (2).^^’^® The molecules absorb and emit in the UV-visible region, have 
high quantum yields ( ^  = -0 .9 ) and low dissociation constants (> 1 nM). The 
sensors utilise fluorescein a s  a reporter and three to five-fold fluorescence 
enhancem ents were observed upon Zn^'"-binding. Photoinduced electron 
transfer from the alkyl nitrogens can quench the fluorescence of the fluorescein 
reporter. As the PET can be suppressed  both by the complexation of zinc and 
protonation of the alkyl nitrogens, the probes were pH-responsive a s  well as  
zinc-responsive.
Another fluorescein-based Zn^^ sensor w as constructed by Hirano et al}^  ACF- 
2 (3) can be excited with visible light and shows -24-fold fluorescent intensity 
enhancem ent upon addition of 5 i^M Zn^^. Most biologically important metal ions
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induced < 20% fluorescence enhancem ent, the only exception being Cd^^, with 
a six-fold fluorescence enhancem ent. No data were available for competition 
with protons (all m easurem ents were performed at pH 7.5), but the aniline-type 
nitrogen is expected to have a lower pKa value than the nitrogen next to the 
chromophore in Zinpyr, consequently being less available for protonation.
— N N —
HO
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The fluorescent probe 4 exploits chelation enhanced quenching (CHEQ) of 
fluorescence caused by the incorporation of transition metal ions^®. 4 is 
sensitive to two transition metal ions, Hg(ll) and Cu(ll). Titrations showed 
eighteen-fold and four-fold overall emission changes with Hg(ll) and Cu(ll) 
respectively. The authors explained the differences in the observed CHEQ by 
proposing different binding m odes for Cu(ll) and Hg(ll). According to their 
suggestion Cu(ll) binds to the four amino groups solely, a s  both 4 and its open- 
chained analogue displayed similar affinities for Cu(ll). Hg(ll) forms the complex 
with the two nitrogens adjacent to the anthracene and also interacts strongly 
with the aromatic rings as  shown in 4a. This idea w as supported by the 
observations in the UV-Vis spectrum of the anthracene. The absorption peak of 
the anthracene at 368 nm changed upon addition of Hg(ll), resulting in complete 
loss when ~3 equivalents of metal ion were added.
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Shen and Sullivan^® have synthesised a series of polypyridine-based rhenium
complexes for applications in luminescent sensing of pH, anions, and cations. 
Treatm ent of the lead-responsive complex 5 in methanolic solution with 
Pb(0 Ac)2 results in 270% increase in integrated intensity and ~20 nm red shift 
in the emission maximum. The sam e complex showed only m oderate red shifts 
and only 25% emission intensity increase upon addition of large (fifty-fold) 
excess of barium. The emission of the zinc analogue of 5a in acetonitrile is red- 
shifted to -6 0 0  nm, and protonation of the lone pair results in quenching of the 
fluorescence.
OC^Re
5 R = H, 5a R = NMe2
2.3.1.2 Alkali and alkaline earth metal ion probes
The detection of alkaline and alkaline earth metal ion in cells, blood sam ples 
and urine is of major importance, because deviations from the normal 
concentrations can be indicators of pathological conditions.
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So far results on the development of fluorescent probes for Na"^ , potassium, Li^ , 
Os'" and Ca^^ have been reported. Although ^®F-NMR detection of Mg^ "" in cells 
has been possible for a long time, and it is possible to estim ate the 
mitochondrial magnesium concentration with luminescent probes,^^ selective 
fluorescent magnesium probes are currently unavailable.
The lariat ether derivative 6 contains two pyrene ring reporters^®. Upon 
complexation with alkaline earth metal ions the exciplex emission (Imax = 480 
nm) attributed to the intramolecular n-n  stacking of the rings decreases, and the 
monomer emission (Imax = 395 nm) increases dramatically. The spectral 
change is ascribed to the co-operative binding of the metal ion by the crown 
ether moiety and one of the sidearms. Alkali metal ions (LF, Na^, K )^ did not 
induce changes in the emission spectra. Stability constants (log K) in 
acetonitrile : chloroform (99:1) for 1:1 complexes 6 :Ca^^, 6 :Sr^^, 6 :Ba^^ were 
determined to be 7.6, 6.8 and 6.9 respectively, the sensor showing size 
selectivity towards Ca^^ and Sr^^ in the presence of seven other alkali or 
alkaline earth metal ions.
6
Tsien and co-workers have synthesised a series of calcium-responsive 
fluorescent probes to determine the physiological role of cytosolic free 
calcium.^® The sensors indo-1 (7) and fura-2 (8) contain 8-coordinate 
tetracarboxylate binding sites and stilbene-type chromophores. The double
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bond of the stilbene is rig id if led by incorporation into a heterocycle. The 
absorption maximum for the free ligand fura-2 is at 362 nm and this is shifted 
by complexation with to 355 nm. Similar results were obtained for indo-1. 
Both the free and the complexed species have bright fluorescent emissions, 
fura-2 having an emission wavelength maximum at 512 nm for the free anion 
and 505 nm for the calcium complex. However, the wavelength shift induced by 
the metal binding is not significant. The quantum yields for the free and the 
complexed indo-1 are 0.38 and 0.56, respectively, while for fura-2 th ese  values 
are 0.23 and 0.49. Apparent dissociation constants determined in aqueous 
solutions containing physiological concentrations of Na^, K ,^ and Mg^ "^  w ere 250 
nM for indo-1 and 224 nM for fura-2. Competition experiments with fura-2 
indicated that the absorption and emission spectrum of the complexed ligand 
changed only slightly unless in the presence of a very large excess  of 
magnesium ions.
CH3
NH
CH.
COO- 000-
indo-1 fura-2
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Blackburn et al. sought a water-soluble extraction agent and lithium-responsive
indicator. The monoaza-crown ether 9 responds to complexation with lithium by 
shifting the emission maximum to shorter wavelengths (from 485 nm to 462 
nm).^° The fluorescence quantum yield of the complex ((% = 0.04) is greater
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than the uncomplexed azacrown ether. The nitrogen next to the aromatic ring is 
less basic than alkyl-substituted nitrogen atom s in general, which minimises 
interference with protons. Complexation m easurem ents were carried out in 
acetonitrile, and there w as no indication of competition by other alkaline metal 
ions. The poor quantum yield is the major drawback of the probe.
■OMe
COOEt
9
Smith et al. have described an early example of a sodium probe, FCryp-1.^^ 
The cryptand w as designed to m easure the concentration of intracellular free 
sodium using ^®F-NMR. The ligand contained four carboxylate groups, m asked 
by estérification, which helped the transfer of the sensor through the cell 
m em branes. Once inside, the e s te rases  cleaved the ester groups, rendering the 
molecule sufficiently water-soluble (up to 10 mM). Incorporation of a 
chromophore provided the fluorescent sensor Fcryp-2 (10).^^ The free molecule 
has emission maximum at 460 nm, which is shifted to 395 nm when sodium is 
added. The quantum yield of the complex in aqueous solution (pH 7.0, 37 °G, 
100 mM KOI) is higher than 0.7. The emission wavelength is too short for 
general applications, but Fcryp-2 proved to be a useful tool for Na’*' 
m easurem ents for cells that do not autofluorescence strongly at 395-450 nm 
(e.g. lymphocytes and fibroblasts). The cryptand forms a 1:1 complex with 
sodium, and the dissociation constant is -6  mM. The affinity of the sen so r
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towards potassium w as too low to be determined, and the p resence of 
biologically relevant concentrations of Ca^^ and did not affect the
absorption or emission spectra.
COOH
COOH
/ — COOH
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Minta and Tsien^^ synthesised a series of compounds to obtain a fluorescent 
sodium indicator applicable to m easurem ents of cytosolic free sodium. Several 
reporter and binding units were tested, until the authors finally settled with 
sodium-binding benzofuran isophthalate (SBFI) (11). SBFI contains two 
benzofuran fluorophores linked to isophthalate groups. The selectivity of SBFI 
for sodium over potassium was determined to be ~20. The effective dissociation 
constant (against the background of -1 2 0  mM K )^ w as approximately 20 nM. In 
order to determine the applicability of the sensors for biological conditions, a 
series of stability m easurem ents w as carried out. At pH 7.05, both in mixtures of 
Na"" and K"", and solutions containing [K'*^ ]+[Na'"] = 135 mM and Mg^^ at 
concentrations reasonable for vertebrate cytoplasm, Ka values were m easured 
to be 17-19 mM. The fluorescence quantum yields are 0.08 and 0.045 with and 
without Na^, respectively. Sodium binding shifts both the excitation and the
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emission spectra to shorter wavelengths. Excitation can be performed at 360 
nm. Emission maxima are 551 nm without Na^ and 525 nm for the complex.
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SBFI (11) and an isomer, sodium-binding benzofuran phthalate (SBFP) were 
tested in lymphocytes and fibroblasts. Both dyes could be introduced by 
microinjections, but when the tetraethyl esters  were synthesised and incubated 
with the cells, only the SBFI appeared in the cytoplasm, which m akes it the 
preferred probe of these  two. "^^
Potassium  is a major ionic constituent of living cells. Intracellular concentrations 
are typically -1 5 0  mmol dm"^, while extracellular levels are approximately 4 
mmol dm'^. Monitoring changes in potassium ion concentration is important in 
order to study for example the effect of drugs, or ionic equilibrium disorders. 
During signal transduction, neurons change their potential by rapidly releasing 
potassium ions into the environment. The cells com pensate for the cation loss 
by initial sodium uptake. The normal [K ]^ and [Na^] are finally restored by the 
sodium-potassium pump. As changes in [K^ are < 5%, responses in 
fluorescence are consequently low. The fluorescent probes GDI 8 (12)^^ and 
CD222 (13)^ ® were prepared for intracellular and extracellular m easurem ents of 
potassium ions. Kd(CD18) is 140 mM under physiological conditions, while 
Kd(CD222) is 13.5. The increased stability of the complex is due to the 
replacem ent of the azacrown-ether for the cryptand in the binding moiety. Both
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CD18 and CD222 offer good selectivity over sodium ions. The coum arin-based 
reporters are excitable at wavelengths close to 400 nm and have emission 
maxima of 486 nm and 476 nm, respectively.
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For the detection of caesium  ions and their removal from nuclear w aste 
calix[4]biscrown ether-type ligands were s u g g e s t e d . Valeur and co-workers 
constructed the fluorescent sensors Calix-C0U1 (14) and Calix-COU2 (15), 
incorporating calixarene ligands.
Calix-COUl
14
Calix-C0U2
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The 3,4-dimethoxycoumarin-derivatives signal the binding of the metal ion. The 
sensors are particularly sensitive to caesium  ions, and also show very good 
selectivity towards potassium ions in the presence of sodium ions. Cation- 
binding m easurem ents were conducted in non-aqueous media (acetonitrile and 
ethanol) to determine the Kg values for the Cs" ,^ K ,^ and Na^ complexes. The 
fluorescent sensors exhibited excellent selectivity towards caesium  vs sodium 
ions and promising results were obtained for the selectivity towards potassium 
vs sodium.
For ion detection in biological sam ples water-soluble probes are usually sought. 
The authors claim that the insolubility of Calix-COUl and Calix-C0U2 in w ater 
is more an advantage than a drawback, as  their aim is to immobilise the 
sensors in polymer films, in which case  w ater solubility could enhance leaking. 
As leaking is determined by several factors (for example the mode of 
immobilisation), however, solubility is not the single most important param eter.
2 .3 .1 3  pH sensors
Examples for the sensing of H"" (pH) are abundant and the vast majority exploit 
the Bronsted-Lowry basicity of aliphatic amines.^® In a ‘typical’ pH senso r the 
chromophore is bound to an amine by a methylene or ethylene spacer. If not 
protonated, fluorescence is quenched by photoinduced electron transfer (PET). 
Protonation of the amine lone pair disrupts the PET, and the p resence of the 
protons is signalled by the ‘switching on’ of the fluorescence. Naturally the pKg 
of the amine can be tuned by attaching groups of varying electronegativity to 
the amine. Two exam ples of pH-sensitive fluorescent probes working on the 
basis of PET-quenching are 16 and 17.
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Som e of the H^-responsive probes, such a s  the Pb^'^-receptor-containing 16,^®
or 17,"^ ° which shows metal ion-induced fluorescence enhancem ent with several 
alkali and alkaline earth metals, were originally designed for the detection of 
other cations, rather than H .^ Due to the presence of the aliphatic am ines, they 
are sensitive to changes in the pH. If it is crucial to avoid the competition 
between the target cation and the protons, it is common to attach the am ines of 
the receptor to an aromatic ring, and thus raising their pKa values.
The compounds 18, 19 and 20^  ^ were designed to be proton probes and have 
pKa values of 7.1, 4.7 and 9.6, respectively. 18 and 19 have the sam e coumarin 
reporter. Substitution of two hydrogens by a hydroxyl in the 2 position on the N- 
ethyl groups decreased  the pKa by 2.4. In 20 the sam e diethylamino receptor 
that is present in 18 is attached to a strongly electron-withdrawing group, which 
decreases the pKa.
NH(CH_)3NELNEtg
MeO MeO
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2.3.2 Anion receptors
Anions play important roles in a number of biological processes, for exam ple a 
large number of enzym es bind anions as  co-factors or substrates, and anions 
can act a s  bases, nucleophiles, redox agents or phase-transfer catalysts/^  
Anion probes have becom e increasingly abundant in the past decade. Several 
exam ples exist for the halides fluoride and chloride, and hydroxide, carbonate 
and hydrogencarbonate, phosphate, and especially the polyanion DNA.
S essler and co-workers have synthesised the extended octaethy I porphyrin 
analogue, sapphyrin (21) and found that the diprotonated form is an efficient 
binder of fluoride ions."^  ^The sapphyrin showed over a thousand-fold selectivity 
for fluoride against both chloride and bromide. Upon addition of TBAF to the 
methanolic or DCM solution of the probe, the fluorescence emission decreased  
and w as shifted to longer wavelengths.
21
A recently synthesised fluorescent anthracene derivative (22) bears two 
phenylurea groups at the 1 and 8 p o s itio n s .F lu o re sc e n c e  w as efficiently 
quenched by fluoride ions. The probe has 120-fold selectivity for fluoride in the 
presence of chloride and even greater than that of bromide.
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The zinc complex of a trls(2-aminoethyi)amine functionalised anthracene 
molecule w as reported to be a useful probe for a series of carboxylate ions."*  ^
The binding event was signalled by quenching of the fluorescence of the zinc 
complex, presumably due to intramolecular electron transfer from the zinc- 
bound carboxylate subunit to the photoexcited anthracene moiety.
The sam e reporter without the metal centre was used by Czarnik and co­
workers for chelation enhanced fluorescence detection of non-metal anions at 
pH 6.^  ^ The anthrylpolyamine molecule is nonfluorescent when the benzylic 
nitrogen lone pair is not protonated. Complexing phosphate or carboxylate 
brings an OH-group of the anion into close proximity of the benzylic nitrogen, 
thus protonating it, which results in the recovery of the fluorescence. A similar, 
although less pronounced, effect is achieved with acetate or sulphate. These 
latter species are fully deprotonated at pH 6 , but are capable of stabilising an 
ammonium ion in their vicinity. If the anthracene is dialkylated with the 
polyamino moiety, the probe is only weakly fluorescent at pH 7.^  ^ Complexation 
with pyrophosphate doubles the fluorescence intensity. The molecule can 
discriminate between pyrophosphate and phosphate, having a 2200-fold higher 
affinity for the former, allowing for real-time pyrophosphate hydrolysis.
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Pyrophosphate and other anions possessing two binding sites are recognised 
by yet another bis-alkylated anthracene derivative. Fluorescence from the 9,10- 
bis(phenylthiourea) modified anthracene reporter is quenched due to PET from 
the thioureas to the anthracene, when dicarboxylates or pyrophosphate are 
bound to the probe."^® The fluorescence of the monoalkylated analogue of the 
sam e receptor w as quenched selectively by acetate, dihydrogen phosphate and 
fluoride, but not with either chloride or bromide."^^
There are several exam ples for the recognition of both nucleotides and DNA, of 
which only a few will be mentioned here. Lehn and co-workers synthesised the 
acridine-appended polyaza-macrocycle probe for the sensing of nucleotides 
and the monitoring of nucleotide hydrolysis.®^ The acridine moiety serves both 
a s  a luminescent reporter and to stabilise the complex by stacking interaction 
with the nucleotide base. The triphosphate polyanionic part forms multiple 
hydrogen bonds with the polyammonium macrocycle. Electrostatic interactions 
play and important role, as  at pH 7 the macrocycle is protonated, and its 
positive charges can interact with the negative phosphates. 23 also binds 
strongly to DNA, but is not capable of promoting its chemical or photochemical 
cleavage.
u u
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Lanthanide luminescence has been exploited in several ca ses  for detecting 
DNA. An elegant way of probing single-stranded DNA by fluorescent sensors 
w as developed by Sam m es and co-workers.®^ The complementary DNA strand 
(probe) w as labelled with europium(lll), which under the analysis conditions is 
not fluorescent. Then an intercalator-sensitiser unit (24), capable of both 
chelating the lanthanide ion and stacking between the nucleobases, w as added.
COOH
COOH
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The presence of the sensitizer unit resulted in ‘switching on' of the lanthanide 
luminescence. The intercalating phenanthridinium salt was linked covalently to 
the lanthanide chelating 1,10-phenanthroline-2,9-dicarboxylic acid. The principle 
of the probe is outlined in Figure 8.
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Figure 8. The principle of the intercaiating DNA-probe with luminescent europium(lil) reporter. 
Step 1: Labelled probe seeks and hybridises to target DNA strand. Step 2: The intercaiator- 
sensitizer moves along the duplex until it reaches the metal ion. Only the co-operative complex
gives rise to a signal upon irradiation.
The europium and terbium complexes of 25 were found to intercalate with 
poly(dAdT), poly(dGdC) and calf-thymus DNA.®  ^ The tetraazatriphenylene 
chromophore serves as  the sensitizer for the lanthanide luminescence. The 
excited state  of the heterocycle is quenched upon intercalation with DNA, and it 
consequently loses its ability to sensitize the lanthanide emission, thus 
signalling the presence of the nucleic acid. Nucleic acid binding had similar 
effects on the near-IR emission of Yb(lll) 26, where a porphyrin derivative 
replaced the tetraazatriphenylene antenna.®^
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The fluorescence of the europium complex 27 is quenched by halide ions, 
presumably due to a heavy atom effect,®"^  and hydroxide ions above pH 10, 
too.®  ^The quenching by chloride w as pH-independent and w as not affected by 
a range of other biologically important ions, i.e. phosphate, citrate, lactate or 
carbonate. The N-demethylated analogue of the complex can function as  a pH- 
responsive fluorescent probe, because protonation and deprotonation of the 
ring nitrogen affects the ability of the antenna to sensitize the terbium.
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The affinity of the water-soluble probe 28 for phosphate, lactate, citrate, 
malonate, hydrogencarbonate / carbonate and acetate w as determined.^® The 
affinity constants were dependent on several factors, among them the charge of 
the anion and the mode of binding. Thus carbonate that is mainly 
hydrogencarbonate, and p o ssesses  one negative charge at the pH of the 
m easurem ents, forms a chelate with the cation, resulting in the loss of a proton 
and a decrease  of the charge; increasing the binding constant. The binding 
event induces up to threefold intensity increases in the emission spectra at 618 
nm. It w as possible to monitor complex formation with carbonate in aqueous 
solutions simulating the anionic composition of extracellular fluids.
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Beer and co-workers have synthesised a series of selective abiotic anion 
receptors.®^ Most of their work on dihydrogenphosphate-responsive probes 
uses electrochemical detection by the m eans of various metallocene reporters, 
but they have also reported a series of ruthenium-bipyridyl com plexes that 
signal the presence of anions.®®
29
Upon addition of chloride or dihydrogen phosphate the MLCT fluorescence 
emission from the ruthenium(ll) polypyridyl complex 29 was blue-shifted. Also 
considerable fluorescence intensity enhancem ents were observed. The acyclic 
(30) and calix[4]arene (31) analogues of 29 were also synthesised and had 
similar spectral and anion binding properties.
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The calix[4]arene ligand 31 sen ses  dihydrogen phosphate selectively (as 
determined electrochemically) in the presence of tenfold excess of 
hydrogensulphate or chloride.®®
While the [Ru(bipy)3f'" (30) has enhanced affinity for dihydrogen phosphate in 
the presence of chloride ions, 32 binds chloride selectively in the p resence of 
phosphate, a s  both NMR and fluorescence m easurem ents confirmed.®® Excess 
H2PO4" had no effect on the emission spectrum of 32, while addition of chloride 
increased the emission intensity and shifted the emission from the ruthenium by 
6 nm to higher wavelengths. This m akes 32 one of the first chloride-selective 
fluorescent probes.
Ru
32
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The metal-centred lum inescence of the europium bipyridyl complex 33 is 
increased eleven-fold when nitrate ions were added to the solution of the ligand 
in acetonitrile.®^ With terbium, sevenfold increases in fluorescence intensities 
were detected. Other anions (chloride, fluoride and acetate) had similar effects 
on the lum inescence of the complexes. The association constants were 
determined to decrease  in the fluoride > acetate > chloride > nitrate order for 
the 1:1, 1:2 and 1:3 (ligand : anion) complexes.
33
2.3.3 Sensing neutral species
Although fluorescent probes for neutral species exist, there are far fewer of 
them, than probes for cation or anion sensing. Only a few exam ples will be 
given here, more can be found in de Silva’s review of molecular switches.
Yoon and Czarnik reported in 1992 the quenching of fluorescence from 
anthrylboronic acid in the presence of sugars.®^ Another exam ple of sugar 
sensing w as described by Shinkai and co-workers, who combined fluorescence 
and circular dichroism to investigate recognition of saccharides in methanol : 
water 1:1.®  ^ The cyanine dye 34 formed intramolecular 1:1 com plexes with 
m onosaccharides, binding D-fructose most strongly (Kg = 1.3-10®). Upon 
complexation the fluorescence intensity increased by approximately threefold, 
probably due to the rigidification of the structure of the dye. Those sugars that
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can only form 2:1 complexes with diboronic acids induced no increase in the 
fluorescence intensity.
Cl
OH HO
OH HO
34
The compound 35 has been designed to serve as  an artificial receptor for uronic 
and sialic acids in aqueous solutions.®"^ Saccharide (did) binding w as ensured 
by the incorporation of the boronic acid moiety into the receptor, while the 1,10- 
phenanthroline-Zn(ll) chelate helped the recognition of the carboxylate.
^1 
/ /  i s
35
The log K values of several m onosaccharides and uronic acids with the zinc- 
free receptor 35 were too low to be determined. Complexation of zinc 
considerably increased the stability of the receptor(Zn(ll)) uronic acid 
complexes. Fluorescence emission spectra were recorded in water / methanol 
(1:2) at pH 8.0, at 375 nm. Addition of D-monosaccharides to the solution of the 
zinc complex induced 1.5-fold, while that of D-glucuronic acid and D- 
galacturonic acid 3.5-fold and twofold fluorescence enhancem ents.
The binaphthyl derivative w as synthesised by Shinkai and co-workers and 
applied for chiral m onosaccharide recognition. Preliminary results with 36, the 
first artificial receptor for chiral sugar recognition, suggested that chiral 
discrimination between enantiom ers could be enhanced by rigidifying the
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structure of the host, a s  in 37. This indeed w as found to be true, a s  the 
magnitude of fluorescence enhancem ent w as different for enantiomeric sugars, 
the greatest difference (1.0:8.7 = D:L) was observed for xylose.
(HO^B
B(OH).
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Cooper and Jam es synthesised the fluorescent probe 38 for the signalling of D-
glucosamine hydrochloride at pH 7.18.®® The boronic acid moiety serves to
recognise the diol ‘unit’ in the target molecule, while the aza-crown ether binds
the ammonium function. As both the boronic acid and the nitrogen atom of the
aza-crown ether can participate in PET, the fluorescence is only recovered
when both receptors are occupied by the guests.
B(0H),
38
The fluorescent PET sensor 39 shows two to three-fold fluorescence 
enhancem ent in methanol / water (3:2) in the presence of GABA, or related 
amino acid zwitterions.®^ The amino function of the amino acid is recognised by 
the monoaza-18-crown-6 ether receptor already known from the D-glucosamine
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probe (38) synthesised by Cooper and Jam es, while the guanidinium unit binds 
the carboxylate end.
NH.+
39
Motesharei and Myles have incorporated the fluorescent probe 40 into 
alkanethiolate-functionalised gold nanoparticles, in order to probe molecular 
recognition events at organic interfaces {Figure 9).®® The receptor moiety of 40 
is fluorescent itself, and when barbiturate ligand 41 occupies the binding pocket 
the fluorescence emission is shifted by 4-11 nm to longer wavelengths, the 
effect being most pronounced for non-polar, aprotic solvents, and can be 
completely reversed by rinsing with ethanol. When covalently bound to the gold 
particles, the recognition event shifted the emission wavelength by 12-14 nm in 
acetonitrile and dichloromethane, respectively.
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Figure 9. Binding of a barbiturate ligand (41) by fluorescent 40 attached to gold nanoparticies.
The electron-deficient double bond in compound 42 can undergo Michael 
addition with thiols, thus signalling the presence of organic molecules using 
irreversible interaction.®^ In the absence of thiols fluorescence is quenched 
because  of PET from the fluorophore to the alkene. When thiols are bound to 
the probes, fluorescence enhancem ents up to threefold can be observed, the 
exact values depending on the thiol, the effect being biggest for 2- 
m ercaptoethanol and smallest for L-cysteine.
>={ N—Bu
42
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Squaraine-derivatives 43a and 43b are sensitive to biologically relevant 
aminothiols cysteine and cystine derivatives, among them glutathione and 
homocysteine/® In acetonitrile / water (20:80) solution both com pounds reacted 
with cystein and their fluorescence, displayed at around 640 nm w as efficiently 
quenched. Furthermore, the initially coloured squaraines were bleached. The 
likely mechanism for this reaction is attack of the nucleophilic sulphur atom on 
the electron-deficient carbon of the central four-membered ring (Scheme 1). 
Other nucleophiles, such as  amines, sulphides, alcohols and phenols did not 
produce colour changes.
NR.
R'— 8
R-SH
OH
NR2
Scheme 1. The reaction likely to be occurring between 43 and thiol derivatives. 
43 a: R = -(CH:^20(CH^20CH^, 43 b: R = -(CH2)20C(0)NH(CH2)3CH3
Catechols occur in a number of biologically important molecules, among them in
catechol estrogens (CE), w hose DNA-adducts are thought to play an important
part in hormonal carcinogenesis. In these  adducts catechol estrogen quinones
react with adenine and guanine. It is also hoped that CE-DNA adducts will be
employed a s  biomarkers for the early detection of estrogen-induced cancers.
Stack et al. have developed the 2,2-dibromomalonamide derivative (44) bearing
two anthracene fluorophores for the detection of catechols, and have tested  it
on a range of catechols, among them the adducts with guanine and adenine.
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Detection of the target compounds occurs via cyclic ketal formation through 
replacem ent of the bromine atom s in the 2 position by the two oxygen atom s of 
the catechol. Reaction between the targets and the probe w as possible only at 
elevated tem peratures (50 °C) in DMF in the presence of caesium  carbonate 
base, and the detection took an hour. The CE-DNA adducts could be detected 
at low femtomolar level with the excess of the probe attached to a polystyrene 
resin.
o o
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Nitric oxide is an important intra- and extracellular messenger,^^ but is produced 
in low concentrations and is unstable, which m akes its detection difficult. 
Nagano and co-workers have equipped a boron dipyrromethane chromophore 
with a 3,4-diaminophenyl group to yield a non-fluorescent molecule (DAMBO) 
(45a), which reacts rapidly with nitric oxide to produce a highly fluorescent 
triazole (DAMBO-T) (45b)/^
Above pH 7, DAMBO-T rapidly lost its fluorescence due to deprotonation of the 
triazole, which resulted in the increased electron-donating ability of the 
triazolate functional group, and acceleration of the PET to the fluorophore. The 
pH-independent DAMBO-P" (46) has an increased electron-density on the 
reaction site, which increases sensitivity for NO, and two propionic acid 
substituents on the dipyrromethane moiety to optimise PET and increase 
hydrophilicity, and avoid quenching through stacking. DAMBO and its
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derivatives proved highly selective for nitric oxide even in the presence of the 
very reactive singlet oxygen {Figure 10).
NH, H N -N NH.
NH, NH,
NO
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46 R = CH2CH2COOH
Figure 10. Nitric oxide-sensitive DAMBO (45a), its triazole derivative DAMBO-T (45b), and pH-
independent DAMBO-PH (46).
The sam e research group have designed and synthesised the fluorescein-
based singlet-oxygen probe 9-[2-(3-carboxy-9,10-dimethyl)anthryl]-6-hydroxy-
3H-xanthen-3-one (DMAX) (47a), which is more sensitive to its target species,
than any known singlet oxygen probe so far/^  The molecule's 9,10-
dimethylanthracene moiety acts a s  a very fast singlet oxygen trap. While DMAX
is practically non-fluorescent, the endoperoxide (DMAX-EP) (47b) formed when
the probe reacts with oxygen is highly fluorescent {Figure 11). The work on this
probe has also provided useful information on the conditions governing the
fluorescence of fluorescein derivatives. It has been found, that dividing the
molecule into a fluorophore part, i. e. the xanthene moiety, and a ‘fluorescence
switch’ part, which is the benzoic acid derivative is a reasonable approximation,
and frontier orbital energies of these  two parts can be calculated separately.
When the HOMO of the fluorescence switch is higher than that of the
fluorophore, fluorescence from the excited fluorophore can be quenched by
PET from the switch. On the other hand, if the HOMO of the fluorophore lies
higher then that of the switch, fluorescence is observed. This theory has been
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tested  by the synthesis and photophysical characterisation of a number of 
fluorescein derivatives.
COOH
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Figure 11. The singlet oxygen-probe DMAX (47a), and its endoperoxide DMAX-EP (47b).
Parker and co-workers have incorporated the terbium complex 48 into sol-gel 
thin films in order to obtain an operational fluorescent probe for sensing oxygen 
concentration changes in aqueous solutions^"^. The quenching of the 
fluorescence by the dissolved oxygen w as independent of the pH over a pH 
range of 2 to 9. The m easurem ents were reproducible after keeping the probes 
for long periods of time open to air, indicating that no serious degradation 
p rocesses take place. Despite slight variations in the microenvironment of the 
films, the data obtained with different sensors and during different 
m easurem ents were comparable, making 48 a promising candidate a s  a widely 
applicable oxygen sensor.
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2.4 Molecular logic systems
Many of the probes mentioned previously can be looked upon a s  molecular- 
scale devices. Obviously, the fact that they perform (or could perform) tasks that 
resem ble the functions of electronic devices that are currently in use, does not 
mean that in the near future computers m ade from molecular switches could 
replace silicon-based computers. One of the crucial problems is the ‘wiring’ 
together of the parts. As the majority of the switches use one or more chemical 
species a s  input combined with light (of a  specific wavelength), and has light (of 
a  different, longer wavelength) output, the connection of even two switches can 
be a difficult task. For example complex molecular logic gates (like INHIBIT, 
NAND or XNOR), which can provide in electronics any truth table by simply 
connecting the necessary AND and XOR gates in the right order, still have to 
perform the desired arithmetic functionally, rather than physically.
Nevertheless, molecular-scale analogues of several currently used electronic 
logic system s exist.^® AND gates can be constructed by slightly modifying the 
PET-based probes mentioned before, by the addition of an extra receptor for a 
second species. Thus PET can quench the fluorescence of the fluorophore from 
either receptors, making the presence of both target species (both inputs are 1) 
necessary  for the output to equal 1 (for emission to take place). ^
^ From the  point of view of the  primary p ro cess  (PET) this is again  a  functional ra th er than  a
physical logic gate , a s  it exploits the  equ ivalence  A + B = NOT(NOT(A) NOT(B)), i.e. if PE T  is 
su p p re sse d  in both recep to r A and  recep to r B, than NOT(PET) (=em ission) is observed .
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An example of AND logic gate is 497® The alkyl amine receptor unit requires 
protonation for PET to be suppressed, while the benzocrown needs sodium 
ions. As the fluorescence can only be observed when both species are present, 
49 fulfils the truth table of a logical AND gate (shown beside 49).
CN
o
h h 0
0 0 0
0 1 0
1 0 0
1 1 1
49 The truth table of an AND logic gate
Another example could be 38, if the two inputs are supplied by two different 
species (i.e. a glucose molecule and an ammonium ion instead of glucosamine 
hydrochloride).
Molecular-scale models of other electronic devices (memories, switches, 
motors, etc) have also been constructed. These molecules perform their 
function upon irradiation, electrochemical activation or stimuli by chemical 
species. The ‘outcome’ of the action can be similarly varying, ranging from the 
emission of light to controlled motion of the molecules.^^
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3 O bjectives  of the  project
Despite the wide range of fluorescent probes already available, there are still a 
number of difficulties to be overcome. The sensitivity of the probes is reduced 
by both autofluorescence from the sample, and the non-zero background. The 
binding of the target is usually signalled by an enhancem ent or d ecrease  of the 
already existing fluorescence signal. As fluorescence is affected by num erous 
factors, it can be difficult to obtain a clear and unambiguous signal from the 
probe.
The sensitivity of the luminescent probes could be increased by exploiting 
triggered resonance energy transfer (RET). Resonance energy transfer has 
been applied to the study of biomolecules as  the fluorescent signal obtained 
has an emission maximum shifted from the fluorescence of the sample. 
Triggered RET m eans that the fluorescence from the acceptor is ‘switched on’ 
when the desired event occurs, otherwise it is switched off. In the ideal ca se  this 
results in the observation of a unique fluorescent signal against a non- 
fluorescent background.
The aim of the project is to synthesise and characterise a series of donor- 
acceptor-quencher (D-A-Q) triads that are able to undergo triggered R esonance 
Energy Transfer in competitive media. The RET from the donor to the acceptor 
is quenched by the quencher that is in the close proximity of the donor. If the 
quencher is bound to a target species, the quenching is disrupted and emission 
from the acceptor can be observed (Figure 12).
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Figure 12. Schematic representation of the designed D-A-Q triads. When the substrate (S) is 
present, fluorescence from the acceptor (A) can be observed, otherwise the quencher (Q) 
quenches RET from the donor (D) to the A and the probe is switched ‘OFF’.
3.1 The organic donor -  acceptor - quencher triad
The first target molecule (50) consists of coumarin 2 as the donor, coumarin 
343 as  the acceptor and uridine as the quencher {Figure 13). The three 
moieties are held together by a suitable scaffold molecule, that was chosen to 
be the 4-amino-3-hydroxybutyric acid. This molecule contains three different 
functional groups and enables selective reaction of each group.
A
:
HO
OHOO 50
Q
Figure 13. The first triad (50), consisting of coumarin 2 (D), coumarin 343 (A) and uridine (Q). 
The emission spectrum of coumarin 2 overlaps the absorption spectrum  of 
coumarin 343, making them a suitable donor-acceptor pair for RET. Uridine was
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chosen a s  the quencher, as  it is known to be able to quench coumarin excited 
states,^® and combines this ability with a recognition site. The quenching 
process is expected to be interrupted by the binding of the uridine to the 
complementary base  (adenosine). If the coumarin 343-uridine pair is replaced 
by other A-Q pairs, the binding events between the quenchers and their 
substrates are signalled by emission of lights of different wavelengths. If a 
‘cocktail’ of the D-A-Q triads is used, the common excitation wavelength 
enables the simultaneous monitoring of a series of binding procedures.
3.2 The triads with europium and terbium lumophores
Coumarin 2 can act not only as  a donor for the coumarin 343 acceptor, but also 
as  a sensitizer for the lanthanide ions europium and terbium. Europium and 
terbium have emission wavelengths in the > 450 nm region, long-lived emission, 
and their lifetimes are typically on the millisecond timescale. This enables the 
removal of any short-lived background luminescence by time gating. As 
emission from the lanthanide ions occurs between electronic energy levels, the 
emission bands are sharp peaks.
D-A-Q triad (51) with the sam e coumarin 2 donor and uridine quencher, but a 
lanthanide ion acceptor w as designed. As incorporation of the lanthanide into 
the triad occurs through complexation with a suitable chelator, the 4-amino-3- 
hydroxybutyric acid scaffold w as replaced by cyclen (Figure 14).
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Figure 14. The second D-A-Q triad (51). D: coumarin 2, A: acceptor: europium(iil) or 
terbium(ili), Q: quencher uridine or adenosine. Scaffoid: cyclen
Cyclen can be N-substituted to enable binding of the donor and the quencher, 
and the four nitrogen atom s chelate the lanthanide ion. To further increase the 
stability of the complex and avoid fluorescence quenching of the lanthanide by 
bound water molecules, ethylacetylcarboxylate arm s are to be attached to the 
cyclen to saturate the co-ordination sphere of the metal ion.
The presence of a quencher in the ligand can have various effects on the 
lanthanide luminescence. The luminescence intensity of the complex would 
decrease  compared to that of an analogous compound without the quencher. It 
is also possible that while the luminescence intensity remains intact, the 
lum inescence lifetime changes. It is possible that the presence of a substrate 
could induce further changes in the lifetime. As europium and terbium lifetimes 
can be m easured conveniently and precisely, it would be a fast and very 
specific way of detecting the substrate.
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3.3 The triads with neodymium and ytterbium lumophores
Near infrared emitting lanthanide ions neodymium and ytterbium cannot be 
sensitised by coumarin 2, w hose emission energy levels are too high above the 
excited sta te  energy levels of these  lanthanides. As there is no overlap between 
the donor emission spectrum and the acceptor excitation spectrum. Therefore 
other an tennae with longer emission wavelengths are needed. It is known that 
both fluorescein and rhodamines are able to sensitise neodymium and 
ytterbium. Preliminary m easurem ents suggested that lum inescence from both 
com pounds decreases in the presence of the nucleotides adenosine and 
uridine. As these  m easurem ents have not indicated the superiority for our 
purposes of either antennae, rhodamine w as chosen for the antenna - near IR -  
quencher triads, as  rhodamine is easier to functionalise and handle than 
fluorescein (Figure 15).
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Figure 15. The third D-A-Q triad. D: rhodamine B, A: acceptor: neodymium (Hi) or ytterbium(iii), 
Q: quencher uridine or adenosine. Scaffold: cycien
3.4 Exciplex for DMA detection
A wide range of polyaromatic compounds are known to intercalate with DMA. It 
is possible that the flat bicyclic coumarin structure of the coumarin 2 donor
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could fit into the DNA double strand. This is expected to be signalled by a 
decrease  in the fluorescence intensity of the coumarin 2, or, if coumarin 2 is 
used as  a donor for a further luminescent molecule, a decrease  in its ability to 
sensitize the acceptor. If this acceptor is not coumarin 343 or the lanthanides 
europium or terbium, but rhodamine, a decrease  in the lum inescence intensity 
of the rhodamine is expected. As rhodamine can be used to sensitize the near 
infrared emitting lanthanides neodymium and ytterbium, the interaction of the 
coumarin 2 with the DNA would be in the end signalled by changes in the 
lanthanide lum inescence {Figure 16).
3+OEt
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Figure 16. The coumarin 2 -  rhodamine B excipiex D1: coumarin 2, A or D2: acceptor or donor 
2: rhodamine B, Ln: neodymium or ytterbium. Scaffold: cyclen
Rhodamine B is not expected to intercalate with DNA, as  it has four ethyl 
groups attached to two nitrogen atoms, which would prevent it from fitting 
between the DNA base  pairs. Therefore the presence of the DNA would be 
indicated by a decrease  of lanthanide luminescence intensity when the 
coumarin 2 is excited at approximately 330 nm, while the lum inescence 
intensity would remain intact when direct excitation of the rhodamine antenna at 
around 450-550 nm is carried out. It is also possible that DNA would affect the 
lanthanide luminescent lifetimes.
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4 Experim ental
Cyclen, anhydrous europium(lll) chloride, terbium(lll) chloride, neodymium(lll) 
chloride and ytterbium(lll) chloride were obtained from Strem Chemicals, DEAD 
from Lancaster Synthesis. Fmoc-chloroformate and rhodamine B were supplied 
by Aldrich. All other chemicals were purchased from Acros and used without 
further purification. N-Fmoc-y-O-^Bu-glutamic acid, dry acetonitrile and dry DMF 
were purchased from Fluka. Sodium iodide, magnesium sulphate, potassium 
carbonate and all solvents, apart from DMF and acetonitrile were obtained from 
Fischer.
1,4-Cyclen oxalamide,^® 5’-oxidised 2’,3’-isopropylideinenucleotides, and N- 
Boc-glycine were synthesised according to literature procedures.^®
Sodium iodide and potassium carbonate were dried at 90 °C for 24 hours prior 
to use. Tetrahydrofuran w as distilled from potassium and benzophenone, 
dioxan from lithium aluminium hydride, acetonitrile from phosphorus pentoxide, 
under argon atm osphere, and stored over molecular sieves. Chloroform w as 
distilled from lithium aluminium hydride under argon and used immediately. TEA 
w as distilled from calcium hydride under argon and stored under argon over 
molecular sieves. All other solvents were used as  purchased.
Reactions involving N-methylaniline or coumarins were conducted in the dark. 
Thin Layer Chromatography w as done on Merck fluorescent silica or on Fluka 
fluorescent alumina plates with iodine, KMn04 or UV visualisation. NMR and 
^®C NMR data were obtained using a 300 MHz JEOL instrument. LC-MS w as 
performed on a VG Quattro 2 equipment coupled to a W aters HPLC system . 
Accurate m asses were obtained through the EPSRC Sw ansea M ass
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Spectrometry Service (University of W ales, Swansea). Melting points were 
determined using an Electrothermal digital melting point apparatus, and are 
uncorrected. Infrared spectra were recorded on a Perkin Elmer 1710 Infrared 
Fourier Transform Spectrometer. Elemental analysis was performed by MEDAC 
Ltd, Egham, Surrey. UV spectra were m easured on a Uvikon XL (Bio-Tek 
Instruments) spectrom eter. Excitation spectra and emission spectra of the 
organic triads, the europium and terbium complexes, and the luminescent 
lifetimes of the europium and terbium complexes were m easured on a 
Fluoromax-P (Jobin-Yvon) fluorimeter. Luminescent lifetimes of the organic 
triads were determined by a Jobin-Yvon Fluorolog FL-3-22 / Tau-3 
Spectrofluorimeter.
Emission intensities and luminescent lifetimes of the Nd and Yb com plexes 
were determined the following way. Sam ples were illuminated over an area  of 1 
cm^ with the 355 nm Q-switched output of a Nd:YAG laser (Spectra Physics) 
operating at 10 Hz. Typical pulse energies were 3-4 mJ with a pulse FWHM of 8 
ns. The IR photoluminescence w as collected at right angles and focussed onto 
the entrance slit of a Jobin-Yvon Triax 320 monochromator with a  grating 
blazed at 900 nm and w as detected with a nitrogen-cooled germanium 
photodiode/amiplifier (North Coast EO-817P) operating in high sensitivity mode. 
The signal w as captured and averaged by a digital storage oscilloscope 
(Tektronix TDS320) and transferred to a PC for data analysis. Decays were 
analysed by iterative deconvolution and non-linear least-squares analysis of the 
instrument response profile with single functions.
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4.1 Organic triads
4.1.1 Triad synthesis with the 4-Amino-3-hydroxybutyric acid scaffold
4.1.1.1 N-Boc-4-amino-3-hydroxybutyric acid
OH OH dioxaniwater Q|_| q |  ^ ^
54 55
D,L-4-amino-3-hydroxybutyric acid (54) (1.19 g, 10 mmol) was dissolved in 
water (6 mL), triethylamine (2.1 mL, 1.6 g, 15 mmol, 1.5 eq), 1,4-dioxan (6 mL) 
and di-tert-butyl dicarbonate (2.42 g, 11 mmol, 1.1 eq) were added and the 
mixture w as stirred at room tem perature. The mixture becam e clear after 1 hour 
and the reaction w as allowed to proceed for two more hours. Ethyl aceta te  (25 
mL) and water (30 mL) were added and the phases were separated. The 
aqueous phase w as acidified to pH 2 with 1:1 HCI and extracted with ethyl 
acetate  (3 25 mL). The combined organic phases were dried over MgS04 , 
filtered, and the ethyl acetate w as removed in vacuo. The product (55) is a 
white solid. Yield: 96% (2.10 g); MS: 219 [M+Hf; NMR (CD3CN, 5): 1.35 (s, 
9 H, Boc), 2.29 (dd, 1 H, CH2-I, Ji = 8.4 Hz, J2 = 15.7 Hz), 2.43 (dd, 1 H, CH2- 
2, Ji = 4.4 Hz, J2 = 15.7 Hz), 3.22-3.05 (m, 2 H, CH2) 3.66 (s, 1 H, OH), 4.13-
4.00 (m, 1 H, CH-OH), 5.41 (b rs , 1 H, NH); NMR (CDCI3) 28.18 (CH3 , Boo),
38.33 (CH2), 45.33 (CH2), 60.37 (CH), 171.36 (CO), 175.62 (CO); mp: 98-99 °C; 
IR (vmax/ (cm"'), KBr): 3573, 3505, 3387, 2983, 2940, 2680, 2584, 1685, 1531.
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4.1.1.2 N-Fmoc-4-amino-3-hydroxybutyric acid
o
NH.
OH OH
54
Fmoc-chloroformate
10% NaHCOg 
dioxan
X
OH OH
56
D,L-4-amino-3-hydroxybutyric acid (54) (1.19 g, 10 mmol) w as dissolved in 10% 
NaHCOs (25 mL), 1,4-dioxan (15 mL) w as added and the solution w as cooled in 
an ice-water bath. Fmoc-chloroformate (2.60 g, 11 mmol, 1.1 eq) was 
introduced in small portions, and the reaction w as conducted at ice-water bath 
tem perature for 4 hours and at room tem perature for a further 8 hours. The 
reaction mixture w as poured into water (600 mL) and w ashed with diethyl ether 
(2-100 mL). The water phase w as acidified to pH 2 with conc. HCI. Precipitation 
of the product occurred immediately. The vessel w as kept in the fridge overnight 
and the white, voluminous solid w as filtered out by suction. The product is 
w ashed with small portions of water on the filter and dried in vacuo. 56 Is a 
white, crystalline solid. Yield: 91% (3.11 g); MS: 342 [M+H]^; ^H NMR (CDCI3, 
5): 2.33 (dd, 1 H, C H 2-I, Ji = 11.1 Hz , J2 = 8.6 Hz), 2.47 (dd, 1 H, 0 ^ - 2 ,  Ji =
15.4 Hz , J2 = 3.8 Hz), 3.17 (d, 2 H, c H ,  J = 5.1 Hz), 3.92 (m, 1 H, CH-OH),
4.14 (t, 1 H, CH-Fmoc, J  = 6.6 Hz), 4.32 (d, 2 H, CH2-Fmoc, J = 6.6 Hz), 7.22- 
7.36 (m, 4 H, CH), 7.60 (d, 2 H, CH, J = 7.3 Hz), 7.73 (d, 2 H, CH, J  = 7.3 Hz); 
^^C NMR: 40.38 (CH2), 47.36 (CH2), 67.71 (CH2), 68.52 (CH), 120.88 (CH-ar), 
126.100 (CH-ar), 128.10 (CH-ar), 128.72 (CH-ar), 142.51 (CH-ar), 145.22 (CH- 
ar), 159.00 (CO), 175.16 (CO); mp: 87-88 °C; IR (vmax / (cm"'), KBr): 3321, 
3067, 2956, 2361, 2341, 1697, 1654, 1636, 1617, 1542, 1508, 1449.
66
4.1.1.3 Coupling NMA to N-Boc-4-amino-3-hydroxybutyric acid
NHBoc
EDCI
DCM/AcN 
r.t, 3 days
OH
57 58
NMA (57) (112 pL, 0.11 g, 1 mmol) w as dissolved in DCM (10 mL), a solution of 
N-Boc-4-amino-3-hydroxybutyric acid (56) (0.22 g, 1 mmol dissolved in 5 mL 
AcN) w as added and the solution w as stirred at room tem perature while EDCI 
(0.19 g, 1 mmol) w as added in small portions. The reaction w as allowed to 
proceed for 3 days. DCM (25 mL) and water (30 mL) were added to the reaction 
mixture, the phases were separated, and the water phase w as extracted with 
DCM (3 25 mL). The combined organic phases were washed with w ater (30 
mL), dilute acid (25 mL 1 M HCI), dilute base  (30 mL 1 M NaOH) and w ater (25 
mL), dried over MgS04 , filtered, and evaporated concentrated to ~2 mL. The 
solution was applied onto a silica column and chromatographed with hexane / 
EtOAc (6:4). Evaporation of the solvents yielded 58 as  a colourless solid. Yield: 
46% (0.15 g); NMR (CDCI3, Ô): 1.32 (s, 9 H, Boc), 1.75 (br s, 1 H, NHBoc),
2.12-2.15 (m, 2 H, CHg), 2.83-2.97 (m, 1 H, CH2-I, Ji = 12.9 Hz, J 2 = 6.3 Hz, J 3 
= 5.7 Hz), 3.10-3.27 (m, 1 H, CH2-2), 3.20 (s, 3 H, N-CH3), 3.94 (m, 1 H, CH- 
OH), 4.93 (br s, 1 H, NH), 4.55 (br s, 1 H, OH), 7.10 (d, 2 H, CH, J = 7.1 Hz),
7.26-7.38 (m, 3 H, CH); ^^C NMR: 28.28 (B0C-CH3), 37.36 (CH2), 37.10 (N- 
CH3), 45.36 (CH2), 67.99 (CH-0), 79.21 (Cq), 127.09 (CH), 127.99 (CH), 128.23 
(CH), 172.43 (CO).
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4.1.1.4 Removal of the Boc protection from 58
OH
NHBoc
33% TFA/DCM
r.t.
1 hour
OH
58 59
58 (0.15 g, 0.5 mmol) was dissolved in DCM (10 mL), TFA (5 mL) w as added, 
and the reaction mixture w as stirred at room tem perature for 1 hour. The volatile 
com ponents were evaporated and the sam ple dried in vacuo to obtain the TFA- 
salt of the product (59) in quantitative yield as  a brown solid. MS: 209 [M+H]^;
NMR (CD3OD, Ô): 2.21 (dd, 1 H, CH2-I, Ji = 15.9 Hz, J 2 = 5.5 Hz), 2.31 (dd, 
1 H, CH2-2 , Ji = 15.9 Hz, Ü2 = 7.0 Hz), 2.67 (dd, 1 H, CH2-I, Ji = 12.5 Hz, J2 = 
2.9 Hz), 2.97 (dd, 1 H, CH2-2 , Ji = 12.5 Hz, J 2 = 9.3 Hz), 3.12 (s, 3 H, NCH3), 
4.08-4.15 (m, 1 H, CH-OH), 7.20-7.23 (m, 2 H, CH), 7.29 (m, 2 H, CH); 
NMR: 37.74 (NCH3), 40.21 (CH2), 45.43 (CH2), 66.06 (CH-OH), 128.49 (CH),
129.42 (CH), 131.12 (CH), 144.71 (CN), 172.01 (CO).
4.1.1.5 Alkylation of N-methylaniline with chloroacetic acid
H N ^  \  ^OH
• Chloroacetic acid N
O
DMF 
Ar, 24 h
57 60
A/-Methylaniline (57) (112 pL, 0.11 g, 1 mmol) w as dissolved in DMF (8 mL),
chloroacetic acid (0.45 g, 5 mmol, 5 eq) and potassium carbonate (2 g) were 
added, and the reaction mixture was stirred at 80 °C under argon atm osphere 
for 24 hours. The DMF w as removed in vacuo, the residue suspended in DCM 
(30 mL), water (30 mL) was added and the phases were separated . The water
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phase w as acidified to pH 3 and extracted with DCM (3 30 mL). The combined 
organic phases were dried over MgS04 , filtered, and evaporated to dryness to 
yield the product (60) as  a yellow solid in 70% yield (0.12 g). ^H NMR (CDCI3 , 
8 ): 2.98 (s, 3 H, NCH3), 4.10 (s, 2 H, CH2), 6.66 (d, 2 H, J = 8.6 Hz), 6.69- 
6.93 (m, 1 H, C H ), 7.12-7.41 (m, 2 H, C^®H), 9.37 (b rs , 1 H, COOH); '^0  NMR:
31.98 (NCH3), 54.11 (CH2), 112.80 (CH), 118.00 (CH), 129.24 (CH), 170.53 
(CO).
4.1.1.6 Alkylation o f aniline with ethyl bromoacetate
Ethyl bromoacetate HN
O
ACN, reflux 
Ar, 3 days
61 62 
Aniline (61) (0.09 g, 1 mmol) w as dissolved in acetonitrile (8 mL), ethyl 
brom oacetate (1.7 g, 10 mmol), sodium iodide (1.23 g, 10 mmol), and 
potassium carbonate (2 g) were added, and the reaction mixture w as refluxed 
under argon atm osphere for 3 days. The acetonitrile w as removed in vacuo, the 
residue suspended in DCM (30 mL), w ater (30 mL) w as added and the phases 
were separated. The water phase w as extracted with DCM (2 30 mL). The 
combined organic phases were dried over MgS04 , filtered, and evaporated to 
dryness to give product (62) as a dark brown oil. ^H NMR (CDCI3 , 5): 1.19 (t, 3 
H, CH3 , J = 7.1), 4.06 (s, 2 H, NCHz), 4.16 (q, 2 H, CHz, J = 7.1), 6.60 (d, 2 H, 
C^'^H, J = 7.9 Hz), 6.55-6.60 (m, 1 H, CH), 7.03-7.17 (m, 2 H, CH); ^^C NMR:
14.12 (CH3), 45.84 (CHz), 53.46 (CHz), 113.00 (CH), 118.23 (CH), 129.24 (CH),
146.90 (Cq), 171.04 (CO);
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4.1.1.7 Alkylation of N-methylaniline with ethylbromoacetate
Ethyl bromoacetate
^ O
DMF 
Ar, 24 h
57 63
N-Methylaniline (57) (112 pL, 1 mmol, 0.11 g) w as dissolved in DMF (8 mL),
ethyl brom oacetate (554 \iL, 0.84 g, 5 mmol, 5 eq), and potassium carbonate (2 
g) were added, and the reaction mixture was stirred at 80 °C under argon 
atm osphere for 24 hours. The DMF w as removed in vacuo, the residue 
suspended in DCM (30 mL). W ater (30 mL) was added to the solution, and the 
phases were separated . The water phase w as extracted with DCM (3 30 mL). 
The combined organic phases were dried over MgS04 , filtered, concentrated to 
~2 mL and applied onto a silica column. Elution with ethyl aceta te  / hexane (1:9) 
gave the desired product (63) as  a yellow oil in 86% yield (0.17 g). MS: 194 
[M+H*]; 'H  NMR (GDCb, 8): 1.13 (t, 3 H, CH3, J = 7.1 Hz), 2.97 (s, 3 H, NCH3), 
3.95 (s, 2 H, NCH2), 4.07 (q. 2 H, CH2, J = 7.1 Hz), 6.59-6.68 (m, 3 H, CH-ar), 
7.10-7.18 (m, 2 H, CH-ar); ’='C NMR; 14.13 (CH3), 39.38 (NCH3), 54.39 (CH2),
60.72 (CH2), 112.19 (CH-ar), 117.19 (CH-ar), 129.07 (CH-ar), 148.80 (N-Cq),
170.91 (GO).
4.1.1.8 N-Boc-aminoethanol
_ ^ ^ 0 H B0C2O OH
H,N ^   ► BocHN
TEA, CHCI3
64 65
2-Aminoethanol (64) (1.22 g, 20 mmol) w as dissolved in a mixture of chloroform 
(20 mL) and TEA (4 mL, 2.88 g, 28.5 mmol, 1.5 eq). B0C2O (4.00 g, 18.3 mmol,
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0.92 eq) w as added in small portions to the solution, and the reaction mixture 
w as stirred at room tem perature for 3 hours. W ater (20 mL) w as added to the 
reaction mixture, and the stirring continued for 12 hours at room tem perature. 
The phases were separated, the aqueous phase w as extracted with chloroform 
(2 30 mL), the combined organic phases were w ashed with 0.5 M HCI (30 mL) 
and w ater (2 25 mL), dried over MgS04 , filtered, and evaporated to dryness. 
The sam ple purified by silica column chromatography by elution with DCM to 
yield 65 as  a colourless oil. Yield: 70% (2.30 g); MS: 161 [M+H]^; NMR 
(CDCIs, Ô): 1.36 (s, 9 H, Boo), 3.18 (t, 2 H, CHz, J = 5.1 Hz). 3.58 (t, 2 H, CHz, J 
= 5.1 Hz), 3.99 (br s, 1 H, NH), 5.49 (br s, 1 H, OH); NMR; 28.10 (CH3), 
45.53 (CH2), 61.37 (CH2), 79.07 (C,), 156.48 (CO); IR (v„ax /  (cm'^), film): 3348, 
2977, 2934, 2882, 1685, 1526.
4.1.1.9 Alkylation of NMA with 65 via the Mitsunobu reaction
PPII3, DEAD 
dioxan/Ar, reflux, 3 days
57 66
N-Methylaniline (57) (112 |iL, 0.11 g, 10 mmol), TPP (0.26 g, 10 mmol) and N- 
Boc-aminoethanol (65) (0.16 g, 10 mmol) were dissolved in dry 1,4-dioxan (10 
mL). The reaction mixture was stirred under argon in an ice-water bath while 
DEAD (156 pL, 0.17 g, 10 mmol) in dry dioxan (10 mL) w as added dropwise. 
The solution w as allowed to warm up to room tem perature and then w as 
refluxed for 3 days under argon. The solvent was removed at reduced pressure, 
the residue dissolved in 3 mL DCM / EtOAc (95:5), applied onto a silica column, 
and chromatographed with hexane / EtOAc (9:1). Yield: -10%  (0.02 g); MS: 250
71
[M+Hf; NMR (CDCI3, 8): 1.37 (s, 9 H, Boc), 2.75 (s, 3 H, CH3), 3.23-3.26 (m, 
2 H, CH2), 3.36-3.40 (m, 2 H, CH2), 6.92-7.66 (m, 5 H, CH); NMR: 28.56 
(CH3), 29.95 (NCH3), 38.28 (CH2), 77.60 (C,), 112.33 (CH), 116.72 (CH),
129.43 (CH), 156.16 (CO).
4.1.1.10 Coupling N-Boc-glycine to coumarin 120
EDCI
NHBoc
NHBocDCM/THF
O "  ' O
67 68 69
Coumarin 120 (67) (0.50 g, 2.86 mmol) w as dissolved in DCM (20 mL) and THF 
(10 mL), N-Boc-Glycine (68) (2.00 g, 11.43 mmol, 4 eq) and EDCI (2.02 g,
10.52 mmol, 3.7 eq) were added and the solution w as stirred at room 
tem perature for 24 hours. The solvents were evaporated, the residue dissolved 
in DCM (30 mL) and w ater (30 mL), the phases were separated  and the 
aqueous phase w as extracted with DCM (2 30 mL). The combined organic 
phases were w ashed with water (2 30 mL), dried over MgS04 , filtered and 
evaporated to dryness. The solid w as suspended in Et20 (50 mL), filtered, 
w ashed with Et20 (2 10 mL), and dried. The product (69) w as obtained in 31% 
yield (0.30 g) a s  a  white solid. MS: 332 [M]\ 665 [M+M+H]^; 'H  NMR (CDCI3 , 
5): 1.32 (s, 9 H, Boc), 2.29 (s, 3 H, CH3), 3.72 (s, 2 H, CH2), 6.06 (s, 1 H, CH),
7.52 (s, 1 H, CH), 7.62 (s, 1 H, CH); " C  NMR: 18.20 (CH3), 29.83 (CH3), 43.81 
(CHz), 106.90 (CH), 112.70 (CH), 115.68 (CH), 125.04 (CH), 141.53 (Cq),
152.98 (Cq), 152.99 (CO), 161.69 (CO).
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4.1.1.11 Removal of the Boc protection from 69
Q TFA/DCM
NHBoc *
69 70
69 (0.29 g, 0.87 mmol) w as dissolved in DCM (15 mL) and TFA (11 mL), and 
the solution w as stirred at room tem perature for 0.5 hours. The solvents were 
evaporated and the sam ple dried at reduced pressure for 24 hours to give the 
trifluoroacetate salt of 70 in quantitative yield. MS: 232 [M+H] ,^ 465 [M+M+H] ;^ 
'H  NMR (CD3OD, S): 2.32 (s, 3 H, CH3), 3.77 (s, 2 H, CH2), 6.11 (s, 1 H, CH), 
7.28-7.31 (m, 1 H, CH), 7.52-7.56 (m, 1 H, CH), 7.68 (s, 1 H, CH); ®^C NMR: 
18.49 (CH3), 42.40 (CH2), 107.81 (CH), 113.75 (CH), 116.73 (CH), 117.32 (Cq), 
126.77 (CH), 142.71 (Cq), 155.13 (Cq), 155.22 (CO), 161.10 (Cq), 161.59 (CO),
163.12 (CO), 166.16 (CO).
4.1.1.12 Coupling 70 to N-Boc-4-amino-3-hydroxybutyric acid
OH EDCI
nh, + ho
:NHBoc
OH
NHBoc
70 55 71
70 (0.27 g, 1.2 mmol) was dissolved in w ater (10 mL), EDCI (0.26 g, 1.3 mmol,
1.1 eq) DIPEA (0.203 mL, 1.2 mmol, 0.15 g) and N-Boc-4-amino-3- 
hydroxybutyric acid (55) (0.25 g, 1.2 mmol) were added, and the solution w as 
stirred at room tem perature for 4 hours. The product precipitates out from the 
reaction mixture. When the reaction had reached completion the solid w as
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filtered off and w ashed thoroughly with water, DCM, dilute NaOH (1 M) and 
diethyl ether (20 mL each). The product (71), a white solid w as isolated in 58% 
yield (0.29 g). MS: 432 [M]\ 866 [M+M+H+Hf; 'H NMR (CD3OD. 8 ): 1.34 (s, 9 
H, CH3), 2.18-2.31 (m, 1 H, CH2-I), 2.35 (s, 3 H, CH3), 2.90-3.14 (m, 6 H, 
overlapping CH2‘s), 3.87 (tn, 1 H, CH-0), 6.16 (s, 1 H, CH), 7.41-7.44 (m, 1 H, 
CH), 7.62-7.66 (m, 1 H, CH), 7.70 (s, 1 H, CH); NMR: 17.06 (CH3), 27.53 
(CH3), 40.73 (CH2), 42.48 (CH2), 67.05 (CH), 105.58 (CH), 112.16 (CH), 115.00 
(CH), 125.30 (CH), 141.51 (Cq), 153.79 (Cq), 168.29 (CO), 171.67 (CO).
4.1.1.13 Removal o f the Boo protection of 71
TFA/DCM
:
OH
NHBoc'
71 72
71 (0.27 g, 0.63 mmol) w as dissolved in DCM (15 mL) and TFA (10 mL), and 
the solution w as stirred at room tem perature for 1 hour. The solvents were 
evaporated and the sam ple dried at reduced pressure for 24 hours to give the 
trifluoroacetate salt of 72, a white solid, in quantitative yield. MS: 332 [M] ,^ 667 
[M+M+Hf; NMR (CD3OD, Ô): 2.37 (s, 3 H, CH3), 2.49-2.54 (m, 2 H, CHz), 
3.99-4.05 (d, 2 H, CHg), 4.09-4.17 (m, 1 H, CH-0), 6.15 (s, 1 H, CH), 7.33-7.36 
(m, 1 H, CH), 7.62-7.65 (m, 1 H, CH), 7.76 (s, 1 H, CH); ^^C NMR:18.49 (CH3). 
42.26 (CHz), 44.06 (CHg), 45.46 (CHg), 66.26 (CH), 107.90 (CH), 113.59 (CH),
117.10 (CH), 126.74 (CH), 143.39 (Cq), 155.22 (CO), 170.12 (CO), 173.21 
(CO).
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4.1.1.14 Coupling N-Boc-glycine to coumarin 151
CF3
Q EDCI
NHBoc
NHBocDCM/THF
'O '  'WH O '' 'O
73 68 74
Coumarin 151 (73) (0.53 g, 2.37 mmol) was dissolved in THF (15 mL) and DCM
(10 mL), N-Boc-Glycine (68) (1.66 g, 9.46 mmol, 4 eq) and EDCI (1.82 g, 9.48 
mmol, 4 eq) were added and the solution w as stirred at room tem perature for 3 
days. The solvents were evaporated, the residue dissolved in DCM (30 mL) and 
w ater (30 mL), the phases were separated  and the aqueous phase  w as 
extracted with DCM (2 30 mL). The combined organic phases were w ashed 
with w ater (2 30 mL), dried over MgS04 , filtered and concentrated. The sam ple 
w as applied onto a silica column and chromatographed with DCM / MeOH (1%) 
to give 74 in 51.5% yield (0.46 g). '‘h  NMR (CD3OD, Ô): 1.46 (s, 3 H, CH3), 3.89 
(s, 2 H, CH2), 6.65 (s, 1 H, CH), 7.49-7.52 (m, 1 H, CH), 7.67-7.69 (m, 1 H, CH), 
7.93 (s, 1 H, CH); Sam ple solubility w as too low to obtain a good ^^C NMR 
spetrum.
4.1.1.15 Removal o f the Boc protection from 74
CP,
TFA/DCM
NHBoc
74 75
74 w as dissolved in DCM (10 mL) and TFA (10 mL), and the solution w as 
stirred at room tem perature for 1 hour. The solvents were evaporated and the
75
sam ple dried at reduced pressure for 24 hours to give the trifluoroacetate salt of 
75 in quantitative yield. MS: 232 [Mf, 465 [M+M+H]*; 'H NMR (CD3OD, S): 3.90 
(s, 2 H, CH2), 6.71 (s, 1 H, CH), 7.38-7.41 (d, 2 H, CH), 7.88 (s, 1 H, CH); ^^C 
NMR: 42.44 (CHz), 108.40 (CH), 110.71 (CH), 115.52 (CH), 117.23 (Cq), 126.96 
(CH), 143.79 (Cq), 156.61 (Cq), 160.59 (CO), 166.44 (CO);
4.1.1.16 Coupling 75 to 55
CF
O" o
OH EDCI
' '" /H O
:NHBoc
OH
NHBoc
75 55 76
75 (0.27 g, 0.94 mmol) w as dissolved in water (10 mL), EDCI (0.26 g, 1.34 
mmol, 1.4 eq) DIPEA (0.203 m l, 0.152 g, 1.1 mmol, 1.1 eq) and N-Boc-4- 
amino-3-hydroxybutyric acid (55) (0.25 g, 1.2 mmol, 1.2 eq) were added, and 
the solution was stirred at room tem perature for 4 hours. The product 
precipitated out from the reaction mixture. When the reaction had reached 
completion the solid w as filtered off and w ashed thoroughly with water, DCM, 
NaOH (1 M) and diethyl ether (20 m l each). The product (76), a white solid w as 
isolated in 63% yield (0.29 g). MS: 487 [M+Hf, 974 [M+M+H^; 'H  NMR 
(CDsOD, 5): 1.38 (s, 9 H, B0C-CH3), 2.26-2.43 (m, 2 H, CH2), 2.98-3.16 (m, 2 H, 
CH2), 3.95-3.99 (m, 3 H, CH + CH2), 6.75 (s, 1 H, CH), 7.47 (dd, 1 H, CH, Ji =
8.8 Hz, J2 = 2.0 Hz), 7.62 (dd, 1 H, CH, Ji = 8.0 Hz, J2 = 1.7 Hz), 7.89 (d, 1 H, 
CH, J = 2.0 Hz); Sam ple solubility w as too low to obtain a  good '®C NMR 
spetrum.
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4.1.1.17 Removal of the Boc protection of 76
TFA/DCM
:
OH
NHBoc
O
HN ^ O
^ O H
H^N
76 77
76 (0.11 g, 0.23 mmol) was dissolved in DCM (10 mL) and TFA (10 mL), and
the solution w as stirred at room tem perature for 1 hour. The solvents were 
evaporated and the sam ple dried at reduced pressure for 24 hours to give the 
trifluoroacetate salt of 77 in quantitative yield. MS: 388 [M+H]"", 755 [M+H]' ;^ 
NMR (CD3OD, Ô): 2.53 (d, 2 H, CHz, J = 7.9 Hz), 2.90 (dd, 1 H, CH2-I, Ji = 12.7 
Hz, Ü2 = 9.2 Hz), 3.13 (dd, 1 H, GH2-2 , Ji = 12.7 Hz, J2 = 2.9 Hz), 4.01 (d, 2 H, 
CH2, J = 4.6 Hz), 4.14-4.22 (m, 1 H, CH-0), 7.34 (dd, 1H, CH, Ji = 8.8 Hz, J 2 = 
2.0 Hz), 7.53 (dd, 1H, CH, Ji = 9.0 Hz, J 2 = 1.9 Hz), 7.83 (d, 1H, CH, J = 2.0 
Hz); ^^C NMR: 42.18 (CH2), 44.19 (CH2), 45.48 (CH2), 60.30 (CH), 108.25 (CH), 
110.28 (CH), 115.16 (CH), 117.29 (Cq), 126.70 (CH), 144.29 (Cq), 156.29 (CO),
160.72 (Cq), 170.30 (CO), 173.30 (CO).
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4.1.1.18 Coupling N-Boc-glycine to coumarin 2
O EDCI
NHBoc
NHBocDCM/THF
O'^  "O'"'"
78 68 79
Coumarin 2 (78) (0.22 g, 1 mmol) w as dissolved in DCM (5 mL), N-Boc-glycine
(6 8 ) (0.71 g, 4 mmol, 4 eq) and EDCI (0.79 g, 4 mmol, 4 eq) were added and 
the solution w as stirred at room tem perature for 3 days. The solvents were 
evaporated, the residue dissolved in DCM (30 mL) and w ater (30 mL), the 
phases were separated  and the aqueous phase w as extracted with DCM (2 30 
mL). The combined organic phases were w ashed with water (2 30 mL), dried 
over MgS04 , filtered and concentrated. The sam ple was applied onto a  silica 
column and chromatographed with EtaO to give 79 in 10% yield (0.04 g). MS: 
374 [M+Hf; 'H NMR (CDCI3 , Ô): 1.03-1.06 (t, 3 H, CH3), 1.33 (s, 9 H, CH3), 2.21 
(s, 3 H, CHs), 2.32 (s, 3 H, OHs), 3.17-3.27 (sext., 1 H, GH2-I), 3.44-3.46 (d, 2 
H, CH2), 4.02-4.14 (sext., 1 H, CH2-I), 5.32 (br s, 1 H, NH), 6.25 (s, 1 H, CH),
7.02 (8, 1 H, CH), 7.45 (s, 1 H, CH); '^C NMR: 12.76 (CH3), 14.39 (CH3), 17.18 
(CHs), 28.25 (CHs), 38.18 (CH2), 43.36 (CH2), 79.65 (Cq), 109.14 (CH), 115.95 
(Cq), 117.52 (CH), 118.41 (CH), 125.07 (CH), 127.34 (Cq), 132.08 (Cq), 149.57 
(Cq), 152.94 (Cq), 154.73 (CO), 162.18 (CO), 167.80 (CO).
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4.1.1.19 DL-4-Amino-3-hydroxybutyric acid ethyl ester
O OH p-TsOH O OH
H O ' 100% Eton
54 80
DL-4-amino-3-hydroxybutyric acid (54) (2.38 g, 20 mmol) w as suspended in
100% EtOH (80 mL), p-TsOH monohydrate (4.18 g, 22 mmol, 1.1 eq) w as 
added, and the solution w as refluxed under argon for 24 hours. The ethanol 
w as removed at reduced pressure and the residue triturated with diethyl ether 
(60 mL). After filtration the product (80), a white, crystalline solid, w as isolated 
a s  the p-toluenesulfonate salt in 63% yield (3.99 g). MS: 147 [M] ;^ NMR 
(CDCIs, Ô): 1.24 (dt, 3 H, CHs, Ji = 7.1 Hz, Jg = 2.6 Hz), 2.36 (s, 3 H, CHs), 2.53 
(dd, 2 H, CHz, Ji = 9.2 Hz, Jz = 3.1 Hz), 2.88 (dd, 2 H, CHz, Ji = 12.7 Hz, Jz =
9.2 Hz), 3.10 (dd, 2 H, CHz, Ji = 12.7 Hz, Jz = 3.1 Hz), 4.07-4.24 (m, 3 H, CHz + 
CH-0), 7.23 (d, 2 H, 2 CH, J = 7.9 Hz), 7.69 (d, 2 H, 2 CH, J = 8.3 Hz); '®C 
NMR; 14.46 (CHs), 21.30 (CHs), 40.66 (CHz), 45.36 (CHz), 61.83 (CHz-0), 
65.57 (CH-OH), 126.92 (CH), 129.83 (CH), 141.76 (Cq), 143.41 (Cq), 172.18 
(CO); mp; 73 “C, IR (vmax /  (cm"'), KBr); 3338, 3099, 2971, 1740, 1621, 1504, 
1456.
4.1.1.20 DL-N-Boc-4-amino-3-hydroxybutyric acid ethyl ester
OH BoCgO / TEA O OH
EtO' \x N H 3 O T s
80 81
DL-4-amino-3-hydroxybutyric acid ethyl ester (80) (3.19 g, 10 mmol) w as
dissolved in DCM (17 mL), TEA (2.10 mL, 1.52 g, 15 mmol, 1.5 eq) and BoczO 
(2.42 g, 1.10 mmol, 1.1 eq) were added, and the reaction mixture was stirred at
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room tem perature for 24 hours. DCM (30 mL) and water (30 mL) were added, 
the phases were separated, and the aqueous phase was extracted with DCM 
(2 30 mL). The combined organic extracts were w ashed with water, 0.1 M HCI 
and 1 M KHCO3, dried over MgS04 , filtered, and the solvent w as evaporated to 
afford the product (81) as  a colourless oil in 80% yield (1.97 g). MS: 247 [M] ;^ 
NMR (CDCI3, Ô); 1.20 (t, 3 H, CH3, J  = 7.1 Hz), 1.37 (s, 9 H, 3CH3), 2.41 (d,
1 H, CH2-I, J = 3.1 Hz), 2.43 (s, 1 H, CHz-2), 4.00-4.08 (m, 1 H, CH-0), 4.10 (q,
2 H, CHz, J = 7.1 Hz), 5.01 (br s, 1 H, NH); '^C NMR: 14.07 (CH3), 28.30 (CH3), 
38.66 (CHz), 45.48 (CHz), 60.77 (CHz-0), 67.00 (CH-OH), 79.52 (Cq), 156.49 
(CO), 172.41 (CO); IR (vmax / (cm"'), paraffin): 3387, 2927, 2854, 1723, 1530, 
1461.
4.1.1.21 Coupling coumarin 343 to 80
EDCI
DCM
HOOC
NH. +
N
HO
EtO
80 82 83
80 (0.25 g, 0.77 mmol, TsOH-salt) w as dissolved in DCM (6 mL), DIPEA (130
|iL, 0.098 g, 0.77 mmol), coumarin 343 (82) (0.22 g, 0.77 mmol) and EDCI (0.16 
g, 0.85 mmol, 1.1 eq) were added, and the solution w as stirred at room 
tem perature for 12 hours. DCM (30 mL) and water (30 mL) were added, the 
phases were separated, and the aqueous phase w as extracted with DCM (2 20 
mL). The combined organic phases were w ashed with w ater (30 mL), 1 M 
NaOH (30 mL), 1 M HCI (30 mL), dried over MgS04 , filtered and evaporated to 
dryness. The product (83) w as obtained in 60% yield (0.19 g) a s  an orange
80
solid. MS: 415 [M+Hf, 829 [M+M+Hf; 'H  NMR (CDCI3, 5): 1.20 (t, 3 H, CH3. J 
= 7.1 Hz), 1.87-1.95 (m, 4 H, 2 CHz), 2.48 (d, 2  H, CHz, J = 6.4 Hz), 2.70 (t, 2 H, 
CHz, J = 6 .1  Hz), 2.81 (t, 2  H, CHz, J = 6.4 Hz), 3.24-3.29 (m, 4 H, CHz), 3.39- 
3.48 (m, 1 H, CHz-1), 3.55-3.62 (m, 1 H, CHz-2 ), 4.07 (q, 2  H, CHz, J  = 7.1 Hz),
4.13-4.22 (m, 1 H, CH-OH), 6.92 (s, 1 H, CH), 8.50 (s, 1 H, CH), 9.13 (t, 1 H, 
NH, J  = 5.7 Hz); ®^C NMR: 14.07 (CH3), 19.95 (CHz), 20.97 (CHz), 27.33 (CHz), 
35.55 (CHz), 39.23 (CHz), 45.19 (CHz), 49.72 (CHz), 50.15 (CHz), 60.59 (CHz),
68.07 (CH), 105.51 (Cq), 108.05 (Cq), 119.63 (Cq), 126.59 (Cq), 126.99 (CH),
148.12 (CH), 148.27 (Cq), 152.63 (Cq), 162.81 (CO), 165.07 (CO), 171.98 (CO); 
mp: 123 °C; IR (vmax / (cm’'), KBr): 3321, 2937, 2849, 1734, 1693, 1618, 1586, 
1520.
4.1.2 Triad synthesis with glutamic acid scaffold
4.1.2.1 Coupling coumarin 120 to N-Fmoc-]^0-Bu glutamic acid
EDCI
NHFmocHOOC. NHFmocNH2
OtBu OtBu
67 84 85
Coumarin 120 (67) (0.50 g, 2.9 mmol) and N-Fmoc-;^0-*Bu glutamic acid (84) 
(1.27 g, 2.9 mmol) were dissolved in a  mixture of 30 mL THF and 30 m l DCM, 
EDCI (0.60 g, 3.1 mmol, 1.1 eq) w as added, and the solution w as allowed to 
proceed at room tem perature for 24 hours. The solvents were removed at 
reduced pressure, the residue dissolved in DCM (30 mL) and w ater (30 mL), the 
phases were separated , and the aqueous phase w as extracted with DCM (2 25
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mL). The combined extracts were w ashed with water (2 25 mL), dried over 
MgS04 , filtered, and concentrated. The sam ple w as purified on a silica column 
by elution with DCM / MeOH, to give the desired product (85) as  a pale yellow 
solid in 64% yield (1.08 g). HR-ESMS (C34H34N2O7): calc: 583.2439 [M+H]\ 
m easured: 583.2441 [M+Hf; Anal. calc, for C34H34N2O7: C: 70.09, H: 5.88, N: 
4.81; Found: C: 68.27, H: 5.95, N: 4.49; NMR (CDCb); 1.34 (s, 9 H, CH3- 
'Bu), 1.91-2.46 (m, 7 H, CH3 + 2 CH2), 4.07-4.12 (m, 1 H, CH), 4.29-4.59 (m, 3 
H, CHz + CH), 6.04 (s, 1 H, CH), 6.18 (br s, 1 H, NH), 7.16-7.69 (m, 11 H, CH),
9.33 (br s, 1 H, NH); '®C NMR: 18.41 (CH3), 27.74 (CHz), 27.96 (CH3), 31.76 
(CHz), 46.93 (CH), 55.32 (CH), 67.32 (CHz), 81.17 (Cq), 100.89 (CH), 107.07 
(CH), 111.68 (CH), 113.10 (CH), 115.59 (CH), 115.83, 119.89 (CH), 124.98 
(CH), 125.67 (CH), 126.98 (CH), 127.03 (CH), 141.15 (Cq), 134.49 (Cq), 152.54 
(Cq), 153.81 (Cq), 156.67 (CO), 161.14 (CO), 170.44 (CO), 172.82 (CO); mp; 
112-113 °C; IR(vmax/(crn-'), KBr); 3309, 3066, 2978, 1698, 1618, 1583,1525.
4.1.2.2 Removal o f the Fmoc protecting group from 85
NHFmoc
OtBu
piperidine
NH.
DMF, r.t.
OtBu
85 86
85 (0.38 g, 0.63 mmol) w as dissolved in DMF (5 mL), piperidine (1.0 mL) w as
added, and the solution w as stirred at room tem perature for 1.5 hours. The
DMF and the piperidine were removed at reduced pressure and the solid
residue dissolved in DCM (3 mL). The product (86) w as isolated a s  an off-white
solid by chromatography on silica with DCM / MeOH in 79% yield (0.19 g). MS:
82
361 [M+Hf, 722 [M+M+Hf; 'H NMR (CDCI3): 1.38 (s, 9 H, 3 CH3), 1.67 (s, 2 H, 
NH), 1.78-1.90 (m, 1 H, CH2-I), 2.11-2.22 (m, 1 H, CHz-2), 2.34 (s, 3 H, CH3),
2.26-2.44 (m, 2 H, CH2), 3.45-3.50 (m, 1 H, CH), 6.12 (s, 1 H, CH), 7.44-7.52 
(2d, overlapping peaks, 2 H, CH), 7.57-7.58 (s, 1 H, CH), 9.73 (br s, 1 H, NH); 
'®C NMR: 18.53 (CH3), 28.05 (CH3), 29.99 (CH2), 32.14 (CH2), 55.22 (CH), 
80.86 (Cq), 106.77 (CH), 113.31 (CH), 115.29 (CH), 116.01 (Cq), 125.16 (CH),
141.02 (Cq), 152.13 (Cq), 154.30 (Cq), 161.03 (CO), 172.65 (CO), 173.12 (CO).
4.1.2.3 Coupling coumarin 343 to 86
coumarin 343 
EDCI. DCM0 NH
OtB
NH'2
NHO
OtBu
NH
86 87
86 (1.33 g, 3.69 mmol) was dissolved in DCM (7 mL), coumarin 343 (82) (1.05 
g, 3.69 mmol) and EDCI (0.78 g, 4.06 mmol, 1.1 eq) were added, and the 
reaction w as allowed to proceed at room tem perature for 24 hours. The reaction 
w as stopped, DCM (20 mL) and w ater (30 mL) were added to the reaction 
mixture, the layers were separated and the aqueous phase w as extracted with 
DCM (2 30 mL). The combined organic layers were w ashed with w ater (40 mL) 
and dilute NaOH (1 M, 40 mL), dried over MgS04 , filtered, and concentrated in 
vacuo. The desired product (87) w as isolated a s  a bright red solid in 50.5%
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yield (1.17 g) by chromatography on silica with CHCI3 /  MeOH. HR-ESMS 
(C35H37N3O8): calc: 628.2653 [M+H]^, m easured: 628.2660 [M+H]^; Anal. calc, 
for C35H37N3O8: C: 66.97, H: 5.94, N: 6.69; Found: C: 64.87, H: 6.02, N: 6.99;
NMR (CDCI3, Ô): 1.32 (s, 9 H, CH3), 1.88-1.90 (m, 4 H, CH2), 2.02-2.17 (m, 1 
H, CH2-I), 2.23-2.51 (m, 6 H, CH3 + CH2-2 , CH2), 2.71 (t, 4 H, CH2, J = 6.1 Hz), 
2.81 (t, 4 H, CH2, J = 6.2 Hz), 3.26-3.27 (m, 4 H, 2 CH2), 4.68 (dd, 1 H, CH, Ji =
13.7 Hz, J2 = 7.1 Hz), 6.07 (d, 1 H, CH, J = 1.1 Hz), 6.95 (s, 1 H, CH), 7.11-7.30 
(m, 2 H, 2 CH), 7.66 (s, 1 H, CH), 8.40 (s, 1 H, CH), 9.34-9.36 (d, 1 H, NH, J  =
6.8 Hz), 9.97 (s, 1 H, CH); ^^C NMR: 18.25 (CH3), 19.77 (CH2), 19.86 (CH2), 
20.82 (CH2), 26.83 (CH2), 27.22 (CH2), 27.89 (CH3), 31.69 (CH2), 49.69 (CH2),
50.12 (CH2), 53.35 (CH2), 54.24 (CH), 80.51 (Cq), 105.38 (Cq), 106.86 (Cq),
107.10 (CH), 107.63 (Cq), 112.69 (CH), 115.21 (CH), 115.44 (Cq), 124.51 (CH),
127.11 (CH), 141.56 (Cq), 147.90 (Cq), 148.53 (Cq), 152.22 (Cq), 153.67 (Cq), 
160.89 (CO), 162.66 (CO), 164.53 (CO), 170.30 (CO), 171.73 (CO); mp: 166- 
167 °C;
IR (vmax / (cm-'), KBr): 3299, 2936, 2849, 1698, 1618, 1583, 1562, 1516, 1445, 
1416, 1390, 1368, 1310.
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4.1.2.4 Removal o f the ^Bu protection in 87
NH0 TFA
OtBu r.t.
0 NH
OH
.NH
87 88
87 (0.43 g, 0.7 mmol) w as dissolved in DCM (5 mL), TFA (5 mL) w as added, 
and the solution w as stirred at room tem perature. The reaction w as monitored 
by TLC on silica plates (developed in MeOH / DCM (1%)). W hen the 
transformation w as complete, the volatile com ponents were evaporated and the 
sam ple w as dried in vacuo for 12 hours. The trifluoroacetate salt of 88 w as 
obtained as  a dark red solid in quantitative yield. MS: 571 [M+H]^, 1142 
[M+M+Hf; NMR (CDCI3 , Ô): 1.87 (br s, 4 H, 2CH2), 2.07-2.14 (m, 1 H, CHg-
1), 2.29 (s, 3 H, CHs), 2.46-2.48 (m, 2 H, CHg), 2.64-2.70 (m, 3 H, CHg + CHg-
2), 3.27 (br s (m), 4 H, CHz), 4.72 (br s (m), 1 H, CH), 6.03 (s, 1 H, CH), 6.79 (s, 
1 H, CH), 7.33 (d, 1 H, CH, J = 8.4 Hz), 7.40 (d, 1 H, CH, J = 8.4 Hz), 7.65 (s, 1 
H, CH), 8.33 (s, 1 H, CH); NMR 17.98 (CHs), 19.60 (CHz), 20.56 (CHz),
27.02 (CHz), 27.33 (CHz), 29.90 (CHz), 49.50 (CHz), 49.97 (CHz), 53.57 (CH),
105.11 (Cq), 106.16 (Cq), 106.83 (Cq), 107.85 (CH), 112.36 (CH), 112.89 (Cq),
115.58 (CH), 115.77 (Cq), 116.68 (Cq), 119.99 (Cq), 124.85 (CH), 127.02 (CH), 
141.41 (Cq), 147.98 (Cq), 148.75 (CH), 153.49 (Cq), 161.72 (CO), 162.86 (CO),
164.40 (CO), 170.47 (CO), 175.01 (CO).
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4.1.2.5 Coupling 2\3-isopropylidene-5’-aminonucleotides to 88
0
0  OH
Cou 120
2'
B
EDCI
NH
D CM . r.t.0
88 893-b  903-b
88 (0.57 g, 1.0 mmol) w as dissolved in DCM (10 mL). The pH of the solution 
was adjusted to 8.5 with TEA, and the 2 ’,3’-isopropylidene-5’-aminonucleotide 
(89a-b) (1.1 mmol, 1.1 eq) w as dissolved in this solution. EDCI (0.21 g, 1.1 
mmol, 1.1 eq) w as added, and the reaction mixture w as stirred at room 
tem perature for 24 hours. DCM (20 mL) and w ater (30 mL) were added to the 
solution, the phases were separated, and the aqueous phase w as extracted 
with DCM (2 30 mL). The combined organic phases were w ashed with w ater 
(2 30 mL), dried over MgS04 , concentrated, and chromatographed on silica with 
MeOH / DCM (0-5%) to give 90a and 90b as  bright orange-coloured solids.
90a (B = U): Yield: 38% (0.32 g); HR-ESMS (C43H44N60i2Na): calc: 859.2909 
[M+Na]" ,^ m easured: 859.2897 [M+Naf; Anal. calc, for C43H44N6O12: C: 61.72, 
H: 5.30, N: 10.04; Found: C: 52.87, H: 5.00, N: 10.04; ^H NMR (CDCI3 , 5): 1.24 
(s, 3 H, OCH3), 1.44 (s, 3 H, OCH3), 1.87-1.89 (m, 4 H, 2 CHz), 2.10-3.02 (m, 4 
H, 2 CHz), 2.20 (s, 3 H, CH3), 3.68-3.73 (m, 1 H, CH), 2.26-3.39 (m, 19 H, CHz),
4.15 (d, 1 H, CH, J = 4.0 Hz), 4.45 (dd, 1 H, CH, Ji = 12.0 Hz, Jz = 4.0 Hz), 4.58 
(d, 1 H, CH, J = 5.9 Hz), 4.70 (d, 1 H, CH, J = 6.1 Hz), 4.76 (dd, 1 H, CH, Ji =
11.3 Hz, Jz = 5.3 Hz), 5.09 (d, 1 H, CH, J = 6.7 Hz), 5.63 (d, 1 H, CH, J = 8.1
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Hz), 6.00 (s, 1 H, CH), 6.23 (s, 1 H, CH), 6.89 (s, 1 H, CH), 7.19 (s, 1 H, CH), 
7.60 (s, 1 H, CH), 8.44 (d, 1 H, CH, J = 1.5 Hz), 8.63 (d, 1 H, CH, J = 7.1 Hz), 
9.39 (d, 1 H, NH, J = 7.0 Hz), 9.93 (s, 1 H, NH), 10.55 (s, 1 H, NH); "C NMR:
18.36 (CHs), 19.73 (CHs), 19.96 (CHs), 20.87 (CHs), 24.60 (CHs), 25.18 (CHs), 
26.25 (CHs), 27.08 (CHs), 27.26 (CHs), 28.46 (CHs), 33.25 (CHs), 38.57 (CHs),
40.58 (CHs), 49.82 (CHs), 50.18 (CHs), 52.23 (CHs), 53.39 (CHs), 54.59 (CH),
68.09 (CH), 80.38 (CH), 83.63 (CH), 83.70 (CH), 85.17 (CH), 86.76 (CH), 87.91 
(CH), 91.72 (CH), 97.00 (CH), 102.74 (CH), 105.63 (CH), 106.91 (Cq), 107.01 
(Cq), 108.17 (CH), 111.99 (Cq), 112.75 (CH), 114.62 (Cq), 115.68 (Cq), 115.68 
(CH), 119.92 (Cq), 124.75 (CH), 127.23 (CH), 141.71 (Cq), 143.62 (CH), 148.41 
(Cq), 148.69 (CH), 150.89 (Cq), 151.11 (Cq), 152.37 (Cq), 152.59 (Cq), 153.79 
(CO), 161.05 (CO), 163.25 (CO), 164.45 (CO), 167.86 (CO), 170.37 (CO), 
172.91 (CO); mp: 172-174 “C; IR (vq,ax / (cm’'), KBr): 3320, 3081, 2987, 2940, 
2851, 2361, 2342, 1696, 1617, 1583, 1560, 1516.
90b (B = A): Yield: 84% (0.72 g); HR-ESMS (C44H46N9O10): cale: 860.3362 
[M+H^, m easured: 860.3350 [M+H ;^ Anal. calc. for C44H46N9O10: C: 61.39, H: 
5.39, N: 14.64; Found: C: 56.56, H: 4.88, N:13.54; NMR (CDCI3, ô): 1.29 (s, 
3 H, OCH3), 1.54 (s, 3 H, OCH3), 1.86-1.88 (m, 4 H, CHz), 2.25 (s, 3 H, CH3), 
2.18-2.26 (m, 1 H, CHz-1), 2.39-2.46 (m, 1 H, CHz-2), 2.57-2.66 (m, 4 H, 2 
CHz), 2.72 (d, 1 H, CH, J = 6.4 Hz), 3.21-3.25 (m, 4 H, CHz), 4.01-4.04 (m, 1 H, 
CH), 4.42 (d, 1 H, CH, J = 2.4 Hz), 4.76-4.79 (m, 2 H, CHz), 5.23-5.24 (m, 1 H, 
CH), 5.75 (d, 1 H, CH, J = 4.6 Hz), 6.01 (d, 1 H, CH, J = 1.1 Hz), 6.28 (b rs , 2 H, 
NHz), 6.83 (s, 1 H, CH), 7.30 (d, 1 H, CH, J = 8.8 Hz), 7.39 (d, 1 H, CH, J = 1.8 
Hz), 7.60 (d, 1 H, CH, J = 1.8 Hz), 7.75 (s, 1 H, CH), 8.26 (s, 1 H, CH), 8.35 (d, 
1 H, NH, J = 8.3 Hz), 8.39 (s, 1 H, NH), 9.42 (d, 1 H, NH, J = 7.3 Hz), 9.94 (s, 1
87
H, NH); NMR: 18.49 (CH3), 19.96 (CHz), 20.07 (CHz), 21.03 (CHz), 25.33 
(CH3), 27.35 (CHz), 27.50 (CHz), 28.10 (CH3), 32.61 (CHz), 41.11 (CHz), 49.81 
(CHz), 50.23 (CHz), 53.40 (CH), 54.00 (CH3)?, 81.44 (CH), 82.45 (CH), 83.47 
(CH), 92.32 (CH), 105.32 (CH), 105.58 (Cq), 107.11 (Cq), 107.68 (Cq), 108.11 
(Cq), 112.97 (CH), 114.73 (Cq), 115.63 (Cq), 115.70 (CH), 119.66 (CH), 120.77 
(Cq), 124.82 (CH), 127.15(CH), 140.09 (CH), 141.66 (Cq), 148.12 (Cq), 148.45 
(CH), 148.70 (Cq), 152.27 (Cq), 152.70 (CH), 154.01 (Cq), 155.98 (Cq), 161.18 
(CO), 162.66 (CO), 170.08 (CO), 172.96 (CO); mp: 193-195 °C; IR (vmax / (cm' 
)^, KBr): 3325, 2938, 2361, 1698, 1636, 1617, 1582, 1560, 1516.
91 The major isolated product of the reaction:
MS: 554 [M+Hf, 1109 [M+M+Hf; NMR (CDCI3, S): 1.61 (br s, 3 H, NH), 
1.86-1.94 (m, 4 H, CHs), 2.18-2.37 (m, 4 H, CHs), 2.38 (s, 3 H, CH3), 2.47-2.53 
(m, 2 H, CHs), 2.68-2.72 (m, 2 H, CHs), 2.79-2.83 (m, 2 H, CHs), 2.87-3.04 (m, 4
H, CHs), 3.25-3.30 (m, 4 H, CHs), 4.84-4.92 (m, 1 H, CH), 6.25 (d, 1 H, CH, J =
I.3 Hz), 6.94 (s, 1 H, CH), 7.03 (d, 1 H, CH, J = 2.0 Hz), 7.06 (d, 1 H, CH, J =
2.0 Hz), 7.12 (d, 1 H, CH, J = 2.0 Hz), 7.61 (d, 2 H, CH, J = 8.4 Hz), 9.50 (d, 1 
H, NH, J = 6.9 Hz): NMR: 18.78 (CHs), 20.15 (CHs), 21.14 (CHs), 24.30 
(CHs), 27.51 (CHs), 32.22 (CHs), 49.93 (CHs), 50.35 (CHs), 51.78 (CH), 105.77 
(CH), 107.91 (CH), 108.25 (CH), 115.76 (Cq), 117.74 (CH), 119.86 (CH), 120.24 
(Cq), 124.70 (Cq), 125.27 (Cq), 127.27 (Cq), 138.10 (Cq), 148.50 (Cq), 148.63
88
(Cq), 151.86 (Cq), 153.82 (Cq), 160.39 (CO), 162.98 (CO), 164.10 (CO), 171.15 
(CO), 171.38 (CO).
4.1.2.6 Coupling coumarin 151 to N-Fmoc-j^O-Bu giutamic acid
CF,
EDCI
+
HOOC NHFmoc o ^ O ^ ^ ^ N '  ^
H
O
OtBu O OtBu
73 84 92
Coumarin 151 (73) (0.47 g, 2.05 mmol) and N-Fmoc-y-0-*Bu glutamic acid (84) 
(0.87 g, 2.05 mmol) were dissolved in DCM (20 mL), EDCI (0.43 g, 2.26 mmol, 
1.1 eq) w as added, and the solution w as allowed to proceed at room 
tem perature for 3 days. Coumarin 151 is initially only partially dissolved, but 
gradually dissolves as  the reaction proceeds. W ater (30 mL) w as added to the 
reaction mixture, the phases were separated, and the aqueous phase  w as 
extracted with DCM (2- 25 mL). The combined extracts were w ashed with water 
(2 30 mL), dried over MgS04 , filtered, and concentrated. The sam ple w as 
purified on a silica column by elution with EtzO / Hexane (6:4), to give the 
desired product (92) a s  a white solid in 34% yield (0.44 g). HR-ESMS 
(C34H31N2O7F3): calc: 637.2156 [M+Hf, m easured: 637.2157 [M+Hf; Anal, 
calc, for C34H31N2O7F3: C: 64.15, H: 4.91, N: 4.40; Found: C: 64.40, H: 5.02, N: 
4.23; NMR (CDCI3, ô): 1.37 (s, 9 H, 3 CH3), 1.83-2.50 (m, 8  H, 2.5 CHz + 
CH3), 4.10-4.15 (m, 1 H, CH), 4.32-4.35 (d, 2 H, CHz), 6.03-6.08 (m, 2 H, 2  CH), 
7.18-7.66 (m, 11 H, 11 CH), 9.26 (b rs, ~1 H, NH); ’ C^ NMR: 27.72 (CHz), 28.99 
(CH3), 46.92 (CHz), 31.73 (CHz), 55.18 (CH), 81.56 (Cq), 107.48 (CH), 109.27
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(Cq), 113.77 (CH), 116.23 (CH), 119.97 (CH), 124.92 (CH), 127.01 (CH), 127.75 
(CH), 141.18 (Cq), 141.20 (Cq), 142.20 (Cq), 143.42 (Cq), 143.48 (Cq), 155.00 
(CF3), 156.81 (CO), 159.12 (CO), 170.48 (CO), 173.15 (CO); mp: becom es 
glassy at 109-110 °C, complete melting a t 129-130 °C; IR (vmax / (cm"’), KBr): 
3285, 1733, 1698, 1669, 1618, 1583, 1524, 1419, 1408, 1369.
4.1.2.7 Removal o f the Fmoc protecting group from 92
NHFmoc
OtBu
piperidine
DMF, r.t.
OtBu
92 93
92 (0.41 g, 0.64 mmol) w as dissolved in DMF (5 mL), piperidine (1 mL) w as 
added, and the solution w as stirred at room tem perature for 1.5 hours. The 
volatile com ponents were removed at reduced pressure and the solid residue 
dissolved in DCM (3 mL). The product (93) w as isolated as  a yellow solid by 
chromatography on silica with DCM / MeOH in 90% yield (0.24 g). MS: 415 
[Mf, 455 [M+Kf, 828 [M+Mf; H^ NMR (CDCI3 , 5): 1.38 (s, 9 H, CH3), 1.76-1.85 
(m, 1 H, CH2-I), 2.12-2.44 (2 m, 3 H, CH; + CH2-I), 3.46-3.51 (m, 1 H, CH),
6.68 (s, 1 H, CH), 7.44-7.56 (m, 1 H, CH), 7.56-7.59 (m, 1 H, CH), 7.82 (s, 1 H, 
CH); '®C NMR: 28.18 (CH3), 30.06 (CH2), 32.25 (CH2), 55.37 (CH), 81.10 (Cq),
107.26 (CH), 113.78 (CH), 116.15 (Cq), 126.00, 142.29 (Cq), 155.50 (Cq), 
162.69 (CO), 172.80 (CO), 173.53 (CO).
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4.1.2.8 Coupling coumarin 343 to 93
0
C ou'151
Coumarin 3 4 3
.NH,EDCI  
D CM . r.t.
C 0 u.jgC
OtBu
G ' ^ G t B u
93 94
93 (0.33 g, 0.8 mmol) w as dissolved in DCM (10 mL), coumarin 343 (82) (0.23 
g, 0.8 mmol) and EDCI (0.17 g, 0.88 mmol, 1.1 eq) were added, and the 
reaction w as allowed to proceed at room tem perature for 24 hours. The reaction 
w as stopped, DCM (20 mL) and w ater (30 mL) were added to the reaction 
mixture, the layers were separated and the aqueous phase was extracted with 
DCM (2 30 mL). The combined organic layers were w ashed with w ater (40 mL) 
and 1 M NaOH (40 mL), dried over MgS04 , filtered, and concentrated in vacuo. 
The desired product (94) w as isolated as  a bright red solid in 50% (0.27 g) yield 
by chromatography on silica with CHCI3 / MeOH. HR-ESMS (C35H34N3O8F3): 
calc: 682.2371 [M+H]^, m easured: 682.2378 [M+H]^; Anal. calc, for
C35H34N3O8F3: C: 61.67, H: 5.03, N: 6.16; Found: C: 60.86, H: 5.01, N: 6.10; ^H 
NMR (CDCI3, Ô): 1.33 (s, 9 H, CH3), 1.87-1.90 (t, 4 H, CHg), 2.05-2.17 (m, 1 H, 
CH2-I), 2.25-2.48 (m, 3 H, CH2-2 + CH2), 2.63-2.78 (m, 4 H, CH2), 3.26-3.30 
(m, 4 H, CH2), 4.71 (dd, 1 H, CH, Ji = 13.5 Hz, J 2 = 7.0 Hz), 6.47 (s, 1 H, CH), 
6.84 (s, 1 H, CH), 7.30 (dd, 1 H, CH, Ji = 8.9 Hz, J 2 = 1.8 Hz), 7.38 (d, 1 H, CH, 
J =7.5 Hz), 7.76 (d, 1 H, CH, J = 1.8 Hz), 8.36 (s, 1 H, NH), 9.35 (d, 1 H, NH, Ji 
= 6.8 Hz), 10.04 (s, 1 H, NH); ^^C NMR: 19.76 (CH2), 20.84 (CH2), 26.70 (CH2),
27.26 (CH2), 27.91 (CH3), 31.66 (CH2), 49.73 (CH2), 50.16 (CH2), 54.28 (CH), 
80.64 (Cq), 105.46 (Cq), 106.95 (Cq), 107.27 (Cq), 107.95 (Cq), 108.65 (CH),
91
113.11 (Cq), 116.31 (CH), 119.75 (CH), 123.17 (Cq), 125.25 (CH), 127.15 (CH),
140.71 (Cq), 141.14 (Cq), 142.88 (Cq), 147.95 (Cq), 148.62 (CH), 152.62 (Cq), 
154.87 (Cq), 158.99 (CO), 162.73 (CO), 164.69 (CO), 170.55 (CO), 171.82 
(CO); mp: 164-165 “C; IR (vmax / (cm ''), KBr): 3477, 3299, 3087, 2938, 2850, 
2735, 1698, 1618, 1586, 1510, 1446, 1409, 1368, 1311.
4.1.2.9 Removal o f the'Bu protection o f 94
Cou.
0  ^  OtBu
T F A
.NH,
DCM
OH
94 95
94 (0.25 g, 0.37 mmol) w as dissolved in DCM (6 mL), TFA (6 mL) w as added, 
and the solution w as stirred at room tem perature. The reaction w as monitored 
by TLC. When the transformation w as complete, the volatile com ponents were 
evaporated and the sam ple w as dried in vacuo for 12 hours. 95 W as obtained 
a s  a dark red solid in quantitative yield. MS: 571 [M+H] ,^ 1142 [M+M+H^; 
NMR (CDCIs, Ô): 1.89 (m, 4 H, 2 CHg), 2.24-2.69 (m, 2 H, CHz), 3.32 (m, 4 H, 2 
CHz), 4.86-4.87 (m, 1 H, CH), 6.66 (s, 1 H, CH), 6.95 (s, 1 H, CH), 7.44 (dd, 1 
H, CH, Ji = 9.0 Hz, Jz = 2.0 Hz), 7.58 (d, 1 H, CH, J = 7.3 Hz), 7.78 (d, 1 H, CH, 
J = 2.0 Hz), 8.40 (s, 1 H, CH), 9.31 (s, 1 H, NH), 9.58 (d, 1 H, NH, J = 7.5 Hz),
11.38 (s, 1 H, COOH): ^^ C NMR: 27.71 (CHz), 28.81 (CHz), 31.05 (CHz), 55.46 
(CH), 108.36 (CH), 110.39 (Cq), 115.10 (CH), 117.49 (CH), 122.21 (Cq), 124.85 
(Cq), 126.76 (Cq), 127.99 (CH), 144.09 (Cq), 149.42 (Cq), 156.29 (Cq), 160.46 
(CO), 160.96 (CO), 162.38 (CPs), 171.90 (CO), 176.09 (CO), 176.16 (CO).
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4.1.2.10 Coupling 2 3 ’-isopropylidene-5-aminonucleotides to 95
o
0
>'^k^NHCou343 
Cou151 I ^
Cou151
2'
B
EDCI
NH
D C M . r.t.0
X
95 8 9 a-b  96
95 (0.57 g, 1.0 mmol) w as dissolved in DCM (4 mL) and acetonitrile (1 mL). The
pH of the solution w as adjusted to 8.5 with TEA, and the 2',3'-isopropylidene-5'- 
aminonucleotide (89a-b) (2.0 mmol, 2 eq) was dissolved in this solution. EDCI 
(0.21 g, 1.1 mmol, 1.1 eq) w as added, and the reaction mixture w as stirred at 
room tem perature for 48 hours. DCM (20 mL) and water (30 mL) were added to 
the solution, the phases were separated, and the aqueous phase w as extracted 
with DCM (2 30 mL). The combined organic phases were w ashed with water 
(30 mL), dried over MgS04 , concentrated, and chromatographed on silica to 
give 96a and 96b as  bright yellow-coloured solids.
96a (B = U): Yield: 6% (0.05 g) HR-ESMS (C43H41N6O12F3): calc: 891.2807 
[M+H]\ 891.2813 [M+H^: ^H NMR (CDCI3 , Ô): 1.28 (s, 3 H, OCH3), 1.46 (s, 3 H, 
OCH3), 1.90-1.92 (m, 6 H, 3 CHz), 2.20-2.47 (m, 5 H, 2.5 CHz), 2.67-2.71 (t, 2 
H, CHz), 2.86-2.89 (m, 2 H, CHz), 3.34-3.40 (m, 6 H, 3 CHz), 3.78-3.82 (m, 1 H, 
CH), 4.17-4.19 (d, 1 H, CH), -4 .70  (m / br s, 1 H, CH), 4.79-4.83 (t, 1 H, CH),
5.15 (dd, 1 H, CH, Ji = 6.7 Hz, Jz = 2.0 Hz), 5.22 (d, 1 H, CH, J = 2.0 Hz), 5.67 
(dd, 1 H, CH, Ji = 8.0 Hz, Jz = 2.0 Hz), 6.52 (s, 1 H, CH), 6.95 (s, 1 H, CH), 7.13 
(d, 1 H, CH, J = 8.3 Hz), 7.23 (s, 1 H, CH), 7.36 (dd, 1 H, CH, Ji = 8.8 Hz, Jz =
2.0 Hz), 7.45 (d, 1 H, CH, J = 7.3 Hz), 7.75 (d, 1 H, CH, J = 2.0 Hz), 8.51 (s, 1
93
H, NH), 9.42 (d, 1 H, NH, J = 6.8 Hz), 10.07 (s, 1 H, NH), 10.53 (s, 1 H, NH);
NMR: 19.76 (CHz), 20.06 (CHz), 20.95 (CHz), 25.25 (CH;), 27.19 (CHs),
27.40 (CHz), 28.05 (CHz), 33.65 (CHz), 49.98 (CHz), 50.31 (CHz), 54.82 (CH),
80.13 (CH), 83.70, 85.18 (CH), 97.85 (CH), 103.02 (CH), 105.92 (CH), 106.77 
(Cq), 107.42 (Cq), 108.34 (CH), 114.88 (CH), 116.45 (Cq), 120.16 (Cq), 125.53 
(CH), 127.34 (CH), 142.93 (Cq), 143.70 (Cq), 148.69 (Cq), 148.98 (Cq), 151.16 
(Cq), 152.75 (CO), 155.10 (CO), 159.21 (CO), 163.04 (CF3), 163.59 (CO),
165.01 (CO), 170.42 (0 0 ), 172.97 (CO); mp: decomposition above 157 °C; IR 
(vmax / (cm-’), KBr): 3429, 2939,1697, 1617,1584, 1560,1517.
96b (B = A) : Yield: 15% (0.14 g); HR-ESMS (C44H43N9O10F3): calc: 914.3079 
[M+Hf, 914.3078 [M+Hf; Anal. calc. for C44H43N9O10F3: C: 57.77, H: 4.74, N: 
13.77: Found: C; 53.21, H: 4.31, N: 12.83; ’H NMR (CDCI3 , 5): 1.30 (s, 3 H, 
OCH3), 1.55 (s, 3 H, OCH3), 1.88 (m, 4 H, 2 CHz), 2.17-2.24 (m, 1 H, CHz-1), 
2.39-2.46 (m, 1 H, CHz-2), 2.55-2.68 (m, 4 H, 2 CHz), 2.75 (t, 2 H, CHz, J = 6.4 
Hz), 3.23-3.26 (m, 6 H, NH + 2 CHz), 4.04-4.11 (m, 1 H, CH), 4.43 (d, 1 H, CH, 
J  = 2.4 Hz), 4.75-4.79 (m, 1 H, CH), 4.78 (dd, 1 H, CH, Ji = 6.2 Hz, Jz = 2.2 Hz), 
5.20-5.24 (m, 1 H, CH), 5.75 (d, 1 H, CH, J = 4.6 Hz), 6.07 (br s, 1 H, NH), 6.53 
(s, 1 H, CH), 6.86 (s, 1 H, CH), 7.20 (s, 1 H, CH), 7.39 (dd, 1 H, CH, Ji = 8.8 
Hz, Jz = 2.0 Hz), 7.45 (d, 1 H, CH, J = 1.8 Hz), 7.75 (s, 1 H, CH), 7.78 (d, 1 H, 
CH, J = 1.8 Hz), 8.29 (s, 1 H, CH), 8.40 (s, 1 H, NH), 9.42 (d, 1 H, NH, J = 7.1 
Hz), 10.19 (s, 1 H, NH): NMR: 20.10 (CHz), 20.20 (CHz), 21.17 (CHz), 25.46
(CH3), 27.53 (CHz), 27.66 (CH3), 28.04 (CHz), 32.78 (CHz), 41.26 (CHz), 49.97 
(CHz), 50.38 (CHz), 53.53 (CHz), 54.14 (CH), 81.57 (CH), 82.56 (CH), 83.57 
(CH), 92.54 (CH), 105.80 (CH), 107.55 (Cq), 107.73 (Cq), 108.26 (Cq), 109.12 
(Cq), 114.93 (Cq), 116.56 (CH), 119.84 (Cq), 121.04 (Cq), 125.68 (CH), 127.30
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(CH), 140.41 (Cq), 142.96 (CH), 148.30 (Cq), 148.67 (CH), 148.88 (Cq), 152.90 
(Cq), 155.29 (Cq), 155.94 (CO), 159.46 (CO), 162.84 (CF3), 164.75 (CO),
170.36 (CO), 173.15 (CO); mp: decomposition above 148 °C; IR (vmax / (cm'^), 
KBr): 3333, 2939, 1738, 1695, 1636, 1616, 1583, 1516.
97 The major isolated com ponent of the reaction mixture:
ÇF.
HR-ESMS (C31H24N3O7F3): calc: 608.1639 [IVI+H]\ m easured: 608.1633 
[M+Hf; ^H NMR (CDCI3, Ô): 1.84-1.91 (m, 4 H, 2CH2), 2.22-2.36 (m, 1 H, CH2-
1), 2.41-2.47 (m, 1 H, CH2-2), 2.67 (t, 2 H, CH2, J = 6.0 Hz), 2.77 (t, 2 H, CH2, J 
= 6.2 Hz), 2.83-2.97 (m, 2 H, CH2), 3.20-3.27 (m, 4 H, 2 CH2), 4.91 (octet, 1 H, 
CH, Ji = 12.4 Hz, J2 = 6.1 Hz, J 3 = 5.3 Hz), 6.75 (s, 1 H, CH), 6.90 (s, 1 H, CH),
7.13 (dd, 1 H, CH, Ji = 8.5 Hz, J2 = 2.0 Hz), 7.24 (s, 1 H, CH), 7.70 (dd, 1 H, 
CH, Ji = 8.6 Hz, Ü2 = 1.7 Hz), 8.46 (s, 1 H, CH), 9.46 (d, 1 H, NH, J = 6.9 Hz); 
^^C NMR: 19.93 (CH2), 19.96 (CH2), 20.92 (CH2), 24.02 (CH2), 27.29 (CH2),
32.01 (CHz), 49.72 (CHg), 50.15 (CHg), 51.48 (CH), 105.50 (Cq), 107.61 (Cq),
108.03 (Cq), 113.47 (Cq), 116.45 (CH), 118.31 (CH), 119.42 (Cq), 119.68 (Cq), 
123.06 (Cq), 125.62 (CH), 125.72 (CH), 127.09 (CH), 139.44 (Cq), 148.27 (CH),
148.44 (CH), 152.74 (Cq), 154.35 (CO), 158.23 (CO), 162.74 (CF3), 163.86 
(CO), 170.99 (CO), 171.23 (CO); mp: decomposition above 188 °C; IR (vmax / 
(cm"''), KBr): 3432, 3091, 2942, 2852, 1747, 1699, 1618, 1585, 1652, 1519.
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4.1.2.11 Coupling coumarin 2 to N-Fnnoc-y-O-Bu glutamic acid
+
HOOC. NHFmoc
NH
k
OtBu
EDCI
NHFmocDCM, r.t. o '
OtBu
78 84 98
Coumarin 2 (78) (0.21 g, 1.0 mmol) and N-Fmoc-y-0-*Bu glutamic acid (84) 
(0.43 g, 1.0 mmol) were dissolved in DCM (6 mL), EDCI (0.20 g, 1.1 mmol, 1.1 
eq) w as added, and the solution was allowed to proceed at room tem perature 
for 1 week. W ater (30 mL) and DCM (30 mL) were added to the reaction 
mixture, the phases were separated, and the aqueous phase w as extracted with 
DCM (2 30 mL). The combined extractions were w ashed with w ater (2 30 mL), 
dried over MgS04 , filtered, and concentrated. The sam ple w as purified on a 
silica column by elution with EtOAc / hexane, to give the desired product (98) as  
a pale yellow solid in 15.6% yield (0.10 g). MS: 642 [M+Hf ; NMR (CDCI3, 5): 
1.08 (t, 3 H, CH3, J = 6.8 Hz), 1.30 (s, 9 H, CH3), 1.63-1.76 (m, 2 H, CHg), 2 .01-
1.14 (m, 2 H, CH2), 2.18 (s, 3 H, CH3), 2.37 (s, 3 H, CH3), 3.41-3.48 (m, 1 H, 
CH2-I), 3.82-3.99 (m, 2 H, CH2), 4.08-4.12 (m, 1 H, CH), 5.55-5.58 (m, 1 H, 
CH2), 6.26 (s, 1 H, CH), 6.38 (s, 1 H, CH), 7.14 (s, 1 H, CH), 7.19-7.70 (m, 8 H, 
CH); NMR: 12.81 (CH3), 14.43 (CH3), 17.30 (CH3), 18.54 (CH3), 27.99 
(GH3), 30.49 (CH2), 31.55 (CH2), 38.17 (CH2), 44.04 (CH2), 47.10 (CH), 51.26 
(CH), 66.88 (CH2), 80.49 (Cq), 96.20 (CH), 109.24 (CH), 115.82 (CH), 117.34 
(CH), 118.32 (Cq), 119.94 (CH), 120.19 (CH), 125.07 (CH), 127.03 (CH), 141.24 
(CO), 143.71 (CO), 149.58 (CO), 171.60 (CO).
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4.1.2.12 5-Mesyl-2’3 ’-isopropylideneadenosine
O H  / z = N  M s O  / = H
Msci/TEA^
.- :  D M F  / A r  ^  ^0 ^ 0  0 ^ 0
99 100
2’,3’-lsopropylideneadenosine (99) (2.17 g, 7.1 mmol) was dissolved in dry DMF 
(15 mL) and TEA (3 mL, 2.14 g, 21.2 mmol, 3 eq). The solution w as cooled in 
an ice-water bath, and MsCI (602 pL, 0.89 g, 7.8 mmol, 1.1 eq) w as added in 
small portions. The reaction mixture w as allowed to warm to room tem perature, 
and the stirring continued for a further 12 hours. The DMF w as removed in 
vacuo, and the residue was dissolved in DCM (40 mL) and water (40 mL). The 
phases were separated  and the aqueous phase w as extracted with DCM (2 40 
mL). The combined organic phases were w ashed with water (2 30 mL), dried 
over MgS04 , filtered, and concentrated to ~2 mL. The sam ple w as applied onto 
a silica chromatographic column and purified by elution with DCM / MeOH (0- 
2%). The product (100) w as obtained as  a white solid in 70% yield. MS: 385 
[M+Hf, 'H NMR (CDCb, 5): 1.33 (s, 3 H, OCH3), 1.55 (s, 3 H, OCH3), 2.92 (s, 3 
H, SCH3), 4.33-4.49 (m, 4 H, CH2 + CH), 5.08-5.11 (m, 1 H, CH), 5.39-5.42 (m, 
1 H, CH), 5.87 (b rs , 2 H, NH2), 6.07 (d, 1 H, CH, J  = 2.0 Hz), 7.91 (s, 1 H, CH),
8.48 (s, 1 H, CH): " C  NMR: 24.85 (CH3), 27.12 (OCH3), 62.99 (CH2), 81.39 
(CH), 83.14 (CH), 85.78 (CH), 93.22 (CH), 113.82 (CH), 139.95 (CH), 152.38 
(CH3):
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4.1.2.13 5 ’-Azido-2’3 ’-isopropylideneadenosine
OH
NH,
1. M sCI/TEA
NHg
99 101
2’3’-lsopropylideneadenosine (99) (6.01 g, 19.6 mmol) w as dissolved in DMF
(15 mL) and TEA (8.23 mL, 5.90 g, 58.7 mmol, 3 eq) was added. The solution 
w as cooled in an ice-water bath and a solution of methanesulfonyl chloride 
(3.03 mL, 4.49 g, 39.2 mmol, 2 eq) w as added in small portions, while the 
solution w as stirred vigorously. The reaction mixture w as allowed to reach room 
tem perature, and the stirring w as continued for 12 hours. NaNs (3.82 g, 58.8 
mmol, 3 eq) w as added in small portions, and the tem perature w as raised to 45 
°C. The reaction w as continued for 48 hours. The solvents were removed in 
vacuo, the residue dissolved in a mixture of DCM (40 mL) and w ater (20 mL), 
the phases were separated, and the aqueous phase was extracted with DCM 
(2 30 mL). The combined organic layers were w ashed with w ater (30 mL), dried 
over MgS04 , concentrated, and purified on a silica column to give 101 a s  a 
yellow solid in 12% yield (0.80 g). MS; 332 [M^; NMR (CDCI3, 6): 1.33 (s, 3 
H, OCH3), 1.55 (s, 3 H, OCH3), 3.50-3.53 (m, 2 H, CH2), 4.29-4.34 (m, 1 H, CH),
5.00 (dd, 1 H, CH, Ji = 6.4 Hz, J 2 = 3.5 Hz), 5.41 (dd, 1 H, CH, Ji = 6.4 Hz, J2 =
2.2 Hz), 5.70 (s, 2 H, NH2), 6.05 (d, 1 H, CH, J = 2.2 Hz), 7.20 (s, 1 H, NH), 7.86 
(s, 1 H. NH), 8.43 (s, 1 H, NH); NMR: 25.32 (OCH3), 27.12 (OCH3), 52.30 
(CH2), 82.03 (CH), 84.60 (CH), 85.64 (CH), 90.63 (CH), 114.73 (Cq), 120.27 
(Cq), 139.89 (Cq), 149.18 (CH), 155.09 (Cq), 162.54 (CH); mp: decomposition
98
with gas evolution above 136 °C; IR (vmax / (cm’’'), paraffin): 3317, 2922, 2853,
2096, 1641, 1596, 1575, 1465, 1377.
4.1.2.14 5’-Amino-2 ’3 -isopropylidene-adenosine
Ng /= N  HgN /= N
, p p ,  V v O
N
X X
101 89b
101 (0.42 g, 1.27 mmol) w as dissolved in dry THF (10 mL), PPhs (0.33 g, 1.27 
mmol) w as added, and the solution w as stirred at room tem perature for 2 hours. 
W ater (35 pL, 35 mg, 1.91 mmol, 1.5 eq) was added, and the reaction w as 
allowed to proceed overnight. The THF w as removed at reduced pressure, the 
residue dissolved in water (30 mL) and DCM (30 mL), the phases were 
separated, the organic layer w as extracted with water (3 30 mL). The combined 
aqueous phases were w ashed with DCM (30 mL), and the w ater w as removed 
in vacuo. The sam ple w as dried and 89b w as crystallised by the addition of 
diethyl ether (40 mL). After filtration, 89b w as obtained as  a white solid in 72% 
yield (0.29 g). MS: 307 [M+Hri NMR (CDCI3 , 5): 1.32 (s, 3 H, OCH3), 1.53 
(s, 3 H, OCH3), 2.79 (s, 2 H, NH2), 2.94 (d, 2 H. CH2 , J  = 5.7 Hz), 2.98 (s, 2 H, 
NH2), 4.24 (dt, 1 H, CH, Ji = 5.7 Hz, J2 = 3.3 Hz), 5.01 (dd, 1 H, CH, Ji = 6.4 
Hz, J2 = 3.3 Hz), 5.45 (dd, 1 H, CH, Ji = 6.4, Hz, J2 = 2.9 Hz), 6.14 (d, 1 H, CH, 
J  = 2.9 Hz), 8.21 (s, 1 H, NH), 8.30 (s, 1 H, NH); ^^ C NMR: 25.57 (CH3), 27.49 
(CH3), 44.37 (CH2), 83.23 (CH), 84.91 (CH), 88.04 (CH), 91.64 (CH), 115.69 
(Cq), 120.72 (Cq), 141.93 (CH), 150.24 (Cq), 153.97 (CH), 157.42 (Cq), 164.82
99
(Cq): mp: decomposition above 183 °C; IR ((vmax/ (cm"\ paraffin): 3551, 2923,
2853, 2730, 2678, 1675, 1603, 1569, 1512, 1463, 1371.
4.1.2.15 2 ’, 3 -Isopropylideneuridine
OH
OH
acetone NH
NH
cat H+
OH XHO
102 103
Uridine (102) (0.49 g, 2.01 mmol) w as suspended in acetone (100 mL), conc. 
HOI (2 mL) w as added, and the mixture w as stirred at room tem perature 
overnight. As the reaction proceeds the solid gradually dissolves. After the 
completion of the reaction anhydrous K2GO3 (10 g) w as added, the stirring w as 
continued for a further 10 minutes, and the K2CO3 w as filtered out. The acetone 
w as removed at reduced pressure, and 103 w as isolated as  a white solid in 
90% yield (0.51 g). MS: 284 [M+Hf, 568 [M+Hf, 869 [M+M+M+Hf; ’H NMR 
(ds-Acetone, 5): 1.33 (s, 3 H, OCH3), 1.52 (s, 3 H, OCH3), 3.79 (dd, 2 H, CHj, Ji 
= 5.7 Hz, J2 = 3.5 Hz), 4.19 (dd, 1 H, CH, Ji = 7.0 Hz, J ; = 3.5 Hz), 4.89 (dd, 1 
H, CH, Ji = 6.2 Hz, J2 = 2.8 Hz), 4.95 (dd, 1 H, CH, Ji = 6.2 Hz, J 2 = 3.3 Hz), 
5.62 (d, 1 H, CH, J = 8.1 Hz), 5.92 (d, 1 H, NH, J = 2.8 Hz), 7.84 (d, 1 H, CH, J 
= 8.1 Hz); '^C NMR: 25.54 (OCH3), 27.58 (OCH3), 62.79 (CH2), 81.61 (CH), 
85.16 (CH), 87.64 (CH), 93.03 (CH), 102.70 (CH), 114.31 (Cq), 142.67 (CH); 
mp: 154-155 “C; IR ((vmax / (cm"'), KBr): 3246, 2986, 2935, 2901, 2359, 1776, 
1704, 1675, 1619, 1519, 1468.
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4.1.2.16 5-Mesyl-2 ’3 ’-isopropylideneuridine
O H  M s O
•” y r  MSCI,TEA s - v y ^ r ^
> 0 DMF / Ar *" c  ^ 0
°X .°  “X . °
103 104
2’,3’-lsopropylideneuridine (103) (2.98 g, 10.5 mmol) w as dissolved in dry DMF 
(15 mL) and TEA (4.42 mL, 3.18 g, 31.5 mmol, 3 eq). The solution w as cooled 
in an ice-water bath, and MsCI (1.62 mL, 2.40 g, 21.0 mmol, 2 eq) w as added in 
small portions. The reaction mixture w as allowed to warm to room tem perature, 
and the stirring continued for a further 12 hours. The DMF w as removed in 
vacuo, and the residue w as dissolved in DCM (40 mL) and w ater (40 mL). The 
phases were separated and the aqueous phase w as extracted with DCM (2 40 
mL). The combined organic phases were w ashed with water (2 30 mL), dried 
over MgS04 , filtered, and concentrated to -  2 mL. The sam ple w as applied onto 
a silica chromatographic column and purified by elution with DCM/MeOH (0- 
5%). The product (104) w as obtained as  an off-white solid in 80% yield (3.04 g).
NMR (CDCb, 5): 1.33 (s, 3 H, OCH3), 1.54 (s, 3 H, OCH3), 3.02 (s, 3 H, 
SCH3), 4.34-4.39 (m, 1 H, CH), 4.44 (d, 2 H, CH2 , J = 5.0 Hz). 4.86 (dd, 1 H, 
CH, Ji = 6.5 Hz, J2 = 3.4 Hz), 5.03 (dd, 1 H, CH, Ji = 6.4 Hz, J2 = 1.8 Hz), 5.58 
(d, 1 H, CH, J = 1.8 Hz), 5.75 (d, 1 H, CH, J = 7.9 Hz), 8.05 (d, 1 H, CH, J  = 8.1 
Hz); '^C NMR: 26.98 (CH3), 31.39 (CH3), 68.91 (CH2), 81.01 (CH), 84.26 (CH),
85.55 (CH), 95.86 (CH), 102.85 (CH), 114.65 (CH), 142.82 (CH), 162.52 (CO).
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4.1.2.17 5 ’-Azido-2’3 ’-isopropylidene-uridine
OH
NH 1. MsCI/TEA NH
X X
103 105
103 (4.29 g, 15.1 mmol) w as dissolved in DMF (15 mL) and TEA (6.40 mL, 4.60 
9 , 45.3 mmol, 3 eq) w as added. The solution w as cooled in an ice-water bath 
and a solution of methanesulfonyl chloride (2.34 mL, 3.46 g, 30.2 mmol, 2 eq) 
was added in small portions, while the solution w as stirred vigorously. The 
reaction mixture w as allowed to reach room tem perature, and the stirring w as 
continued for 12 hours. NaNs (4.91 g, 75.5 mmol, 5 eq) w as added in small 
portions, and the tem perature was raised to 45 °C. The reaction w as continued 
for 48 hours. The solvents were removed in vacuo, the residue dissolved in a 
mixture of DCM (40 mL) and water (20 mL), the phases were separated , and 
the aqueous phase w as extracted with DCM (2 30 mL). The combined organic 
layers were w ashed with water (30 mL), dried over MgS04 , concentrated, and 
purified on a silica column to give 105 a s  a yellow solid in 85% yield (3.98 g). 
MS; 'H NMR (CDCI3 , Ô): 1.29 (s, 3 H, OCH3), 1.56 (s, 3 H, OCH3 ), 3.58 (d, 2 H, 
CH2 , J = 7.3 Hz), 4.17 (dd, 1 H, CH, J, = 9.5 Hz, J2  = 5.1 Hz), 4.76 (dd, 1 H, CH, 
Ji = 6.4 Hz, J2 = 4.2 Hz), 4.95 (dd, 1 H, CH, Ji = 6.4 Hz, J2 = 2.0 Hz), 5.56 (d, 1 
H, CH, J = 2.0 Hz), 5.70 (d, 1 H, CH, J = 8.0 Hz), 7.24 (d, 1 H, CH, J = 8.0 Hz), 
9.94 (br s, 1 H, NH); '^C NMR: 25.16 (CH3), 27.01 (CH3 ), 52.28 (CH2 ), 81.47 
(CH), 84.25 (CH), 85.81 (CH), 94.79 (CH), 102.79 (CH), 114.67 (CH), 142.45 
(CH), 162.55 (CO), 163.49 (CO); mp: 68-69 °C, g as  evolution above 87 °C; IR 
(vmax/(cm-^), paraffin): 2927, 2854, 2104, 1692, 1461, 1378, 1273, 1214.
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4.1.2.18 5 ’-Amino-2 ’3 ’-isopropylidene-uridine
NHg
NH
X
1. PPhs 
0 : ^ 0  °  2
105 89a
105 (2.15 g, 6.96 mmol) w as dissolved in dry THF (10 mL), PPha (1.82 g, 6.96 
mmol) w as added, and the solution was stirred at room tem perature for 2 hours. 
W ater (150 pL, 150 mg, 8.35 mmol, 1.2 eq) w as added, and the reaction was 
allowed to proceed overnight. The THF w as removed at reduced pressure, the 
residue dissolved in water (30 mL) and DCM (30 mL), the phases were 
separated, the organic layer was extracted with water (3 30 mL). The combined 
aqueous phases were w ashed with DCM (20 mL), and the water w as removed 
in vacuo. The sam ple w as dried and 89a w as crystallised by the addition of 
diethyl ether (40 mL). After filtration the product w as obtained a s  a white solid in 
79% yield (1.56 g). MS: 284 [M+H]\ 566 [M+M+Hf, 850 [M+M+M+Hf; ^H NMR 
(CD3OD, Ô): 1.25 (s, 3 H, OCH3), 1.45 (s, 3 H, OCH3), 2.85 (d, 2 H, CHg, J = 4.6 
Hz), 4.05 (dd, 1 H, CH, Ji = 10.4 Hz, J2 = 5.7 Hz), 4.68-4.80 (m, 2 H, 2 CH),
5.03 (dd, 1 H, CH, Ji = 6.6 Hz, J2 = 2.4 Hz), 5.68 (d, 1 H, CH, J = 7.9 Hz), 5.73 
(d, 1 H, NH, J = 2.6 Hz), 7.64 (d, 1 H, CH, J = 8.1 Hz); ^^C NMR: 24.28 (CH3), 
25.95 (CH3), 51.95 (CH2), 68.09 (CH), 83.57 (CH), 86.76 (CH), 87.78 (CH),
91.59 (CH), 111.96 (CH), 151.48 (CO), 168.59 (CO); mp: melting accom panied 
by gas evolution at 94-95 °C; IR (vmax / (cm'^), KBr): 3364, 3207, 3061, 2988, 
2939, 1698.
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4.1.2.19 5-Azido-2’3 ’-isopropylidene-guanosine
OH /= N
O J  ,0  1. MsCI/TEA
N. ^  2. NaN,
c '  D M F/A r
NH,■2 NHg
107106
2’,3’-lsopropylideneguanosine (106) (7.24 g, 22.4 mmol) w as dissolved in dry 
DMF (50 mL) and TEA (3 eq, 67.2 mmol, 9.4 mL, 6.8 g). The solution w as 
cooled in an ice-water bath, and MsCI (1.91 mL, 2.82 g, 24.6 mmol, 1.1 eq) w as 
added in small portions. The reaction mixture w as allowed to warm to room 
tem perature, and the stirring continued for a further 12 hours. NaNs (8.74 g, 
134.4 mmol, 6 eq) w as added, and the tem perature was raised to 45 °C. The 
reaction w as continued for 48 hours. The DMF was removed in vacuo, and the 
residue w as suspended in DCM (50 mL). After filtration the sam ple w as dried 
over MgS04 , filtered again, and concentrated to -8  mL. The sam ple w as 
applied onto a silica chromatographic column and purified by elution with 
DCM/MeOH (0-15%). The product (107) was obtained as  an off-white solid in 
21% yield. NMR (CDCI3, 5): 1.27 (s, 3 H, OCH3), 1.47 (s, 3 H, OCH3), 3.49- 
3.53 (m, 2 H, CH2), 4.10 (dd, 1 H, CH, Ji = 8.2 Hz, J 2 = 5.1 Hz), 4.95 (m, 1 H, 
CH), 5.03 (t, 1 H, CH, J  = 5.1 Hz), 5.30 (dd, 1 H, CH, J, = 6.3 Hz, J2 = 2.8 Hz), 
6.56 (s, 1 H, NH), 7.94 (s, 1 H, CH), 10.68 (s, >1 H, NH2); ’^C NMR: 25.23 
(OCH3), 27.06 (OCH3), 61.60 (CHz), 81.18 (CH), 83.57 (CH), 86.63 (CH), 88.42 
(CH), 113.04 (Cq), 135.86 (CH), 150.73 (Cq), 153.69 (Cq), 156.72 (Cq), 162.31 
(CH).
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4.1.2.20 2 ’3 ’-Isopropylidene-cytidine
9 *^  1. acetone/cat H+ ^
N N y'Y  2. NH, : i O
i  '  o  3 . K2CO3 O  O
HO OH
108 109
Cytidine (108) (7.00 g, 28.8 mmol) w as suspended in acetone (300 mL), conc. 
HCIO4  (4 mL) w as added, and the reaction mixture w as stirred at room 
tem perature overnight. Concentrated aqueous NH3 (5 mL) w as added to the 
mixture, and the stirring w as continued for ten minutes, after which anhydrous 
K2 CO3 (10 g) w as added, and the mixture w as stirred for a further 10 minutes. 
The solid was removed by filtration, and the volatile com ponents were 
evaporated in vacuo. 109 w as obtained as  a white solid in 87% yield (7.12 g).
NMR (CDCI3, Ô): 1.04 (s, 3 H, OCH3), 1.26 (s, 3 H, OCH3), 3.48 (dd, 1 H, 
CH2-I, Ji = 11.9 Hz, J2 = 4.0 Hz), 3.57 (dd, 1 H, CH2-2 , Ji = 11.9 Hz, J2 = 3.5 
Hz), 3.95 (dd, 1 H, CH, Ji = 7.1 Hz, J2 = 3.5 Hz), 4.68 (dd, 1 H, CH, Ji = 6.3 
Hz, Ü2 = 3.5 Hz), 4.75 (dd, 1 H, CH, Ji = 6.3 Hz, J2 = 2.6 Hz), 5.55 (d, 1 H, CH, J 
= 2.4 Hz), 5.74 (d, 1 H, CH, J = 7.5 Hz), 6.96 (br s, > 1 H, NH2), 7.58 (d, 1 H, 
CH, J = 7.3 Hz); ^^C NMR: 25.64 (CH3), 27.66 (CH3), 54.38 (CH2), 81.69 (CH), 
85.56 (CH), 88.27 (CH), 95.59 (CH), 114.00 (Cq), 144.52 (CH), 156.89 (Cq), 
167.57 (CO).
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4.1.2.21 5 ’-Mesyl-2’,3 ’-isopropylidenecytidine
"  - 0 .  ,0  
' ^ N  M s C I / T E A
^ 3. 0 DM F / Ar
“X ,°
109 110
2 ’,3’-lsopropylidenecytidine (109) (8.64 g, 30.5 mmol) was dissolved in dry DMF
(20 mL) and TEA (12.8 mL, 9.24 g, 91.5 mmol, 3 eq). The solution w as cooled 
in an ice-water bath, and MsCI (2.60 mL, 3.84 g, 33.55 mmol, 1.1 eq) w as 
added in small portions. The reaction mixture was allowed to warm to room 
tem perature, and the stirring continued for a further 12 hours. The DMF w as 
removed in vacuo, and the residue w as dissolved in DCM (40 mL) and water 
(40 mL). The phases were separated  and the aqueous phase w as extracted 
with DCM (2 40 mL). The combined organic phases were w ashed with water 
(2 30 mL), dried over MgS04 , filtered, and concentrated to -  2 mL. The sam ple 
w as applied onto a silica chromatographic column and purified by elution with 
DCM / MeOH (0-5%). The product (110) w as obtained as  an off-white solid in 
60% yield. ’H NMR (CDCI3, 5): 1.27 (s, 3H, OCH3), 1.47 (s, 3H, OCH3), 2.98 (s, 
3H, SO3CH3), 4.30-4.32 (m, 1H, CH), 4.42 (d, 2H, CH;, J  = 5.3 Hz), 4.82-4.85 
(m, 1H, CH), 5.03 (d, 1H, CH, J = 6.4 Hz), 5.53 (s, 1H, CH), 5.95 (d, 1H, CH, J 
= 7.3 Hz), 7.35 (d, 1H, CH, J  = 7.7 Hz); ’^C NMR: 25.18 (OCH3), 26.98 (OCH3), 
69.43 (CH;), 81.33 (CH), 84.65 (CH), 85.63 (CH), 95.85 (CH), 114.15 (Cq), 
144.30 (CH), 155.28 (Cq), 165.68 (CO).
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4.1.2.22 5 ’-Azido-2\3’-isopropylidene-cytidine
OH NH2 NHg
Ifr 1. MsCI/TEA r6 h 2. NaNs
109 111
2 ’,3-lsopropylidenecytidine (109) (6.64 g, 23.5 mmol) was dissolved in DMF (15 
mL) and TEA (9.90 mL, 7.11 g, 70.4 mmol, 3 eq) w as added. The solution w as 
cooled in an ice-water bath and solution of methanesulfonyl chloride (2.00 mL,
2.96 g, 25.8 mmol, 1.1 eq) was added dropwise while stirring vigorously. The 
reaction mixture w as allowed to reach room tem perature, and the stirring w as 
continued for 12 hours. NaNs (9.20 g, 141.0 mmol, 6 eq) w as added in small 
portions, and the tem perature w as raised to 45 °C. The reaction w as continued 
for 48 hours. The solvents were removed in vacuo, the residue dissolved in a 
mixture of DCM and water (40 mL each), the phases were separated , and the 
aqueous phase w as extracted with DCM (2 30 mL). The combined organic 
layers were w ashed with water (30 mL), dried over MgS04 , concentrated, and 
purified on a silica column to give 111 as  a yellow solid in 14% yield (1.01 g). 
MS: 330 [M+Naf, 617 [M+M+Hf; 'H NMR (CDCI3, 5): 1.19 (s, 3 H, OCH3), 1.50 
(s, 3 H, OCH3), 3.39-3.66 (m, 1 H, CH), 4.17 (dd, 1 H, CH, Ji = 12.7 Hz, J 2 = 6.4 
Hz), 4.77 (dd, 1 H, CH, Ji = 6.4 Hz, J 2 = 4.2 Hz), 4.98 (dd, 1 H, CH, J , = 6.4 Hz, 
J2 = 1.8 Hz), 5.56 (d, 1 H, CH, J = 1.8 Hz), 5.85 (d, 1 H, CH, J  = 7.3 Hz), 7.35 
(d, 1 H, CH, J = 7.0 Hz), 7.94 (s, 1 H, NH); '='C NMR: 25.23 (CH3), 27.07 (CH3),
52.48 (CH2), 81.80 (CH), 84.77 (CH), 86.15 (CH), 95.59 (CH), 95.79 (CH), 
114.27 (Cq), 143.65 (CH), 155.33 (Cq), 166.19 (CO).
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4.2 Lanthanide triads
4.2.1 Lanthanide ligand synthesis from protected cyclen derivatives
4.2.1.1 N^-Boc-cyclen-1,4-oxamide
I— \ BoCgO o
T E A .C H C I3
O L J
112 113
To a solution of the cyclen oxalamide (112) (0.22 g, 1 mmol in 12 mL
chloroform) w as added triethylamine (183 pL, 0.24 g, 2.4 mmol) w as added and 
the mixture w as vigorously stirred at room tem perature. Di-tert-butyl dicarbonate 
(0.24 g, 1.1 mmol) w as dissolved in chloroform (10 mL) and this solution was 
added dropwise (in 4 hours) to the solution of the cyclen diamide. The mixture 
w as stirred for 24 hours, concentrated, and chromatographed (CHCI3 / 'PrNH2 = 
95:5) to yield 0.44 g (70%) of the title product (113) a s  a yellow solid. HR-ESMS 
(C15H26N4O4): calc: 327.2027 [M+H]\ m easured: 327.2024 [M+H]'’; NMR 
(CDCI3, Ô) 1.42 (s, 9 H, CH3 Boc), 2.43-4.41 (m, 16 H, CH2 macrocycle), the NH 
protons were not seen  in the spectrum; NMR: 28.41 (CH3, Boc), 45.33 
(CH2), 47.58 (CH2), 49.81 (CH2), 55.07 (CH2), 80.58 (Cq), 156.38 (CO), 158.98 
(CO); mp: 109-110 °C; IR (vmax / (cm"'"), KBr): 3565, 3324, 2975, 2937, 2821, 
1685.
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4.2.1.2 Coupling NMA to chloroacetic acid with EDCI
o
CICH,COOH
EDCI 
DCM
57 114
NMA (57) (112 pL, 0.11 g, 1 mmol) w as dissolved in DCM (10 mL), chloroacetic
acid (0.13 g, 1.3 mmol, 1.3 eq) and EDCI (0.19 g, 1 mmol, 1 eq) were added 
and the solution w as stirred at room tem perature for three days. DCM (15 mL) 
and w ater (25 mL) were added, the phases were separated, the aqueous phase 
was extracted with DCM (2 30 mL). The combined organic phases were 
w ashed with dilute acid (0.1 M HCI, 25 mL), dilute NaOH (0.1 M, 30 mL) and 
w ater (25 mL). The organic phase was dried over MgS04 , filtered, and 
evaporated to dryness. The product (114) w as isolated as  an off-white solid in 
79% yield (0.14 g). NMR (CDCI3, 5): 3.25 (s, 3 H, NCH3). 3.78 (s, 2 H, CHz), 
7.16-7.20 (m, 2 H, CH-ar), 7.30-7.42 (m, 3 H, CH-ar); " C  NMR; 37.98 (N-CH3),
41.49 (CH2CI), 127.05 (CH-ar), 128.56 (CH-ar), 130.06 (CH-ar), 142.67 (CarN),
166.26 (CO).
4.2.1.3 Alkylation o f 113 with 114
B o c
BOC ^
k ' Mal
U MH N ^  DMF. Ar
° W
114 113 115
Triprotected cyclen (113) (0.18 g, 0.55 mmol) and 114 (0.10 g, 0.55 mmol) were 
dissolved in DMF (5 mL), K2CO3 (0.5 g) and Nal (0.5 g) were added to the
109
solution and the reaction mixture w as stirred under an argon atm osphere at 80 
°C for 3 days. The DMF w as removed in vacuo, the residue dissolved in DCM 
(40 mL) and water (40 mL), the phases were separated, and the aqueous 
phase w as extracted with DCM (2 30 mL). The combined organic phases were 
w ashed with w ater (2 30 mL), dried over MgS04 , filtered, and concentrated. The 
sam ple w as chrom atographed on silica with DCM / 'PrNH2. The desired product 
(115) w as obtained in 51% yield (0.12 g) as  a pale yellow solid. MS: 474 
[M +nr; 'H NMR (400 MHz, CDCI3, S); 1.30 (s, 9 H, Boc), 2.48-4.72 (m, 21 H, 
CHz + NCH3), 7.23-7.43 (m, 5 H, CH); ^®C NMR: 28.53 (CH3), 37.35 (NCH3), 
several peaks around 47.46 (CH2), 80.81 (Cq), 127.30 (CH), 130.30 (CH), 
156.63 (Cq), 158.75 (CO), 159.00 (CO); mp: 114 “C; IR (vmax / (cm"'), KBr): 
3509, 2975, 2937, 1685, 1596, 1479, 1433, 1408;
4.2.1.4 Coupling coumarin 2 to chloroacetic acid
CICH,C00H
EDCI
DCM
Cl
78 116
Coumarin 2 (78) (0.21 g, 1 mmol) was dissolved in DCM (10 mL), chloroacetic 
acid (0.13 g, 1.3 mmol) and EDCI (0.19 g, 1 mmol) were added and the solution 
w as stirred at room tem perature for three days. DCM (15 mL) and w ater (25 
mL) were added, the phases were separated , the water phase was extracted 
with DCM (2 30 mL). The combined organic phases were w ashed with dilute 
NaOH (30 mL) and water (25 mL). The organic phase w as dried over MgSO^, 
filtered, concentrated to ~2 mL, and applied onto a silica column. Elution with
110
ethyl aceta te  / hexane (1:1) gave recovered coumarin 2 (0.07 g, 33%) and the 
product (116) as  a white, crystalline solid in 67% yield (0.20 g). HR-ESMS 
(C15H16NO3CI): calc: 294.0891 [M +Hf, m easured: 294.0891 [M+Hf; Anal. calc, 
for C15H16NO3CI: C: 61.33, H: 5.49, N: 4.77; Found: C: 60.08, H: 5.53, N: 4.78;
NMR (CDCI3, Ô): 1.11 (t, 3 H, CH3, J = 7.0 Hz), 2.27 (s, 3 H, CH3), 2.39 (s, 3 
H, CH3), 3.14-3.26 (m, 1 H, CH2-I), 3.67 (s, 2 H, CH2CI), 4.04-4.18 (m, 1 H, 
CH2-2), 6.28 (s, 1 H, CH-ar), 7.08 (s, 1 H, CH-ar), 7.48 (s, 1 H, CH-ar); 
NMR: 13.04 (CH3), 17.94 (CH3), 19.17 (CH3), 42.05 (CH2), 44.54 (CH2), 116.62 
(CH-ar), 118.16 (CH-ar), 120.88 (Cq), 127.75 (CH-ar), 132.51 (Cq), 142.55 (Cq),
151.96 (Cq), 152.78 (Cq), 160.55 (CO), 165.86 (CO); mp: 172 °C; IR (vmax/ (cm‘ 
)^, KBr): 1722, 1678, 1626, 1615, 1558, 1502, 1444, 1402.
4.2.1.5 Coupling coumarin 2 to bromoacetic acid
BrCHXOOH
EDCI
DCM
D
Br
78 117
Coumarin 2 (78) (4.06 g, 18.7 mmol) and bromoacetic acid (10.40 g, 74.8 mmol,
4 eq) were dissolved in DCM (30 mL), and EDCI (14.36 g, 74.8 mmol, 4 eq) 
w as added in small portions to the vigorously stirred solution. The reaction w as 
allowed to proceed for 24 hours at room tem perature. W ater (50 mL) and DCM 
(30 mL) were added to the solution, the phases were separated and the product 
w as extracted into DCM (2 30 mL). The combined organic phases were w ashed 
with water (40 mL) and 2 M NaOH (50 mL), dried over MgS04 , filtered, and the 
DCM w as evaporated in vacuo to. The product (117) w as isolated a s  a white
111
solid in 84% yield (5.28 g) in high purity. Analytically pure sam ples were 
obtained by chromatography on silica with EtOAc / DCM (1:9). HR-ESMS 
(CisHieNOaBr): calc: 338.0386 [M+H]"", m easured: 338.0389 [M+H]'"; Anal. calc, 
for GisHieNOaBr: 0 : 53.27, H: 4.77, N: 4.14; Found: 0 : 60.34, H: 5.44, N: 4.72;
NMR (CDCIs, Ô): 1.07-1.12 (t, 3 H, CH3), 2.27 (s, 3 H, CH3); 2.40 (s, 3 H, 
CH3), 3.13-3.23 (m, 1 H, CH2-I). 3.61 (s, 2 H, BrCHg), 4.08-4.18 (m, 1 H, CH2-
2), 6.28 (s, 1 H, CH), 7.09 (s, 1 H, CH), 7.49 (s, 1 H, CH); NMR: 12.49 
(CH3), 17.38 (CH3), 18.64 (CH3), 41.54 (CH2), 43.99 (CH2), 116.04 (CH), 117.58 
(CH), 120.38 (Cq), 127.24 (CH), 131.97 (Cq), 142.17 (Cq), 151.29 (Cq), 152.02 
(Cq), 159.96 (CO), 165.45 (CO); mp: 171 °C, IR (vmax / (cm"^), KBr): 1723, 1676, 
1626, 1614, 1558, 1502, 1444.
4.2.1.6 Coupling bromoacetic acid to coumarin 120
+  BrCH,COOH
EDCI
NHDCM, r.t.
Br
67 118 119
Coumarin 120 (67) (1.10 g, 6.3 mmol), bromoacetic acid (0.87 g, 6.3 mmol) and 
EDCI (1.33 g, 6.93 mmol, 1.1 eq) were suspended in a mixture of THF and 
DCM (20 mL each). The product started to form immediately, a s  indicated by 
the appearance of a white precipitate. After 12 hours the solid w as filtered off 
and w ashed on the filter with several small portions of DCM. The product (119) 
w as obtained in 75% yield (1.39 g). NMR (DMSO, 5): 2.39 (s, 3 H, CH3), 4.31 
(s, 2 H, CHz), 6.27 (s, 1 H, CH), 7.44-7.49 (m, 1 H, CH), 7.71-7.77 (m, 2 H, CH),
10.71 (s, <1 H, NH): NMR: 17.95 (CH3), 43.56 (CHz), 105.86 (CH), 112.57
112
(CH), 115.28 (CH), 115.47 (Cq), 126.07 (CH), 141.68 (Cq), 153.00 (Cq), 153.56 
(Cq), 159.89 (CO), 165.32 (CO).
4 .2 .1 7  Coupling chloroacetic acid to N-Methyl-L-glucamine
o OH OH OH .j e DCI/H O ^  OAc OAc OAc
Cl1 T T 1 2. Py/A%0 -  N
' OH OH OH ' OAc OAc OAc
120 121 122 
Chloroacetic acid (120) (0.95 g, 1 mmol) and N-methyl-L-glucamine (121) (1.95 
g, 1 mmol) were dissolved in 15 mL water, EDCI (3.84 g, 2 mmol, 2 eq) w as 
added to the solution, and the reaction w as allowed to proceed for 12 hours at 
room tem perature. The water w as removed at reduced pressure, the residue 
(colourless oil) w as dissolved in dry pyridine (12 mL), and the solution w as 
cooled in an ice-water bath for ten minutes. The solution w as stirred vigorously 
while acetic anhydride (15 mL) w as added to the solution in small portions. The 
reaction mixture w as allowed to reach room tem perature and the stirring w as 
continued for another 12 hours. The excess acetic anhydride w as consum ed by 
the addition of w ater (10 mL). DCM (30 mL) and water (40 mL) were afterwards 
added to the mixture, the phases were separated and the aqueous phase  w as 
extracted with DCM (3 30 mL). The combined organic phases were w ashed 
with w ater (2 30 mL) and dilute acid (1 M HCI, T40 mL), dried over MgS04 , 
filtered and the DCM w as removed in vacuo. The product (122) w as isolated as  
a  colourless solid in 42% yield (2.06 g). ^H NMR (CDCb, 6): 2.04-2.10 (m, 15 H, 
CH3CO), 2.16 (s, 3 H, NCH3), 3.07 (s, 2 H, CICH2), 3.56-3.57 (m, 2 H, CH2), 
4.03-4.16 (m, 1 H, CH), 4.27-4.31 (m, 1 H, CH), 5.04 (br s / m ,  1 H, CH), 5.30- 
5.37 (m, 1 H, CH); NMR: 19.88 (CH3), 19.99 (CH3), 20.07 (GH3), 20.21
113
(CHs), 2 2 .13  (CHs), 36 .84  (NCH3), 4 7 .3 3  (CHg), 60 .99  (CICH2 ). 68.24(C H ), 
68 .3 3  (CH), 68 .65  (CH), 68 .50  (CH), 168 .94  (CO), 169.20, (CO) 169 .34  (CO), 
169 .59  (CO), 169 .98  (CO), 170 .67  (CO).
4.2.1.8 Coupling bromoacetic acid to N-Methyl-L-glucamine
o OH OH OH EDCI/H O ^  OAc OAc OAc
Br1 T T 1 2 Py/Ac,0 -  N
I OH OH OH I OAc OAc OAc
118 121 123
Bromoacetic acid (118) (1.38 g, 1 mmol) and N-methyl-L-glucamine (121) (1.95 
g, 1 mmol) were dissolved in 15 mL water, EDCI (3.84 g, 2 mmol, 2 eq) w as 
added to the solution, and the reaction w as allowed to proceed for 12 hours at 
room tem perature. The water was removed at reduced pressure, the residue 
(colourless oil) w as dissolved in dry pyridine (12 mL), and the solution w as 
cooled in an ice-water bath for ten minutes. The solution w as stirred vigorously 
while acetic anhydride (15 mL) w as added to the solution in small portions. The 
reaction mixture w as allowed to reach room tem perature and the stirring w as 
continued for another 12 hours. The excess acetic anhydride w as consum ed by 
the addition of water (10 mL). DCM (30 mL) and water (40 mL) were afterwards 
added to the mixture, the phases were separated and the aqueous phase  w as 
extracted with DCM (3 30 mL). The combined organic phases were w ashed 
with water (2 30 mL) and dilute acid (1 M HCI, T40 mL), dried over MgS04 , 
filtered and the DCM was removed in vacuo. The product (123) w as isolated a s  
a  colourless solid in 34% yield (1.80 g). NMR (CDCI3, S): 2.00-2.05 (m, 15 H, 
CH3), 2.09 (s, 3 H, NCH3), 2.94 (s, 2 H, BrCHz), 3.46-3.60 (m, 2 H, CHz), 3.98- 
4.09 (m, 1 H, CH), 4.20-4.25 (m, 1 H, CH), 4.95-4.99 (m, 1 H, CH), 5.23-5.28
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(m, 1 H, CH), 5.38-5.41 (m, 1 H, CH); '^C NMR: 20.31 (CH3), 20.44 (CH3),
20.52 (CH3), 20.65 (CH3), 20.69 (CH3), 21.09 (CH3), 21.43 (CH3), 33.56 (CH3),
37.20 (CH3), 47.77 (CHz), 50.69 (CHz), 61.29 (CHz), 61.46 (CHz), 67.61 (CH),
68.50 (CH), 68.59 (CH), 68.65 (CH), 68.74 (CH), 69.08 (CH), 69.20 (CH), 69.50 
(CH), 169.39 (CO), 169.76 (CO), 169.87 (CO), 170.16 (CO), 170.56 (CO),
171.55 (CO).
4.2.1.9 Alkylation o f 113 with 116
Boc
[ H N ^  D M F . Ar 'A
1 ^ 0  ° L -f l ' à °
116 113 124
Triprotected cyclen (113) (0.18 g, 0.55 mmol) and 116 (0.16 g, 0.37 mmol) were
dissolved in DMF (10 mL), K2CO3 (2 g) and Nal (2 g) were added to the solution 
and the reaction mixture was stirred under an argon atm osphere at 80 °C for 3 
days. The DMF w as removed in vacuo, the residue dissolved in DCM (40 mL) 
and w ater (40 mL), the phases were separated, and the aqueous phase  w as 
extracted with DCM (2 30 mL). The combined organic phases were w ashed 
with water (2 30 mL), dried over MgS04 , filtered, and concentrated. The sam ple 
was chromatographed on silica with DCM / 'PrNH2. The desired product (124) 
w as obtained in 45% yield (0.12 g) a s  a pale yellow solid. MS: 584 [M+H]""; 
NMR (CDCI3, Ô): 1.08 (t, 3 H, CH3, J = 7.1 Hz), 1.40 (s, 9 H, 3CH3), 2.18 (s, 3 H, 
CH3), 2.40 (s, 3 H, CH3), 2.61-4.62 (m, 24 H, CH2), 6.28 (s, 1 H, CH), 7.04 (s, 1 
H, CH), 7.57 (s, 1 H, CH); '®C NMR: 12.69 (CH3), 46.61 (CH3), 48.04 (CH3),
115
50.68 (CHs), 53.48 (CH3), 62.36 (CH3), 80.64 (Cq), 116.00 (CH), 117.36 (CH),
120.44 (Cq), 125.39 (CH), 127.39 (Cq), 141.11 (Cq), 152.02 (Cq), 156.31 (CO),
159.18 (CO), 159.93 (CO), 166.34 (CO)
Side-product (125):
MS: 513 [M+H]-; ^H NMR (CDCI3, Ô): 1.11 (t, 6 H, 2 CH3, J = 7.1 Hz), 2.23 (s, 6 
H, 2 CH3), 2.39 (s, 6 H, 2 CH3), 3.20-3.31 (m, 2 H, 2 CH2-I), 3.45 (d, 2 H, 2 
CH2-I, J = 15.8 Hz), 3.74 (d, 2 H, 2 CH2-2 , J = 15.8 Hz), 4.07-4.19 (m, 2 H, 2 
CH2-2), 6.28 (s, 2 H, 2 CH), 7.03 (s, 2 H, 2 CH), 7.53 (s, 2 H, 2 CH); ^^C NMR:
12.76 (CH3), 17.12 (CH3), 18.65 (CH3), 30.29 (CH2), 43.67 (CH2), 60.66 (CH2),
116.18 (CH), 117.58 (CH), 120.56 (Cq), 132.01 (CH), 140.39 (Cq), 151.24 (Cq),
152.20 (Cq), 159.79 (CO), 171.14 (CO); mp: 133-134 °C;
IR (vmax / (cm"'’), KBr): 3450, 3066, 2983, 2930, 1728, 1662, 1611, 1557, 1499, 
1448.
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4.2.1.10 Removal of the Boc protection 124
B o c
124 126
124 (0.06 g, 0.11 mmol) w as dissolved in a mixture of DCM (10 mL) and TFA 
(10 mL), and the solution w as stirred at room tem perature for 1 hour. The 
solvents were evaporated, and the yellow residue was dissolved in DCM (40 
mL) and NaOH (2 M , 40 mL). The phases were separated and the product was 
extracted from the aqueous phase with DCM (3 40 mL). The combined organic 
p hases were dried over MgS04 , filtered and evaporated to dryness to give 126 
as  a pale yellow solid in 75% yield (0.04 g). NMR (CD3OD, 6 ): 1.08 (t, 3 H, 
CH3 , J = 6.8 Hz), 2.30 (s, 3 H, CH3), 2.42 (s, 3 H, CH3), 3.14-4.37 (m, 20 H, 
CHz), 6.30 (s, 1 H, CH), 7.24 (s, 1 H, CH), 73 (s, 1 H, CH); ^^C NMR: 12.91 
(CH3), 17.25 (CH3), 18.67 (CH3), 44.66-55 several peaks (CHz), 64.29 (CHz),
116.46 (CH), 117.92 (Cq), 118.57 (CH), 122.00 (Cq), 125.75 (CH), 129.16 (Cq),
139.10 (Cq), 153.32 (Cq), 154.50 (Cq), 162.30 (CO), 164.35 (CO), 168.99 (CO).
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4.2.1.11 Alkylation of 113 with 119
B o c
H
D M F. Ar
119 113 127
Triprotected cyclen (113) (0.70 g, 2.15 mmol) and 119 (0.63 g, 2.15 mmol) were 
dissolved in DMF (20 mL), K2CO3 (2 g) and Nal (2 g) were added to the solution 
and the reaction mixture w as stirred under an argon atm osphere at 80 °C for 3 
days. The DMF w as removed in vacuo, the residue dissolved in DCM (40 mL) 
and w ater (40 mL), the phases were separated, and the aqueous phase  w as 
extracted with DCM (2 30 mL). The combined organic phases were w ashed 
with w ater (2 30 mL), dried over MgS04 , filtered, and concentrated. The sam ple 
w as chromatographed on silica with DCM / MeOH (0-5%). 127 w as obtained in 
29% yield (0.34 g) a s  a pale yellow solid. MS: 542 [M+Hf, 1082 [M+Hf; 
NMR (CD3OD / CDCI3, 5): 1.39 (s, 9 H, CH3-B0 C), 2.13 (s, 3 H, CH3), 2.55-4.84 
(m, 18 H, CH2) 3.94 (s, 2 H, CH;), 5.24 (s, 1 H, CH), 6.11 (s, 1 H, CH), 7.44-
7.52 (m, 2 H, CH), 7.82 (br s, <1 H, NH); ^^C NMR 18.12 (CH3), 28.03 (CH3), 
46.79 (CH2), several peaks at 47-53 ppm (CH2), 53.18 (CH2), 61.73 (CH2),
80.91 (Cq), 106.91 (CH), 112.63 (CH), 115.66 (CH), 115.94 (Cq), 124.83 (CH),
140.61 (Cq), 141.16 (Cq), 152.92 (Cq), 153.61 (CO), 153.75(00), 156.53 (CO),
161.63 (CO), 171.47 (CO).
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4.2.1.12 Removal of the Boc protection 127
127 128
127 (0.10 g, 0.18 mmol) w as dissolved in a mixture of DCM (10 mL) and TFA
(10 mL), and the solution w as stirred at room tem perature for 1 hour. The 
solvents were evaporated, and the yellow residue w as dissolved in DCM (40 
mL) and NaOH (2 M , 40 mL). The phases were separated and the product w as 
extracted from the aqueous phase with w ater (3 40 mL). The combined organic 
phases were dried over MgS04 , filtered and evaporated to dryness to give 128 
a s  a pale yellow solid in 92% yield (0.08 g). MS: 441 [M+H]"", 474 
[M+H+MeOH]\ 883 [M+M+Hf, 915 [M+M+MeOHr; NMR (CD3OD, Ô): 2.32 
(s, 3 H, CH3), 2.78-3.65 (m, 18 H, CHg), 6.12 (s, 1 H, CH), 7.47 (d, 1 H, CH, J =
8 . 6  Hz), 7.94 (d, 1 H, CH, J = 8.4 Hz), 7.81 (s, 1 H, CH), 8.13 (br s, 1 H, NH),
9.24 (br s, 1 H, NH); ^^ C NMR: 18.52 (CH3), several peaks at 45-52 ppm (CH2),
54.09 (CHz), 57.32 (CHz), 62.71 (CHz), 107.08 (CH), 113.49 (CH), 115.76 (Cq),
116.27 (CH), 125.19 (CH), 141.48 (Cq), 152.50 (Cq), 153.86 (Cq), 159.75 (CO),
161.28 (CO), 166.79 (CO).
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4.2.1.13 Alkylation of 128 with N-Boc bromoethylamine
NHBoc
N N-Boc-bromoethylamine
K2CO3, Nal 
DMF, Ar
128
o
128 (0.28 g, 0.64 mmol) was dissolved in DMF (8 mL), K2CO3 (0.53 g, 3.81 
mmol, 6 eq), Nal (0.57 g, 3.81 mmol, 6 eq) and N-Boc-bromoethylamine (131) 
(0.71 g, 3.12 mmol, 5 eq) were added, and the mixture w as stirred at 80 °C 
under argon atm osphere for 24 hours. The DMF w as removed in vacuo, the 
residue dissolved in a mixture of DCM and water (40 mL each), the phases 
were separated , and the aqueous phase was extracted with DCM (2 30 mL). 
The combined organic phases were w ashed with water (2 30 mL), dried over 
MgS04 , filtered, and concentrated to ~5 mL. The product (129) w as isolated as  
a pale yellow solid after purification on a silica column by elution with DCM / 
'PrNHa in 12% yield. MS: 622 [M+Kf; NMR (CD3OD, 8): 1.32 (s, 9 H, Boc), 
2.15-2.48 (m, 10 H, CH3 + CH2), 2.33 (s, 3 H, CH3), 2.70-3.02 (m, 10 H, CH2), 
4.28-4.62 (m, 3 H, CH2), 6.09 (s, 1 H, CH), 7.49 (d, 1 H, CH, J = 8.6 Hz), 7.89 
(dd, 1 H, CH, Ji = 2.0 Hz, J2 = 8.8 Hz), 8.15 (d, 1 H, CH, J = 1.5 Hz), 9.37 (s, 
1H, NH); '^C NMR: 18.50 (CH3), 28.27 (CH3), 43.73 (CH2), 44.34 (CH2), 46.71 
(CH2), 48.16 (CH2), 53.07 (CH2), 53.40 (CH;), 54.24 (CH2), 61.52 (CH2), 107.70 
(CH), 112.89 (CH), 115.56 (Cq), 116.85 (CH), 124.65 (CH), 142.12 (Cq), 152.38 
(CO), 154.05 (CO), 160.20 (CO).
120
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4.2.1.14 N-Boc Bromoethylamine
B0C2O / TEA 
dioxan / water
130 131
Bromoethylamine hydrobromide (130) (2.05 g, 10 mmol) w as dissolved in a 
mixture of dioxan and water ( 6  mL each), TEA (4.20 mL, 3.02 g, 30 mmol, 3 
eq,) and B0C2O (2.3 g, 11 mmol, 1.1 eq) were added, and the solution w as 
stirred at room tem perature for three hours. DCM and water (30 mL each) were 
added, the phases were separated, and the aqueous phase w as extracted with 
DCM (2 20 mL). The combined organic extracts were w ashed with w ater (40 
mL) and dilute acid (0.1 M HCI, 40 mL), were dried over MgS04 , filtered and 
concentrated to ~3 mL. Purification of the sam ple by column chromatography 
(silica column, elution with ether / hexane (2:8)) gave the product (131) as  a 
colourless oil in 48% yield (1.02 g). MS: 223 [M+Hf, 241 [M+H+H2 0 r; NMR 
(CDCb, 8): 1.38 (s, 9 H, CH3), 3.38-3.55 (m, 4 H, 2 CH2), 4.96 (br s, ~1 H, NH); 
"C NMR: 28.30 (CH3), 32.73 (CH2), 42.32 (CH2), 79.75 (Cq), 155.55 (CO); IR 
(vmax/ (cm-'), paraffin): 3347, 2924, 2854, 2361, 2342, 1725, 1709,1503, 1462.
4.2.1.15 N-Boc Ethanolamine methanesulphonate
65 132
N-Boc Ethanolamine (65) (3.60 g, 22.5 mmol) w as dissolved in DCM (20 mL),
TEA (9.5 mL, 6.84 g, 67.7 mmol, 3 eq) w as added, and the reaction mixture
w as cooled in an ice-water bath. MsCI (1.75 mL, 2.58 g, 22.5 mmol) w as added,
and the solution w as allowed to reach room tem perature. The reaction w as
121
allowed to proceed overnight, then water (20 mL) was added to the mixture, the 
phases were separated  and the aqueous phase was extracted with DCM (2 20 
mL). The combined organic phases were w ashed with water (40 mL), dried over 
MgS04 , filtered, and concentrated. Column chromatography on silica with DCM 
gave 132 in 58% yield (3.09 g) as  a colourless, viscous oil. NMR (CDCI3, 6):
1.41 (s, 9 H, CHs), 2.94 (s, 3 H, CH3). 3.40-3.47 (m, 2 H, CH2), 4.24 (t, 2 H, 
CH2, J  = 5.1 Hz), 4.95 (br s, 1 H, NH); NMR: 28.35 (CH3), 37.43 (CH3), 
65.86 (CH2), 68.94 (CH2) 79.97 (Cq), 156.90 (GO).
4.2.1.16 Removal o f the Boc protection from 129
NHBoc NH,
TFA/ DCM
O
O
" t O > -
o
129 133
129 (0.10 g, 0.17 mmol) was dissolved in DCM (10 mL), TFA (5 mL) w as added 
to the solution, and the reaction w as allowed to proceed for 30 minutes. The 
solvents were removed at reduced pressure, the residue neutralised with 
saturated aqueous KHCO3 solution (25 mL), and the product w as extracted into 
DCM (4 30 mL). The combined organic phases were dried over MgS04 , filtered, 
and evaporated to dryness to afford the desired product (133) a s  a yellow solid 
in 78% yield (0.065 g). 'H  NMR (CDCI3, 5): 2.32 (s, 3 H, CH3), 2.50-4.00 (m, 18 
H, CH2), 4.05-4.63 (m, 3 H, CH2), 6.09 (s, 1 H, CH), 7.45-8.00 (m, 3 H, CH),
9.20 (br s, 1 H, NH), 9.86 (br s, 1 H, NH); ^^C NMR: 18.62 (CH3), 43.03 (CH2),
122
46.21 (CHs), 47.51 (CH3), 53.50 (CH3), 113.12 (CH), 116.26 (CH), 117.10 (CH),
124.89 (CH), 141.99 (Cq), 152.46 (CO), 154.26 (CO), 161.39 (CO), 169.84 
(CO).
4.2.1.17 Uridine-S’-carboxylic acid pentafluorophenyl ester
HOpFPh
DCC, DMF F
O
134 135
Uridine-5’-C 0 0 H  (0.37 g, 1.30 mmol) w as dissolved in DMF (5 mL),
pentafluorophenol (0.24 g, 1.30 mmol) and DCC (0.27 g, 1.30 mmol) were 
added, and the reaction mixture w as stirred at room tem perature for 24 hours. 
The urea w as removed by filtration to the activated este r w as isolated as 
colourless crystals (0.68 g crude product, >90% purity). ^H NMR (CDCI3 , 6):
1.21 (s, 1 H, OCH3), 1.47 (s, 1 H, OCH3), 5.00 (s, 1 H, CH), 5.20 (t, 1 H, CH, J =
6.1 Hz), 5.48 (s, 1 H, CH), 5.55 (d, 1 H, CH, J = 6.0 Hz), 5.68 (d, 1 H, CH, J =
7.9 Hz), 7.20 (d, 1 H, CH, J = 7.9 Hz); NMR: 24.81 (CH3), 25.64 (CH3).
84.76 (CH), 88.31 (CH), 99.28 (CH), 103.03 (CH), 113.91 (CH), 143.95 (CH),
150.80 (Cq), 162.76 (CO), 163.19 (CO).
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4.2.1.18 Coupling uridine-5’-carboxylic to bromethylamine
.0
z ' O water c - ®
134 130 136
Uridine-5’-C 0 0 H  (134) (0.64 g, 2.0 mmol) w as dissolved in water (20 ml), TEA
(301 |liL , 0.22 g, 2.1 mmol, 1.05 eq), 2-bromoethylamine hydrobromide (130) 
(0.44 g, 2 mmol) and EDCI (0.84 g, 4.0 mmol, 2 eq) were added, and the 
reaction mixture w as stirred at room tem perature for 3 hours. The product w as 
extracted into EtOAc (4 25 mL), the combined organic phases were w ashed 
with dilute acid (0.01 M p-TsOH, 30 mL), and dried over MgS04 . The product 
(136) w as isolated in 12% yield (0.10 g) as  a pale yellow solid. NMR (CDCb, 
Ô): 1.29 (s, 3 H, OCH3), 1.48 (s, 3 H, OCH3), 3.29-3.59 (m, 4 H, 2 CHz), 4.55 (d, 
1 H, CH, J = 2.8 Hz), 5.08 (dd, 1 H, CH, Ji = 6.4 Hz, J2 = 1.5 Hz), 5.25 (dd, 1 H, 
CH, Ji = 6.4 Hz, Ü2 = 2.6 Hz), 5.45 (d, 1 H, CH, J = 1.5 Hz), 5.70 (d, 1 H, CH, J 
= 7.9 Hz), 6.73 (br s, 1 H, NH), 7.18 (d, 1H, C H, J = 8 . 8  Hz), 8.91 (br s, 1 H, 
NH); ^^ C NMR: 24.71 (OCH3). 26.53 (OCH3), 32.28 (CHz), 40.43 (CHz), 83.37 
(CH), 83.54 (CH), 88.14 (CH), 98.11 (CH), 102.69 (CH), 113.77 (Cq), 143.86 
(CH), 150.13 (CO), 163.62 (CO), 169.31 (CO).
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4.2.2 Ligand synthesis from unprotected cyclen
4.2.2.1 Alkylation of cyclen with 119
o" o
N
DMF, ArN
N
O
119 137 138
Cyclen (137) (0.61 g, 3.55 mmol, 1.2 eq) and coumarin 120 brom oacetate (119) 
(0.70 g, 3.0 mmol) were dissolved in dry DMF (5 mL), K2CO3 (1.3 g, 9 mmol, 3 
eq) and Nal (1.35 g, 9 mmol, 3 eq) were added to the solution and the reaction 
mixture w as stirred at 80 °C under argon atm osphere for 3 days. The DMF w as 
removed at reduced pressure, the residue w as dissolved in w ater (40 mL) and 
DCM (40 mL) the phases were separated and the aqueous phase w as 
extracted with DCM (2 30 mL). The combined organic phases were w ashed 
with water (30 mL), dried over MgS04 , filtered, and concentrated. The sam ple 
w as applied onto a silica column and eluted with chloroform containing 
isopropylamine. The product (138) was obtained after the evaporation of the 
solvent a s  pale yellow solid in 33.5% yield (0.46 g). MS: 388 [M+H]^ ; NMR 
(CDCI3, Ô): 2.29 (s, 3 H, CH3), 2.49-2.80 (m, 16 H, CHg), 3.32 (s, 2  H, CHz), 6.04  
(s, 1 H, CH), 7.37-7.40 (m, 1 H, CH), 7.63-7.66 (m, 1 H, CH), 7.78 (s, 1 H, CH); 
^^C NMR: 18.37 (CH3), 42.60 (CHz), 46.05 (CHz), 46.57 (CHz), 47.33 (CHz), 
53.45 (CHz), 60.18 (CHz), 106.65 (CH), 112.70 (CH), 115.40 (CH), 115.48 (Cq), 
124.87 (CH), 141.86 (Cq), 152.33 (Cq), 153.71 (Cq), 153.91 (Cq), 161.91 (CO), 
170.75 (CO).
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4.2.2.2 Alkylation of 138 with ethyl bromoacetate
NH
EtOH/TEA
NH
EtO
EtO
138 139
138 (0.41 g, 1.06 mmol) w as dissolved in 100% EtOH (10 mL), TEA (372 i^L,
2.64 eq) and ethyl brom oacetate (244 |iL, 0.38g, 2.32 mmol, 2.2 eq) were 
added, and the solution was refluxed under argon for 4 days. The ethanol w as 
evaporated at reduced pressure and, the residue w as dissolved in a mixture of 
DCM and water (30 mL each). The phases were separated and the aqueous 
phase w as extracted with DCM (2 30 mL). The combined organic p h ases were 
w ashed with w ater (40 mL) and dried over MgS04 . The sam ple w as 
concentrated to ~5 mL and 139 w as isolated by silica column chromatography 
(DCM / 'PrNH2, 0-10%) to afford the product in 21% yield (0.12 g). NMR 
(CDCIs, Ô): 1.12 (t, 3 H, CHs, J = 7.1 Hz), 1.21 (td, 3 H, CHs, Ji = 7.1 Hz, Jg = 
2.4 Hz), 2.34 (d, 3 H, CHs, J = 0.9 Hz), 2.40-3.32 (m, 17 H, CHg), 3.25 (s, 2 H, 
CHz), 3.31 (s, 2 H, CHz), 3.99 (q, 2 H, CHz, J = 7.1 Hz), 4.09 (q, 2 H, CHz, J =
7.1 Hz), 6.11 (d, 1 H, CH, J = 1.3 Hz), 7.42 (d, 1 H, CH, J = 7.7 Hz), 7.70 (d, 1 
H, CH, J = 2.0 Hz), 7.73 (dd, 1 H, CH, J , = 5.1 Hz, J 2 = 2.0 Hz); ®^C NMR: 14.24 
(CHs), 14.29 (CHs), 18.60 (CHs), 46.32 (CHz), 47.01 (CHz), 51.10 (CHz), 51.17 
(CHz), 51.56 (CHz), 51.89 (CHz), 52.10 (CHz), 53.07 (CHz), 53.47 (CHz), 54.62 
(CHz), 56.01 (CHz), 56.51 (CHz), 60.20 (CHz), 60.35 (CHz), 60.49 (CHz), 106.96
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N HN
(CH), 113.22 (CH), 115.62 (CH), 115.91 (Cq), 125.11 (CH), 141.77 (Cq), 152.17 
(Cq), 154.31 (Cq), 161.08 (CO), 170.72 (CO), 170.94 (CO), 171.33 (CO).
4.2.2.3 Alkylation o f cyclen with 116
K2CO3, Nal
T h ----------------
H N ^  DMF, Ar
116 137 140
Cyclen (137) (2.52 g, 14.7 mmol, 1.5 eq) and coumarin 2 chioroacetate (116) 
(2.87 g, 9.78 mmol) were dissolved in dry DMF (30 mL), K2CO3 (3 g, 22 mmol,
2.2 eq) and Nal (3 g, 20 mmol, 2 eq) were added to the solution and the 
reaction mixture w as stirred at 80 °C under argon atm osphere for 24 hours. The 
DMF w as removed at reduced pressure, the residue w as dissolved in 40 mL 
w ater and 40 mL DCM the phases were separated and the aqueous phase  w as 
extracted with 2 30 mL DCM. The combined organic phases were w ashed with 
30 mL water, dried over MgS04 , filtered, and evaporated to dryness. The 
residue, a dark yellow oil w as dissolved in minimum amount of methanol and 
triturated with ether. The crystals were filtered and w ashed with small portions 
of cold diethyl ether. The product (140) was isolated as  pale yellow crystals in 
87% yield (3.65 g). Lower yields, but very high purity can be achieved by 
alkylation in refluxing 100% EtOH (25 mL), in the presence of TEA (3 eq), in 24 
hours, under inert atm osphere. Removal of the ethanol and the TEA, followed 
by chromatography on basic alumina (pH 9.5) with DCM / MeOH gave the 
product in 45% yield. HR-ESMS (C23H35N5O3): calc: 430.2813 [M+H]\
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m easured: 430.2814 [M+Hf; 'H  NMR (CDCI3 , 8): 1.11-1.16 (t, 3 H, 3 CH3, J =
6 . 8  Hz), 2.27 (s, 3 H, CH3), 2.40 (s, 3 H, CH3), 2.66-3.32 (m, 17 H, CH2), 3.38-
3.44 (q, 2  H, CHz), 3.99-4.11 (m, 1 H, CHz-2), 6.26 (s, 1 H, CH), 7.04 (s, 1 H, 
CH), 7.50 (8 , 1 H, CH); ®^C NMR: 12.80 (CH3), 15.22 (CH3), 17.53 (CH3), 18.69 
(CH3), 43.36 (CHz), 45.33 (CHz), 46.40 (CHz), 47.65 (CHz), 51.87 (CHz), 65.79 
(CHz), 115.81 (CH), 117.27 (CH), 120.21 (Cq), 127.48 (CH), 131.95 (Cq), 142.23 
(Cq), 151.58 (Cq), 152.07 (Cq), 160.10 (CO), 169.88 (CO).
4.2.2A Alkylation of 140 with 2’,3 ’-isopropylidene-5-0-Ms-uridine
MsO
+
HN.
NH
TEA, CHCI3
HN
140 104 141
140 (0.37 g, 1.26 mmol) w as dissolved in dry chloroform (10 mL), TEA (1.77
mL, 1.27 9 , 12.6 mmol, 10 eq) w as added, and the solution w as flushed with 
argon for 10 minutes. 104 (0.45 g, 1.26 mmol, dissolved in 10 mL dry 
chloroform) w as added dropwise, and the reaction w as allowed to proceed for 
18 hours. The volatile com ponents were removed in vacuo, and the sam ple w as 
purified by column chromatography (alumina, pH = 9.5, DCM / MeOH). The 
product (141) w as isolated in 41% yield (0.36 g) as  a pale yellow solid. ^H NMR 
(CDCIs, Ô): 1.09 (t, 3 H, CHs, J = 7.1 Hz), 1.29 (s, 3 H, OCHs), 1.46 (s, 3 H, 
OCHs), 2.25 (d, 1.5 H, 0.5 CHs, J = 5.0 Hz), 2.29 (s, 1.5 H, 0.5 CHs), 2.39 (s, 3
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H, CHs), 2.67-3.32 (m, 19 H, GHz’s), 3.97-4.10 (m, 1 H, CHg-l), 4.33 (t, 1 H, 
CH, J = 4.6 Hz), 4.40 (d, 2 H, CHz, J = 4.6 Hz), 4.82 (dd, 1 H, CH, Ji = 6.4 Hz, 
Jz = 3.8 Hz), 5.00 (dd, 1 H, CH, Ji = 6.4 Hz, Jz= 1.7 Hz), 5.55 (d, 1 H, CH, J =
I.8 Hz), 5.68 (dd, 1 H, NH, Ji = 8.0 Hz, Jz = 0.9 Hz), 6.26 (s, 1 H, CH), 7.00 (d, 
0.5 H, 0.5 CH, J = 6.2 Hz), 7.14 (d, 0.5 H, 0.5 CH, J = 6.2 Hz), 7.21 (d, 1 H, NH, 
J = 8.0 Hz), 7.48 (s, 1 H, CH), 7.51 (d, 1 H, NH, J = 3.8 Hz); ^^ C NMR: 12.70 
(CHs), 17.53 (CHs), 18.68 (CHs), 25.17 (CHs), 27.00 (CHs), 37.70 (CHz), 43.64 
(CHz), 44.68 (CHz), 45.85 (CHz), 46.66 (CHz), 51.92 (CHz), 53.41 (CHz), 68.86 
(CHz), 80.97 (CH), 84.26 (CH), 85.42 (CH), 95.69 (CH), 102.88 (CH), 
114.70(CH), 115.85 (CH), 117.48 (Cq), 120.26 (Cq), 127.40 (CH), 132.05 (Cq), 
142.73 (CH), 151.56 (CO), 152.07 (CO), 160.13 (CO), 170.20 (CO).
4.2.2.5 Alkylation o f 140 with 2 \3 ’-isopropylidene-5’-0-Ms-adenosine
M s O ^  TEA, CHCI3
* %  —
140 100 142
140 (1.34 g, 3.12 mmol) w as dissolved in dry chloroform (20 mL), TEA (4.38 
mL, 3.15 9 , 31.20 mmol, 10 eq) w as added, and the solution w as flushed with 
argon for 10 minutes. 100 (1.20 g, 3.12 mmol, dissolved in 10 mL dry 
chloroform) w as added dropwise, and the reaction w as allowed to proceed for 
18 hours. The volatile components were removed in vacuo, and the sam ple w as
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purified by column chromatography (alumina, pH = 9.5, DCM / MeOH). The 
product (142) w as isolated in 32% yield (0.71 g) as  a pale yellow solid. MS: 716 
[Mf; ’H NMR (CDCI3, 8): 1.06 (t, 3 H, CH3, J = 7.1 Hz), 1.31 (s, 3 H, OCH3), 
1.58 (s, 3 H, OCH3), 2.22 (s, 3 H. CH3), 2.39 (s, 3 H, CH3), 2.21-3.15 (m, 27 H, 
CH2’s), 3.72 (d, 1 H, CH, J = 12.5 Hz), 3.90 (d, 1 H, CH, J = 12.8 Hz), 4.05 (m, 
1 H, CH2-2), 4.47 (s, 1 H, CH), 5.04 (d, 1 H, CH, J  = 5.9 Hz), 5.14 (t, 1 H, CH, J 
= 5.5 Hz), 5.89 (d, 1 H, CH, J = 5.0 Hz), 6.01 (br s, ~ 2 H, NH, Ji = 8.0 Hz, J 2 = 
0.9 Hz), 6.26 (S, 1 H, CH), 7.00 (s, 1 H, CH), 7.45 (s, 1 H, CH), 8.24 (d, 1 H, 
CH, J = 2.4 Hz): NMR: 12.83 (CH3), 17.33 (CH3), 18.65 (CH3), 25.20
(OCH3), 27.61 (OCH3), 42.98 (CHz), 50.64 (CH;), 53.40 (CH2), 54.67 (CH2),
55.21 (CHz), 58.36 (CHz), 63.32 (CHz), 81.66 (CH), 82.98 (CH), 86.06 (CH),
94.16 (CH), 113.94 (CH), 115.76(CH), 117.42 (CH), 119.98 (Cq), 127.05 (CH), 
131.84 (Cq), 140.20 (CH), 148.38(Cq), 151.43 (Cq), 152.09 (Cq), 152.60 (Cq), 
155.99 (Cq), 160.15 (CO), 170.22 (CO).
4.2.2.6 Alkylation o f 140 with ethyl bromoacetate
o
EtOH/TEA
OEt
O
EtO
140 143
140 (0.92 g, 2.1 mmol) w as dissolved in absolute ethanol (12 mL), TEA (902 pL, 
0.65 g, 6.4 mmol, 3 eq) w as added, and the solution was flushed with argon for 
10 minutes. Bromoacetic acid ethyl este r (513 pL, 0.77 g, 4.6 mmol, 2.2 eq) w as
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added to the solution and the reaction mixture was refluxed under an argon 
atm osphere for 5 days. The ethanol w as evaporated, the residue w as dissolved 
in 30 mL water and 30 mL DCM the phases were separated and the aqueous 
phase w as extracted with 2 30 mL DCM. The combined organic phases were 
w ashed with 30 mL water, dried over MgS04 , filtered, and concentrated to -  2 
mL. The sam ple was chromatographed on a silica column with DOM containing 
2-5% isopropylamine. After evaporation of the solvent the desired product (143) 
was obtained in 15% yield (0.22 g) as  an off-white solid. MS: 601 [M+Hf; 
NMR (CDCIs, Ô): 0.97-1.26 (m, 9 H, O CHs), 2.35 (m, 3 H, CHs), 2.40 (m, 3 H, 
CHs), 2.55-3.32 (m, 23 H, CHs), 3.99-4.11 (m, 5 H, CHs), 6.25 (s, 1 H, CH), 7.03 
(s, 1 H, CH), 7.47 (s, 1 H, CH); ^^ C NMR: 12.70 (CHs), 14.17 (CHs), 14.21 
(CHs), 17.19 (CHs), 18.55 (CHs), 25.97 (CHs), 42.81 (CHs), 42.92 (CHs), 46.86  
(CHs), 47.33 (CHs), 50.53 (CHs), 50.98 (CHs), 51.74 (CHs), 51.88 (CHs), 55.39 
(CHs), 55.96 (CHs), 56.41 (CHs), 56.82 (CHs), 59.93 (CHs), 60.01 (CHs), 60.09 
(CHs), 115.65 (CH). 117.33 (CH), 119.90 (CH), 127.07 (Cq), 142.73 (Cq), 151.35 
(Cq), 152.04 (Cq), 159.98 (Cq), 169.76 (CO), 171.06 (CO), 171.24 (CO), 171.38 
(CO).
Isolated side-products
(144) Symmetric trisubstituted:
EtO
EtO
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NMR (CDCIs, Ô): 1.03-1.05 (t, 3 H, CHs, J = 4.1 Hz), 1.17-1.21 (t, 3 H, CHs, J 
= 7.1 Hz), 2.25 (s, 3 H, CHs), 2.36 (s, 3 H, CHs), 2.31-2.92 (m, 19 H, CHs), 3.21 
(s, 4 H, CHs), 3.23-3.37 (m, 1 H, CHs-2), 4.06 (q, 4 H, 2 CHs, J = 7.1 Hz), 6.26 
(s, 1 H, CH), 7.03 (s, 1 H, CH), 7.49 (s, 1 H, CH); ^^ C NMR: 12.54 (CHs), 13.91
(CHs), 14.01 (CHs), 17.08 (CHs), 18.43 (CHs), 42.65 (CHs), 46.50 (CHs), 50.32
(CHs), 51.25 (CHs), 51.77 (CHs), 52.04 (CHs), 55.68 (CHs), 55.68 (CHs), 59.81
(CHs), 115.41 (CH), 117.15 (CH), 119.77 (CH), 127.00 (Cq), 131.42 (Cq), 142.54
(Cq), 151.35 (Cq), 152.85 (Cq), 159.90 (Cq), 170.19 (CO), 171.21 (CO).
(145) Fully substituted:
MS: 689 [M+Hf, 706 [M+H^ O]^ ; 'H NMR (CDCI3, S): 1.03-1.30 (m, 12 H, 
4  CH3), 2.22-3.71 (m, 31 H, 2 CH3 + CHz’s), 3.99-4.16 (m, 7 H, CHa’s), 6.25 (s, 
1 H, CH), 6.94 (s, 1 H, CH), 7.63 (s, 1 H, CH); NMR: 13.83 (CH3), 13.87 
(CH3), 18.78 (CH3), 31.09 (CHa), 36.27 (CHa), 43.32 (CHa), several minor peaks 
at -  50 ppm, 54.67 (CHa), 54.86 (CHa), 60.95 (CHa), 61.01 (CHa), 115.35 (CH), 
116.62 (CH), 120.12 (CH), 127.76 (Cq), 131.65 (Cq), 141.69 (Cq), 151.68 (Cq),
159.91 (Cq), 162.19 (Cq), 170.15 (CO), 173.22 (CO), 173.37 (CO).
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4 .2 .21  Alkylation of 143 with N-Boc ethanolamine methanesulphonate
o
'OEt
NHBoc
143 146
143 (0.39 g, 0.57 mmol) w as dissolved in DMF (8 mL), potassium carbonate 
(0.45 g, 3.24 mmol, 5.7 eq) and N-Boc-ethanolaminemethanesulfonate (0.39 g,
1.63 mmol, 2.9 eq) were added, and the mixture was stirred at 80 °C under 
argon for 24 hours. The DMF was removed at reduced pressure, the residue 
suspended in DCM (30 mL), water w as added to the suspension (30 mL), and 
the phases were separated. The aqueous phase w as extracted with DCM (2 30 
mL), the combined organic extracts were w ashed with water (2 25 mL), were 
dried over MgS04 , and after filtration the sam ple w as concentrated to ~3 mL. 
The product (146) was isolated as  an off-white solid after chromatography on 
silica with DCM / 'PrNHg (2-5%) in 12% yield (0.06 g). MS: 746 [M+Hf; NMR 
(CDCIs, 8): 1.04-1.38 (18 H, m, 6-CHs), 2.10-3.40 (m, 33 H, I6.5 CH2), 3.58-
4.09 (m, 5H, 2.5 CH2), 6.26 (s, 1 H, CH), 7.04 (s, 1 H, CH), 7.48 (s, 1 H, CH); 
^^ C NMR: 12.76 (CHs), 14.20 (CHs), 17.37 (CHs), 18.63 (CHs), 28.36 (Boc- 
CHs), 24.99 (CH2), 42.97 (CH2), 43.25 (CH2), 43.43 (CH2), 45.43 (CH2), 51.26 
(CH2), 51.65 (CH2), 52.34 (CH2), 52.74 (CH2), 52.84 (CH2), 58.25 (CH2), 60.21 
(CH2), 77.21 (Cq), 115.69 (CH), 117.21 (CH), 117.69, 120.06 (CH), 127.02 (Cq), 
127.25 (Cq), 131.75 (Cq), 151.48 (Cq), 151.53 (Cq), 151.99 (Cq), 152.17 (CO),
160.27 (CO), 171.03 (CO), 171.20 (CO), 171.34 (CO).
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4.2.2.8 Alkylation of 143 with 100
MsO
+
:0
NH
EtO
EtO
K2CO3
DMF, Ar
EtO
EtO
143 100 147
143 (0.75 g, 1.25 mmol) was dissolved in DMF (6 mL), K2CO3 (3 g) and 100 
(0.96 g, 2.49 mmol, 2 eq) were added, and the mixture was stirred at 80 °C 
under argon for 24 hours. The DMF was removed at reduced pressure, the 
residue dissolved in a mixture of DCM and water (30 mL each), and the phases 
were separated. The aqueous phase was extracted with DCM (3 30 mL), the 
combined organic phases were washed with water (T30 mL), dried over 
MgS04, filtered, and concentrated. After extensive chromatography on silica 
(DCM / 'PrNH2, 0-20%) and alumina (DCM / MeOH, 0-5%) 147 was isolated as 
a pale pink solid in 3.5% yield (40 mg). MS: 906 [M+H20r; NMR (CDCI3, 5):
1.06 (t, 3 H, CH3, J = 7.0 Hz), 1.10-1.24 (m, 6 H, 2 CH3), 1.27 (s, 3 H, OCH3),
1.48 (s, 3 H, OCH3), 2.23 (s, 3 H, CH3), 2.35 (s, 3 H, CH3), 2.54-3.69 (m, 23 H, 
CH2’s), 3.97-4.11 (m, 6 H, CHgs), 4.51 (d, 1 H, CH, J = 5.7 Hz), 4.63 (br s, 1 H, 
CH), 4.93 (d, 1 H, CH, J = 5.5 Hz), 5.76 (s, 1 H, CH), 6.26 (s, 1 H, CH), 7.04 (s, 
1 H, CH), 7.47 (s, 1 H, CH), 7.87 (s, 1 H, CH); ^^ C NMR: 12.83 (CH3), 14.24 
(CH3), 17.35 (CH3), 18.65 (CH3), 24.41 (OCH3), 26.01 (OCH3), 42.63 (CH2),
43.03 (CH2), 47.25 (CH2), 49.68 (CH2), 51.83 (CH2), 52.02 (CH2), 52.13 (CH2),
52.52 (CH2), 53.02 (CH2), 53.40 (CH2), 54.46 (CH2), 55.28 (CH2), 55.74 (CH2),
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56.33 (CHz), 60.21 (CHz), 60.38 (CHz), 82.17 (CH), 85.49 (CH). 85.74 (CH),
90.89 (CH), 112.76 (CH), 115.76 (CH), 117.52 (CH), 119.98 (Cq), 127.06 (CH),
131.10 (CH), 131.79 (Cq), 132.01 (Cq), 142.9 (CH)7, 152.13 (Cq), 160.18 (Cq),
163.36 (Cq), 164.97 (CO), 169.88 (CO), 171.09 (CO), 171.25 (CO).
4 .2 .29  Alkylation of 140 with N-Boc-bromoethylamine
N - V ^ N  NN BrCH,CH,NHBoc
TEA/CH CIg/A r
O
NHBoc
140 148
140 (3.10 g, 7.23 mmol) was dissolved in chloroform (100 mL), TEA (10.20 mL, 
7.40 9 , 72.3 mmol, 10 eq) w as added, and the solution w as flushed with argon 
for ten minutes. N-Boc-Bromoethylamine (131) (1.77 g, 7.95 mmol, 1.1 eq), 
dissolved in chloroform (20 mL) w as added dropwise to the solution (the 
addition took approximately 1 hour) and the reaction w as allowed to continue for 
24 hours. The solvents were removed under reduced pressure and the residue 
was chromatographed on silica with DCM / 'PrNHz (0-20%) to give 148 in 29% 
(1.21 g) yield as  a pale yellow solid. HR-ESMS (C30H48N6O5): calc: 573.3759 
[M+Hf, m easured: 573.3765 [M+Hf; 'H NMR (CDCI3 , S): 1.06 (t, 3 H, CH3, J =
7.1 Hz), 1 . 2 2  (s, 9 H, 3 CH3), 2.24 (s, 3 H, CH3), 2.39 (s, 3 H, CH3), 2.38-3.23 
(m, 24 H), 4.02 (dt, 1 H, 0.5 CHa, Ji = 13.5 Hz, J2 = 7.3 Hz), 6.26 (s, 1 H, CH),
7.00 (s, 1 H, CH), 7.48 (s, 1 H, CH); ^^ C NMR: 12.72 (CH3), 17.22 (CH3), 18.55 
(CH3), 28.19 (CH3), 38.79(CHa), 43.09 (CHa), 45.96 (CHa), 47.41 (CHa), 47.63 
(CHa), 51.49 (CHa), 51.75 (CHa), 51.98 (CHa), 53.16 (CHa), 53.35 (CHa), 77.98
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(Cq), 115.67 (CH), 117.07 (CH), 120.02 (Cq), 127.25 (CH), 131.65 (Cq), 142.70 
(Cq), 151.44 (Cq), 152.05 (Cq), 156.07 (Cq), 159.96(CO), 169.56(CO), 172.73 
(CO); mp: 55 °C; IR (vmax / (cm"'), KBr): 3368, 2975, 2933, 2824, 1703, 1664, 
1626, 1614, 1559, 1502.
4.2.2.10 Alkylation of 148 with ethyl bromoacetate
OEt
Y v , : )
NHBoc
O
KaCOj/Nal U y Ü ^  gV
AcN /Ar /
NHBoc
148 146
148 (1.09 g, 1.91 mmol) w as dissolved in AcN (6 mL), K2CO3 (4.25 g, 30.6
mmol, 8 eq), Nal (4.58 g, 30.6 mmol, 8 eq) and ethyl brom oacetate (2118 jiL, 
3.19 g, 19.1 mmol, 5 eq) were added, and the mixture w as stirred at 80 °C 
under argon for 24 hours. The DMF w as removed in vacuo, the residue 
dissolved in water (40 mL) and DCM (40 mL), the phases were separated  and 
the aqueous phase w as extracted with DCM (2 30 mL). The combined organic 
phases were w ashed with w ater (2 30 mL), dried over MgS04 , filtered, and the 
sam ple w as concentrated to 3 mL. The desired product (146) w as obtained by 
purification with silica column chromatography using DCM / 'PrNH2 eluants (0- 
5%). Yield: 70% (0.99 g); MS: 743 [M+Hf, 765 [M+Na]*: H^ NMR (CDCb, S):
1.12 (m, 3 H, CHa), 1.25 (m, 6 H, 2 CHa), 1.38(s, 9 H, 3 CHa), 2.32 (s, 3 H, 
CHa), 2.45 (s, 3 H, CHa), 2.00-3.21 (m, 33 H), 4.15 (m, 1 H, CH), 6.29 (s, 1 H, 
CH), 6.95 (s, 1 H, CH), 7.62 (s, 1 H, CH); ^^ C NMR: 12.58 (CHa), 14.06 (CHa),
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14.12 (CHs), 17.53 (CHs), 18.87 (CHs), 28.38 (CHs), 43.48 (CHz), 43.71 (CHz),
50.52 (CHz), 53.40 (CHz), 55.10 (CHz), 55.73 (CHz), 56.27 (CHz), 61.23 (CHz),
61.36 (CHz), 67.74 (CHz), 79.98 (Cq), 105.01 (Cq), 115.84 (CH), 116.78 (CH), 
117.10 (CH), 120.49 (Cq), 127.99 (CH), 141.48 (Cq), 141.55 (Cq), 151.86 (CO), 
160.06 (CO), 170.64 (CO), 173.24 (CO);
4.2.2.11 Removal o f the Boc protection from 146
OEt OEt
OTFA / DCM
r.t, 30 min
OEt
NHBoc
N
N
o ^
NH,
146 149
146 (0.99 g, 1.33 mmol) w as dissolved in DCM (10 mL), TFA (5 mL) w as added
to the solution, and the reaction mixture was stirred vigorously at room 
tem perature for 30 minutes. The volatile com ponents were removed at reduced 
pressure and the residue dissolved in DCM (30 mL). Concentrated aqueous 
solution of KHCOs w as added in small portions until the pH of the solution 
reached 8. The aqeous phase was extracted with DCM (2 30 mL), and the 
combined organic phases were w ashed with water (40 mL). The organic phase  
w as dried over MgS04 , filtered, and the DCM w as evaporated, to give 149 in 
84% yield (0.72 g) as  a pale yellow solid. MS: 643 [M+Hf, 686 unassigned; H^ 
NMR (CDCIs, Ô): 1.07 (t, 3 H, CHs, J = 6.9 Hz), 1.13-1.26 (m, 6 H, 2CHs), 2.25 
(s, 3 H, CHs), 2.39 (s, 3 H, CHs), 2.32-3.74 (m, 27 H, CHz), 4.04-4.17 (m, 5 H, 
CHz), 6.26 (s, 1 H, CH), 7.00 (s, 1 H, CH), 7.50 (s, 1 H, CH), 7.95 (s, 1 H, NH),
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8.01 (br s, 1 H, NH); NMR: 12.63 (CHs), 14.00 (CHs), 17.20 (CHs), 18.64 
(CHs), 43.22 (CHs), 49.16 (CHs), 49.82 (CHs), 50.95 (CHs), 51.88 (CHs), 53.39 
(CHs), 54.95 (CHs), 60.42 (CHs), 63.99 (CHs), 115.74 (CH), 117.11 (CH),
127.47 (CH), 151.99 (Cq), 160.09 (Cq), 162.44 (CO), 164.67 (CO), 166.44 (CO), 
1 7 1 .3 8 (0 0 ).
4.2.2.12 Coupling 5-carboxylic nucleotides to 149
OEt
OEt 
O
5'-COOH-nucIeotide
EDCI, DMF
NH,
OEt
HN
149 150a-b
149 (0.65 g, 1.0 mmol) w as dissolved in DMF (5 mL), and a solution of the 5’- 
carboxylic nucleotide (2.0 mmol, 2 eq) and EDCI (0.43 g, 2.2 mmol, 2.2 eq) w as 
added. The reaction mixture w as stirred at room tem perature for 24 hours. The 
DMF w as removed at reduced pressure and the sam ple w as dissolved in a 
mixture of DCM and w ater (40 mL each). The phases were separated  and the 
aqueous phase w as extracted with DCM (2 40 mL). The combined organic 
phases were w ashed with water (2 25 mL), dried over MgS04 , filtered, and 
concentrated to 3 mL. Purification of the sam ple by silica column 
chromatography (DCM / 'PrNH2, 0-20%) gave the products 150a and 150b.
150a (B = U): Yield: 84% (0.78 g); HR-ESMS (C45H64N8O13): calc: 947.4485 
[M+Na^, m easured: 947.4477 [M+Na^]; Anal. calc, for C45H64N8O13: C: 58.43,
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H: 6.97, N: 12.11; Found: C: 56.25, H: 6.86, N: 11.58; NMR (CDCI3, ô): 1.06 
(t, 3 H, CH3, J = 7.1 Hz), 1.17 (t, 6 H, 2 CH3. J = 7.1 Hz), 1.28 (s, 3 H, OCH3), 
1.51 (s, 3 H, OCH3), 2.23 (d, 3 H, CH3, J = 1.7 Hz), 2.35 (s, 3 H, CH3), 2.17-3.35 
(t, 33 H, CHz), 3.22 (s, 4 H, arms-NCHz), 4.05 (q, 4 H, arms-CHz, J = 7.1 Hz), 
4.01-4.15 (m, 1 H, coumarin-CHz-l), 4.53 (dd, 1 H, C^H, Ji = 7.1 Hz, Jz = 2.0 
Hz), 4.92-4.98 (m, 2 H, C^H and C^H), 5.66 (dd, 1 H, CH, Ji = 6.0 Hz, Jz = 1.8 
Hz), 5.74 (dd, 1 H, CH, Ji = 9.9 Hz, Jz = 2.2 Hz), 6.26 (d, 1 H, CH, J = 0.9 Hz),
7.03 (d, 1 H, CH, J = 4.0 Hz), 7.48 (s, 1 H, CH), 7.66 (dd, 1 H, CH, Ji = 8.1 Hz, 
Jz = 7.7 Hz), 7.80 (br s, 1 H, NH); ^^ C NMR: 12.62 (CH3), 13.93 (CH3), 14.10 
(CH3). 17.19 (CH3), 17.30 (CH3), 18.55 (CH3). 25.00 (OCH3), 26.94 (OCH3), 
37.00 (CHz), 43.00 (CHz), 51.82 (CHz), 52.57 (CHz), 53.35 (CHz), 54.86 (CHz),
55.48 (CHz), 59.94 (CHz), 60.02 (CHz), 82.99 (CH), 83.97 (CH), 102.44 (CH),
113.81 (Cq), 115.48 (CH), 117.20 (CH), 119.84 (Cq), 127.11 (CH), 131.72 (Cq),
142.27 (CH), 151.54 (Cq), 151.85 (Cq), 160.09 (CO), 169.00 (CO), 169.64 (CO),
169.64 (CO), 169.76 (CO), 171.27 (CO); mp: turns glassy at 87 °C, gas 
evolution at 110 °C, complete melting at 122 °C; IR (vmax / (cm"''), KBr): 2983, 
2938, 2826, 1729, 1697, 1669, 1627, 1614, 1558, 1526, 1455.
150b (B = A): Yield: 47% (0.45 g); HR-ESMS (C46H66N11O11): calc: 948.4938 
[M+Hf, m easured: 948.4947 [M+Hf; Anal. calc, for C46H66N11O11: C: 58.21 H:
7.01 N: 16.23; Found: C: 56.15 H: 6.82 N: 15.35; ^H NMR (CDCI3 , 5): 1.05 (t, 3 
H, CHs, J = 7.1 Hz), 1.12-1.21 (m, 6 H, 2CHs), 1.33 (s, 3 H, OCH3), 1.54 (s, 3 H, 
OCHs), 2.22 (s, 3 H, CHs), 2.40 (s, 3 H, CHs), 2.15-3.34 (m, 33 H, CHz’s), 4.01-
4.07 (m, 4 H, CHz), 5.34-5.36 (m, 1 H, CH), 5.40 (m, 1 H, CH), 5.84 (br s, 2 H, 
NHz), 6.15 (d, 1 H, CH), 6.25 (s, 1 H, CH), 7.10 (d, 1 H, CH, J = 11.34 Hz), 7.47 
(s, 1 H, CH), 8.03 (d, 1 H, CH, J = 1.5 Hz), 8.22 (d, 1 H, CH, J = 1.5 Hz);
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NMR: 12.79 (CHs), 14.24 (CHs), 14.27 (CHs), 17.35 (CHs), 18.67 (CHs), 25.04 
(OCHs), 26.83 (OCHs), 43.15 (CHz), 51.45 (CHz), 51.58 (CHz), 51.80 (CHz),
52.41 (CHz), 55.15 (CHz), 56.32 (CHz), 56.51 (CHz), 60.21 (CHz), 83.56 (CH),
84.07 (CH), 86.78 (CH), 91.43 (CH), 113.85 (Cq), 115.70 (CH), 117.48 (CH),
117.61 (Cq), 119.75 (Cq), 119.98 (Cq), 127.05 (CH), 131.86 (Cq), 140.19 (CH),
149.50 (Cq), 151.54 (Cq), 151.60 (Cq), 152.03 (CH), 153.09 (CO), 155.54 (CO),
160.24 (CO), 168.77 (CO), 171.48 (CO); mp: turns glassy at 105 °C, gas 
evolution a t 114 °C, complete melting at 137 “C; IR (vmax /  (cm"^), KBr): 2981, 
2828, 2361,2341, 1654, 1577, 1559, 1541, 1522, 1507, 1498.
4.2.2.13 Complexation o f europium with ISOa and 150b
EuCU
M e O H , A r •O E t
O E t
— I 3+
150a-b  151a-b
The ligands (150a and 150b), (74 mg and 71 mg, 0.074 mmol, 1.1 eq) were 
dissolved in HPLC-grade methanol (0.5 mL), anhydrous europium chloride 
(17.5 mg, 0.067 mmol) was added, and the solution w as refluxed under argon 
overnight. The reaction mixture was allowed to cool back to room tem perature 
and w as pored into cold diethyl ether (5 mL). The mixture w as centrifuged and 
the ether w as poured off the white precipitate. The solid w as suspended in 5 mL 
of ether, and centrifuged again. The ether w as poured off again, the residue 
dissolved in distilled water (1 mL), filtered through a plug of cotton wool and the
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sam ple w as freeze-dried. The complexes (151a and 151b) were obtained as  
white solids. The purity of the sam ples were checked by TLC (alumina plates, 
DCM / MeOH).
151a (B = U): Yield: 74% (60 mg); MS: 897 [Ligand-2 E tf; NMR (CD3OD, 5): 
9.23, 9.97, 12.02, 13.42, 15.81, 17.28, 18.53, 19.70, 20.94, 21.41, 22.58;
151b (B = A): Yield; 76% (63 mg); MS: 920 [Ligand-2 E tf, 1043 [M-Eta]*; 'H 
NMR (CD3OD, Ô): several peaks between 1.63 and 8.40, 10.84, 18.01;
4.2.2.14 Complexation o f terbium with 150a and 150b
E tO
E tO
TbCU
MeOH, Ar
3+
•O E t,'Tb:
O E t
150a-b  152a-b
The ligands (150a and 150b), (74 mg and 71 mg, 0.074 mmol, 1.1 eq,
respectively) were dissolved in HPLC-grade methanol (0.5 mL), anhydrous 
terbium chloride (19 mg, 0.67 mmol, 0.9 eq) w as added, and the solution w as 
refluxed under argon overnight. The reaction mixture was allowed to cool back 
to room tem perature and was poured into cold diethyl ether (5 mL). The mixture 
w as centrifuged and the ether was poured off the white precipitate. The solid 
w as suspended in 5 mL of ether, and centrifuged again. The ether w as poured 
off again, the residue dissolved in distilled w ater (1 mL), filtered through a  plug 
of cotton wool and the sam ple was freeze-dried. The com plexes (152a and
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152b) were obtained as  white solids. The purity of the sam ples were checked 
by TLC (alumina plates, DCM / MeOH).
152a (B = U): Yield: 78% (63 mg); MS: 1101 [M+HzO^, 897 [Ligand-2 E tf; 
NMR could not be obtained.
152b (B = A): Yield: 80% (66 mg); MS; 920 [Ligand-2 E tf; ’H NMR (CD3OD, 8); 
10.76, 13.85, 16.05, 18.04, 20.91; NMR could not be obtained.
4.2.2.15 Alkylation of cyclen with N-Boc bromoethylamine
NH BrCHjCHjNHBoc p -N H
" O '  ' [ _ ]N HN TEA, EtOH N
NHBoc
137 153
Cyclen (137) (7.60 g, 60.3 mmol, 1.1 eq) w as dissolved in 100% EtOH (30 mL), 
TEA (16.92 mL, 12.18 g, 120.6 mmol, 3 eq) and N-Boc bromoethylamine (8.93 
g, 40.2 mmol) were added, and the solution was refluxed under argon 
atm osphere for 24 hours. The ethanol and the triethylamine were evaporated, 
the residue dissolved in DCM (40 mL), and the solution w as w ashed with 1 M 
NaOH (30 mL). The aqueous phase ws extracted with DCM (2 30 mL), the 
combined organic phases were dried over MgS04 , filtered, concentrated to ~5 
mL, and purified by column chromatography on a basic alumina column (pH 
9.5) by elution with DCM / MeOH (0.2-4%). The product (153) w as isolated a s  a 
white solid in 23% yield (4.27 g). MS: 315 [M+Hf; 'H NMR (CDCb, 5): 1.37 (s, 9 
H, CH3), 2.48-2.78 (m, 18 H, CH2), 3.14-3.22 (m, 4 H, CHz), 5.54; '=‘C NMR;
28.42 (CH3), 46.08 (CHz), 47.04 (CHz), 47.80 (CHz), 51.95 (CHz), 54.20 (CHz), 
78.76(Cq), 155.98 (CO); mp: 119-120°C; IR (vmax / (cm"'), KBr): 3344, 3269, 
3186, 2956, 2803, 2700, 1697, 1566.
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4.2.2.16 Alkylation of 153 with coumarin 2 bromoacetate (117)
TEA, CHCU
NHBoc
NH N
N N
NHBoc
153 148
153 (1.54 g, 4.90 mmol) w as dissolved in dry chloroform (100 mL), TEA (3.44 
mL, 2.47 9 , 24.5 mmol, 5 eq) w as added to the solution, and the mixture w as 
flushed with argon for 10 minutes. Coumarin 2 brom oacetate (1.66 g, 4.90 
mmol) in chloroform (23 mL) was added dropwise (in 1 hour) to the reaction 
mixture, and the stirring w as continued for 36 hours at room tem perature. W ater 
(40 mL) w as added, the phases were separated , and the organic phase  w as 
w ashed with water again (40 mL). The organic phase was dried over MgS04 , 
filtered, and concentrated to ~5 mL. The desired product (148) w as isolated by 
silica column chromatography by elution with DCM / 'PrNH2 (2.5-10%) a s  a pale 
yellow solid in 13% yield (0.37 g). Data equal to those reported at 4 .22 .9 .
4.2.2.17 N-Fmoc Bromoethylamine
Br'
-NH/HBr
Fm oc-ch lo rofo rm ate
10% KHCOS 
dioxan
Br'
.0YO
154130
Bromoethylamine hydrobromide (130) (4.10 g, 20 mmol) w as dissolved in 10% 
KHCO3 solution (20 mL), dioxin (20 mL) w as added, and the solution w as 
cooled in an ice-water bath. In small portions Fmoc-chlorocarbonate (5.20 g, 20
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mmol) w as added, and the mixture w as stirred at ice-water tem perature for 4 
hours and room tem perature for 12 hours. DCM and water (30 mL each) were 
added to the reaction mixture, the phases were separated, and the aqueous 
phase  w as extracted with DCM (12-30 mL). The combined organic p h ases were 
w ashed with w ater (30 mL) and dilute acid (0.5 M HCI, 50 mL). The DCM 
solution w as dried over MgS04 , filtered, concentrated to -  5 mL, and 
chrom atographed on silica with Et20 / Hexane (2 : 8). After evaporation of the 
solvents N-Fmoc bromoethylamine (154) w as obtained in 23% yield (1.60 g) as  
a  shiny white, fluffy solid. MS: 345 [M+H*], 363 [M+HaO ;^ 'H NMR (S, CDCb): 
3.43-3.47 (m, 2 H, CHa), 3.53-3.69 (m, 2 H, CHa), 4.09-4.13 (m, 1 H, CH), 4.40-
4.42 (m, 2 H, CHa), 7.27-7.77 (m, 8 H, CH); "C NMR: 32.48 (CHa), 42.73 (CHa),
47.17 (CHa), 66.88 (CH), 120.00 (CH), 124.99 (CH), 127.05 (CH), 127.72 (CH), 
141.31 (Cq), 143.77 (Cq); mp: 86-87 °C; IR (vmax /  (cm"'), KBr): 3330, 1699, 
1608, 1547, 1477.
4.2.2.18 Alkylation of cyclen with t-Butyl bromoacetate
n  r \
-NH N ^  BrCH,C00‘Bu ,^N H  N-p-I II IN---. WrUMgUUU'bU I— 'Nn in - --
^ N  H N ^  TEA, Eton N___N ;J  /?
O
137 155
Cyclen (137) (10.00 g, 58.1 mmol, 1.5 eq) was dissolved in 100% EtOH (45 
mL), TEA (16.3 mL, 11.7 g, 116.2 mmol, 3 eq) and tert-butyl brom oacetate 
(6.30 mL, 7.56 g, 38.8 mmol) were added, and the solution w as refluxed under 
argon for 24 hours. The ethanol and the triethylamine were evaporated, and the 
residue dissolved in DCM (30 mL). The solution w as w ashed with w ater (30
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mL), and the aqueous phase was extracted with DCM (2 30 mL). The combined 
organic phases were w ashed with water (30 mL), dried over MgS04 , filtered, 
and concentrated to ~5 mL. The crude sam ple w as purified on a basic alumina 
column (pH 9.5) by elution with DCM / MeOH (0.2-4%) to give the 
monoalkylated product (155) in 45% yield (5.00 g) as  an off-white, viscous 
liquid. MS; 286 [M+Hf; NMR (CD3OD, 8): 1.40 (s, 9 H, CH3), 2.54-2.86 (m, 
16 H, CH2), 3.14-3.31 (m, 2 H, CHz); NMR: 28.14 (CH3), 45.23 (CHa), 45.98 
(CH2), 46.93 (CH2), 51.68 (CH2), 56.94 (CH2), 80.85 (Cq). 170.70 (CO); IR (vmax 
/ (cm"'), KBr): 2923, 2853, 2360, 1735, 1462.
4.2.2.19 Alkylation of 151 with tBu bromoacetate
I  ^ I ----- V __
^N H  BrCHsCOO'Bu nH \
 ^  ^ NHBoc ^ ^  ^ ^ ^ N H B o c
151 156
151 (3.00 g, 9.6 mmol) w as dissolved in dry chloroform (120 mL), TEA (13.40 
mL, 9.65 g, 95.5 mmol, 10 eq) w as added to the solution, which w as then 
flushed with argon for 10 minutes. *Butyl brom oacetate (1.55 mL, 1.86 g, 9.6 
mmol) in chloroform (29 mL) w as added dropwise (in 1 hour) to the vigorously 
stirred reaction mixture, and the reaction was allowed to proceed for 36 hours at 
room tem perature. W ater (40 mL) w as added to the solution, the phases were 
separated , and the organic phase w as w ashed with w ater (40 mL). The organic 
phase w as dried over MgS04 , filtered, and concentrated to ~5 mL. The desired 
product (156) w as isolated by silica column chromatography by elution with 
DCM / 'PrNH2 (2.5-10 %) in 25% yield (1.01 g) as  a white solid. NMR
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(CDaOD, 5): 1.37 (s, 9 H, CH3), 1.39 (s, 9 H, CH3), 2.43-3.42 (m, 24 H, CH2),
inside the multiplet: 3.29 (s, 2 H, ChbCOO'Bu); NMR: 28.07 (CH3), 28.39
(CH3), 38.85 (CH2), 45.57 (CH2), 46.18 (CH2), 47.65 (CH2), 47.96 (CH2), 50.91
(CH2), 51.73 (CH2), 51.85 (CH2), 52.52 (CH2), 53.40 (CH2), 54.28 (CH2), 78.39
(Cq), 80.84 (Cq), 156.12 (CO), 170.53 (CO).
4.2.2.20 Alkylation of 156 with ethyl bromoacetate
EtO
  ^   , __
_ N H  n C Y  \  BrCH^COOEt n Ç Y  \
'----- ' NHBoc EtO -----  NHBoc
156 157
156 (1.01 g, 2.36 mmol) w as dissolved in acetonitrile (10 mL), K2CO3 (4.80 g,
37.7 mmol, 8 eq), Nal (5.66 g, 37.7 mmol, 8 eq) and ethyl brom oacetate (2617 
\xL, 3.94 g, 23.6 mmol, 5 eq) were added, and the mixture w as stirred at 80 C 
under argon for 24 hours. The acetonitrile w as removed in vacuo, the residue 
dissolved in w ater (40 mL) and DCM (40 mL), the phases were separated  and 
the aqueous phase w as extracted with DCM (2 30 mL). The combined organic 
phases were w ashed with water (2 30 mL), dried over MgS04 , filtered, and the 
sam ple w as concentrated to 3 mL. The desired product (157) w as obtained by 
purification with silica column chromatography using DCM / MeOH eluants. 
Yield: 0.97 g (69%); ^H NMR (CD3OD, Ô): 1.11-1.23 (m, 6 H, CH3), 1.34 (s, 9 H, 
B0C-CH3), 1.43 (s, 9 H, CH3), 2.32-3.47 (m, 25 H, CH2), 4.00-4.23 (m, 5 H, 
CH2); ^^C NMR: 14.04 (CH3), 14.13 (CH3), 27.97 (CH3), 28.31 (CH3), 37.81 
(CH2), 50.24 (CH2), 51.14 (CH2), 54.04 (CH2), 55.04 (CH2), 55.84 (CH2), 56.57
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(CH2), 61.37 (CH2), 61.69 (CH2), 79.23 (Boc-Cq), 82.86 (Cq), 173.31 (CO), 
173.92 (CO).
4.2.2.21 Removal o f the Boc protection from 157
EtO EtO
o TFA/DCM ^ r - N  \
9\ M—' 9\
EtO '----- ' NHBoc EtO NH^
157 158
157 (0.97 g, 1.63 mmol) w as dissolved in DCM (10 mL), TFA (5 mL) w as added 
to the solution, and the reaction mixture w as stirred vigorously at room 
tem perature for 30 minutes. The volatile com ponents were removed at reduced 
pressure and the residue dissolved in DCM (30 mL). Concentrated aqueous 
solution of KHCO3 w as added in small portions until the pH of the solution 
reached 8 . The aqeous w as extracted with DCM (2 30 mL), and the combined 
organic phases were w ashed with water (40 mL). The organic phase w as dried 
over MgS04 , filtered, and the DCM w as evaporated, to give 158 in 84% (0.68 g) 
yield as  an off-white solid. ^H NMR (CDCI3 , 6 ): 0.96-1.01 (m, 6  H, CH3), 1.39 (s, 
9 H, CH3), 2.53-2.75 (m, 2 1  H, CH2), 3.21 (s, 2  H, CH2), 3.32-3.36 (m, 4 H, 
CH2), 3.98-4.11 (m, 4 H, CH2); ^^C NMR: 14.17 (CH3), 14.21 (CH3), 28.14  
(CH3), 51.17 (CH2), 51.82 (CH2), 55.34 (CH2), 56.20 (CH2), 60.20 (CH2), 60.35 
(CH2), 81.03 (Cq), 171.15 (CO), 171.54 (CO), 171.69 (CO).
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4.2.2.22 Attachment of adenosine to the 158
E tO E tO
NH,
n r\
A -5 '- C 0 0 H
E D C I
V_J
NH, E tO
158 159
158 (0.47 g, 0.94 mmol) w as dissolved in DMF (6 mL), and a solution of the 5’- 
carboxylic adenosine (2 eq, 1.88 mmol, 0.60 g) and EDCI (2 eq, 1.88 mmol, 
0.36 g) w as added. The reaction mixture w as stirred at room tem perature for 24 
hours. The DMF w as removed at reduced pressure and the sam ple w as 
dissolved in a mixture of DCM and w ater (40 mL each). The p h ases were 
separated and the aqueous phase w as extracted with DCM (2 40 mL). The 
combined organic phases were w ashed with w ater (2 25 mL), dried over 
MgS04 , filtered, and concentrated to 3 mL. Purification of the sam ple by silica 
column chromatography (DCM / 'PrNH2) gave the product 159 in 25% yield 
(0.19 g). ’H NMR (CDCb, 8); 1.16-1.23 (m, 6 H, CHs), 1.33 (s, 3 H, OCH3), 1.38 
(s, 9 H, B0C-CH3), 1.55 (s, 3 H, OCH3), 2.10-3.38 (m, 25 H, CH2), 4.03-4.12 (m, 
4 H, CH2), 5.33 (d, 1 H, CH, J = 6.0 Hz), 5.40 (d, 1 H, CH, J = 6.0 Hz), 5.77- 
5.81 (m, 1 H, CH), 6.18 (s, 1 H, CH), 7.18 (b rs, NHz), 8.06 (s, 1 H, NH), 8.16 (s, 
1 H, CH); ^^C NMR; 14.35 (CH3), 14.38 (CH3), 25.14 (OCH3), 26.94 (OCH3), 
28.28 (B0C-CH3), 31.48 (CH2), 36.53 (CH2), 51.96 (CH2), 52.47 (CH2), 52.89 
(CHz), 55.54 (CH2), 56.40 (CH2), 60.21 (CH2), 60.30 (CH2), 80.93 (CH2), 80.93 
(Cq), 83.70 (CH), 84.34 (CH), 86.80 (CH), 91.58 (CH), 113.96 (CH), 119.84, 
140.29 (CH), 149.64 (Cq), 153.21 (Cq), 155.56 (Cq), 168.87 (CO), 170.90 (CO), 
1 7 1 .5 5 (0 0 ), 1 7 1 .7 2 (0 0 ).
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4.2.2.23 Removal of the tBu protection from 159
E tO  _  E tO \ ^ 0
O H
9  C ,  J  /  9. C  J  °
E tO  E tO  /7 O H
O H
159 160
159 (0.19 g, 0.24 mmol) w as dissolved in DCM ( 6  mL), TFA ( 6  mL) w as added 
to the solution, and the reaction mixture w as stirred vigorously at room 
tem perature for 2 hours. The volatile com ponents were removed at reduced 
pressure and the sam ple was dried at reduced pressure overnight to give 160 in 
quantitative yield as  a pale brown solid. NMR (CD3OD, 6): 1.28,-1.41 (m, 6  
H, CHs), 2.89-3.67 (m, 6  H, CHs), 4.19-4.31 (m, 2 2  H, CHg), 4.45-4.47 (m, 8  H, 
CHz), 4.58-4.60 (m, 1 H, CH), 4.65-4.70 (m, 1 H, CH), 6.17-6.21 (m, 1 H, CH), 
7.98 (br s, 2 H, NHz), 8.74 (s, 1 H, CH), 8.85 (m, 1 H, CH); ^^ C NMR: 14.13 
(CHs), 14.27 (CHs), 31.79 (CHz), 37.05 (CHz), 45.79 (CHg), 50.77 (CHg), 51.18 
(CHz), 52.28 (CHz), 53.50 (CHz), 53.73 (CHz), 54.25 (CHz), 55.07 (CHz), 62.42 
(CHz), 63.49 (CHz), 74.11 (CHz), 83.95 (CH), 84.14 (CH), 84.98 (CH), 90.19 
(CH), 110.62 (Cq), 114.43 (CH), 118.23 (CH), 122.04 (Cq), 144.94 (Cq), 160.38 
(CO), 160.89 (CO), 164.89 (CO), 172.28 (CO).
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4.2.2.24 Attachment of rhodamine B to147
OEt
OEt
EtO
EDCI, DCMEtO
NEt,
Rhodamine B O
0
NEt2
147 161
147 (0.65 g, 1.01 mmol) w as dissolved in DCM (10 mL), rhodamine B (0.73 g,
1.52 mmol, 1.5 eq) and EDCI (0.29 g, 1.52 mmol, 1.5 eq) were added, and the 
solution w as stirred at room tem perature for 24 hours. W ater (30 mL) and DCM 
(20 mL) were added to the solution, and the phases were separated. The 
aqueous phase w as extracted with DCM (3 30 mL), and the combined organic 
phases were w ashed with w ater (50 mL). The organic phase  w as dried over 
MgS04 , filtered, and concentrated to ~5 mL. The crude sam ple was purified by 
silica column chromatography by elution with DCM containing 2.5% 
isopropylamine to yield the 161 in 65% yield (0.70 g) a s  a deep  purple solid. 
MS: 1046 [M, one ethyl ester cleaved]'"; 1070 [M+H]'"; NMR (CDCI3, 5): 1.04-
1.15 (m, 21 H, 7 ethyl CH3), 2.09-3.31 (m, 45 H, CHz), 4.01-4.06 (m, 3 H, 1.5 
CHz), 6.16-6.36 (m, 6 H, CH), 7.01-7.02 (m, 1 H, CH), 7.14 (d, 1 H, CH, J = 7.5 
Hz), 7.35-7.37 (m, 2 H, CH), 7.49-7.56 (m, 3 H, CH), 7.89 (m, 1 H, CH), 7.91 (d, 
1 H, J = 7.5 Hz); NMR: 12.44 (CH3), 12.52 (CH3), 12.73 (CH3), 14.09 (CH3),
14.20 (CH3), 14.23 (CH3), 18.60 (CH3), 18.84 (CH3), 42.97 (CHz), 44.25 (CHz),
44.35 (CHz), 45.15 (CHz), 50.67 (CHz), 51.73 (CHz), 52.08 (CHz), 53.36 (CHz),
55.00 (CHz), 56.31 (CHz), 59.94 (CHz), 61.33 (CHz), 97.50 (CH), 97.61 (CH),
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105.57 (Cq), 107.84 (CH), 107.95 (CH), 115.44 (Cq), 115.71 (Cq), 117.49 (Cq), 
119.79 (Cq), 122.42 (Cq), 123.73 (Cq), 124.05 (Cq), 124.52 (Cq), 125.37 (CH),
127.71 (CH), 128.79 (CH), 129.03 (CH), 131.55 (Cq), 131.97 (CH), 132.12 (Cq), 
134.34 (CH), 148.67 (Cq), 149.31 (Cq), 153.04 (Cq), 153.20 (Cq), 153.23 (CO),
160.20 (CO), 167.33 (CO), 169.75 (CO), 171.40 (CO).
4.2.2.25 Complexation o f neodymium with 161
OEt OEt
E t o ^ r ^  °
O C .N  %  MeOH
COU2
RhoB
EtO
RhoB
161 162
161 (200 mg, 0.19 mmol) w as dissolved in HPLC-grade methanol (3 mL), 
anhydrous neodymium chloride (42 mg, 0.17 mmol, 0.9 eq) w as added, and the 
solution w as refluxed under argon overnight. The reaction mixture was allowed 
to cool back to room tem perature and w as poured into cold diethyl ether (15 
mL). The mixture was centrifuged and the ether was poured off the dark purple 
precipitate. The solid w as suspended in 5 mL of ether, and centrifuged again. 
The ether was poured off again, the residue dissolved in distilled water (5 mL), 
filtered through a plug of cotton wool and the sam ple w as freeze-dried. The 
complex (162) w as obtained as  a dark purple solid in 70% yield. The purity of 
the sam ple w as checked by TLC (alumina plates, DCM / MeOH, various ratios, 
up to 20% MeOH). MS; 1157 [M(-ethyl esters)+H]*; ^H NMR (CD3OD, 5): 0.75- 
1.45 (m), 3.29-3.73 (m, approximately 22 H), 6.42-6.46 (br m, 2 H), 6.97 (br s  2 
H), 7.06-7.09 (br m, 3 H), 7.60 (br m, 2 H) 7.83 (br m, 1 H) 9.01 (br m, 2 H); '^C
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NMR: 12.65, 12.94, 38.00, 45.08, 46.62, 66.60, 73.92, 78.07, 87.93, 97.28, 
113.32, 115.62, 157.00, 160.14, 162.11.
4.2.2.26 Complexation of ytterbium with 161
OEt OEt
^  \  YbCI
EtO
C o
MeOH
Cou
»
RhoB
EtO
RhoB
Cou'
163161
161 (200 mg, 19 mmol) was dissolved in HPLC-grade methanol (3 mL), 
anhydrous ytterbium chloride (0.044 g, 0.17 mmol, 0.9 eq) w as added, and the 
solution w as refluxed under argon overnight. The reaction mixture w as allowed 
to cool back to room tem perature and w as poured into cold diethyl ether (15 
mL). The mixture w as centrifuged and the ether w as poured off the white 
precipitate. The solid w as suspended in 5 mL of ether, and centrifuged again. 
The ether w as poured off again, the residue dissolved in distilled w ater (4 mL), 
filtered through a plug of cotton wool and the sam ple w as freeze-dried. The 
complex w as obtained as  purple solids in 85% yield. The purity of the sam ple 
w as checked by TLC (alumina plates, DCM / MeOH, 0%, 2%, 10%). MS: 1189 
[M(-ethyl esters)+H]'^.
152
4.2.2.27 Reaction of bromoethylamine with rhodamine B
NEt,NEtj-NE^NEt.
EDCI, TEA
HO
164 165
Rhodamine B (164) (14.24 g, 30 mmol) w as dissolved in DCM (40 mL), EDCI
(5.73 g, 30 mmol) w as added to the solution, and the carboxylic acid w as pre­
activated for 10 minutes. Bromoethylamine hydrobromide (6.15 g, 30 mmol) and 
TEA (4.21 mL, 3.03 g, 30 mmol) were added, and the reaction w as allowed to 
proceed for 24 hours. W ater (40 mL) w as added to the solution, the phases 
were separated, and the aqueous phase was extracted with DCM (2 40 mL). 
The combined organic phases were w ashed with water (50 mL) and dilute acid 
(0.1 M HCI, 40 mL), dried over MgS04 , filtered, and concentrated. The sam ple 
w as purified by chromatography on silica by elution with DCM / MeOH (0-1%). 
The product (165) w as obtained as  a pale pink solid in 41% yield (7.08 g). MS: 
550 [M+Ht; NMR (Ô, CDCI3): 1.10 (t, 12 H, 4 CH3 , J = 7.0 Hz), 2.91 (t, 2 H, 
CHz, J = 7.3 Hz), 3.26 (q, 8 H, CHz, J = 7.0 Hz), 3.45 (t, 2 H, CHz, J = 7.3 Hz), 
6.18 (d, 1 H, CH, J = 2.8 Hz), 6.21 (d, 1 H, CH, J = 2.6 Hz), 6.31 (d, 1 H, CH, J 
= 2.6 Hz), 6.34 (s, 1 H, CH), 6.37 (s, 1 H, CH), 6.96-7.02 (m, 1 H, CH), 7.33- 
7.39 (m, 2 H, CH), 7.80-7.86 (m, 1 H, CH); ^^C NMR: 12.54 (CH3 ), 41.76 (CHz),
44.31 (CHz), 64.65 (CHz), 97.72 (CH), 105.07 (CH), 108.12 (CH), 122.89 (CH),
123.77 (CH), 128.04 (CH), 128.64 (CH), 130.50 (Cq), 132.64 (CH), 148.84 (Cq),
153.15 (Cq), 153.54 (CO).
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4.2.2.28 Alkylation of cyclen with 165
NH N
N HN
n
TEA |--N H
EtOH, Ar N ; ^ ^ ^
'-----  NHRho
137 165 166
Cyclen (137) (3.21 g, 18.66 mmol, 1.5 eq) w as dissolved in 100% EtOH (25
mL), TEA (5.24 mL, 3.77 g, 37.33 mmol, 3 eq) and (165) (7.08 g, 12.44 mmol)
were added, and the solution w as refluxed under argon for 24 hours. The
ethanol and the triethylamine were evaporated, and the residue dissolved in
DCM (30 mL). The solution was w ashed with water (30 mL), and the aqueous
phase  w as extracted with DCM (2 30 mL). the combined organic p h ases were
w ashed with water (30 ml), dried over MgS04 , filtered, and concentrated to ~5
mL. The crude sam ple was purified on a basic alumina column (pH 9.5) by
elution with DCM / MeOH (0.2-4%) to give the monoalkylated product (166) in
39% yield (3.12 g) as  a pale pink solid. MS: 641 [M+H]^; ^H NMR (8, CDCb):
1.10 (t, 12 H, 4  CHs, J = 7.0 Hz), 2 .17-3 .37  (m, 28  H, 14 CHz), 6 .17-6 .21 (m, 2
H, CH), 6.31-6.41 (m, 5 H, CH), 6.97-7.01 (m, 1 H, CH), 7.32-7.36 (m, 1 H, CH),
7.44-7 .47  (m, 1 H, CH), 7 .80-7 .86  (m, 1 H, CH); NMR: 12 .56  (CHs), 37 .83
(CHz), 4 1 .76  (CHz), 44 .32  (CHz), 4 5 .36  (CHz), 46 .32  (CHz), 4 7 .1 8  (CHz), 51 .13
(CHz), 52.05 (CHz), 64 .78  (CHz), 97.83 (CH), 105.68 (CH), 108.00 (CH), 122.57
(CH), 123.68 (CH), 127.87 (CH), 128.84 (CH), 131.41 (Cq), 132.11 (CH), 148.67
(Cq), 153.34 (Cq), 153.45 (CO), 167.61 (Cq).
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4.2.2.29 Alkylation of 166 with N-Boo bromoethylamine
^ ^ nhboc
^ N H  BrCHjCHjNHBoc ^ N H
TEA, CHCI3
^ ^  NHRho ^ ^  ^ ^ ^ N H R h o
166 167
166 (3.12 g, 4.73 mmol) w as dissolved in dry chloroform (55 mL), TEA (6.64 
mL, 4.80 g, 47.3 mmol, 10 eq) w as added to the solution, and the mixture w as 
flushed with argon for 10 minutes. N-Boc Bromoethylamine (1.06 g, 4.73 mmol) 
in chloroform (15 mL) w as added dropwise (in 1 hour) to the reaction mixture, 
and the stirring w as continued for 36 hours at room tem perature. W ater (35 mL) 
w as added, the phases were separated, and the organic phase w as w ashed 
with water again (40 mL). The organic phase w as dried over MgS04 , filtered, 
and concentrated to -  5 mL. The desired product (167) w as isolated by silica 
column chromatography by elution with DCM / 'PrNHz (2.5-10%) as  an off-white 
solid in 20% yield (0.75 g). MS: 784 [M+H]^; NMR (Ô, CDCI3): 1.10 (t, 12 H, 4 
CHs, J = 7.0 Hz), 1.29 (s, 9 H, Boc), 2.08-2.64 (m, 20 H, 10 CHz), 2.92-3.30 (m, 
12 H, 6 CHz) 6.18 (d, 1 H, CH, J = 2.7 Hz), 6.21 (d, 1 H, CH, J = 2.7 Hz), 6.30-
6.35 (m, 5 H, CH), 6.44 (br s, 1 H, NH), 6.99-7.04 (m, 1 H, CH), 7.34-7.40 (m, 2 
H, CH), 7.80-7.84 (m, 1 H, CH); ^^ C NMR: 12.62 (CHs), 28.50 (CHs), 34.79 
(CHz), 38.76 (CHz), 44.31 (CHz), 45.28 (CHz), 45.36 (CHz), 46.75 (CHz), 47.46 
(CHz), 48.11 (CHz), 50.73 (CHz), 51.38 (CHz), 51.63 (CHz), 52.39 (CHz), 53.26 
(CHz), 64.79 (CHz), 97.54 (CH), 105.61 (CH), 108.03 (CH), 122.53 (CH), 123.79 
(CH), 128.05 (CH), 129.11 (CH), 131.81 (Cq), 132.17 (CH), 148.75 (Cq), 153.11 
(Cq), 153.49 (CO), 167.36 (Cq).
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4.2.2.30 Alkylation of 167 with ethyl bromoacetate
—  NHBoc [  —  NHBoc
^ N H  N ^  BrCHgCOOEt ^
L h K,CO, Nal O
\ I AcN \ _ J
NHRho EtO   NHRho
167 168
167 (1.08 g, 1.56 mmol) was dissolved in AcN (8 mL), K2CO3 (3.50 g, 25.0
mmol, 8 eq), Nal (3.74 g, 25.0 mmol, 8 eq) and ethyl brom oacetate (1733 pL, 
2.61 g, 15.6 mmol, 5 eq) were added, and the mixture w as stirred at 80 °C 
under argon for 24 hours. The AcN w as removed in vacuo, the residue 
dissolved in water (40 mL) and DCM (40 mL), the phases were separated  and 
the aqueous phase was extracted with DCM (2 30 mL). The combined organic 
phases were w ashed with water (2 30 mL), dried over MgS04 , filtered, and the 
sam ple w as concentrated to 3 mL. The desired product (168) w as obtained by 
purification with silica column chromatography using DCM / MeOH eluants (0- 
2 .5 %). Yield: 83% (1.24 g); MS: 957 [M+Hf; 'H  NMR (S, CDCb): 1.07-1.25 (m, 
18 H, 6 CHs), 1.34 (s, 9 H, Boc), 2.18-3.58 (m, 36 H, CHs), 4.00-4.53 (m, 4 H, 
CHs), 6.18 (d, 1H, CH, J  = 2.6 Hz), 6.21 (d, 1H, CH, J = 2.6 Hz), 6.26-6.37 (m, 4 
H, CH), 7.01-7.04 (m, 1 H, CH), 7.36-7.39 (m, 2 H, CH), 7.80-7.83 (m, 1 H, CH); 
'^C NMR: 12.61 (CHs), 14.24 (CHs), 14.27 (CHs), 28.48 (CHs), 44.32 (CHs), 
50.75 (CHs), 51.27 (CHs), 51.91 (CHs), 52.41 (CHs), 53.40 (CHs), 60.18 (CHs), 
97.62 (CH), 105.57 (CH), 108.02 (CH), 122.58 (CH), 123.79 (CH), 128.04 (CH),
129.00 (CH), 148.76 (Cq), 153.46 (Cq), 156.23 (CO), 167.47 (CO), 171.39 (CO).
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(169) Side-product isolated:
" V o
N
(  ----  NHRho
E .0 ^ °
MS: 899 [M+Hf; NMR (6, CDCb): 1.09-1.29 (m, 21 H, CHs), 2.10-2.82 (m, 
22 H, CHs), 2.81 (s, 1 H, CHs-1), 2.89 (s, 1 H, CHs-2), 3.07-3.17 (m, 2 H, CHs), 
3.23-3.39 (m, 12 H, CHs), 4.00-4.14 (m, 6 H, CHs), 6.18 (d, 1 H, CH, J = 2.6 
Hz), 6.21 (d, 1 H, CH, J = 2.6 Hz), 6.30-6.36 (m, 3 H, CH), 7.01-7.03 (m, 1 H, 
CH), 7.33-7.39 (m, 2 H, CH), 7.79-7.82 (m, 1 H, CH); '®C NMR: 12.58 (CHs), 
14.27 (CHs), 14.31 (CHs), 44.31 (CHs), 50.74 (CHs), 51.85 (CHs), 51.93 (CHs), 
52.11 (CHs), 52.56 (CHs), 55.80 (CHs), 60.03 (CHs), 64.78 (CHs), 97.68 (CH),
105.72 (Cq), 108.02 (CH), 122.57 (CH), 123.77 (CH), 127.96 (CH), 128.98 (CH), 
131.70 (Cq), 132.13 (Cq), 148.72 (CH), 153.19 (Cq), 153.41 (Cq), 167.47 (CO), 
171.67 (CO).
4.2.2.31 Removal o f the Boc protection from 168
NHj/ . ^ / N hboc /
TFA/DCM
EtO   NHRho EtO   NHRho
168 170
168 (1.24 g, 1.30 mmol) was dissolved in DCM (12 mL), TFA (6 mL) w as added 
to the solution, and the reaction mixture was stirred vigorously at room 
tem perature for 30 minutes. The volatile com ponents were removed at reduced 
pressure and the residue dissolved in DCM (30 mL). Concentrated aqueous
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solution of KHCO3 w as added in small portions until pH 8 w as reached. The 
aqeous w as extracted with DCM (2 30 mL), and the combined organic phases 
were w ashed with water (40 mL). The organic phase w as dried over MgS04 , 
filtered, and the DCM w as evaporated, to give 170 in 84% yield a s  an pale 
purple solid. MS: 856 [M+Hf, 428 [M+H+Hf^; NMR (Ô, CDCI3): 1.07-1.23 
(m, 18 H, 6 CH3), 2.10-3.39 (m, 36 H, 18 CHz), 3.98 (q, 2 H, CHz, J = 7.2 Hz), 
4.07-4.14 (m, 2 H, CHz), 6.20 (d, 1 H, CH, J = 2.6 Hz), 6.23 (d, 1 H, CH, J = 2.6 
Hz), 6.30-6.37 (m, 4 H, CH), 7.01-7.04 (m, 1 H, CH), 7.35-7.40 (m, 2 H, CH), 
7.81-7.84 (m, 1 H, CH), 8.07 (br s, 2 H, NHz); NMR: 12.58 (CH3), 14.01 
(CH3), 34.87 (CHz), 37.00 (CHz), 44.31 (CHz), 49.13 (CHz), 49.59 (CHz), 49.92  
(CHz), 50.79 (CHz), 51.33 (CHz), 52.35 (CHz), 55.62 (CHz), 60.35 (CHz), 60.91 
(CHz), 64.93 (CHz), 97.51 (CH), 105.50 (CH), 108.10 (CH), 122.69 (CH), 123.77 
(Cq), 128.12 (CH), 129.06 (CH), 131.45 (CH), 132.33 (Cq), 148.80 (Cq), 152.95 
(Cq), 153.46 (Cq), 167.61 (CO), 171.35 (CO), 171.89 (CO).
4.2.2.32 Attachment o f 5-COOH-nucleosides tolTO
-N S'-CGOH-nucleoside N N
N N-N EDCI, DMF
EtO  ^  ^ NHRho Etc" '---- ' NHRho
170 171a-b
170 (0.86 g, 1.0 mmol) w as dissolved in DMF (7 mL), and a solution of the 5'-
carboxylic nucleotide (1.1 mmol, 1.1 eq) and EDCI (0.23 g, 1.2 mmol, 1.2 eq) 
w as added. The reaction mixture w as stirred at room tem perature for 24 hours. 
The DMF was removed at reduced pressure and the sam ple w as dissolved in a 
mixture of DCM and water (40 mL each). The phases were separated  and the
158
aqueous phase w as extracted with DCM (2 40 mL). The combined organic 
phases were w ashed with water (2 25 mL), dried over MgS04 , filtered, and 
concentrated to 3 mL. Purification of the sam ple by silica column 
chromatography (DCM / 'PrNHz, 0-20%) gave the products 171a and 171b.
171a (B = U): Yield; 48% (0.54 g); MS: 1140 [M+Hf; NMR (8, CDCb): 1.07-
1.21 (m, 18 H, 6 CHs), 1 2 5  (s, 3 H, OCH3), 1.48 (s, 3 H, OCH3), 1.87-3.31 (m, 
39 H, CH + CH2), 4.01-4.10 (m, 5 H, CH + CH2), 4.55 (br s, 1 H. NH), 5.63 (d, 2 
H, 2 CH, J = 8.1 Hz), 6.18-6.23 (m, 2 H, CH), 6.30-6.35 (m, 3 H, CH), 7.02-7.05 
(m, 1 H, CH), 7.38-7.41 (m, 2 H, CH), 78.2-7.85 (m, 1 H, CH); ’^C NMR: 12.60 
(CHs), 14.20 (CHs), 24.52 (OCHs), 26.96 (OCHs), 33.52 (CH2), 44.35 (CH2),
45.25 (CH2), 50.66 (CH2), 50.74 (CHz), 51.91 (CHz), 52.48 (CHz), 52.17 (CHz), 
60.48 (CHz), 77.93 (CH), 84.21 (CH), 89.70 (CH), 97.61 (CH), 102.67 (CH), 
108.09 (CH), 109.86 (CH), 122.79 (CH), 123.86 (Cq), 125.49 (Cq), 128.94 (CH),
129.05 (Cq), 132.48 (Cq), 132.92 (Cq), 148.85 (Cq), 153.48 (CO), 171.31 (CO), 
173.66 (CO).
171b (B = A): Yield: 40% (0.46 g); MS: 1163 [M+H]*; ’H NMR (S, CDCb): 1.06-
1.22 (m, 18 H, 6 CHs), 1.30 (s, 3 H, OCHs), 1.52 (s, 3 H, OCHs), 1.87-3.29 (m, 
39 H, CH + CHz), 4.01-4.10 (m, 5 H, CH + CHz), 5.89 (b rs, 2 H, NHz), 6.17-6.22 
(m, 2 H, CH), 6.29-6.37 (m, 3 H, CH), 7.01-7.04 (m, 1 H, CH), 7.36-7.39 (m, 2 
H, CH), 7.80-7.83 (m, 1 H, CH), 8.06 (s, 1 H, CH), 8.22 (s, 1 H, CH); '®C NMR: 
12.59 (CHs), 14.24 (CHs), 14.30 (CHs), 25.11 (OCHs), 26.83 (OCHs), 44.33 
(CHz), 45.24 (CHz), 51.54 (CHz), 52.09 (CHz), 55.23 (CHz), 55.34 (CHz), 60.03 
(CHz), 60.11 (CHz), 64.87 (CHz), 83.70 (CH), 84.33 (CH), 87.07 (CH), 91.51 
(CH), 97.62 (CH), 97.71 (CH), 105.61 (CH), 108.01 (CH), 113.72 (CH), 119.75 
(Cq), 122.60 (CH), 123.80 (CH), 128.04 (CH), 128.97 (CH), 129.14 (Cq), 132.21
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(Cq), 140.34 (Cq), 148.74 (CH), 149.49 (Cq), 153.08 (Cq), 153.43 (Cq), 155.50 
(Cq), 167.43 (CO), 168.60 (CO), 171.48 (CO), 171.59 (CO).
4.2.2.33 Complexation of neodymium with 171a and 171b
EtO
Q
O
NdCI,
MeOH
NH
Rho
EtO
NHEtO
Rho
3+
171a-b  172a-b
171a and 171b (75 mg and 80 mg, 0.066 mmol and 0.069 mmol) were 
dissolved in HPLC-grade methanol (0.5 mL), anhydrous neodymium chloride 
(15.7 mg and 16.4 mg, 0.95 eq) w as added, and the solution w as refluxed 
under argon overnight. The reaction mixture w as allowed to cool back to room 
tem perature and w as poured into cold diethyl ether (20 mL). The mixture w as 
centrifuged and the ether w as poured off the white precipitate. The solid w as 
suspended in 5 mL of ether, and centrifuged again. The ether w as poured off 
again, the residue dissolved in distilled water (3 mL), filtered through a  plug of 
cotton wool and the sam ple w as freeze-dried. The complexes were obtained as  
pink solids. The purity of the sam ples were checked by TLC (alumina plates, 
DCM / MeOH).
172a (Q = uridine): Yield: 82% (62.5 mg); MS: 1183 [Ligand -  Both ethyl 
esters+ H f, 1111 unassigned; ^H NMR (6, CD3OD): 0.82-0.88 (m), 1.07-1.09 
(m), 1.19 (br s), 1.42 (br s), 1.07-1.59 (m), 2.56-3.61 (m), 3.04 (s), 4.11-4.13 
(m), 5.08 (brs), 5.18 (brs), 5.61 (brs), 6.32-6.37 (m), 7.00 (brs), 7.48-7.81 (m).
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172b (Q = adenosine): Yield: 58% (49.5 mg); MS: 630 [M p, 1261 [M]\ 1135 
[Ligand -  Both ethyl esters+H f; 'H  NMR (8, CD3OD): 1.13-1.19 (m, 12 CH3, 
Rhodamine ethyl), 1.40 (s, 3 H, OCH3), 1.58 (s, 3 H, OCH3), 2.15 (s, 2 H, CH2), 
2.41-2.96 (m, CH2), 3.35-3.40 (m, CH2), 3.67 (s), 3.69 (s), 4.70 (br s), 5.45-5.47 
(m), 5.61 (m), 6.36-6.45 (m), 7.10-7.12 (m), 7.56-7.60 (m), 7.88-7.90 (m), 8.17 
(m), 8.25 (m).
4.2.2.34 Complexation o f ytterbium with 171a and 171b
EtO
V J ^
Q
YbCI,
MeOH
NH
Rho
EtO
NHEtO
Rho
3+
1 7 l3 "b  1733-b
171a and 171b (75 mg and 80 mg, 0.066 mmol and 0.069 mmol) were 
dissolved in HPLC-grade methanol (0.5 mL), anhydrous ytterbium chloride (17.5 
mg and 18.3 mg, 0.95 eq) w as added, and the solution w as refluxed under 
argon overnight. The reaction mixture w as allowed to cool back to room 
tem perature and w as poured into cold diethyl ether (20 mL). The mixture w as 
centrifuged and the ether was poured off the white precipitate. The solid w as 
suspended in 5 mL of ether, and centrifuged again. The ether w as poured off 
again, the residue dissolved in distilled water (3 mL), filtered through a plug of 
cotton wool and the sam ple w as freeze-dried. The complexes were obtained as  
white solids in 30-50% yields. The purity of the sam ples were checked by TLC 
(alumina plates, DCM / MeOH).
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173a (Q = uridine): MS: 1183 [Ligand -  Both ethyl esters+ H f, 1111 
unassigned; 879 [M+Mf"^; NMR (8 , CD3OD): 1.14 (br s, Rhodamine ethyl 
CHs), 1.39 (br s, OCH3), 1.57 (br s, OCH3), 2.67-3.36 (m, cyclen), 3.69 (br s, 
Rhodamine, ethyl CH2), 5.46 (br s), 5.61 (br s), 6.36 (br s), 6.42 (br s), 7.06 (br 
s), 7.58 (br s), 7.95 (br s), 8.17 (br s), 8.26 (br s).
173b (Q = adenosine): MS: 1135 [Ligand -  Both ethyl esters+H]"^; ^H NMR (8, 
CD3OD): 1.07-1.16 (m), 1.25 (s), 1.42 (s), 2.55-3.60 (m), 4.05 (br s), 4.48 (br s),
5.10 (br s), 5.16 (br s), 5.62 (br s), 6.32-6.37 (m), 7.00 (m), 7.47 (m), 7.61 (m),
7.77 (m).
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5 R esults  and  discussion
5 .1 Synthesis of the coumarin 343 acceptor-containing triads
5.1.1 Functionalising the 4-amino-3-hydroxybutyric acid
5.1.1.1 Amide bond formation between the coumarin 2 donor and the 
carboxylic acid of the scaffold molecule
The first target triad consisted of a coumarin 2 donor, a coumarin 343 acceptor 
and a uridine quencher. The three functional units would be held together by a 
4-amino-3-hydroxybutyric acid scaffold (Figure 17).
HO
OH
Figure 17. The first target molecule (50), consisting of coumarin 2 donor, coumarin 343 acceptor 
and uridine quencher, held together by 4-amlno-3-hydroxybutyric acid.
The proposed reaction route to the synthesis of 50 is shown in Scheme 2. 
Coumarin 2 is attached to the carboxylic acid via an amide bond through its 
amino group. Coumarin 343 esterifies the 3-hydroxyl group of the scaffold, while 
uridine is oxidised to its 5’-carboxylic acid derivative, and coupled to the 4- 
amino group of the HBA.
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Q OH coumarin 2 ^
HO
NHBoc -------------------- --
Coumarin 343 
Acceptor
D o n o r ----------------------------------------------- D o n o r ^ ^ ^ " = "
uridine-5'-C00H 
/Acceptor
0 0 
ÏÏ ï  H
D o n o r ^ ^ ^ ^ '^ ^ ^ ^  '"Quencher
Scheme 2. Synthetic route to 50.
Our initial attem pts were directed at the formation of a peptide bond between 
the secondary amino group of coumarin 2 and the carboxylic acid function of 
the 4-amino-3-hydroxybutyric acid. Test reactions were carried out using N- 
methylaniline a s  a model compound for coumarin 2. Like coumarin 2, NMA is an 
aromatic secondary amine. Its main advantage is its easy  availability and low 
price.
The amino group of the HBA w as protected by reaction with Boc carbonate 
under standard conditions used in peptide chemistry.®^ The desired N-protected 
product w as isolated in high yield and purity, and w as reacted with NMA in the 
presence of EDCI coupling reagent (Scheme 3).
OH 0  OH
"
EDCI 1  TFA
+ N-Boc-HBA
DCM II I DCM
57 58 59
Scheme 3. Test reaction between N-methylaniline and N-Boc-hydroxybutyric acid, followed by
removal of the Boc protection.
The expected product w as formed in m oderate yields under mild conditions and 
w as isolated by m eans of silica column chromatography. Removal of the Boc
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protecting group by TFA in DCM proceeded smoothly and gave the unprotected 
amine in quantitative yields.
In the reaction between the N-Boc-HBA and coumarin 2 under the sam e 
conditions no product formation w as observed.
W hen reactions were allowed to proceed for several days, on TLC the formation 
of several highly fluorescent compounds w as seen . Attempts at isolating these  
showed that they were present in < 1% each, and due to the small am ounts 
NMR-analysis could not be performed. M ass spectrometric analysis suggested, 
that loss of the N-ethyl substituent could have happened. There are also 
exam ples in the literature for the photodimerization and subsequent cleavage 
for coumarin derivatives.®^
Therefore it is possible that the observed com pounds were various coumarin 2 
dimers and cleavage products. Unfortunately the ES-MS system  routinely 
produces cluster ions of two or three molecules, and it could not be determined, 
whether the 434 M / z peak corresponding to 2-MW(coumarin 2) w as a dimer or 
an aggregate. The formation of the new fluorescent com pounds could be 
efficiently suppressed  when reactions were conducted in the dark, and 
exposure to light w as reduced during the work-up and purification steps, which 
further supports the proposal that the side-products were formed by 
photodimerization.
As coumarin 2 did not react at room tem perature in dichloromethane in the 
presence of EDCI, a range of reaction conditions were explored (Table 1). As 
reaction rates are strongly dependent on the stabilities of the transition state, 
solvents of different polarities and boiling points were tried, to facilitate the 
formation of the transition complex. A range of solvents and solvent mixtures
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were explored to enhance the solubility of the protected amino acid. 
Dichloromethane w as replaced by high boiling point solvents, which enabled the 
increase of the reaction temperature.
Reactant Coupling agent Solvent T t Yield (%)
N“BoC”AA EDCI DCM 25°C 3 days 0
N-Boc-AA DCC THF 25°C 3 days 0
N-Boc-AA DCC ACN 25°C 3 days 0
N-Boc-AA EDCI DMF 25°C 3 days 0
N”BoC”AA EDCI DMSO 25°C 3 days 0
N-Boc-AA EDCI Water/DCM 25°C 3 days 0
N-Boc-AA EDCI Water/DMF 25°C 3 days 0
N-Boc-AA EDCI DCM Reflux 3 days 0
N-Boc-AA DCC DMF 40°C 3 days 0
N-Boc-AA EDCI DMSO 60°C 3 days 0
N-Boc-AA EDCI THF Reflux 3 days 0
N-Boc-AA EDCI ACN Reflux 3 days 0
N-Boc-AA DCC/HOBt THF 25°C 2 days 0
N-Boc-AA EDCI/HOBt THF 25°C 2 days 0
N-Boc-AA-OPFP - DCM 25°C 1 day 0
N-Boc-AA chloride - DCM 25°C 1 day 0
Table 1. Test reactions for the peptide bond formation between the amino group of coumarin 2 
and the carboxylic acid function of the N-Boc-protected HBA-derivatives.
The lack of reaction in all cases  suggests that the coumarin 2 has a very low 
reactivity. The non-bonding pair of the amino group will be delocalised and in 
conjugation with the coumarin aromatic system. The carbonyl group has an 
electron-withdrawing effect not present in the NMA, making the non-bonding 
pair less available. Although the N-ethyl substituent of the coumarin 2 is not
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expected to cause a much more significant steric hindrance than the N-methyi 
group of NMA, it probably contributes to the slowing down of the reaction. 
Although the reaction w as attempted in a range of solvents, in neither case  was 
product formation seen. As in more polar solvents the transition sta te  would be 
more stable, and this would help advance the reaction, and no such 
advancem ent w as observed, it is possible that the coupling stops at the 
activated este r stage. This supports the theory that it is the lack of reactivity of 
the coumarin 2 that forbids the product formation.
5.1.1.2 Protection of the 3-hydroxyl o f HBA
M ass spectrometric analysis of the reaction mixtures of the coupling reactions 
between N-Boc-HBA and coumarin 2 showed M / z peaks at 619. This is 
equivalent to the M / z of the product of the estérification reaction between three 
N-Boc-HBA molecules. Two w ater molecules have been eliminated, as  
indicated by the weigth loss of 36 from the 657, which 3 M(N-Boc-HBA). This 
suggested  a side reaction occurring between the secondary hydroxyl group of 
the HBA and the carboxylic acid of another HBA molecule. Further evidence 
cam e from the NMR spectra of the sam ples, where the signals of the hydrogens 
of the secondary and tertiary carbons becam e indistinguishable from each 
other, resulting in a series of overlapping, broad multiplets. In the proton NMR 
spectrum of the pure N-Boc-HBA the hydrogens are well separated  and it is 
even possible to distinguish between the two C®H2-signals.
To eliminate the estérification reaction protection of the hydroxyl group w as 
attempted. Surprisingly, applications of standard and widely used methods gave 
the 0-protected products in poor yields. Attempts at acetylating the hydroxyl
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functionality with acetic anhydride / pyridine produced the 0-acetyl derivative 
(174) in approximately 20-30% yields (Scheme 4). Furthermore, significant 
losses in the Boc protection occurred during the acidic workup.
HOOC"'^^''"y^NHBoc HOOC''""'''Y"^NHBoc
OH 0 ^ 0
I 174
Scheme 4. Acétylation of the 3-hydroxyl group of N-Boc-HBA with acetic anhydyde / pyridine.
W hen the N-Boc HBA w as reacted with two equivalents of sodium hydride 
followed by benzyl bromide in DMF, only traces of the 0-benzyl (175) derivative 
were isolated (Scheme 5).
HOOC'''^^'"Y''^NHBoc Nah / Bz-Br  ^ HOOC^ y ^ N H B o c  
OH DMF O 175
Scheme 5. Alkylation of the 3-hydroxyl group with benzyl bromide.
As the 0-acetylation route seem ed promising, and a large part of the losses 
w ere due to the cleavage of the Boc during the work-up, an acid-resistant N- 
protecting group w as introduced instead of the Boc protection. The N-Fmoc 
HBA derivative w as synthesised by the reaction of the HBA and Fmoc- 
chloroformate in a mixture of 10% potassium hydrogencarbonate and dioxan. 
0-actylation in acetic anhydryde / pyridine provided the N-Fmoc-O-Acetyl HBA 
derivative in -40%  yield. Separation of the product from the un reacted starting 
material proved inefficient and time-consuming and reduced the yields 
significantly.
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Both N-Fmoc-HBA and N-Fmoc-O-acetyl-HBA were reacted with coumarin 2. 
Various coupling reagents were tested, but neither using DCC, nor the similar, 
but water-soluble EDCI, nor the more potent PyBop resulted in product 
formation. The usually harsher carboxylic acid-activation methods, such as  acid 
chloride formation, in situ and isolated hydroxysuccinimide activated esters  
were also unsuccessful. In order to be able to increase the concentration of the 
reagents and conduct the reactions at higher tem peratures, the coupling 
reaction w as attempted in several solvents and solvent mixtures, as  shown in 
Table 2. In neither reaction w as formation of the product observed.
Reactant Coupling agent Solvent T t Yield (%)
N-Fmoc-O-Ac-AA EDCI DCM 25 °C 1 week 0
N-Fmoc-O-Ac-AA EDCI/HOBt DCM 25 °C 1 week 0
N-Fmoc-O-Ac-AA DCM 25 °C 3 days 0
N“FmoC“0 ”AC“AA THF Reflux 3 days 0
N-Fmoc-O-Ac-AA N-HOSu DCM 25 °C 1 week 0
N-Fmoc-O-Ac-AA N-HOSu THF Reflux 1 week 0
Table 2. Tested condition for the peptide bond formation reaction between coumarin 2 and N- 
Fmoc- and 0-acetyl protected HBA. * acid chloride formation
The lack of reaction between either of the HBA-derivatives and coumarin 2 
indicates that the poor nucleophilicity of coumarin 2 is a major problem. In 
addition to this, the low yields for the 0-protecting reactions for the N-protected 
HBA suggests that the position of the carboxylic acid and the hydroxyl group of 
the HBA is hindering the reactions involving the COOH group. As the OH and 
COO' moieties can form a six-membered ring (Figure 18) via hydrogen bonds, it 
is likely that the stability of that ring is reducing the reactivity of the carboxylic 
acid.
169
' 'NHX
0„H.0
Figure 18. Possible structure of the HBA. X  = F moo of Boc
To further investigate this hypothesis, other organic acids were brought into 
peptide bond formation reactions with coumarin 2.
5.1.2 Amide bond formation between coumarin 2 and haloacetic acids 
Results of the peptide coupling reactions suggested that coumarin 2 has a very 
low nucelophilicity. Curious to find out if it is possible to engage the amino group 
of coumarin 2 in amide bond formation, coumarin 2 w as reacted with 
chloroacetic acid in DOM in the p resence of EDGI coupling reagent at room 
tem perature (Scheme 6).
XCHjCOOH 
EDCI
O'' "O' DCM
Scheme 6. Coupling coumarin 2 to chloracetic acid (X = Ci) or bromoacetic acid (X = Br).
W hen fourfold excess of acid and coupling reagent were used, the coumarin 2 
chloroacetate w as isolated in 60-70% yield after 3 days. Replacem ent of 
chloroacetic acid with bromoacetic acid brought the reaction to completion 
overnight under the sam e conditions. The coumarin 2 chloroacetate and 
brom om oacetate found use during the synthesis of the cyclen-based ligands 
(150a-b and 161, described later in this thesis). The reactions between NMA or 
coumarin 2 and chloro- or bromoacetic acid are summ arised in Table 3.
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Amine X Coupling agent Solvent I t Yield (%)
NMA Cl EDCI DCM 25°C 3 days 79
Coumarin 2 Cl DCC AcN 25°C 3 days 64
Coumarin 2 Cl EDCI THF 25°C 5 days 88
Coumarin 2 Cl EDCI DCM 25°C 3 days 86
Coumarin 120 Cl EDCI DCM 25°C overnight 60
Coumarin 120 Br EDCI DCM 25°C overnight 75
Coumarin 2 Br EDCI DCM 25°C overnight >98
Table 3. Reactions ofXCH2COOH with coumarin 2, coumarin 120 and NMA. X =  Ci or Br.
Attempts to alkylate either the secondary oxygen in the N-Boc-HBA, or the 
primary amino group in the unprotected HBA with coumarin chloroacetate 
resulted in the complete decomposition of the alkylating agent to coumarin 2 
within a short time. The sam e result w as obtained in a range of solvents such 
as  acetonitrile, ethanol, or DMF, and in the presence of both potassium 
carbonate and TEA bases. Sodium iodide w as not necessary  for the reaction to 
occur, therefore halogen exchange is not a key step  in the mechanism.
5.1.3 Alkylation of the secondary amine of coumarin 2
In order to overcome the difficulties associated with amide bond formation in 
this case, alternative m eans were sought to functionalise coumarin 2.
There are exam ples available in the literature of alkylation of coumarin 2 on the 
amino group with benzyl-bromide-type reagents in acetonitrile.®^ Reaction of 
coumarin 2 with ethyl brom oacetate in acetonitrile in the p resence of potassium  
carbonate and sodium iodide gave small am ounts of the alkylated derivative.
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but the reaction w as difficult to reproduce. No reaction occured between 
coumarin 2 and N-Boc-bromoethylamine under similar conditions.
Attempts to alkylate coumarin 2 with N-Boc-ethanolamine in a Mitsunobu 
reaction®"^’®® to introduce a masked primary amine functionality were 
unsuccessful under various conditions (Table 4).
Amine Reagent Solvent T Amine : alcohol : TPP : DEAD Yield (
NMA DEAD THF 25 °C 1:1:1:1 0
NMA DEAD THF Reflux 0
NMA DEAD dioxan Reflux 1:1:1:1 0
NMA DEAD THF Reflux 1:2:2:2 6
NMA DEAD dioxan Reflux 1:2:2:2 9
NMA* DEAD dioxan Reflux 1:2:2:2 -2
Coumarin 2 DIAD THF Reflux 1:1:1:1 0
Coumarin 2 DEAD THF Reflux 1:2:2:2 0
Coumarin 2 DEAD dioxan Reflux 0
Coumarin 2 DEAD dioxan Reflux 1:2:2:2 0
Table 4. Mitsunobu reactions of NMA or C2 with N-Boc-ethanolamine. * Alcohol: N-Boc-HBA.
Neither replacem ent of the DEAD with DIAD, nor changing of the THF to 
dioxane, nor increasing the reaction tem perature resulted in product formation. 
Varying the ratio of the reagents did not help product formation either. If the 
NMA test compound was used instead of coumarin 2, small am ounts of 
alkylated product were isolated, albeit rather forcing conditions were needed, 
such a s  large excess of reagents and refluxing dioxane. Also, long reaction 
times were necessary, w hereas the Mitsunobu reaction on primary aliphatic 
am ines usually proceeds swiftly, and affords the product in a matter of hours. 
Alkylation of NMA with N-Boc-HBA in a Mitsunobu reaction through the
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secondary hydroxyl group of the HBA was successful, but afforded the product 
in very low yields. (~2%)
5.1.4 Attachment of the donor through a glycine linker
To suppress the side-reaction between the secondary hydroxyl group of HBA 
and its carboxylic acid, coumarin 2 w as reacted with N-Boc glycine first. Glycine 
has only a  COOH group and no side reactions were possible. It w as expected 
that the primary amino group of the glycine would afterwards react with the 
carboxylic acid of the HBA. The glycine would becom e a linker in the final 
product. Peptide bond formation between a primary aliphatic amine and a 
carboxylic acid is usually much faster than estérification of the COOH with a 
secondary hydroxyl group, so introduction of the glycine would reduce the 
significance of the self-esterificaion.
Unfortunately the desired product w as obtained in -15%  yield after a week-long 
reaction in the presence of excess N-Boc glycine and EDCI (Scheme 7).
o
xNHBocNHBoc
EDCI
DCM
68
Scheme 7. Amide bond formation between coumarin 2 and N-Boc giycine.
The low yield of the peptide bond formation reation between coumarin 2 and 
glycine has proved that the major obstacle is the poor nucleophilicity of the 
coumarin 2. Therefore other donors, with better reactivities were sought.
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5.1.5 The coumarin 120 and coumarin 151 donors.
Replacem ent of coumarin 2 w as required and two new donors were introduced. 
Both coumarin 120 and coumarin 151 are primary amines, and were thought to 
be more reactive than coumarin 2. Both have excitation and emission 
wavelengths close to those of coumarin 2, therefore RET between the new 
donors and the coumarin 343 acceptor is possible (Table 5).
coumarin 2
NHz
coumarin 120
NHz
coumarin 151
^max (absorption) 366 nm 343 nm 377 nm
8 2 . 1 - 10® 2 .2 - 10 ® 2 . 1 - 10®
Xmax (emission) 432 nm 433 nm 487 nm
Table 5. Photophysical properties of coumarin 2, coumarin 120^^and coumarin 151.^  ^ Spectra 
were recorded in methanol, and the data are for underivatized compounds.
Neither coumarin 120, nor coumarin 151 reacted with HBA, but both formed 
amide bonds readily with N-Boc glycine, affording the corresponding products in 
high and moderate yields, respecitvely. The Boc protection of the glycine w as 
removed in both cases  by cleavage with 33% TFA in DCM, and the free amino 
groups were coupled to the carboxylic acid of N-Boc-HBA. Deprotection of the 
amino groups gave the donors attached to the HBA scaffold through a glycine 
linker. The products thus obtained were insoluble in m ost solvents, which 
prohibited further reactions, and coupling of coumarin 343 to the scaffold was 
unsuccessful (Scheme 8).
174
NHBocNHBoc
DCM O "  O
69, 7467, 73 TFA/DCM
NHBoc
O
71,76 70, 75
TFA/DCM BocHN
j U
X = CH3 (coumarin 120) 
or
0
0^ 0^ J
"  " O y l
X = CF3 (coumarin 151)
72, 77
H^N
Scheme 8. Attachment of coumarin 120 (67) and coumarin 151 (73) to the HBA scaffoid
moiecuie through a giycine linker.
Another approach to the synthesis of the donor-acceptor diad held together by 
glycine-HBA involved coupling coumarin 343 to the free amino group of HBA 
ethyl este r (Scheme 9) followed by saponification of the ethyl ester using 1 M 
NaOH solution in methanol.
O OH
EtO
80
HO
NHj +
OEt OHDCM
83
Scheme 9. Reaction of coumarin 343 with ethyl ester protected HBA.
Although the ester hydrolysis went to completion under mild conditions, isolation 
and purification of the free acid w as problematic, as  the product is water-
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soluble, and attem pts of its extraction into organic solvents were unsuccessful. 
Chromatography on either silica or alumina w as hindered by its zwitterionic 
nature, and in particular its ionisable carboxylic acid functionality.
Reduced solubility of the donor-glycine-HBA and the acceptor-HBA was 
possibly due to the rigid structure of the HBA scaffold, which probably helped n- 
n stacking of the donors. Therefore replacem ent of the HBA with a more flexible 
‘backbone’ w as necessary. The commercially available N-Fmoc-y-O-^Butyl 
glutamic acid w as chosen, as  apart from a free carboxylic acid to which the 
donor could be coupled, a second carboxyl group and an amino group are 
present in orthogonally protected forms.
5.1.6 Synthesis o f the organic triad held together by a glutamic acid scaffold 
Coumarin 120 w as reacted with N-Fmoc-y-0-*Butyl glutamic acid in DCM at 
room tem perature in the presence of 10% excess of EDCI coupling reagent for 
two days. After acidic workup and silica column chromatography the product 
w as isolated in high yields. The Fmoc protecting group w as removed by 
cleavage with piperidine or diethyl amine, the latter being preferred for its lower 
boiling point and easier removal. a-Amino acids with free amino groups are 
known to undergo diketopiperazine formation, therefore it is essential to reduce 
the isolation and purification time to the minimum, and avoid high tem peratures. 
Removal of the solvent and the nucleophile w as followed by silica column 
chromatography to separate  the free amine from the high boiling point solvent 
residues and the dibenzofulvene. The isolated product w as reacted immediately 
with the coumarin 343 acceptor in DCM at room tem perature in the p resence of 
10% excess of EDCI. After 24 hours the reaction w as stopped. Removal of the
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EDCI, the residual free amine and coumarin 343 by aqueous, acidic and basic 
w ashings respectively gave the donor-acceptor-scaffold product in > 95% purity. 
Analytically pure compound w as obtained after subjecting the crude sam ple to 
silica column chromatography {Scheme 10).
NHFmoc
HO
EDCI
NHDCM
NHg OtBu
OtBu NHFmoc
piperidine
DMF
coumarin 343
EDCI, DCM NH
NH
OtBu
OtBu NHg
NH
D = donor (coumarin 120)
OH
A = acceptor (coumarin 343)NH
Scheme 10. Synthesis of the organic diad 87. The donor and the acceptor are attached to a 
tert-butyl ester protected glutamic acid backbone.
Cleavage of the *Butyl este r with 50% TFA in DCM afforded the free acid in 
quantitative yields after evaporation of the solvents. This work-up afforded the 
free acid diad with the tertiary amino group of the coumarin 343 protonated. 
After neutralising the TFA salt with triethylamine, the carboxylic acid w as 
reacted with the 5'-hydroxyl group of uridine. The estérification reaction 
proceeded smoothly and afforded the desired triad in the p resence of EDCI and 
catalytic amount of DMAP. Although after aqueous workup TLC, m ass 
spectrometry and NMR spectroscopy suggested almost com plete
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transformation of the reactants into the product, removal of the remaining 
starting materials via column chromatography w as necessary. This resulted in 
the hydrolysis of the este r bond between the diad and the quencher. As the 
este r bond proved unstable under the chromatographic conditions, a more 
stable attachm ent method w as sought. It is possible to transform the 5'-hydroxyl 
group of the nucleoside into an amino group, offering the possibility of an amide 
bond formation between the scaffold and the quencher. Therefore the 
nucleoside w as transformed into the 5’-amino derivative.
5.1.7 Synthesis of the 5’-aminonucleosides
There are a number of routes available in the literature to the synthesis of 5'- 
aminonucleosides. The synthetic strategy presented below is based  on known 
transformations of various other types of molecules. It utilises readily available 
chemicals, our target being a fast, effective route for the production of at least 
one 5’-aminonucleoside.
The 5’-hydroxyl group of the 2',3'-isopropylidene-protected nucleoside w as 
activated in situ by methanesulphonyl chloride in the presence of three 
equivalents of triethylamine under argon atm osphere, and w as replaced by an 
azido group derived from sodium azide. The 5’-azido nucleosides were purified 
by column chromatography. Reduction of the azido group w as attem pted 
initially in dry DCM with lithium aluminium hydride, but even at room 
tem perature a mixture of decomposition products were formed.
The azides were successfully reduced in dry THF with triphenylphosphine to the 
corresponding P=N compounds, which were hydrolysed in situ by the addition 
of water (Scheme 11). After evaporation of the THF, the 5’-am inonucleosides
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were dissolved in water, and the triphenylphosphine oxide w as removed by 
washing with DCM. The products were isolated by evaporation of the water, and 
pure sam ples were obtained by trituration with diethyl ether. This method w as 
applicable for the synthesis of 5’-aminouridine and 5-am inoadenosine. Both 5’- 
azidocytidine and 5'-azidoguanosine were also synthesised, albeit in poor 
yields. Reduction of these  compounds produced a mixture of compounds, 
among them substantial am ounts of decom posed material.
OH N3 NHg
1 .M s C I /T E A  
2. NaN,
3
2. water
89a-b
0 ^ 0  D M F /A r  O.^ ^ O  THF
99,103 101,105
Scheme 11. Synthesis of 5’-aminouridine (89a) (B = U) and 5’-aminoadenosine (89b) (B = A).
Activation of the 5’-hydroxyl group of the 2 \3 ’-protected ribose is followed by substitution with 
azide. The azide is reduced by a combination of triphenylphosphine and water.
5.1.8 Synthesis of the triads
The 5’-aminonucleoside w as coupled to the ;^carboxylic acid of the donor- 
acceptor diad in DCM with EDCI and the product w as isolated after silica 
column chromatography in moderate yields (Scheme 12). The major product of 
the reaction w as the cyclised compound 91 that presumably formed after 
activation of the carboxylic acid with EDCI. Its production w as facilitated by the 
removal of the amide proton by the triethylamine, making it prone to an attack 
by the activated carboxylic acid. The molecule also contains a  stable six- 
m em bered diamide ring. The triad with uridine quencher w as isolated in 38% 
yield, while the one with adenosine quencher in 84% yield after silica column 
chromatography.
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EDCI, base
EDCI, base 
5'-aminonucleoside
90a-b
A = acceptor (coumarin 343)
Q = quencher (uridine or adenosine)
Scheme 12. Synthesis of the coumarin 120-coumarin 343-uridne and coumarin 120-coumarin 
343-adenosine triads (90a-b) from the corresponding diad.
5.1.9 Coumarin 151 donor
Triads bearing coumarin 151 donors and uridine or adenosine quenchers were 
prepared in syntheses analogous to those of the coumarin 120-donor triads. 
The reaction between the diprotected glutamic acid and the coumarin 151 w as 
slower and less efficient than in the case  of the coumarin 120, due to the lower 
reactivity and poorer solubility of the coumarin 151. The corresponding diad w as 
isolated in good yields, and removal of the *butyl este r w as unproblematic 
{Scheme 13).
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CF.
NHF moc
EDCI
DCM*
0 " 0
OtBu
NHO
'OtBu
NHFmoc92
CF. piperidine
DMF
CF.
coumarin 343
EDCI,DCM NH
NHO
OtBu
OtBu NH,NH
D = donor (coum arin 151 ) 
A= acceptor (coumarin 343)
OH
,NH
Scheme 13. Synthesis of the organic died 95. The donor and the acceptor are attached to a 
tert-butyi ester protected giutamic acid backbone.
The reaction between the free acid diad and the 5 -aminonucleosides produced 
almost uniquely the cyclised side-product. The target C151-C343-A and C151- 
C343-U triads (96a-b) were isolated in 15% and 6% yields, respectively 
(Scheme 14).
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CF,
96
EDCI, base
EDCI, base 
S'-aminonudeoside
^  D = donor (coumarin 151 )
A = acceptor (coumarin 343)
Q  Q = quencher (uridine or adenosine)
96a-b
Scheme 14. Synthesis of the coumarin 151-coumarin 343-uridne and coumarin 151-coumarin 
343-adenosine triads (96a-b) from the corresponding diad.
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5.2 Characterisation of the organic triads
M easurem ents concerning the organic diads and triads were carried out in 
methanol, while those on the lanthanides were performed in water, buffered to 
pH 7.4 with MOPS. Adenosine was dissolved in DMSG and uridine in water. 
DMA w as dissolved in pH 7.4 water. Sam ple concentrations were 0.3-1.0 mM, 
and absorptions were in the 0.2-0.5 AU range.
Our attem pts to titrate organic diads and triads in aqueous solutions failed due 
to the low solubility of the compounds in pH 5.5 water and the quenching of the 
sam ple lum inescence caused by the medium (Figure 19). The latter is probably 
due to a protonation of the coumarin 343 tertiary nitrogen. At pH 7.4 the 
solubility of the diads and triads w as even lower, because  of the lack of 
ionisation on the acceptor. Therefore in neutral or basic solutions 
m easurem ents could not be carried out.
A em ission60000 n
50000 -
-  40000 -
D em ission30000 -
20000 -
10000
420 440 460 480 500 520 540 560 580 600 620
w avelength (nm)
Figure 19. Changes in the emission spectrum of the c120-c343 diad in distilied water/DMSO 
upon the addition of uridine in DMSO. The maximum at 560 nm decreased, that at 440 nm
increased during the titration.
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In pH 5.5 w ater the emission spectrum had a maximum around 560 nm, which 
rapidly decreased  in intensity during the m easurem ent, independent of the 
am ount of nucleoside present. The fluorescence quenching by the w ater is 
supported by NM R-measurements in de-DMSO / D2O, where the chemical shifts 
and multiplicities of the aromatic C-H hydrogen signals remained unchanged. 
There w as no sign of decomposition either in the ^H or the spectrum. 
Protonation of the tertiary amino group of the coumarin 343 reduces the 
fluorescence quantum yield of the acceptor and also shifts the emission 
wavelength of the A, together with its absorption wavelength. This m akes RET 
from the D less efficient, and the new peak, centred around 440 nm is likely to 
be the donor emission. As the amide-bound c120 and c151 have no easily 
protonable sites, their photophysical properties are unaffected by the medium. 
As RET becom es less efficient, emission from the donor becom es more and 
more pronounced.
Attempts at determining the donor lifetime by direct excitation of the donor and 
monitoring emission at 440 nm w as not possible, as  the donor emission 
intensity w as not high enough in a mixture of DMSO and water. A lifetime of
3.63 ns w as m easured by detection at 475 nm, emission of the unprotonated 
acceptor, which is slightly longer than the 3.31 ns m easured in methanol for the 
diad lifetime, although it is still within experimental error. The acceptor lifetime 
w as 4.03 ns upon direct excitation (@ 440 nm, detection @ 540 nm), while 
excitation of the donor with emission from the acceptor yielded a lifetime of 4.11 
ns. The increase of the acceptor lifetime might be due to the protonation of the 
amino group, which, when unprotonated could act as  an electron donor in PET, 
and shorten t. Similar m easurem ents for the diad with c l 51 D could not be
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carried out, a s  the emission wavelength for the c151 is at longer wavelengths, 
and is buried under the acceptor absorption band even in aqueous solutions.
5.2.1 Organic diads
The organic diads, having no quencher moiety in the molecule, could not be 
m easured against the complementary base  of the Q.
The organic diads were titrated in methanol with salmon testis DMA. The 
interaction between DMA and both diads w as strong (K > 10"^ ). The binding 
constant could not be determined more accurately because of the inaccuracies 
caused  by the low concentrations of the sam ples. In the case  of the coumarin 
120 -  coumarin 343 diad, initially only inconsistent results were obtained, as 
neither quenching nor increase in the lum inescence intensity w as observed. If 
the sam ples were allowed at least 24 hours between preparation and 
m easurem ent, the reproducibility of the results increased significantly. It is 
possible that the complete dissolution of the compounds is not instantaneous, 
despite the clear solutions obtained.
In the presence of DMA, the coumarin 120 -  coumarin 343 diad (87) w as 
’turned on’ {Figure 20).
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Figure 20. Increase in the emission intensity of the coumarin 120-coumarin343 diad (87) in 
methanol, upon addition of double stranded DNA (dissolved in pH 7.4 water).
The coumarin 151 -  coumarin 343 diad (94) was quenched by DNA. In both 
cases  the donor is possibly intercalating between the DNA base  pairs, causing 
the effects. While the coumarin 120, substituted with a methyl group in the 4 
position is an electron-donating moiety, the coumarin 151 is strongly electron- 
withdrawing. If the quenching of the donor by the DNA occurs through electron 
transfer, intercalation of the coumain 120 m eans that the excited sta te  donor is 
in an electron-rich environment, and cannot be readily oxidised, and thus 
quenched. The oxidising coumain 151 on the other hand is placed in the 
electron-rich environment of the negatively charged phosphate backbone, and 
can be reduced easily. Thus in the case  of coumarin 151 it is probably reductive 
electron transfer that quenches the fluorescence.
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When comparing the excitation and emission spectra of the two diads, a striking 
difference between the fluorescence intensity is seen  {Figure 21 and Figure 22).
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Figure 21. Excitation spectra of the diads in methanoi (emission detected @ 480 nm). Emission 
from the diad 87 is much more intense than emission form diad 94.
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Figure 22. Emission spectra of the diads in methanol (excitation wavelength 328 nm).
The UV-Vis spectra of the organic diads and triads were recorded in methanol 
containing 3% DCM. The absorption spectra of the two com pounds are  very
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similar, showing a strong absorption band with a maximum at 440 nm, due to 
the coumarin 343, and a smaller band at 336 nm (coumarin 151) or 326 nm 
(coumarin 150). The donor absorption bands are of similar intensities, and 
according to the data available in the literature, both com pounds emit in the 
430-450 nm range (Figure 23).
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Figure 23. Absorption spectrum of the coumarin 151-coumarin 343-uridine triad in methanol 
(0.033 mM). The maximum at 340 nm corresponds to the donor absorption, the one at 440 nm 
is that of the acceptor. Similar spectra were obtained for the other organic diads and triads.
The UV-Visible spectroscopic properties of the organic diads and triads are 
sum m arised in Table 6. The absorption maxima and absorption coefficients for 
the nucleosides were similar to those found in the literature. Thus, both uridine 
and adenosine absorbed strongly at around 260 nm, with absorption 
coefficients in the 10"^  range. As excitation of the com pounds w as performed at 
wavelengths exceeding 300 nm, this is not a problem.
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C120-C343 C151-C343 C120-C343-U C120-C343-A c151-c343-U c151-c343-A
Amax(D) 325 nm 334 nm 325 nm 325 nm 334 nm 334 nm
s 1.1 10"^ 1.2 10"^ 1.1 10"^  1.1-10^ 1.2 10"^ 1.2 10"^
m^ax(A) 441 nm
£ 3.1 10"^
Table 6. Absorption maxima and e of the organic diads and triads.
The shifts in the absorption bands, compared to those of the free coumarins, to 
shorter wavelengths by 20-40 nm is due to the participation of the primary 
amino groups in the amide bonds of the diads. It is likely that the emission 
maximum of the coumarin 120 is exactly at the absorption maximum of the 
coumarin 343, or immediately below it, while that of the coumarin 151 is slightly 
over 440 nm. This could account for a difference in the efficiency of the 
resonance energy transfer between the donor and the acceptor, and the 
resulting variations in the donor fluorescence (Figure 24a and 24b).
Acceptor absorption
Donor emission Acceptor emission
Donor absorption
400 500450
Donor emission
wavelengtti (nm)
Acceptor absorption Acceptor emission
Donor absorption
400 500450
waveiengtti (nm)
Figure 24a and b. Possible explanation of the differences in the luminescence intensity of the 
diads with different donors. The emission maximum of coumarin 120 is below the absorption 
maximum of the acceptor, making the RET very efficient, while that of the coumarin 151 is 
possibly marginally over the c343 absorption, making RET difficult.
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5.3 Organic triads and complementary bases
5.3.1 Coumarin 120 donor and uridine quencher
The fluorescence of the organic triad consisting of coumarin 120 donor, 
coumarin 343 acceptor and uridine quencher (90a) in methanol showed no 
changes when small quantities of the complementary base  (adenosine) were 
added. At adenosine concentrations hugely exceeding the triad concentrations 
(50-100-fold), lum inescence intensity decreased  (Figure 25).
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Figure 25. Decrease in the emission intensity of the triad 90a in methanol, upon addition of the
complementary base adenosine.
This might be due either to the adenosine, or the solvent in which the adenosine 
w as dissolved (1:1 mixture of DMSO and water). A 100-fold excess  in 
adenosine m eans the introduction of 236 pL of DMSO : water, about 7% of the 
total volume. This could account for the change, a s  the coumarin 343 emission 
is very sensitive to solvent polarity. On the other hand, the p resence of a  100- 
fold excess m eans that it is more likely that the adenosine is quenching the
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donor directly. The scattering of the data points does not allow the calculation of 
a binding constant.
In acetonitrile the association between the triad and the complementary base  
w as indicated by decrease  of fluorescence {Figure 26). Acetonitrile, being polar 
but aprotic, can only act a s  an acceptor in hydrogen bonding, thus facilitating 
the interaction between the host and the guest.
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Figure 26. Decrease in the emission intensity of the 90a in acetonitriie, upon addition of the
complementary base adenosine.
5.3.2 Coumarin 120 donor and adenosine quencher
Addition of the complementary base  uridine to 90b (coumarin 120 -  coumarin 
343 - adenosine) resulted in increased fluorescence intensity {Figure 27). The 
effect w as more pronounced in acetonitrile, where the final intensity w as 15% 
higher than the initial intensity. In methanol the increase was only 3% {Figure 
28).
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Figure 27. Increase in the emission intensity of the triad 90b in acetonitriie, upon addition of the 
complementary base uridine. The intensity change corresponds to approximately 15%.
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Figure 28. increase in the emission intensity of 90b triad in methanoi, upon addition of the 
complementary base uridine. The intensity change corresponds to approximately 3%.
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The difference could be caused by the w eaker interaction in the highly polar and 
protic methanol. 90b was the only one of the four organic triads that behaved in 
the way predicted originally. Although the fluorescence of the donor -  acceptor 
diad is not turned completely off, it is decreased  considerably. Addition of the 
substrate of the quencher (the complementary base  uridine) reduces the 
quenching. According to the data available, quenching of the coumarins by 
nucleosides happens via electron transfer.^® Base pairing between the 
adenosine and the uridine could change the redox potential of the quencher by 
affecting the electron distibution of the heterocycle. This in turn could reduce the 
rate of the electron transfer, resulting in an increase in lum inescence intensity.
5.3.3 Coumarin 151 donor and uridine quencher
The coumarin 151 -  coumarin 343 -  uridine triad (96a) w as titrated with 
adenosine in methanol. Addition of the complementary base  quenched the 
emission from the acceptor. The interaction between the host and the guest 
w as strong, as  indicated by a 13% change in the lum inescence intensity upon 
addition of 1 equivalent of the complementary base. The intensity changes 
induced by adding more adenosine were small. The binding constant could not 
be determined unambiguously because  of the low concentration of both 
compounds.
This triad w as also titrated with uridine, guanosine and cytidine, to determ ine if it 
is possible to distinguish between them. In DNA, base  pairing is strictly 
controlled, but the free nucleosides can form hydrogen bonds freely with each  
other in any combination. Adding solutions of the nucleosides resulted 
invariably in quenching of the luminescence. The degree of the quenching w as
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of the sam e order of magnitude in all four cases, therefore it w as not possible to 
distinguish between the four nucleosides this way.
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Figure 29. Excitation spectra of the diads and triads (D = c151) in methanol (det: 480 nm). 
Above 350 nm direct excitation of the acceptor becomes significant.
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Figure 30. Emission spectra of the organic diads and triads in methanol (excitation: 328 nm). 
Only emission from the coumarin 343 donor is observed (484 nm).
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Under identical experimental conditions the excitation and emission spectra of 
the c151-0343 diad and the corresponding triads were compared (Figure 29 and 
30). The triad fluorescence is effectively quenched by the nucleosides in both 
cases. As the addition of the complementary b ases caused further quenching, it 
is possible that the base  pairs can quench the coumarin 151 more effectively 
than the unpaired nucleoside (Figure 31), or they are quenching the donor 
directly.
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Figure 31. Quenching of the triad 96a by the addition of adenosine. (Methanol, c(triad) = 0.033
mM, excitation @ 328 nm)
5.3 .4 Coumarin 151 donor and adenosine quencher
The triad consisting of coumarin 151 donor, coumarin 343 acceptor and 
adenosine quencher (96b) w as less luminescent than its corresponding diad. 
Addition of the complementary base  uridine induced further quenching, which
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might be due to the increased quenching ability of the b ase  pair compared to 
the adenosine (Figure 32) or direct quenching of the donor by the uridine.
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Figure 32. Quenching of the c151-c343-A triad (96b) by the addition of uridine. (Methanol, 
c(triad) = 0.033 mM, excitation @ 328 nm)
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5.4 Organic triads and DNA
5.4.1 Coumarin 120 donor
Both coumarin 120 -  donor bearing triads dissolved in methanol were titrated 
with DNA. In neither case  were consistent and reproducible data obtained. At 
high DNA excess a slight decrease  in fluorescence intensity w as observed, but 
this w as not significant until the DNA was in ~100-fold excess (Figure 33).
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Figure 33. Quenching of 90b by DNA. (MeOH, c(triad) = 0.033 mM, excitation @ 328 nm) 
5.4.2 Coumarin 151 donor
The triads equipped with coumarin 151 donors displayed strong interaction with 
DNA. Both triads were efficiently quenched by DNA, which is probably the result 
of the intercalation of the donor with the double strand. It is possible, that the 
previously mentioned increase in the quenching of the coumarin 151 by b ase  
pairs plays a role in this case  too, and contributes to the quenching.
197
900000
880000
^  860000
840000
820000
0.00005 0.0001 0.00015 0.0002 0.00025 0.00030
[DNA]/M
Figure 34. Quenching of the c151-c343-A (96b) triad by the addition of DNA. (Methanoi, c(triad)
= 0.033 mM, excitation @ 328 nm)
A summary of luminescent properties, the binding constants of the triads and 
their complementary bases, the triads and the diads with DNA, and the effects 
of the targets on the probe luminescence is shown in Table 7.
c120-c343 cl 51-0343 C120-C343-U c120-c343-A c151-c343-U C151-C343-A
c.b. - - * increase decrease decrease
K - - * > 10"* > lO'^ > 10'‘
DNA increase decrease * * decrease decrease
K > 10"* > lO"* * * > 10"^ 10"*
o.b. - - decrease® increase® decrease‘s
K - - ~ 10^ ~ 10^ > 10'‘
Tabie 7. All measurements were conducted in methanoi, unless stated otherwise. *no consistent 
data were obtained, ^measurement in acetonitriie, ‘^ measurement with C, G, A and U separately, 
c.b. complementary base, o.b. own base, increase = increase in fluorescence intensity, 
decrease = decrease in fluorescence intensity.
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5.5 Stern-Volmer constants for the quenching of the triads
In most ca se s  the data obtained from the fluorescence titrations of the triads did 
not allow the calculation of a binding constant for the nucleosides. The apparent 
constants obtained were significantly higher than those found in the literature, 
typically 70 M‘^  in DMSO, for the association of the adenine-uridine b ase  pair.®® 
Although the triad -  nucleoside system s are different from the free A -  U base  
pair, the association constant should be of a similar magnitude, given the 
number of possible hydrogen bonds between the two heterocycles.
Plotting lo / I versus the quencher concentration gives information about the 
nature of the quenching procedure. The c120-c343-U (90a) triad w as quenched 
both in methanol and acetonitriie by adenosine, but it w as not possible to fit a 
binding curve to the data. The Stern-Volmer plot revealed that until the 1 : 1 
ratio of the [Q] : [triad] w as reached, the quenching of the triad w as increasing 
with the concentration. In the presence of excess Q the quenching did not 
becom e more efficient, a s  shown by a break in the curve drawn over the data 
points. Similar results were obtained for the c151-c343 diad with DNA and the 
c151-donor triads with both their complementary b ases  and DNA {Figure 35).
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Figure 35. Quenching of the c120-c343 (87) diad by dsDNA.
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Figure 36. The initial section of the Stern-Volmer plot in Figure 35. 
Stern-Volmer constants were calculated by fitting a straight line to the initial
section of the plot. If the quenching obeys Stern-Volmer kinetics the intercept
should be at 6 = 1, X is the concentration of the quencher, and the slope of the
curve (m) gives the Stern-Volmer constant {Eq 3).
y  - m x  + b Eq. 3
The constants obtained for the organic diads and triads for the quenching by 
their complementary b ases and DNA are summ arised below {Table 8).
C120-C343 C151-C343 C120-C343-A c120-c343-U C151-C343-U C151-C343-A
c.b. - * 12 7.5 10'' 3.2 10"
DNA 6.5 10^ 11 7.3 10^ 7.4 10^
Table 8. Stern-Volmer constants. *The c120-c343-A triad behaved in the predicted way, i.e. its 
fluorescence intensity was increased by addition of its complementary base. **The Stern- 
Volmer constant for its quenching by DNA could not be calculated.
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5.6 Determination of x of the organic diads and triads
The luminescent lifetimes of the triads and the diads were determined in the 
presence of their complementary bases, the solutions of their own quenchers, 
and DNA (Table 9).
87 94 97 90a 90b 96a 96b
T 3.52 ns 1.33 ns 1.71 ns 3.38 ns 3.46 ns 1.33 ns 1.40 ns
C.6.* - - - 3.36 ns 3.48 ns 1.39 ns 1.40 ns
c.b.^ - - - 3.40 ns 3.51 ns 1.30 ns 1.33 ns
DNA^ 3.51 ns 1.27 ns 1.86 ns 3.38 ns 3.51 ns 1.32 ns 1.43 ns
DAM* 3.55 ns 1.14 ns 1.73 ns 3.40 ns 3.51 ns 1.29 ns 1.30 ns
0.6/ - - - 3.38 ns 3.50 ns 1.33 ns 1.45 ns
0.6* _ - - 3.50 ns 3.47 ns 1.39 ns 1.29 ns
Table 9. The lifetimes of the organic diads and triads in methanol, ^one equivalent, ‘^ ten 
equivalents, c.b. complementary base, o.b. same base as quencher base. Lifetimes can be 
measured with ±10% accuracy.
Excitation of the sam ples w as performed at 320 nm, which is close to the 
excitation maximum of the donor, and is at sufficiently short wavelength to avoid 
direct excitation of the acceptor. The two triads bearing c120 donors were also 
excited at 310 nm, without significant changes in t. Direct excitation of the 
acceptor at 450 nm did not change the r, indicating, that in the case  of th ese  
two triads, RET is fast and the rate determining step is the fluorescence 
emission.
The luminescent lifetimes seem  to be dependent on the donor, which is 
som ew hat contradictory with the results obtained by direct excitation of the 
acceptor. A possible explanation is that in the case  of coumarin 151 there are 
several vibronic levels in the excited state that are slightly below the excited
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State of the coumarin 343, and the the acceptor can thermally repopulate the 
donor excited state {Figure 37).
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Figure 37. Energy ievels of the donors and the acceptor.
This would open up a deactivation pathway for the [c151-c343]* system , which 
could com pete with the fluorescence emission from the acceptor. If we assum e 
that (a) no such repopulation occurs for the c 120-donor bearing species, and (b) 
the only de-activation pathways significantly contributing to the de-excitation of 
the acceptor, Eq 4. describes the concentration of A* at any given time after 
excitation.
[a  *], =  [a  *]o • +  [a  *]„ • e-"‘‘ ^9
The rate constants of the luminescent decay and repopulation are k i and /C2, 
respectively, t is the time, [A*]o and [A*]t are the concentrations of the A* at f = 0 
and f = t. As the concentration of A* is reduced by an additional non-radiative 
process, its observed lifetime decreases.
The luminescent lifetimes of the triads are longer than the lifetimes of the 
corresponding diads. Addition of one equivalent of the complementary b ase  of 
the quencher increases t in both m easured cases. Adding the Q nucleotide to 
the solution resulted in increase of the lifetime, probably because b ase  pairing 
is possible in other combinations than the Watson-Crick base  pairs. The drop in
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the T when 10 equivalents of the nucleotides were added can be a solvent 
effect, or due to a competitive reaction, for example association of the free 
bases, or direct quenching of the donor.
DNA decreased  the luminescent lifetime in the case  of the c151-c343-A (96b) 
triad, and increased marginally that of the c120-c343-U triad (90a).
When uridine w as added in small portions to 96b a gradual increase in the r o f  
the triad w as observed, in accordance with the changes seen  in the luminescent 
intensity (Figure 38). Although it w as not possible to fit a binding curve to the 
data points, the increase in the lifetime suggests that in the triad the quencher is 
disrupting the RET, which is aprtially restored upon the addition of the 
complementary base.
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Figure 38. Changes ofx for the triad 90b upon addition of uridine. The scattering of the data 
points is caused by the inaccuracies of the determination of the t , usually ±10%.
Addition of uridine to the triad 96b and addition of DNA to the diad 94 resulted 
in a decrease  in their luminescent lifetimes (Figure 39).
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Figure 39. Changes ofx for the triad 96b upon addition of DNA.
The lifetime of the cyclic side-product with c l 51 D (97) was m easured and w as 
significantly higher than that of the corresponding diads and triads. As the 
amide group through which the c l 51 is attached to the scaffold is replaced by a 
diamide bond, the absorption and excitation maxima of the c l 51 are shifted to 
shorter wavelengths, to approximately 320 nm. This m eans an increase in the 
Si state energy of the donor, which reduces the efficiency of thermal re­
population of the donor Si from the excited-state acceptor. Addition of DNA to 
this compound increased the t. The DNA is probably acting a s  an electron 
donor to the electron-withdrawing coumarin 151. If quenching of the diamide- 
bound D occurs through oxidative PET, electron donation from the DNA could 
decrease  its rate.
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5.7 Lanthanide ligands
A series of lanthanide complexes were designed to serve a s  luminescent 
probes using triggered resonance energy transfer. The m echanism of sensing 
and reporting is similar to the one exploited in the organic triads. A donor 
transfers its energy to an acceptor moiety. The transfer is inhibited by a 
quencher, possessing a recognition unit. Binding of a substrate to the Q 
recognition site disrupts the quenching, and energy transfer between the D and 
the A can take place.
The D of the lanthanide complexes is coumarin 2, which can serve a s  an 
antenna for the metal ions Eu and Tb. This is essential for overcoming the 
barrier of the low absorption coefficients of the lanthanides. The Q is a 
nucleotide. The various functional units are held together by a cyclen scaffold. 
Unlike the organic triads, the lanthanide complexes have an inorganic reporter. 
The line-like, long wavelength lanthanide emission (Figure 40 and Figure 41) 
m akes detection easy  as  most of the interference from biological sam ples is < 
500 nm. Further improvement in the sensitivity can be achieved by filtering out 
short-lived signals (for example t < 500 ns). The intensity ratios of the 
transitions also give information about the symmetry of the complex. C hanges 
upon addition of a substrate indicate significant conformational changes. The 
spectra shown in Figures 40 and 41 belong to highly asymmetric complexes.
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Figure 40. Emission spectrum of 151a in methanoi. Excitation @ 328 nm.
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Figure 41. Emission spectrum of 151b in methanol. Excitation @ 328 nm.
5.7.1 Attachment of the coumarin 2 antenna to the cyclen 
To enable attachm ent of the coumarin 2 antenna to the cyclen scaffold, 
coumarin 2 w as reacted with chloroacetic acid (Scheme 6). The reaction 
proceeded smoothly, and with excess chloroacetic acid and EDCI provided the 
coumarin 2 chloroacetate (116) in very good yields. The excess EDCI and
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chloroacetic acid were removed by aqueous and basic washings. The residual 
coumarin 2 (typically < 5%) could be easily separated from the product by silica 
column chromatography.
Although the coumarin 2 chloroacetate (116) proved an excellent reagent for 
our purposes, replacem ent of chloroacetic acid with bromoacetic acid increased 
both yields and reaction rates, therefore in the final synthetic procedure 
coumarin 2 brom oacetate (117) w as used instead of the chloroacetate.
5.7.2 Cyclen derivatisation starting from the bis-protected cyclen-oxalamide 
Simultaneous protection of the N1,N4 nitrogen atom s of cyclen is known from 
the literature. The oxalamide protecting group can be hydrolysed by 10 M 
aqueous NaOH, or refluxing concentrated hydrochloric acid.
The third nitrogen w as reacted with di-tert Butyl dicarbonate at room
tem perature in chloroform in the presence of 1.5 equivalent triethylamine. The
formation of fully protected (bis-Bocced) cyclen w as not seen , and the 
triprotected cyclen w as easily separated  from the un reacted oxalamide. Typical 
yields were between 70-80% (Scheme 15).
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Scheme 15. Synthesis of the triprotected cyclen (113).
Alkylation of the free fourth nitrogen w as unsuccessful (Scheme 16). Using the 
model molecules, NMA chloroacetate (114) and coumarin 120 brom oacetate
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(119) instead of the coumarin 2 analogue a series of reaction were conducted to 
find the optimal conditions for the alkylation (Table 9).
n  n  yboc
XN'-j N-—, coumarin 2 chloroacetate o
Scheme 16. Alkylation of N I0 of 113. D = coumarin 2, coumarin 120 or NMA.
R eag en t b a se Nal solvent T Yield (%)
NM A -chloroacetate K2CO3 + DMF 100 °c 50
C 2-ch lo roacetate K2CO3 + AcN Reflux 0
C 2-ch lo roacetate TEA - EtOH Reflux 6
C 2-ch!oroacetate K2CO 3 + DMF 80 °C 45
C 120-brom oaceta te K2CO3 + DMF 80 °C 29
Tabie 9. Optimisation reactions for the alkylation of the triprotected cyclen derivative 113. in the 
test reactions, the readily available coumarin 120 and NMA replaced coumarin 2.
The coumarin 2-equipped triprotected cyclen (124) was isolated in low yields. 
This w as due to the poor nucleophilicity of the fourth nitrogen atom under 
relatively mild conditions (warm acetonitriie, 3-5 equivalents of potassium  
carbonate).
At more forcing conditions (refluxing acetonitriie or DMF at 80-90 °C, large 
excess of potassium or cesium carbonate, sodium iodide) the decomposition of 
the chloroacetate occurred. Both coumarin 2 and a dimerised product of the 
coumarin 2 chloroamide (125) were isolated and characterised. A similar 
dimérisation reaction w as seen  when the alkylation w as performed with the 
NMA-chloroacetate, indicated by the appearance of the 2 (m I z) = 594 peak in
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the m ass spectrum of the reaction mixture. The dimérisation of the coumarin 2 
chloroacetate is probably initiated by sodium iodide. In a halogen exchange, the 
chlorine is replaced by iodine. Molecules containing carbon-iodine bonds are 
known to undergo hom ogeneous bond fission, forming the reactive radical, 
which in this system  formed a carbon-carbon bond with an identical radical. It is 
also possible that the base  in the reaction mixture deprotonates the electron- 
deficient a-carbon of 116, and this species reacts further to form the dimer.
After acidolysis of the Boc protection the second substitution reaction w as 
carried out with a series reagents. Direct amide bond formation between uridine 
5’-carboxylic acid and the secondary nitrogen atom of the cyclen w as 
impossible either with DCC or EDCI in DMF or THF. Therefore introduction of a 
linker moiety to provide a masked primary amine to facilitate the attachm ent of 
the 5 -COOH-U w as necessary. Alkylation of the cyclen nitrogen with either N- 
Boc-bromoethylamine or N-Boc-ethanolamine m ethanesulfonate were 
attempted, but gave the desired products in low (10-12%) yields (Scheme 17).
NHBoc
N-Boc-O-Ms-ethanolamine
or
N-Boc-bromoethylamine
O
Scheme 17. Alkylation of the monosubstituted cyclen oxalamide. X = H or Me, Y = H or Et.
5.7.2.1 Sequential synthesis of the asymmetric trisubstituted cycien 
As alkylation of the triprotected cyclen (113) afforded the product in very low 
yields, selective monoalkylation of one of the nitrogen atom s of unprotected
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cyclen w as attempted. Reacting coumarin 2 chloroacetate with 1.5 equivalents 
of cyclen in DMF in the presence of potassium carbonate base  and sodium 
iodide catalyst resulted in the formation of the monoalkylated derivative 
(Scheme 18).
I— H— I coumarin 2 chloroacetate  NH Q'
j A
N
140
Scheme 18. Attachment of the coumarin 2 antenna to the cycien. The major product is 
monosubstituted cyclen (140) (solvent: 100% ethanol, base: TEA).
The major side-products were disubstituted cyclen and dimerised coumarin 2 
chloroacetate (125). Replacem ent of DMF with 100% ethanol and potassium 
carbonate with triethylamine facilitated the purification of the product. W hen the 
coumarin 2 brom oacetate (117) w as used for the alkyaltion the disubstituted 
derivative formed in som ew hat larger quantities (5-10%). This is only a minor 
drawback, a s  the synthesis of the brom oacetate is considerably faster and more 
efficient than that of the chloroacetate.
Previous experimental data suggested that under standard alkylation conditions 
(dipolar solvents, high tem peratures) the second substitution step  occurs at the 
N7 position. Therefore a bis-alkylation reaction was devised, where the 
stabilising ‘arm s’ would be attached to the cyclen scaffold simultaneously. The 
first arm will predominantly alkylate the N7 nitrogen, leaving both nitrogens cis 
to the donor free. The second arm would substitute the hydrogen atom of one of 
the remaining nitrogens. The crucial aspect of this step is the possibility of
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halting the reaction in the trisubstituted cyclen phase, without the formation of 
large quantities of fully substituted cyclen (Scheme 19).
EtO.
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N N
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Scheme 19. Alkylation of monosubstituted cyclen (140) with ethyl bromoacetate.
After optimisation the ideal conditions for the bis-alkylation were found to be 
refluxing 100% ethanol solvent, 3 equivalents of TEA base  and 2.2 equivalents 
of ethyl brom oacetate. These relatively mild conditions still yielded the 
tetrasubstituted cyclen (145) as  the major product, but sufficient quantities 
(typically 500 mg for 2.00 g of starting material 140) of the asymmetric 143 were 
isolated. A small amount (-2% ) of the symmetric trisubstituted derivative (144) 
w as found and purified, along with som e disubstituted compound. W hen DMF 
or acetonitriie were used instead of ethanol, only disubstituted and fully 
substituted derivatives were isolated.
144 145
Figure 42. Side-products isolated during the synthesis of the asymmetric cyclen-derivative 143.
The symmetric 144 was isolated in <5% yieids, but 145 was formed in 30-40% yieids. 
Alkylation of the last secondary nitrogen atom has proved difficult in the
oxalamide approach. As in this case  the N10 nitrogen substitution would be the 
final step, relatively low yields would have been acceptable, a s  all the previous
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steps proceeded with m oderate to good yields. The electron withdrawing effect 
of the ‘arm s’ and the steric hindrance were both assum ed to be lower in the 
trisubstituted cyclen than in the triprotected compound, which both suggested 
that in this case  the substitution reaction might be more efficient.
Alkylation of the N10 nitrogen w as carried out under a number of different 
conditions with both 5’-mesyl-nucleosides and N-Boc bromoethylamine or N- 
Boc-ethanolamine m ethanesulphonate. The latter two could serve a s  linkers to 
which the nucleosides could be coupled. Unfortunately the products were 
formed in very low yields even under rather forcing conditions (Table 10).
Reagent base Solvent T t Yield (%)
BrCHgCHzNHBoc TEA EtOH reflux 24 h 15
MsOCHzCHzNHBoc K2CO3 DMF 80 °C 24 h 12
MsO-2’,3’-isopropyIidene-U K2CO3 DMF 80 °C 36 h 0
MsO-2’,3’-isopropyiidene-A K2CO3 DMF 80 °C 24 3.5
Table 10. Alkylation of the N10 nitrogen of the trisubstituted cycien 143. Aithough various 
reaction conditions and reagents were expiored, yields remained low.
The ligand 147, containing coumarin 2 donor and adenosine acceptor (Figure 
43) w as successfully synthesised and characterised, albeit in very low yields 
and after extensive chromatography. The analogous reaction with uridine-5’- 
m ethanesulphonate w as not successful, and formation of the desired product 
w as not observed.
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Figure 43. The ligand (147) was successfuiiy prepared. The corresponding uridine-containing
molecule could not be synthesised.
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5.7.2.2 Sequential synthesis of the asymmetric ligand
The experimental results obtained so far enabled us to draw a num ber of 
conclusions. Monoalkylation of cyclen is easily accomplished under mild 
conditions, and purification of the product is straightforward by chromatography. 
Substitution of at least two further nitrogens is similarly simple, furthermore, the 
substitution of the third and the fourth nitrogen atom s seem s to occur almost 
simultaneously. On the other hand, the reactivity of the N10 nitrogen in an 
already trialkylated cyclen derivative is poor.
Therefore, the optimal reaction sequence would be the following. 
Monoalkylation with the donor (coumarin 2 bromoacetate, 117) followed by 
selective alkylation of the N4 nitrogen atom, either with a linker, or directly with 
a suitably activated quencher. A final alkylation step would furnish the scaffold 
with the ‘arm s’. In the case  where the quencher w as attached to the scaffold via 
a linker, the last alkylation would be followed by attachm ent of the quencher to 
the linker (Scheme 20).
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Scheme 20. The synthesis route leading to the asymmetric, tetrasubstituted cyclen-based 
ligands (150a-b) for the complexation of europium and terbium.
Recently it has been found that N1,N4 bis-alkylated cyclen derivatives can be 
synthesised in good yields and without the formation of the N1,N7 isomer, when 
the reaction is carried out in apolar solvents (chloroform) in the presence of 
triethylamine base.®®
Based on this, a similar reaction was carried out. Monosubstituted cyclen w as 
alkylated with N-Boc-bromoethylamine in freshly distilled chloroform in the
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presence of 10 equivalents of base. The concentration of the reagents w as kept 
at 50 mM, a s  at higher concentrations significant am ounts of tri- and 
tetrasubstituted derivatives formed. Apart from these  two side-products, only the 
cis disubstituted compound w as isolated. Neither NMR, nor TLC indicated the 
presence of the N1,N7 isomer.
The alkylation reaction w as carried out with 5'-mesyl-activated nucleosides. 
Under the sam e conditions the N1,N4-substituted derivatives formed in low 
yields. Most of the starting material w as recovered intact. Increasing the 
reaction times or the concentrations did not increase the yield. It is interesting 
that 0-mesyl-N-Boc-bromoethanol gave the corresponding disubstituted 
product in similarly low yields. It is possible that the methanesulfonyl group, 
while being an excellent leaving group is too large, and hinders attack of the 
nitrogen lone pair of the cyclen on the electrophile {Table 11).
Reagent eqiuvalent base Time Yield (%)
BrCHzCHzNHBoc* 5 24h 29
MSOCH2CH2NHB0 C* 5 24 h 14
MsO-2’,3’-isopropylidene-U* 10 36 h 41
MsO-2’,3’-isopropylidene-A* 10 24 32
Coumarin 2 chloroacetate** 10 36 h 7
Coumarin 2 bromoacetate** 10 36 h 13
Table 11. Alkylation of the N4 nitrogen of the monosubstituted cyclen. * N1-substituent: acetoxy 
coumarin 2, N1-substituent: N-Boc-2-aminoethyl. Solvent: chloroform.
Alkylation first with N-Boc-bromoethylamine, followed by the coumarin 2 
brom oacetate is also possible, but gives the desired product in lower yields 
(Scheme 21). The reaction gives rise to the coumarin 2 dimer (125), which 
cannot be recovered for further use. As sodium iodide was not present in the
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reaction mixture, this can be explained either by hom ogeneous breaking of the 
Br-C bond, or by base-induced a-elimination of hydrogen bromide from the 
coumarin 2 bromoacetate. B ecause of the better yields, the initial approach, 
where N-Boc bromoethylamine is used for the second alkylation step is 
preferred.
I ~ \
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Scheme 21. Alkylation of N1-monosubstituted cyclen (140) on the N4 nitrogen. The N1,N7-
isomer was not formed.
The disubstituted cyclen (148) was reacted with excess ethyl brom oacetate in 
refluxing dry acetonitriie in the presence of potassium carbonate and sodium 
iodide. The conversion to the fully alkylated derivative (146) {Scheme 20) was 
complete in 24 hours, and only mechanical losses reduced the yield.
Removal of the Boc protection from the linker by acidolysis revealed a  primary 
amine to which 5’-oxidised nucleosides could be attached. Ligands 150a and 
150b {Figure 44) were synthesised in good yields.
EtO
EtO
Figure 44. The iigands (150a-b) of the lanthanide triads. B = uracii or adenine
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5.7.2.3 Complexation of 150a and 150b with europium and terbium 
Complexations of 150a and 150b with the lanthanides europium and terbium 
were carried out in refluxing methanol under inert atm osphere. The ligands 
were added in slight excess to the anhydrous lanthanide chlorides. The 
reactions were allowed to proceed overnight, the solutions were cooled back to 
room tem perature and poured into tenfold volumes of diethyl ether. The 
precipitate w as centrifuged and the solvent w as decanted. The solid residue 
w as suspended in ether and the procedure was repeated. The solid was 
dissolved in the minimum amount of water, filtered through a plug of cotton wool 
to remove the free ligand residues and the complex w as freeze dried.
Thin layer chromatography on both silica and alumina plates showed that the 
sam ple w as free from the uncomplexed ligand. The proton NMR of the 
complexes provided spectra showing signals in the 10-35 ppm region, a clear 
indication of complex formation. Although only som e of the peaks could be 
resolved, loss of the ethyl esters w as suggested. This finding w as supported by 
the m ass spectrometric analysis of the sam ples, where molecular ions 
corresponding to the mono and di-deesterified complexes (with the resulting 
decrease  in the overall charges of the complexes) were seen . This is probably 
caused by the presence of the lanthanide ion, which can act as  a Lewis acid, 
and catalytically hydrolyse the ethyl esters.
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5.8 Determination of the hydration state of the Eu and Tb compiexes
The lanthanide ions in the complexes have nine co-ordination sites. Saturation 
of the co-ordination sphere is essential for the stability of the complexes. Also, 
in solvents with 0-H  and N-H oscillators, and to a much lesser extent, with C-H 
oscillators, the solvent molecules binding to the unfilled co-ordination sites can 
quench the lanthanide emission. Therefore it is essential to know the num ber of 
solvent molecules bound to the solvated complexes. The ligands offer eight co­
ordinating atoms, four nitrogens on the cyclen ring, and four carbonyl oxygens 
on the substrates. In solution the ninth site is expected to be occupied by one 
solvent molecule, although, a s  the solvent molecules surrounding the complex 
can also have an effect on the lanthanide luminescence, it is possible that the 
effective number is more than one, and it does not have to be an integer.
To determine the number of co-ordinating water molecules the lanthanide 
luminescent lifetime has to be m easured in water and deuterated water. The D- 
O oscillators have different vibrational energies than the 0-H oscillators, and 
their quenching of the lanthanide is less efficient, which is indicated by an 
increase in the luminescence lifetimes. With the formula in Eq 5 the num ber of 
bound water molecules can be calculated.
q = A.{kjj2o ~ ^ 0 2 0  ) Eq 5
In the equation q stands for the number of water molecules bound to the central 
atom, A is an experimental value, which is 0.525 ms'^ in the ca se  of europium 
per OH oscillator and 2.1 ms'^ for terbium. The rate constants, assum ing first- 
order decays are the reciprocals of the experimentally determined lifetimes. The 
charge and geometry of the complex can also be taken into account when 
determining the q values.
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The lifetimes of the Eu and Tb complexes have been determined in both 
distilled water and deuterated water, and their hydration states have been 
calculated (Table 12).
Eu(150a) T b(150a) Eu(150b) T b(150b)
7(020) 2.70 ms 0.35 ms 3.11 ms 0.56 ms
î(H2 0 ) 0.61 ms 0.27 ms 0.49 ms 0.40 ms
q 1.34 1.72 1.67 1.47
Table 12. The lifetimes of the Eu and Tb complexes in H2O and D2O, and their hydration states.
The number of bound water molecules are > 1 in all cases. As there are eight 
possible co-ordinating atom s in each complex, it is natural that the ninth co­
ordination site is filled by a solvent molecule. The accuracy of lifetime 
m easurem ents is ±10%, and that of the q is ±0.5. Therefore the variation in the 
calculated q values is within the experimental error.
The complexes equipped with uridine quenchers have shorter luminescent 
lifetimes than their adenosine-bearing analogues. In the case  of the Tb 
complexes Tb(150a) and Tb(150b) the variation is as  high as  38%. This can be 
explained by the differences in the abilities of the quenchers to stop RET from 
the antenna to the metal, uridine being a more efficient quencher of coumarin 2 
than adenosine.
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5.9 Luminescent properties of the Eu and Tb complexes
5.9.1 Europium complexes
5.9.1.1 Changes in the luminescence intensity
M easurem ents of the luminescent intensities of the europium complexes of the 
ligands 150a and 150b in pH 7.4 aqueous solutions, in the p resence of 
increasing am ounts of the complementary b ases of the quenchers did not give 
reproducible results. In methanol, and mixtures of methanol and unbuffered 
water, and methanol and acetonitrile, addition of adenosine to 151a resulted in 
the increase in the intensity of the peaks at 588 nm and 613 nm. The increase 
of lum inescence intensity is caused by removal of the quencher from the D-Q 
interaction, and an increase in the efficiency of the energy transfer from the 
antenna to the lanthanide (Figure 45).
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Figure 45. Changes in the iuminescent iifetime of the europium in the compiex 151a upon the 
addition of the complementary base adenosine, (methanol /  acetonitriie, excitation @ 328 nm,
detection @ 588 nm)
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5.9.1.2 Changes in the luminescent lifetime
The luminescent lifetimes of both 151a and 151b have been determined in the 
presence of increasing levels of the complementary bases. In both cases  an 
increase of -0 .0 5  ms in the europium lifetime was observed (Figure 46 and 
Figure 47). The reason for this is the sam e a s  for the increase in the 
luminescent intensity in methanolic solutions, namely base-pairing between the 
quencher and its complementary base. It is not likely that the complementary 
b ase  is increasing the lifetime of the lanthanide ion by replacing the co­
ordinated w ater molecules, a s  in the case  of the terbium complexes both an 
increase and a decrease  in rw a s  seen  (See 5.9.22).
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Figure 46. Changes in the iuminescent lifetime of the europium in 151a upon the addition of the 
complementary base adenosine. (pH 7.4 aqueous MOPS buffer, excitation @ 328 nm, detection
@615 nm)
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Figure 47. Changes in the luminescent lifetime of the europium in 151b upon the addition of the 
complementary base uridine (pH 7.4 aqueous MOPS buffer, excitation @ 328 nm, detection @
615 nm).
Direct quenching of the antenna by the added nucleoside is possible, but in the 
case  of the europium complexes its lifetime-diminishing effect is com pensated 
for by the lifetime increase caused by base  pairing between the quencher and 
the complementary base.
The deviations in the initial lifetimes can be caused by the differences in the pH 
of the aqueous solutions (non-buffered vs pH 7.4), in addition to the inherent 
imprecision of the lifetime determination.
5.9.2 Terbium complexes
5.9.2.1 Changes in the luminescence intensity
The luminescence intensities of both terbium complexes (152a and 152b)
decreased  upon titration with their complementary bases. One equivalent of
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adenosine decreased  the lum inescence of the coumarin 2 -  uridine -  Tb (152a) 
complex by 37%. One hundredfold excess of adenosine resulted in only 7% 
further loss, suggesting a strong interaction between the complex and the 
nucleoside.
Similar results were obtained for the coumarin 2 -  adenosine -  Tb complex 
(152b), the intensity loss induced by one equivalent of uridine being 20% 
(Figure 48).
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Figure 48. Quenching of the Tb complex of the 150b iigand (152b) with uridine (pH 7.4 aqueous 
MOPS buffer, excitation @ 328 nm, detection @ 545 nm).
Base pairing is probably also occurring in this case  with the result of an 
increase in the lifetime, but it has to com pete with the quenching of the Q in the 
close proximity of the D, and direct quenching of the D by the added 
nucleoside. As Tb is relatively short-lived (approximately 0.5 ms), the diffusion- 
controlled base  pairing, which is also dependent on the orientation of the
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nucleosides, might not be able to com pete with the quenching processes. The 
result is a decrease  in the luminescence intensity.
5 .9 .2 2  Changes in the luminescent lifetime
The two terbium complexes behaved differently when their luminescent lifetimes 
were determined in the presence of their complementary bases. The lifetime of 
the complex 152a increased when adenosine w as added. The change in the t  
levelled after the addition of approximately 50 equivalents of adenosine, and in 
total am ounted to -1  ps (Figure 49). The increase in the lifetime is due to the 
removal of the potent uridine quencher from the proximity of the donor because  
of the formation of the U-A pair.
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Figure 49. Changes in the iuminescent iifetime of the Tb complex 152a upon the addition of 
adenosine (pH 7.4, exc @ 328 nm, det@ 615 nm).
A decrease  in the terbium ro f  152b w as seen  in the presence of uridine (Figure 
50). This is probably caused by direct quenching of the D by the added uridine.
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Figure 50. Changes in the t  of the Tb in 152b upon the addition of uridine (pH 7.4, exc @ 328
nm, det@ 615 nm).
5.10 Lanthanide triads and DNA
5.10.1 Europium complexes
5.10.1.1 Changes in luminescence intensity
Addition of double stranded salmon testis DNA to pH 7.4 aqueous solutions of 
the europium complexes resulted in the decrease  in lum inescence intensities 
(Figure 51). This is probably due to intercalation of the coumarin 2 antenna with 
DNA. This is indicated by the decrease  in the coumarin 2 excitation spectrum.
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Figure 51. Changes in the luminescence intensity of the Eu compiex of the 150b iigand upon 
the addition of DNA (pH 7.4, exc @ 328 nm, det@ 615 nm).
5.10.1.2 Changes in luminescent lifetime
When determining the luminescent lifetimes of the europium com plexes in the 
presence of DNA, no consistent data were obtained. It is probable that there are 
a number of competing reactions going on, including intercalation of the 
antenna, and binding of the central atom to the negatively charged phosphate 
backbone of the DNA. It is impossible for us to determine the individual effects 
of these  processes, and their reaction rates. Intercalation of the antenna would 
decrease  the luminescent lifetime, while base  pairing of the quencher could act 
both ways. Replacem ent of the 0-H oscillators of the bound w ater m olecules 
with P -0  oscillators increases the lifetimes, a s  P -0  bonds cannot vibronically 
couple with Ln excited states.
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5.10.2 Terbium complexes
5.10.2.1 Changes in luminescence intensity
The terbium complex 152a behaves unpredictabiy. When DNA w as added to 
the solution, both increase and decrease  in the intensity has occurred, although 
not within the sam e m easurem ent.
The intensity of the second terbium complex (152b) decreased  considerably 
upon the addition of DNA (Figure 52), probably due to the intercalation of the 
coumarin 2 with the DNA strands.
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Figure 52. Changes in the luminescence intensity of the Tb compiex of the 150b ligand upon 
the addition of DNA (pH 7.4, exc @ 328 nm, det @ 545 nm).
5.10.2.2 Changes in luminescence iifetime
The luminescent lifetime of the terbium complex of ligand 150b decreased  in 
the presence of DNA, until a [complex] : [bp] = 1 :1 ratio (Figure 53) w as 
reached.
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Figure 53. Changes in zof 152b upon the addition of DNA (exc @ 328 nm, det @ 545 nm)
When the ratio of the initial lifetime and the actual lifetime w as plotted against 
the DNA base  pair concentration, a Stern-Volmer-type plot w as obtained, which 
behaved very similarly to the intensity-based plots. Fitting a curve to the linear 
section of the data provided a Stern-Volmer-type constant of 1.7-10^, which is in 
good agreem ent with the 6.8 10  ^calculated previously.
The r  of the Tb complex of ligand 150a increased in the presence of DNA. A 
tenfold excess of dsDNA raised the lifetime by 0.01 ms (Figure 54).
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Figure 54. Stern-Voimer-type piot of the quenching of 152a with DNA (exc @ 328 nm, det
545 nm)
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5.11 Stern~Vo I mer constants for the quenching of the complexes
Stern-Volmer constants were calculated for the quenching of the lanthanide 
com plexes with their complementary b ases  and dsDNA (Figure 55a-b).
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Figure 55a and 55b. Stern-Voimer piot of the quenching of 152a with DNA. Fitting y = mx + b(b  
= 1.0, y  = Iq/ I, x = [Q]) to the first part of the curve (55b) yieids m = 1.0 lOf^ .
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The Stern-Volmer constants obtained by fitting linears to the data are 
summarized below (Table 13). The Stern-Volmer constants' values are in good 
correlation with the intensity changes observed.
Eu(150a) Tb(150a) Eu(150b) Tb(150b)
c.b. 6.8-10^ * 8.4 10^
DNA 1.0 10"^ 1.8 10^ 6.8 10^
Table 13. Stern-Volmer constants of the quenching of the lanthanide complexes by DNA and 
the complementary bases. *No consistent data were obtained and the K could not be 
calculated.
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5.12 Lanthanide iigands emitting in the near infrared region
Luminescent probes emitting in the near IR region have the advantage of 
interference-free detection of the target, a s  autofluorescence of the sam ple is 
usually insignificant at wavelengths longer than 500 nm. Tissue penetration of 
light increases with the wavelength, which m eans that near IR-emitting probes 
are better suited for in vivo imaging than those emitting in the UV-Vis region. 
There are organic chromophores with suitable emission wavelengths 
available,^® but they are usually insoluble in aqueous solutions, making them 
inappropriate for detection in biological sam ples. The lanthanide ions Nd and Yb 
have emission wavelengths > 850 nm, can be sensitized by fluorescein or 
rhodamine, and can be complexed by suitable ligands to yield water-soluble 
complexes.
5.12.1 Synthesis of the iigand with rhodamine B donor
Cyclen-based ligands for the sensitisation of near IR emitting lanthanides (Nd or 
Yb) were designed. The principle of the ligands w as similar to that of the 
coumarin 2 bearing ones: a cyclen scaffold holding together an an tenna -  
quencher pair and serving as  a chelator for the metal. For the sensitisation of 
Yb and Nd antennae with energy levels closer to the lanthanides are necessary, 
typically fluorescein or rhodamine.
Rhodamine B w as attached via an amide bond to 2-bromoethylamine. The 
reaction w as carried out with 1.1 equivalent of EDCI coupling agent, 1 
equivalent of 2-bromoethylamine hydrobromide neutralized by 1 equivalent of 
TEA. The product (165) w as isolated after standard aqueous workup and silica 
column chromatography (Scheme 22).
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Scheme 22. Attachment of rhodamine B to bromoethylamine.
165 w as used to alkylate cyclen in refluxing 100% ethanol under argon 
atm osphere in the presence of three equivalents of triethylamine base. The 
monoalkylated cyclen (166) w as isolated after standard aqueous workup 
followed by chromatography on basic alumina.
166 w as afterwards alkylated in chloroform with N-Boc-bromoethylamine with 
ten equivalents of triethylamine base. After silica column chromatography the 
bis-alkylated cyclen (167) w as obtained in high purity in m oderate (20%) yields 
(Scheme 23).
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Scheme 23. Alkylation of the N4 nitrogen of the rhodamine B-equlpped monoalkylated cyclen
(166) with N-Boc-bromoethylamlne.
Alkylation of the two remaining cyclen nitrogen atom s with ethyl brom oacetate 
proceeded smoothly in dry acetonitrile with potassium carbonate b ase  and 
sodium iodide catalyst. After aqueous workup followed by silica column
chromatography the tetrasubstituted cyclen (168) was isolated in good yields
and high purity. Removal of the Boc protection w as achieved by acidolysis in 
TFA / DCM to yield 170. The 5-carboxylic acid nucleosides (adenosine or
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uridine) were attached to the primary amino group of 170 with EDCI coupling 
reagent. The final products (171a-b) were purified by silica column 
chromatography (Scheme 24).
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Scheme 24. Attachment of the stabilizing ethylacetoxy arms and the nucleoside quenchers to 
the dialkylated cyclen 167 in the synthesis of the rhodamine antenna-bearing ligands 171 a-b.
5.12.2 Synthesis of the ligand with coumarin 2 and rhodamine B donors 
A cyclen-based ligand for near IR-emitter lanthanides was designed to signal 
DNA by the decrease  in lanthanide lum inescence intensity. The ligand w as 
equipped with the fluorescent donor coumarin 2, that after excitation at -3 3 0  nm 
could transfer its energy to rhodamine, situated in the cis position to coumarin 2. 
Rhodamine would act as  an antenna for the lanthanide (Nd or Yb), so  upon 
excitation of coumarin 2, emission from the lanthanide would be seen . W hen 
DNA is present, intercalation of the primary donor coumarin 2 would prevent 
lanthanide emission. If both donors intercalate, lanthanide lum inescence would 
decrease  irrespective of the excitation wavelength. If only coumarin 2 is 
quenched by the DNA, decrease in the lum inescence intensity is expected upon
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excitation of the complex at -3 3 0  nm, while no changes are expected upon 
direct excitation of the rhodamine (440-500 nm).
Rhodamine B + .143 EDCI. DMF
Scheme 25. Coupling the secondary donor Rhodamine B to 149.
The ligand was prepared by attaching rhodamine B to the previously 
synthesised tetraalkylated cyclen-derivative (149). The carboxylic acid of 
rhodamine B w as coupled to the primary amino group in the tetraalkylated 
cyclen (Scheme 25). The reaction w as carried out in DCM with the help of 1.5 
equivalents of EDCI. The rhodamine B was preactivated for 15 minutes, after 
which 1 equivalent of the cyclen derivative w as added to the solution. The 
product w as isolated after silica column chromatography in 65% yield.
5.12.3 Synthesis of the Nd and Yb complexes
Complexation of Nd and Yb with all three rhodam ine-based ligands was carried 
out in refluxing HPLC-grade methanol. In 12 hours, under an inert atm osphere, 
the complexes formed in moderate yields (40-50%). Purification by trituration 
with cold diethyl ether followed by freeze-drying from w ater removed both 
remaining starting materials. Thin layer chromatography on both silica and 
alumina plates confirmed the purity of the sam ples.
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The NMR-spectra of the complexes showed the most affected cyclen 
hydrogens shifted upfield and the aromatic protons shifted downfield. The free 
ligand spectrum w as very complex due to the asymmetry of the ligand. This 
complexity w as reduced significatly after complexation, a s  the CH2 signals 
appeared unresolved. Similarly, the aromatic and sugar CH-signals lost their 
fine structure, and becam e broad singlets instead of multiplets.
The spectra showed the hydrolysis of the ethyl esters. This happened probably 
during the complexation reaction, the presence of the Lewis acid metal and the 
elevated tem perature would both assist. The molecular ion of the complexes 
w as seen  only in one case  on the m ass spectra of the compounds, but the TLC 
in combination with the NMR, and the luminescence spectra prove the 
formation of the Nd and Yb complexes.
5.12.4 Photophysical properties of the near IR-emitting complexes 
After complexation with neodymium and ytterbium the photophysical properties 
of the near IR-emitters were determined in HPLC-grade methanol. The ligands 
and the complexes absorbed strongly at 545 nm and 355 nm, because  of the 
rhodamine. The exciplex ligand (161) had an additional absorption maximum at 
320 nm, due to the coumarin 2 moiety.
The excitation and emission spectra of the exciplex ligand were taken in 
methanol. Excitation of the primary donor coumarin 2 at 328 nm resulted in a 
weak coumarin 2 emission at 440 nm, due to incomplete RET to the rhodamine, 
and a very intense emission at 580 nm from the rhodamine. Addition of dsDNA 
to the solution of the exciplex resulted in rapid decrease  of the emission 
intensity when excitation w as performed on the coumarin 2. Direct excitation of
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the rhodamine w as also possible, but the emission intensity remained 
unchanged. This w as exactly the result expected, as this m eans that the 
rhodamine is not intercalating with the DNA, while the coumarin 2 is efficiently 
quenched by it (Figure 56).
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Figure 56. Changes in the luminescence intensity of the exciplex Iigand 161 upon addition of 
dsDNA. Excitation @328 nm (coumarin 2), emission @ 580 nm (rhodamine).
It w as not possible to fit a binding curve to the data points and calculate an 
association constant. The K is probably >10" ,^ and the interaction between the 
DNA and the ligand is very strong.
5.12.4.1 Nd and Yb complexes of the exciplex 161
The Nd and Yb complexes in methanol displayed the charateristic near IR 
emission. The 161(Nd) complex had an emission line at 890 nm ("^ F3/2 "^ lg/2)
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and one at 1064 nm C^zi2 " l^ii/2). The ytterbium complex emitted at 980 nm 
r F s /2 1^7/2).
The emission intensity at 1065 nm in the Nd complex decreased  significantly 
upon addition of one equivalent of DNA, when the emission was recorded 100 
ns after excitation {Figure 57). The 890 nm emission band remained almost 
intact.
10 1
800 925 1050 1175 1300
wavelength (nm)
Figure 57. Intensity changes of 161(Nd) upon addition DNA. The broad emission band centred 
around 870 nm is partially caused by the rhodamine.
Analysis of the time resolved spectrum at 890 nm revealed a minor decrease  in 
the overall emission intensity {Figure 58). Unfortunately the 1065 emission band 
is overlapping with the beam of 1065 nm wavelength coming from the 
excitation, making it impossible to separate  the two signals.
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Figure 58. Intensity changes of161(Nd) upon addition DNA. Emission detected at 890 nm
between -200 ns and 1800 ns.
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5 .12.4.2 Emission of the Nd and Yb complexes of 171a and b 
The luminescence intensities of the Nd and Yb complexes of 171a and 171b 
were significantly lower than the Nd and Yb complexes of the exciplex (161). 
Although the intensity is strongly dependent on the experimental setup, and it is 
difficult to com pare the two se ts  of compounds, the emission spectra suggest 
that the rhodamine is efficiently quenched by the adenosine, and to a lesser 
extent, by the uridine moieties {Figure 59).
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Figure 59. Increase in the luminescence intensity of 171 b(Nd) at 89 0  nm (emission monitored
for 1.8 /2S).
On the other hand comparision of the emission intensities of the com plexes in 
the presence and in the absence of the Q complementary b ases  is possible. All 
else being equal, the emission intensity depends on the concentration of the 
solutions and the strength of the excitation beam. It is expected that addition of 
the complemetary bases in concentrated solutions is not going to affect the 
concentration significantly. The effect of the variations in the excitation intensity 
can be eliminated by removal of the pump signal from the recorded spectrum. 
This was carried out using data for one wavelength for each complex were 
processed. For the neodymium complexes this w as the emission at 890 nm.
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and for the ytterbium compounds the 980 nm. Theoretically it is possible to use 
the 1065 nm emission of the Nd, but it is very close to the third harmonics of the 
excitation wavelength (355 nm), which could make the results ambiguous.
The lum inescence intensity of the Nd complex of ligand 171a decreased  upon 
addition of one equivalent of adenosine. Initially the complex 171b(Nd) was 
non-luminescent. Addition of uridine complemetary base  disrupted the 
quenching of the rhodamine by the adenosine because of base  pairing between 
U and A. Thus the rhodamine could act as  an antenna for the Nd, and emission 
from the metal was observed upon excitation of the rhodamine.
The lum inescence intensity of the Yb complex of 171b increased upon addition 
of the U complemetary base  {Figure 60), while that of the 171a decreased.
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Figure 60. Increase in the luminescence intensity of 171 a(Yb) at 890 nm (emission monitored
for 1.8 //sj.
This seem s to be contradictory to the results of the Nd complexes, where the 
rhodamine was quenched more efficiently by the adenosine. This contradiction 
can be explained if the differences in the luminescent lifetimes of the metals are 
taken into account. The t for Nd(lll) is typically shorter than 300 ns, it is
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som etim es well below 200 ns.®^  Ytterbium compounds on the other hand can 
have lifetimes as  long as  several microseconds.®^ This m eans that diffusion- 
controlled quenching processes affect the Yb quantum yields more than the Nd 
quantum yields. So in a solution where the complementary base  can both pair 
with the quencher and quench the antenna, both diffusion-controlled processes, 
th ese  effects are going to be more pronounced in the case  of the Yb 
complexes. It is likely that the adenosine, when part of the ligand, quenches the 
rhodamine, while uridine does it much less efficiently. This difference is more 
pronounced for Nd, where energy transfer from the rhodamine to the metal is 
fast, and the quenching by the uridine cannot com pete with it. To Yb the energy 
transfer from the rhodamine is slower, and the uridine can quench the 
rhodamine excited sta te  to som e extent. Addition of the adenosine 
complementary base  results in direct quenching of the rhodamine, which is 
seen  for the Nd complex. Base pairing with the uridine Q is also likely, but is 
probably slower than the direct quenching, as  the b ases  need to be in the 
appropriate orientation. Adenosine increases the Yb intensity by disrupting the 
quenching through base pairing with the U. Uridine is probably also quenching 
the rhodamine directly, but the overall effect is that of an increase in the 
emission intensity. This is supported by the observation that an even greater 
intensity increase is seen  if, instead of adenosine, uridine is added to the 
solution of 171a(Nd). Uridine can form base  pairs with the uridine quencher of 
the ligand, and, as  seen  in 5.3.3 this interaction is of similar strength than the 
one forming the U-A Watson-Crick pair. Therefore the quencher is removed 
from the proximity of the rhodamine, which increases the emission intensity. In 
addition to this, the direct quenching of the dissolved uridine is less efficient
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than that of the adenosine, which explains why adding uridine to the complex 
induces an even bigger intesity increase than adding adenosine.
It also explains why the complexes with adenosine quenchers behave in the 
opposite way. Adenosine is a very good quencher, and stops RET from the 
rhodamine to the metal. As uridine is not quenching the rhodamine very 
efficiently, the small diminishing effect of the direct quenching of the antenna by 
the complemtary base  is overridden by the enhancem ent caused by the 
‘removal’ of the adenosine from the proximity of the antenna. Uridine can pair 
with the adenosine, and disrupt the quenching of the rhodamine, as  seen  in the 
increase of the luminescent intensity of the 171b(Nd) {Figure 59).
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Figure 61. Decrease of the luminescence intensity of the 171b(Yb) complex upon addition of the 
uridine complementary base (methanol, excitation @ 355 nm, emission at 980 nm).
In the case  of the ytterbium complex the base  pairing is probably not slowing 
the quenching down enough to induce an intensity increase, and the direct 
quenching is also able to compete with the energy transfer from the antenna to 
the metal. The result is that of a decrease in the emission intensity {Figure 61).
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5 .12.4.3 Luminescent lifetimes o f the near IR-emitter complexes 
The luminescent lifetimes of the Nd and Yb complex of the exciplex 161 and 
171a and 171b were m easured in methanol. The lifetimes of 161 (Nd) and 
161(Yb) were also determined in the presence of 1 equivalent of dsDNA. The r  
of 171a(Yb) and 171a(Nd) were m easured upon addition of 1 equivalent of 
adenosine, and that of 171b(Yb) and 171b(Nd) in the presence of 1 equivalent 
of uridine. The results are summ arised in Table 14.
The results are in general in good agreem ent with the lum iescence emission 
data.
161(Nd) 161(Yb) 171a(Nd) 171a (Yb) 171b (Nd) 171b(Yb)
x(\is) 0.20 1.08 0.09 2.61 a 2.23
0.54 0.73 - - - -
- - 0.47 0.89 0.23 1.17
- - 0.81 - 0.16 -
Table 14. Lumienescent lifetimes of the near IR-emitting lanthanide complexes in methanol. * 1 
eq DNA added, ** 1 eq complementary base added, *** 1 eq own base added. ® lifetime could 
not be calculated.
The 161(Yb) complex had an initial lifetime of over 1 microsecond, which 
decreased  to 730 ns when DNA w as added. This is expected if the coumarin 2 
is intercalating with the DNA strands and this quenching can com pete with the 
energy transfers from the coumarin 2 to the rhodamine and the from the 
rhodamine B to the Yb.
Complex 161(Nd) had an initial lifetime of 201 ns. This value more than doubled 
when DNA w as added to the solution. The result cannot be explained by
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assum ing that the coumarin 2 quenching by the DNA is much slower than the 
energy transfer steps. If this were the case, the lifetime would not change. The 
excitation spectrum of the free ligand has two maxima below 500 nm, one 
around 330 nm, the other at 355nm, which are overlapping. Excitation at 355 
nm produces both 01* and 02* (excited rhodamine B). The energy levels of 
these  two moieties lie sufficiently close to each other for energy transfer to take 
place both directions. It is likely that intercalation of the D1 slows down the 
energy transfer from the rhodamine to the coumarin 2, and the D2 metal 
transfer does not have to com pete with the D2 D1 process anymore. The 
overall effect is that of an increased lifetime. The decrease  in emission intensity 
is not in contradiction with this. It w as not a huge effect and, a s  at 355 nm the 
rhodamine w as mainly excited and not the coumarin 2 , intercalation rem oves a 
species competing for the energy of the D2. The intensity decrease  is due to a 
d ecrease  in the ‘total antenna area ' of the coumarin 2 and rhodamine B.
The slowing down of the D2 -> D1 transition probably determ ines tha lifetime of 
the Yb complex as  well, but it is probably still not slow enough to m ake an 
efficient contribution to the r. In this case, the removal of the excitable coumarin 
2 donor from the energy accumulation is not com pensated for by the slowing 
down of the 02 -> D1 energy transfer, and r  therefore decreases. The other two 
ytterbium complexes have lifetimes well over 2 ps, indicating that there is an 
efficient procedure competing with metal sensitization in the 161 complexes. To 
decide unambiguously if it is RET from the rhodamine to the coumarin 2 that is 
causing the observed effects, selective excitation of the coumarin 2 should be 
performed at 328 nm, and selective excitation of the rhodamine B at 545 nm. If 
rhodamine B is excited at 545 nm, thermal repopulation of the coumarin 2
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becom es impossible, and the energy transfer rate from the rhodamine to the 
metal can be determined.
The Nd and Yb complexes of the 171a and 171b ligands had luminescent 
lifetimes in accordance with those found in the literature, i.e., on the 
microsecond tim escale for the Yb compounds, and on the nanosecond for the 
Nd compounds.®^ The m easured lifetimes are somewhat shorter than most 
found in the literature for Yb and Nd complexes, suggesting that the quenchers 
are shortening the r  in all cases. Upon addition of the nucleotides to the 
solutions the changes in the lifetimes were of the sam e nature a s  the intensity 
changes. Adding adenosine or uridine to the strongly quenched 171a(Nd) 
complex increased the lifetime because of the removal of the Q from the 
proximity of the rhodamine. The lifetimes of the ytterbium com plexes were 
shortened by the direct quenching of the antenna by the added nucleoside. The 
magnitude of the lifetime shortening w as in accordance with the quenching 
abilities of the nucleosides, a s  adding adenosine to 171a(Yb) caused  a larger 
drop in r th a n  adding uridine to 171b(Yb).
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5.13 NMR titrations
To establish where the interaction between the triads and their complementary 
b ases  occurs, the triads were titrated with their complementary bases, and the 
process w as monitored by NMR. The b ases  could form pairs with the 
quenchers through hydrogen bonding, or it is also possible, that they interact 
directly with the donor. The latter is even more likely in the light of the 
fluorescence titrations, where instead of the expected increase of lum inescence 
intensity, further quenching of the triads w as observed. NMR is able to 
determine which of the two processes goes on. If base  pairing occurs, the 
signal of the quencher base  hydrogens is expected to shift. In the case  of 
adenosine, the amino hydrogen signal could also change, either in intensity, or 
its chemical shift. If the complementary base  interacts directly with the donor, 
the coumarin signals may alter, although the lack of such a change does not 
rule the direct quenching out.
The NMR titrations were carried out in deuterated DMSO, which w as the only 
solvent to dissolve both the triads and the nucleotides in sufficiently high 
concentrations.
Fitting binding curves and calculating binding constants w as not always 
possible. W here quantitative results were obtained the binding constants were 
approximately two orders of magnitude lower than calculated from the 
fluorescence data {Table 15).
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90a 90b 96b 150a 150b
K (de-DMSO) - 5.9-10^ 18 - -
Table 15. Association constants caicuiated from the NMR-titrations in de-DMSO. Compounds 
were titrated with the complementary bases of the quenchers. 90a and 150a qith adenosine, 
90b, 96b, and 150b with uridine.
Due to the diffences in the concentrations and the sensitivity of the two 
techniques, the data cannot be compared directly. Considering that the number 
of hydrgen bonds possible between the triad and the target is three at most, and 
that the binding w as monitored in highly polar solvents at low concentrations, it 
is reasonable to accept the NMR titration results a s  the better approximations.
5.13.1 Organic triads
When the c120-c343-U (90a) organic triad w as titrated with adenosine, neither 
the coumarin nor the uridine signals changed, apart from the shift caused by the 
changes in the solvent polarity.
Titration of the c120-c343-A (90b) triad with uridine shifted the aromatic and 
amide-NH signals downfield. While all coumarin signals, and the aromatic C-H 
protons of the quencher moved together by about 0.14 ppm, the NH2 signal of 
the adenosine quencher w as shifted by a further 0.10 ppm downfield. The 
quencher amine hydrogens moved from a  starting position of 6.87 ppm to a final 
7.11 ppm. Once one equivalent of the complementary b ase  w as added, 
changes were insignificant, suggesting a one to one binding between triad and 
target.
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Similar results were obtained for the c151-c343-A (96b) triad, where the broad 
NH2 signal moved from 6.23 ppm to 6.78 ppm. This titration w as carried out in 
pure DMSO, which accounts for the difference in the position of the NH2 
signals. The large shift caused by the complementary base  is probably due to 
better interaction between the uridine and the quencher in the aprotic DMSO.
5.13.2 Lanthanide iigands
The NMR spectrum of the cyclen-based ligand bearing coumarin 2 antenna 
and uridine quencher showed very interesting properties. The hydrogen signals 
for the OCH3 groups of the uridine were expected to be singlets at 
approximately 1.35 ppm and 1.52 ppm. Similarly, the Me groups in the 4 and 7 
positions of the coumarin are singlets around 2.33 and 2.50 ppm. One peak of 
each se t is a singlet, but the OCHs-signal at 1.36 ppm and the CHs-peak at 2.33 
ppm seem  to be doublets, or two pairs of singlets of equal intensities. The latter 
is supported by the calculated coupling constants, 3.5 Hz and 2.7 Hz. One of 
the coumarin 2 aromatic hydrogens at 7.33 ppm, which is usually a siglet, 
becom es a pair of singlets with slightly different chemical shifts (7.32 and 7.34 
ppm). These peaks cannot be due to som e sort of through-space coupling of 
the groups to each other, and they cannot couple to any other hydrogens either, 
so it is more likely that two isomers of the ligand exist in solution.
During the titration, the two coumarin 2 aromatic hydrogen signals return to 7.33 
ppm, and becom e one singlet again. The two aromatic methyl peaks at 2.33 
and 2.34 ppm move closer to each  other, and by the addition of three 
equivalents of adenosine they becom e one signal at 2.31 ppm. The OCH3 peak
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is more difficult to follow, as  the 2 ’3’-isopropylideneadenosine, added during the 
titration, has two OCH3 groups in very similar chemical environments.
One of the doublets of the uridine base  C-H's, at 5.63 ppm is shifted to 5.73 
ppm during the titration, suggesting the reduction of the electron density in its 
environment. The other signals corresponding to aromatic hydrogens remain at 
the sam e chemical shifts, which m eans that the interaction during the titration 
takes place between the quencher and its complementary base. W hat probably 
happens is that initially there are two isomers of the ligand in the solution. This 
might be because  of the restricted movement of the quencher and the donor, 
caused by either som e steric hindrance, or a stabilizing interaction between the 
aromatic rings of the two moieties. Addition of the complementary b ase  m eans 
that the relative position of the D and the Q will be determined by the interaction 
of the Q and the adenosine. Either the D will be able to move freely, resulting in 
the simplification of the spectrum, or there will be one favoured conformation, 
which will have the sam e effect. Variable tem perature NMR experim ents could 
decide if there are two conformational isomers present. Increasing the 
tem perature would increase the flexibility of the compound, and the two signals 
in the free ligand spectrum would collapse into one.
In the case  of the ligand with the adenosine quencher, the OCH3 peak at 1.59 
ppm appeared as  two singlets, similarly to the previous m easurem ent. During 
the titration the two singlets becam e one singlet with an integration of three. As 
uridine has a much better solubility than adenosine, uridine could be added in 
the 2'3'-unprotected form, making it possible to follow the ligand OCH3 peak. 
The broad singlet corresponding to the amino hydrogens of the adenosine w ere 
not detected, probably because  the hydrogens have been exchanged in the
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deuterated methanol, in which the sam ple w as dissolved. There were som e 
small changes visible in the spectrum, such as  the broadening of the adenosine 
sugar hydrogen signals, and minor chemical shift changes in the aromatic 
region, but these  could all be casued by the changes in solvent polarity.
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6 C o n c l u s io n s  a n d  fu tu r e  w o r k
A range of novel luminescent probes exploiting resonance energy transfer has 
been synthesised and characterised. The probes have a fluorescent donor and 
an acceptor, which can undergo RET, and a  quencher, which regulates RET 
between the D and the A.
Three different types of compounds have been prepared: ‘organic triads', 
bearing coumarin 343 A, lanthanide complexes equipped with europium and 
terbium lumophores, and near IR-emitting Nd and Yb complexes. In addition to 
these, model com pounds with only the D and the A (‘diads’) have been 
synthesised to determine the unaffected photophysical properties of the D-A  
pair. A novel ligand for near IR-emitting Nd and Yb has been synthesised for the 
detection of DNA.
The three organic triads behaved in a way contrary to that expected, a s  their 
lum inescence decreased  in the presence of the target, instead of increasing. 
One of the triads, with c120 (D), c343 (A) and adenosine (Q) was successfully 
‘switched on’ by the interaction with its target compound, the complementary 
base  of the quencher. This indicates that careful tuning of the reaction rates of 
RET and quenching by altering the D-A and D-Q distances in the molecule, and 
varying the D and the Q to optimise the quenching can produce probes with 
enhanced emission wavelengths, zero, or significantly reduced emission in the 
absence of their targets, and increased emission upon target binding. The 
modular synthetic approach enables the simple and straightforward 
replacem ent of the functional units and the insertion of spacers.
Further possible synthetic targets could include the incorporation of novel 
quenchers both to optimise the quenching and to introduce recognition sites
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with better discrimination. One such Q could be folic acid, as  folic acid receptors 
are overexpressed on cancerous cells.^^ Other nucleosides, both natural and 
modified could be quenchers. Better water solubility could be achieved by the 
replacem ent of the ethyl acetylcarboxylate stabilizing arm s with more 
hydrophilic moieties, for example sugars. Two such ‘arm s’ have been 
synthesised (122, 123). Their introduction into the ligands sould be analogous 
to the ethyl acetylcarboxylate introduction.
The lanthanide triads were rapidly quenched in pH 7.4 aqueous solutions by 
both the complementary b ases  and DNA, but in methanol an increase in the 
lum inescence intensity of the Eu complex 150a could be seen . As in the case  of 
the organic triads, changes in the quencher could improve the photophysical 
properties of the probe.
Determination of the lifetimes of the probes both in the absence  and in the 
presence of their target com pounds suggested their ability to act a s  lifetime 
probes. Changes in the lifetimes of three of the organic probes (90b, 96a and 
96b) were reproducible and significant. The changes caused by the nucleosides 
in the lifetimes of the Eu and Tb complexes enable the discrimination between 
adenosine and uridine in aqueous solutions. By determining the photophysical 
properties of the prepared compounds a qualitative overall picture w as obtained 
of the rates of the energy transfer and quenching processes. This m akes the 
design of better triads with optimised donor-quencher pairs possible.
The Yb and Nd complexes were incorporated into novel ligands, and the 
complexes behaved as  near IR-emitting luminescent triads. The results 
obtained complete ‘turning off’ of one of the complexes (171b(Nd)) which w as 
non-luminescent in the absence of its target. The compound becam e highly
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luminescent when its substrate w as added, making this complex the most 
successful of the synthesised triads in fulfilling the initial objectives of the 
project.
In addition of the lum inescence results, a new, widely applicable synthetic 
strategy for the preparation of asymmetric, tetrasubstituted cyclen derivatives 
has been developed. This enables the convenient alteration of the functional 
units in the ligands, and the synthesis of a wide range of lanthanide-based 
luminescent probes.
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7 La b e ll in g  a p t a m e r s  w ith  r a d io n u c l id e s
7A Introduction
7.1.1 Aptamers
Molecular recognition can be achieved with molecules of all sizes. In section 2.3 
work carried out with relatively small molecules was described. Most of the 
probes presented there have been applied for the detection of the target 
species in model solutions containing a small number of components, while 
som e of them were tested  in non-aqueous media. A few of them have been 
used in vitro or in vivo. This is in large part due to their lack of discrimination 
between competing species, which is due to the flexibility of their recognition 
units. Much better specificity can be achieved using highly specified, naturally 
occurring probes. In biomedical research, target recognition by naturally 
occurring macromolecules and their in vitro modified versions is common. 
Antibodies, antibody fragments of various sizes and small proteins are all widely 
used for targeting.
Recently highly specific and selective molecular recognition has been achieved 
by DNA and RNA fragments. The methodology is based upon the selection of 
the better binding recognition units, their amplification, and determination of 
their structure. A library of oligonucleotides consisting of random DNA 
sequences is subjected to asymmetric PCR to obtain single-stranded DNA. In 
solution the DNA strands will each adopt a preferred 3D-geometry, a s  
determined by their abilities to form intramolecular hydrogen bonds and other, 
w eaker secondary bonds. This pool is brought into interaction with a target 
molecule on a solid support. Concentration of the binding seq u en ces  is
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achieved by selective removal of the non-bound sequences, for example by 
washing, or with the application of a salt or pH gradient. If necessary, further 
selection and amplification steps can be performed. After 6-15 cycles the best 
fitting sequence or sequences are obtained, which can be determined by 
sequencing, and from then on produced in large quantities by solid-phase 
synthesis. This selection procedure is called SELEX, or ‘system atic evolution of 
ligands by exponential enrichment’ (Figure A-1).^^
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Figure A-1. The SELEX procedure.
The binding oligonucleotide obtained by this method is called an aptam er. The 
main advantages of aptam ers over antibodies are that their synthesis can be 
autom ated once the sequence is known, chemical modifications can be carried 
out easily, and there is no need for in vivo experiments for their development. 
Compared to antibodies, which need several months to raise, aptam ers can be 
developed in the space of a few weeks. It has also been possible to autom ate 
the aptam er acquisition.
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Aptamers, being small oligonucleotides of 25-60 base  pairs are quite unstable 
in vivo. Both for their increased stability and for the introduction of signalling and 
catalytic functions a number of chemical modifications can be carried out on the 
nucleotides (Figure A-2).^^
-B H 3 . =s
-I, -Br 
-SH
amino acid 
fluorescent molecule
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Figure A-2. Common modifications of nucleotides, introduced to enhance in vivo stability, 
enable attachment of reporting moieties, or a catalytic function.
Replacem ent of either the 3' or the 5’ or both hydroxyl groups with fluoride or 
amino substituents increases nuclease resistance. Substitution of the 0x0 group 
in the phosphate backbone with sulfur, or the use of the non-natural optical 
isomer sugar has similar effects. Signalling or catalytic functions can be grafted 
onto the aptam er by the introduction of fluorescent labels instead of the bases. 
The modification of the natural b ases with the introduction of bromine or iodine 
and thiol groups has been carried out to achieve photo-crosslinking and 
chemical crosslinking, respectively.
In a collaboration with Dr Sotiris Missailidis, aptam ers raised against a tumour 
m arker have been labelled with the fluorescent labels rhodamine and 
fluorescein. As a m eans of providing a standard, they have been labelled with 
the widely used radioactive metal technetium. Technetium-labelled aptam ers 
could serve as  efficient, easy-to-preduce and relatively cheap in vivo imaging
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tools, while their luminescent analogues could be used for in vitro detection of 
the targets.
7.1.2 Labelling of biomolecuies
Molecules that are able to recognise biologically important targets have been 
labelled for various reasons. When having luminescent labels attached to them 
they are capable of visualising their target both in vivo and in vitro. It is possible 
to attach MRI-active com pounds to molecules that are able to cross the blood- 
brain barrier to highlight anomalies in the brain, that are otherwise difficult to 
detect. ;^Emitting radionuclide carrying antibodies and tumour-specific peptides 
are applied for the visualisation of tumours (Table A-1). W hen the ;^emitter is 
replaced by a or cr-emitter, or one emitting low energy electrons (Auger 
electrons), the labelled biomolecule can be used for the treatm ent of a number 
of illnesses, the most common being various forms of cancer.®®’®^
Nuclide Ti /2 E^(keV) ;^ray (keV) Source
“ Cu 12 .8  h 570 511 (10%), 185 (24%) Accelerator
2 .6  d 570 184 (48%), 92 (23%) Accelerator
99m^ C 6 .0 2  h - 141 (89%) ®®Mo/®®"’Tc generator
” 'ln 2.83 d - 171 (8 8 %), 247 (94%) Cyclotron
131| 8 .0  d 810 364 (81%) Reactor
3.3 d - 93 (10%), 185 (24%), 296 (22%) Generator
9 0 y 2.7 d 2270 - ®°Sr parent decay^
3.8 d 1070 137(9%) Reactor
0.7 d 2 1 1 0 155 (15%) i 88^ / i 88Re generator
Table A-1. Radionuclides used for therapeutic and imaging purposes, their half-lives and the
energies of the /3-particles and y-radiation emitted. ^^°Sr is reactor-produced.
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Radioactive labelling for both therapeutic and imaging purposes has as the 
advantage of high sensitivity and selectivity. Radioactive signals are easy  to 
detect in vivo, a s  they are unique, and there is no interaction from the sample. It 
is also a well established method, with a wide range of radionuclides available 
with varying half-lives, LETs and particle energies. In many cases  there are 
convenient methods for the production of the desired radioisotope in high 
isotopic purity. In most cases  the radiolabelling of the biomolecule involves 
simple chemistry and the necessary  ingredients for the therapeutic are available 
in a kit form requiring only the addition of the radionuclide.
The disadvantages associated with radiolabelling are the storage and disposal 
of the hot sam ples, generation of the compounds in acceptable radionuclidic 
purity and the radiation burden placed on the patient and the environment of the 
patient.
Radioactive labelling for imaging has been decreasing in importance, MRI 
contrast agents and fluorescent labelling taking over its place. T hese m ethods 
cannot match the sensitivity of radiolabelling, but are rapidly improving, and in 
the case  of fluorescent labels, under special conditions, single-molecule 
detection has been achieved. Furthermore, the detection of emission from a 
fluorescent label can be achieved with relatively simple instrumentation, unlike 
the ;^cam eras needed for radioimaging.
7.1.2.1 Radioactive iabeliing o f MU C l
Human MUC1 mucin is a membrane-bound m em ber of a glycoprotein family. It 
is expressed at the apical cell surface of normal glandular epithelium of several
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organs, for example stomach, salivary gland, breast, bladder, pancreas and 
uterus. It is also expressed by hematopoietic cells.
Normal mucin is a high-molecular weight (400 kDa) transm em brane 
glycoprotein, with a 69 amino acid-long cytoplasmic tail and a highly 
glycosylated extracellular domain. The extracellular domain consists of tandem 
repeats of 20 amino acids, of which five (19, 27, 34-36) can be glycosylated. 
Half of the residues are proline, threonine and serine.
In carcinom as MUC1 is expressed on the whole cell surface, reducing cell 
adhesion and helping m étastasés. In tumours the underglycolsylated version of 
the normal protein can be found (Figure A-3).
Carbohydrate
Fully glycosilated
MUC1
Peptide backbone
Exposed peptide
backbone
Figure A-3. Normal and tumour-associated MUC1.
Underglycosylation leaves the peptide backbone exposed, and this is a 
potential target for antibodies, peptides and aptam ers. Most monoclonal 
antibodies react with the sam e epitope, the PDTRP sequence (Figure A-4).^^
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Figure A-4. The structure of the core MUC 1 protein.
Radiolabelling of anti-MUC1 antibodies has been performed with a num ber of 
radioactive nuclides, among them copper-64, technetium-99m and rhenium- 
188. As the incorporation of non-metal radionuclides usually requires either total 
synthesis or biochemical production of the radioactive sample, in m ost cases  
radioactive metal atoms are used for the labelling.
Direct attachm ent of the radiometals to the antibodies involves the reduction of 
the disulfide bonds by a suitable reducing agent, mercaptoethanol for example, 
and using the reduced thiols to co-ordinate the radionuclide. This method is 
applicable for the complexation of technetium, but has the disadvantage of 
reducing the stability of the antibody. The complexes thus derived are usually 
not very stable, therefore radioactive metals with longer half-lives cannot be 
incorporated this way. The co-ordination geometry and the oxidation sta te  of the 
central atom cannot be determined, which leaves the characterisation of the 
therapeutics incomplete.
Radiolabelling with a bifunctional chelator is a widely applicable methodology
resulting in stable and fully characterisable bioconjugates. The radiometal is
complexed with a polydentate ligand, which can be coupled to the biomolecule
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through a convenient reactive functional group. The functional groups can be 
carboxylic acids which can form amide bonds with the amino groups of lysine 
residues, and ester bonds with hydroxyl groups in serine and tyrosine. Thiols 
can be alkylated with maleimide selectively and isothiocyanates can form 
thiourea bonds with primary amines. The choice between the reactive groups 
depends on the labelling conditions, a s  all three have different optimal pH 
ranges for the reactions, which might be unsuitable for the given biomolecule. 
The aptam ers used in the studies have been 5’-amino modified to increase their 
stability against nucleases and to enable the attachm ent of the label. The 
introduction of amino groups m akes the attachm ent of labels possible via amide 
bonds.
The chelate structure is determined by the chemical properties of the 
radiometal, its co-ordination number, oxidation state  and hardness.
For imaging purposes the radionuclide of choice is the ®^ "^ Tc, as  it has a half-life 
of 6 hours, which m akes simple preparations and efficient imaging of the 
tumours possible. The short half-life also enables the administration of millicurie 
doses of activity without the patient suffering significant radiation exposure. The 
photons emitted are monochromatic with 140 keV energy, which are easy  to 
collimate to obtain im ages of excellent spatial resolution. Furthermore, 
technetium shares very similar chemical properties with rhenium, which is below 
technetium in the periodic table. It m eans that the chemistry of the therapeutic 
can be optimised using the non-radioactive rhenium. As an additional 
advantage, this chemistry can also be applied to two therapeutically important, 
y^emitting radioactive isotopes, ”'®®Re and ^®®Re.
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Technetium-99m is the decay product of the parent radionuclide, ®®Mo, and is 
available from ^^Mo-^^'^Tc generators by elution with saline in the form of 
sodium pertechnetate. Molybdenum-99 molybdate is absorbed on alumina, 
where the decay of the ®®Mo yields Som e of the ®®Mo decays directly to 
the decay product of the long-lived ®®Tc. Therefore the hot technetium 
sam ple is never carrier free. The specific activity of the sam ple can be very 
high, and is dependent on the age of the generator and the concentration of the 
sample.
7 .12 .2  Bifunotional ligands for the complexation of technetium and rhenium 
There are a large number of bifunctional chelators in the literature for the 
complexation of technetium and rhenium. It is common to divide them into three 
parts: the functional group for the attachm ent to the biomolecule, the binding 
site for the metal complexation, and the spacer, which helps to minimise the 
interaction between the targeting molecule and the metal. The spacer might be 
completely missing, as, especially in the case  of macromolecules, the 
properties of the biomolecule remain intact when a relatively small technetium 
complex is attached to them far away from the biologically active site. 
Technetium has a rich redox chemistry and under a given se t of conditions 
more than one oxidation state may be stable. The Mo-Tc generator provides 
technetium in the form of sodium pertechnetate, in which the technetium central 
atom is in the +7 oxidation state and its co-ordination sphere is saturated with 
four oxygen atoms. To enable complexation with a chelator the pertechnetate 
has to be reduced. This can be carried out with a variety of reducing agents, for 
exam ple sodium borohydride, stannous chloride, water-soluble phosphines.
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Sn(0), Ti(lll), Cu(l), Fe(ll), Zn(0). It is important for the reducing agent not to 
reduce the chelator. S tannous chloride is the most commonly used reagent 
because of its fast reduction kinetics, cheapness, availability and its reluctance 
to com pete with the technetium for the binding site of the chelator. During the 
reduction of the pertechnetate with stannous chloride the initial reduction step 
yields Tc(VI), which can disproportionate, yielding the colloidal TcOz. This not 
only reduces the labelling efficiency with respect to the radionuclide, but also 
m akes the purification of the bioconjugate difficult. The oxidised tin can also 
precipitate out of solution, by the formation of the tin dioxide colloid. Therefore it 
is common practice to introduce a weak complexing agent, for example tricine,^ 
which stabilises the metals and which the strongly binding chelator can replace 
as  the ligand for the technetium.
The ligands can be categorised by the number of their donor atoms. Most of 
them have four donors, som e have five, and there are exam ples of ligands with 
three donors (Figure A-5). Technetium, being a soft metal atom, can form stable 
complexes with the soft donors nitrogen and sulfur. It is not surprising to se e  
that in m ost chelators there are 4-2 nitrogen atoms, the remaining being sulfurs 
or phorphorous. Although technetium can form stable complexes with open- 
chain ligands, the stability of the complexes can be further increased by closing 
the ligand structure into a ring.
*  N-Tris-(hydroxymethyl)-methylglycine
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[TcO(Cys-Gly-Cys)] Tc(Cp-R)(C0 )3  [TcOzCCyclam)]
Figure A-5. Some commonly used technetium complexes.
The ligand designed for the labelling of the anti-MUC1 aptam ers for labelling 
with technetium-99m is shown in Figure A-6.
Figure A-6. The cyclen-based bifunctional chelator for the labelling of amlno-modlfled aptamers 
with technetium. N^-(methlonylcarboxymethyl)-1,4,7,10-tetraazacyclohexadecane.
The technetium ion is co-ordinated by the four nitrogen atom s of the cyclen. The 
stability of the complex is increased by the introduction of a methionine arm, 
that can donate a sulfur atom for binding the technetium. The methionine is 
attached to the cyclen via an acetylcarboxylate linker, derived from chloroacetic 
acid.
Attachment of the aptam er is possible through amide bond formation with the 
carboxylic acid moiety of the methionine. Although the ligand contains 
secondary amino groups, it is unlikely that these  would com pete with the 
primary amino group of in the modified aptamer.
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7.2 Experimental
Sodium perrhenate w as supplied by Aldrich. All other chemicals were 
purchased from Acros and used without further purification. Sodium iodide and 
potassium carbonate were dried at 90 °C for 24 hours prior to use. TEA was 
distilled from calcium hydride under argon and stored under argon over 
molecular sieves. All other solvents were obtained from Fischer and used as 
purchased.
Tri-Boc-cyclen and methionine ethyl este r were synthesised according to 
literature procedures.^®’
Thin Layer Chromatography w as done on Merck fluorescent silica or on Fluka 
fluorescent alumina plates with iodine, KMn04 or UV visualisation. NMR and 
NMR data were obtained using a 300 MHz JEOL instrument. LC-MS w as 
performed on a VG Quattro 2 equipment coupled to a W aters HPLC system . UV 
spectra were m easured on a Uvikon XL (Bio-Tek Instruments) spectrom eter. 
Radioactive sodium pertechnetate solution in saline w as obtained from a 
Molybdenum-technetium generator, typical activity values being 2000-6000 
MBq in 1 to 2 mL. Modified aptam ers were purchased from Aldrich. The labelled 
aptam ers were purified by size-exclusion chromatography on PD-10 SEC 
columns (Amersham Biosciences). Three week-old nude female mice with mcf- 
7 xenografts in the left flank were supplied by the Department of Academic 
Medical Physics, University of Nottingham.
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7.2.1 Ligand synthesis for aptamer iabeliing
7.2.1.1 DL-Methionine-ethyl ester chloroamide
H,N OEt CICHXOOH C1CH2C(0)N OEt
°  d S ' ^  °
r .l, 24 h —S
176 177
DL-Methionine ethyl ester (176) (0.18 g, 1 mmol) was dissolved in DCM (10
mL), chloroacetic acid (0.18 g, 2 mmol) and EDCI (0.38 g, 2 mmol) were added, 
and the solution w as stirred at room tem perature for 24 hours. DCM (30 mL) 
and water (40 mL) were added, the phases were separated, and the aqueous 
phase  w as extracted with DCM (2 25 mL). The combined organic phases were 
w ashed with w ater (30 mL), dilute acid (30 mL, 1 M HCI), dilute base  (30 mL, 1 
M NaOH), dried over MgS04 , filtered, and evaporated to dryness to yield 177 in 
>95% yield a s  a colourless solid. NMR (CDCI3, 6): 1.16-1.26 (t, 3 H, CH3), 
1.92-2.20 (m, 2 H, CHg), 2.02 (s, 3 H, S-CH3), 2.40-2.49 (t, 2 H, CHz), 2.78 (s, 1 
H, NH), 4.02 (s, 2 H, CICH2), 4.60-4.67 (m, 1 H, CH); ®^C NMR: 14.09 (CH3), 
15.44 (CH3), 29.81 (CHz), 31.40 (CHz), 42.41 (CHg), 51.89 (CH), 61.87 (CICH2), 
165.89 (CO), 171.18 (CO).
7.2. Y.2 Alkylation o f tri-Boc-cyclen with 177
Boc I—  ^ Boc Boc j— ^ Boc
C IC H jC O N H M e tO E tL J -------------  ^ L ] 0S n Kz C0 3 . N a l  S "  " A j /
Boc \ i Boc \-----
■ OEt
H
178 179
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Tri-Boc-cyclen (178) (0.23 g, 0.5 mmol) w as dissolved in DMF (8 mL), K2CO3 
(2.00 g), Nal (1.00 g) and DL-methionine ethyl este r chloroamide (177) (0.26 g, 
1 mmol) were added and the mixture was stirred at 80 °C under argon for 24 
hours. The DMF w as removed in vacuo, the residue was suspended in DCM 
(50 mL), water w as added (50 mL), the phases were separated, and the 
aqueous phase w as extracted with DCM (3 30 mL). The combined organic 
phases were w ashed with water (2 30 mL), dried over MgS04 , filtered, and 
concentrated to -2  mL. The solution w as applied onto a silica column and 
chrom atographed with EtOAc / hexane (1:1). Evaporation of the solvents gave 
179 in 35% yield (0.12 g) a s  a  colourless solid. NMR (CDCI3, 5): 1.17-1.25 
(m, 3 H, CH3). 1.38 (s, 18 H, Boo), 1.40 (s, 9 H, Boc), 2.03 (s, 3 H, SCH3), 2.44- 
2.53 (m, 1 H, CH2-I), 2.53-3.55 (m, 19 H, CH2+CH2-2), 4.04-4.15 (m, 1 H, CH).
7.2.1.3 Removal o f the ethyl ester protection from 179
Boc I \  Boc Boc /  \ ^Boc
k  „ J j  V O B. U  J j  Y o H
Boc \— /  A .  r.i. 12 h Boc \ f
A  " (
/ f
179 180
179 (0.27 g, 0.4 mmol) w as dissolved in DCM (10 mL), NaOH (1 M, 10 mL) w as
added, and the solution w as stirred vigorously at room tem perature overnight. 
The pH w as adjusted to 2 with 1:1 HCI, dichloromethane (30 mL) was added to 
the mixture, the phases were separated, and the water phase  w as extracted 
with DCM (2 25 mL). The combined organic phases were w ashed with w ater 
(2 30 mL), dried over MgS04 , filtered, and evaporated to dryness to give 180 a s
267
a white solid. Yield: >95% (0.26 g), NMR (CDCI3, 6): 1.40 (s, 18 H, Boc), 
1.43 (s, 9 H, Boc), 1.98 (s, 3 H, S-CH3), 2.46-2.54 (m, 2 H, CH2), 2.75-3.45 (m, 
18 H, CH2), 4.47-4.54 (m, 1 H, CH); ^®C NMR: 15.32 (SCH3), 28.35 (CH3-B0C), 
28.60 (CH3-B0C), 30.18 (CH2), 47.09 (CH2), 48.71 (CH2), 50.24 (CH2), 50.43 
(CH2), 51.95 (CH2), 53.38 (CH2), 79.85 (Cq), 81.02 (Cq), 156.26 (CO), 156.36 
(CO), 170.57 (CO).
7.2 A A  Removal of the Boo protecting groups from 180
Boc I—  ^ Boc I— ^
180 181
180 (0.26 g, 0.4 mmol) was dissolved in dichloromethane (10 mL),
trifluoroacetic acid (5 mL) w as added and the solution w as stirred at room 
tem perature for 30 min. The volatile com ponents were evaporated and the 
sam ple w as dried for 24 hours at high vacuum. Recrystallisation from ethanol / 
conc. HCI gave 181 in 50% yield the HCI salt as  an off-white solid. MS: 381 
[M+NH4r ,  519 unassigned; NMR (CD3OD, Ô): 1.77-2.23 (m, 5 H, CH; + 
SCH3), 2.08 (s, 3 H, SGH3), 2.45-3.76 (m, 21 H, GHz + GH); '^G NMR: 14.02 
(GH3), 14.83 (GHz), 24.85 (GHz), 30.17 (GHz), 52.65 (GHz), 55.73 (GH3), 128.94 
(GO).
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7.2.1.5 Alkylation of cyclen with 177
n
I— NH N--.. 'Arm'
H J TEA. E ton N: ' ^ O E t
NH N
137 182
Cyclen (137) (4.71 g, 27.4 mmol, 1.5 eq) w as dissolved in 100% ethanol (25
mL), TEA (0.70 mL, 5.54 g, 54.9 mmol, 7 3 eq) w as added, and DL-methionine
ethyl este r choloracetate (177) (4.64 g, 18.3 mmol). The solution w as refluxed
under argon atm osphere for 24 hours. The ethanol and the triethylamine were
removed at reduced pressure, the residue redissolved in a mixture of DCM and
w ater (mL each), the phases were separated, and the aqueous phase  w as
extracted with DCM (2 30 mL). The combined organic phases were w ashed
with w ater (40 mL), dried over MgS04 , filtered, and concentrated to ~5 mL. The
desired compound w as isolated after purification of the crude sam ple by m eans
of alumina column chromatography (pH 9.5, elution with DCM / MeOH (0.2-
4%)). After evaporation of the solvents the product (182) w as obtained in 13.5%
yield (0.96 g) a s  a colourless solid. ^H NMR (CDCI3, 6): 1.21 (t, 3 H, CH3, J =
7.2 Hz), 1.87-2.15 (m, 2 H, CHg), 2.04 (s, 3 H, SCH 3), 2.45-3.01 (m, 18 H, CHg),
3.15 (dd, 2 H, CHz, Ji = 17.4 Hz, J2 = 12.5 Hz), 4.11 (q, 2 H, CH2, J = 7.2 Hz),
4.57-5.65 (m, 1 H, CH), 8.76 (d, 1 H, NH, J = 8.4 Hz); ^®C NMR: 14.07 (CH3),
15.40 (SCH 3). 30.37 (CH2), 31.55 (CH2), 45.84 (CH2), 46.23 (CH2), 47.19 (CH2).
51.23 (CH2), 53.43 (CH2), 58.99 (CH2), 61.32 (CH), 172.37 (CO).
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7.2.1.6 Removal of the ethyl ester protection from 182
182 181
182 was dissolved in methanol (10 mL), 2 M NaOH (10 mL) w as added, and the 
solution w as stirred at room tem perature overnight. The pH of the solution was 
adjusted to 7.0 with dilute MCI (2 M), and the solvents were evaporated at 
reduced pressure. The residue w as dissolved in a mixture of DCM and 10% 
methanol, dried over MgS04 , filtered, and evaporated to dryness to give the 
ligand as  an off-white solid in 75% yield. Characterisation data sam e as 
reported before for 181. MS: 361 [M+H]^.
7.2.2 Complexation with To and Re and bioconjugation
7.2.2.1 Synthesis of the technetium complex of 181
NH N
^  r  NsBH.
181 183
M etastable sodium pertechnetate in saline (0.2 mL) w as reduced for ten 
minutes with sodium borohydride (4 mg, 0.1 mmol). 181 (36 mg, 0.1 mmol) in 
HPLC-grade methanol (2 mL) w as added, and the solution w as heated to reflux. 
The reaction continued overnight. The solution w as allowed to cool back to
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room tem perature and the sam ple w as filtered through a plug of cotton wool into 
diethyl ether (5 mL). The white precipitate w as concentrated by centrifugation. 
The ether w as poured off the sample, the solid residue was dissolved in distilled 
water, filtered, and freeze-dried to give 183 in 14% yield a s  an off-white solid. 
MS: 361 [M(181)+Hr;
7 .2 2 .2  Synthesis of the rhenium complex o f 181
0 -OH
r - \  r - \
f-'NH NaBH*
V "  -
f  ' !
181 184
Sodium perrhenate (25 mg, 0.1 mmol) w as suspended in HPLC-grade methanol
(2 mL), and sodium borohydride (4 mg, 0.1 mmol) w as added to the 
suspension. The reaction w as allowed to proceed at room tem perature for ten 
minutes, after which 181 (36 mg, 0.1 mmol) was added, and the solution w as 
heated to reflux. The reaction continued overnight. The solution w as allowed to 
cool back to room tem perature and the sam ple w as filtered through a plug of 
cotton wool into diethyl ether (5 mL). The white precipitate w as concentrated by 
centrifugation. The ether w as poured off the sample, the solid residue w as 
dissolved in distilled water, filtered, and freeze-dried to give 184 in 25% yield as  
an off-white solid. MS: 361 [M(181)+H]^.
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7.2.2.3 Attachment of 183 to the modified aptamer
n  n
N—  FDCI r^ N  N —
f f
183 185
Sodium pertechnetate in saline (1 mL, varying activity) w as incubated with 
sodium borohydryde (4 mg, 0.11 mmol) at room tem perature for 10 minutes. 
181 (36 mg, 0.1 mmol) w as added, and the solution w as heated to 
approximately 60 °C, and was kept at this tem perature for 30 minutes. The 
solution w as allowed to cool back to room tem perature and w as used without 
further purification for the labelling of the amino-modified aptam ers.
Aptamer (25-mer, 5’-amino-3’-fluoropirimidine-modified, 11 mg) and EDCI (19 
mg, 0.1 mmol) were added to the solution of the technetium complex, and the 
reaction w as allowed to proceed for 45 minutes at room tem perature. The 
reaction volume w as adjusted to 3 mL with sterile distilled water, and the 
sam ple w as applied onto a PD-10 size exclusion chromatographic column. 
Elution with sterile distilled water yielded the labelled aptam er in the second, 
third and fourth fractions. The presence of the aptam ers w as detected with UV- 
spectrometry, and the activity of the sam ples w as m easured, confirming the 
presence of the technetium in the bioconjugates. The complexed but 
unconjugated technetium eluted in the following fractions (fractions 5 to 8). 
Fraction four, containing 185 w as used for the animal studies without further 
purification.
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7.3 Results and discussion
7.3.1 Ligand synthesis
7.3.1.1 Ligand synthesis starting with protected cycien derivatives
For the selective and unambigous labelling of aptam ers with chelators it is 
necessary  for the chelators to be monofunctional. More than one reactive group 
in the molecule could result in bioconjugates having other than 1:1 
chelator:aptam er ratio, giving rise to a mixture of products. Therefore only one 
nitrogen atom of the cycien should be functionalised with a carboxylic acid. 
Bioconjugation between the ligand and the aptam er is carried out in aqueous 
solutions, and in the case  of the short-lived isotopes techetium-99m and 
rhenium-188, under a short period of time (typically 45-60 minutes). It is 
expected that under these  conditions the secondary nitrogens of the cycien 
react more slowly than the primary amine in the 3'-modified aptamer.
The triprotected cycien derivative (113) already prepared for the lanthanide 
syntheses w as alkylated with chloroacetic acid in the p resence of potassium  
carbonate and sodium iodide. The product w as isolated in m oderate yields and 
w as reacted with methionine ethyl este r and EDCI to form an amide bond 
between the amino group of the methionine and the carboxylic acid function of 
the cycien derivative. Removal of the ^Butyl-oxycarbonyl group w as followed by 
alkalyne hydrolysis of the oxalamide protection with 10 M aqueous sodium 
hydroxide at room temperature. The final step also resulted in the decom posion 
of the product and and alternative protection strategy was necessary  (Scheme 
A-1).
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Scheme A-1. Synthesis of the bifunctional chelator 181 from protected cycien 113.
As the orthogonal oxalamide and ^butyloxycarbonyl protecting groups are not 
needed in this reaction sequence, they can be replaced by three identical 
protecting groups. Unlike the oxalamide, this group can be non-electron 
withdrawing. This is essential for the efficient alkylation of the fourth nitrogen 
atom. The introduction of three Boc protecting groups onto the cycien w as 
carried out according to a literature procedure.^°° The fourth nitrogen atom w as 
alkylated with methionine ethyl este r chloroamide (177) in DMF solvent with 
potassium carbonate base  and sodium iodide catalyst. The desired product 179 
w as obtained in high purity and m oderate yields after conventional workup 
followed by silica column chromatography. The ethyl es te r protection w as 
removed by hydrolysis in 1 M sodium hydroxide solution. After isolation of the 
free acid, the Boc protecting groups of 180 w ere cleaved by 33% TFA in DCM.
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Evaporation of the solvents, followed by recrystallisation from hot ethanol / 
conc. HCI afforded the final ligand (181) as an off-white solid (Scheme A-2).
Boc j—  ^ Boc Boc I—  ^ Boc
^  CICHjCONHMetOEt ^
L m  i_ im — ' h i„ i  L m  M - 3  P  ' i ; : ^ O E t/"I HN K^Û3.Nal /N
Boc \ f Boc 1___I ^"^^1
178 179
Boc j—  ^ Boc !— \
^  ^NH
Ç  3  O ° y O H  ^ 3 % ! ^  C h 3  O O y O H
180 181
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Scheme A-2. Synthesis of 181 form tri-Boc cycien (178).
7.3.2 Synthesis of 181 from unprotected cycien
During the synthesis of the lanthanide-binding ligands (150a-b, 161, 171a-b) it 
w as found that it is possible to achieve monosubstitution of cycien in absolute 
ethanol with triethylamine b ase  with a number of alkylating agents. The reaction 
gives rise to a small amount of side-products, but these  can be easily removed. 
The gain in yields and required time far outweighs the losses caused by 
overalky lation.
Cycien w as reacted in refluxing hot ethanol in the presence of triethylamine 
under inert atm osphere with methionine ethyl ester chloroacetate (177). The 
monoalkylated derivative w as isolated in good yields and high purity after 
conventional aqueous workup followed by chromatography on basic alumina. 
The ethyl ester w as hydrolysed with 1 M sodium hydroxyde to yield the final 
product in good yields (Scheme A-3).
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Scheme A-3. Two-step synthesis of 181 from cycien (137).
7.3.3 Complexation o f 181 with technetium and rhenium 
The ligand-rhenium complex (184) was prepared a s  a model molecule for the 
radioactive ligand-technetium complex. Rhenium is below technetium in the 
periodic table, and their chemical properties are very similar. Sodium 
perrhenate is readily available in large quantities as  a solid. Furthermore, 
rhenium has two y^emitting isotopes (^ ®®Re and ^®®Re), that have found 
application in radiotherapy. It is common practice to use the technetium 
complex for imaging tumours, and the rhenium analogues for therapy.
Sodium perrhenate w as suspended in HPLC-grade methanol, and 1 equivalent 
of sodium borohydride w as added. The reduction w as allowed to proceed for 15 
minutes, after which the ligand was added in 10% excess to the solution. The 
mixture w as refluxed under inert atm osphere overnight. The product w as 
isolated by pouring the solution into diethyl ether, and collecting the solid 
precipitate by centrifugation. The complex w as formed in m oderate yields. TLC 
showed that no free ligand residues were remaining in the sample.
The oxidation sta te  of the metal cannot be decided, and the overall charge of 
the complex depends on the redox state  of the metal and the pH of the medium. 
The complexation reaction with m etastable technetium w as carried out under 
similar conditions, using a mixture of saline and methanol for the reaction, as
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technetium pertechnetate w as supplied as  a saline solution. Both complexes 
w ere stable in solution for up to 24 hours at room temperature, a s  confirmed by 
TLC (Scheme A-4).
NH N
Ch 3  ,9 °N N
NaMO.
NaBHj 3 3  °
H
183,184
Scheme A-4. Reduction and complexation of technetium and rhenium with 181. M = Tc (183) or 
Re (184). The overali charge of the compiex depends on the exact experimental conditions.
7.3.4 Synthesis of the radiometal-labelled aptamers
The radioactive technetium complex w as prepared by the reduction of a 
aqueous solution of sodium pertechnetate by sodium borohydryde, and heating 
the solution to 60 °C for 45 minutes. The complex w as coupled to the aptam er 
without isolation. Test reactions with non-radioactive sam ples were carried out 
to couple the complex to 3', 5', or both-end amino-modified. Initially these  
modifications served to stabilise the molecule against nucleases, but they also 
provide a convenient attachm ent site for the label.
The conjugation to 3’-modified aptam er w as carried out at room tem perature
with the water-soluble EDCI coupling reagent. After one hour the labelled
aptam er w as isolated by size-exclusion column chromatography.
Characterisation of the product (185) w as possible by UV-spectroscopy and by
measuring the labelling efficiency with a scintillation counter. In an analogous
reaction technetium w as complexed with the commercially available MAG3
ligand, and this complex w as attached to the aptam er to compare the new
compound to an established label. All bioconjugates were stable and there w as
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no leakage of the metal seen. The excess radioactive salt could be efficiently 
separated  from the labelled aptamer. Fractions 1-4 contained the labelled 
aptam er, while in fractions 5 and 6 the salt w as eluted (Table A-2).
Fraction (1 mL each) Apt-MAG3(Tc) (MBq) Apt-999(Tc) (MBq)
0 0.013 0.013
1 0.286 0.199
2 18.35 10.45
3 15.67 9.99
4 12.34 15.81
5 8.564 19.68
6 5.653 12.10
column 856 1054
Table A-2. Activity of the fractions after the purification of the labelled aptamers.
Due to the low concentration of the aptamer, the labelling efficiency w as poor 
for both complexes, although it w as marginally higher for the cyclen-based 
ligand. Despite the low labelling efficiencies there was enough labelled aptam er 
available in each experiment to inject three mice with approximately 5 MBq 
activity in 0.1-0.2 mL.
After injection the mice were monitored with a ;^camera for 10 minutes to follow 
the takeup of the radioactivity. It was found that the labelled aptam er w as 
immediately metabolised in the liver and excreted through the kidneys and the 
bladder, without any tumour uptake (Figure A-6).
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Figure A-6. /-Camera images of a mouse injected with the aptamer-181-Tc conjugate. The 
radioactivity is accumulated in the liver, the kidneys and later the bladder. The tumour is not 
visible, but is located next to the syringe. The tail is radioactive as it was the injection site.
After 30 minutes almost all the radioactivity w as accumulated in the bladder. 
This w as caused by the small size of the aptamer, as  it is approximately % of 
the size considered ideal for tumour targeting. Data collection w as continued for 
5 hours, after which the mice were sacrificed, the tumours removed and 
analysed. No radioactivity w as detected in the tumour slices.
In further experiments conducted by C. S. M. Ferreira and S. Missailidis a 
DOTA-Tc-complex was equipped with four identical aptam er arms, giving rise to
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a fourfold increase in the molecular weight. Efficient tumour uptake occurred 
under identical conditions, as  dem onstrated by the images of the tumour slices 
{Figure A-7).
Tc abe ed cancer
Figure A-7. Images of tumour slices. Mice were injected with multiaptamer-DOTA Tc complex.
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7.4 Conclusions
A novel, cyclen-based ligand (181) for the complexation of technetium and 
rhenium w as designed and synthesised. The ligand contains an attachm ent site 
for biomolecules with amino groups available. It forms stable complexes with 
both metals within 30-60 minutes, and can be coupled to amino-modified 
aptam ers in good yields.
The tumour uptake of radiolabelled aptam ers with 181 and MAG3 chelators 
w as determined by injecting them into 3 week-old nude female mice with mcf-7 
xenografts in the left flank, and monitoring the distribution of the radioactivity. 
No tumour uptake w as observed for either the 181-labelled or the MAG3- 
labelled aptam ers. In consecutive studies, when four aptam ers, held together by 
a tetravalent DOTA(Tc) scaffold were injected, good accumulation of the 
bioconjugates in the tumour w as seen.
The quality of the imaging could be further improved by the usage of double­
modified tetravalent aptam ers, to which 181(Tc) complexes could be attached. 
This method could also be therapeutically useful if technetium is replaced by the 
yg-emitting ^®®Re. A multivalent aptam er with potentially five metal-binding sites 
could deliver a large dose of radiation specifically to the tumour.
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S t r u c tu r e s  o f  p r o d u c ts
H O
B = U 1 5 0 a  
B = A 1 5 0 b
H O
1
161
Rho B
H O
H O
O
B = U 1 7 0 a  
B = A 1 7 0 b
NH
.NH
X = H, B = U 9 0 a
X = H, B = A 9 0 b
X = CF3  , B = U 9 6 a
X = CF3  . B = A 9 6 b
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